

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 26, 2002, 15:37:32 ; Search time 34.17 seconds  
(without alignments)  
2080.399 Million cell updates/sec

Title: US-09-905-056-292

Perfect score: 3362  
Sequence: 1 MLNKMTHLPQOIMIGIPFNR.....VHEPLLRMSKDNVQETQI 640

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_032802.\*

- 1: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1980.DAT.\*
- 2: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1981.DAT.\*
- 3: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1982.DAT.\*
- 4: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1983.DAT.\*
- 5: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1984.DAT.\*
- 6: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1985.DAT.\*
- 7: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1986.DAT.\*
- 8: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1987.DAT.\*
- 9: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1988.DAT.\*
- 10: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1989.DAT.\*
- 11: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1990.DAT.\*
- 12: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1991.DAT.\*
- 13: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1992.DAT.\*
- 14: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1993.DAT.\*
- 15: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1994.DAT.\*
- 16: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1995.DAT.\*
- 17: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1996.DAT.\*
- 18: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1997.DAT.\*
- 19: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1998.DAT.\*
- 20: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA1999.DAT.\*
- 21: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA2000.DAT.\*
- 22: /SIDSI/gcgdata/hold-geneq/geneq-emb1/AA2001.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3362	100.0	640	20 AAY08100	Human PRO331 prote
2	3362	100.0	640	20 AAW85722	Novel protein (Clo
3	3362	100.0	640	20 AAV13394	Amino acid sequenc
4	3362	100.0	640	21 AAB24407	Human PRO331 prote
5	3362	100.0	640	21 AAY70673	Human PRO331 prote
6	3362	100.0	640	22 AAU12355	Human PRO331 polyp
7	3362	100.0	640	22 AAU00826	Human immune respo
8	3362	100.0	640	22 AAB80262	Human PRO331 prote
9	3362	100.0	640	22 AAB65292	Human PRO331 prote
10	3362	100.0	640	22 AAB53089	Human angiogenesis
11	2131.5	63.4	713	22 AAE13006	Human leucine-rich

best post-av

ALIGNMENTS

RESULT 1  
ID AAY08100 standard; Protein: 640 AA.

XX AC AAY08100;

DT 11-SEP-2000 (first entry)

XX XX Human PRO331 protein.

XX Inflammatory cell infiltration; immune response; T cell proliferation;  
KW anti-inflammatory; anti-autoimmune; anti-diabetic; spondyloarthropathy;  
KW T cell-mediated disease; spondyloarthropathy; sclerosis; renal disease;  
KW inflammatory myopathy; hemolytic anemia; thrombocytopenia; thyroiditis;  
KW diabetes mellitus; demyelinating polyneuropathy; Guillain-Barre syndrome;  
KW multiple sclerosis; polyneuropathy; hepatitis; cirrhosis; enteropathy;  
KW sclerosing cholangitis; inflammatory bowel disease; Whipple's disease;  
KW skin disease; dermatitis; psoriasis; asthma; allergic rhinitis; tumor;  
KW food hypersensitivity; urticaria; eosinophilic pneumonia; transplant;  
KW idiopathic pulmonary fibrosis; graft rejection; PRO245; human;  
KW PRO331.

OS Homo sapiens.

XX WO9914241-A2.

XX PD 25-MAR-1999.

XX PF 17-SEP-1998; 98WO-US19437.

XX PR 17-SEP-1997; 97US-0059119.

XX PR 18-SEP-1997; 97US-0059263.

XX PR 28-OCT-1997; 97US-0063550.

XX PR 12-NOV-1997; 97US-0065186.

Human PRO1111 prot  
Membrane-bound pro  
Human sbgPRO331a p  
Human PRO1111 poly  
Human PRO1111 (UNQ  
cc339\_4 secreted p  
Human immunoglobul  
Human SLIT protein  
Human CDNA SEQ ID  
Human SLIT protein  
Human ORFX ORF2855  
Human secreted pro  
Human gene 3 encod  
Human CDNA SEQ ID  
Human immunoglobul  
Human secreted pro  
Human gene 3 encod  
Amino acid sequenc  
Human membrane ass  
Human neuronal gui  
Amino acid sequenc  
Human PRO227 polyp  
Human PRO227 prote  
Mature human neuro  
Human sbgTango79a  
Amino acid sequenc  
Amino acid sequenc  
Drosophila melanog  
Amino acid sequenc  
Amino acid sequenc  
Human PRO293 prote  
Human hh00149 prot  
Human brain-specif

PR 21-NOV-1997; 97US-0066364.  
 PR 24-NOV-1997; 97US-0066770.  
 PR 04-JUN-1998; 98US-0088026.  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Fong S, Goddard A, Gurney AL, Tumas D, Wood WI;  
 XX WPI; 1999-229499/19.  
 DR N-PSDB; AAX37738.  
 XX  
 XX Composition containing novel polypeptide PRO245, its agonist or  
 PT antagonist -  
 XX  
 XX Example 1; Fig 33; 177pp; English.  
 XX  
 CC This invention describes a novel composition containing (apart from a  
 CC carrier or excipient), a novel PRO245 polypeptide (I), its agonist or  
 CC antagonist, or their fragments, for modulating: (i) infiltration of  
 CC inflammatory cells into tissue; (ii) an immune response; or (iii) T cell  
 CC proliferation. The composition increases or decreases any of the effects  
 CC (i)-(iii). The products of the invention have anti-inflammatory,  
 CC anti-autoimmune and anti-diabetic activity. (I), and its (ant)agonists  
 CC and their fragments, are used to treat immune-related diseases,  
 CC particularly T cell-mediated diseases. The diseases treated include  
 CC systemic lupus erythematosus, rheumatoid arthritis, juvenile chronic  
 CC arthritis, spondyloarthropathies, systemic sclerosis (scleroderma),  
 CC idiopathic inflammatory myopathies (dermatomyositis, polymyositis),  
 CC Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune  
 CC hemolytic anemia (immune pancytopenia, paroxysmal nocturnal  
 CC hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic  
 CC purpura immune-mediated thrombocytopenia), thyroiditis (Grave's disease,  
 CC Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic  
 CC thyroiditis), diabetes mellitus, immune-mediated renal disease  
 CC (glomerulonephritis, tubulointerstitial nephritis), multiple sclerosis,  
 CC idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome, chronic  
 CC inflammatory demyelinating polyneuropathy, infectious hepatitis  
 CC (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune  
 CC chronic active hepatitis, primary biliary cirrhosis, granulomatous  
 CC hepatitis, and sclerosing cholangitis, inflammatory bowel disease  
 CC (ulcerative colitis; Crohn's disease), gluten-sensitive enteropathy, and  
 CC Whipple's disease. Autoimmune or immune-mediated skin diseases including  
 CC bullous skin diseases, erythema multiforme, contact dermatitis, psoriasis,  
 CC asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity,  
 CC urticaria, eosinophilic pneumonia, idiopathic pulmonary fibrosis,  
 CC hypersensitivity pneumonitis, and transplantation associated diseases  
 CC (graft rejection, and graft-versus-host-disease). (I), its (ant)agonists  
 CC or fragment can also be used as an adjuvant in treatment of tumors.  
 CC Antibodies against (I) can also be used for diagnosing such diseases.  
 CC This sequence represents the human PRO331 protein which is described in  
 CC the method of the invention.  
 XX  
 XX Sequence 640 AA;

Query Match 100.0%; Score 3362; DB 20; Length 640;  
 Best Local Similarity 100.0%; Pred. No. 2.3e-234;  
 Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLNKTLLPQOIMIGPRFNRALFPLLVLLALQLLVVAGLVRAQTCPSCVCSNQFSKV 60  
 Db 1 mLnKmtLhpqQimigprfNrAlfPlLvLLaLqLLvVaglvRaqtCpScvCsNqfskv 60  
 QY 61 ICVRKRLREVDPGISTNRLNLHENOITQIKVNSFKHLRHLLETLQLSRNRHRTIEIGAF 120  
 Db 61 icvrkrlrevdpdgistnrlnlhengiqlikvnsfkhrlhlleilqlsrnhrtieigaf 120  
 QY 121 NGLANLTLELFDNRLTTPNGAFVYLSKULKELWLRNPIESIPSYAFNRIPSLRRLDLG 180  
 Db 121 nglanltlelfdnrlttpngafvylskelwlrnpiessyafnrslrldlg 180  
 QY 181 ELKRLSYISEGAFGLSNRLRYLNAMCNLRIPNLTPLIKLDLDELGNLSAIPRGSFG 240  
 XX 181 elkrLSYISegafGLsNRLrYlNAmCNlRiPNlTPlIKLDlDELgNLSaIPRGSFG 240

Db 181 elkrLSYISegafGLsNRLrYlNAmCNlRiPNlTPlIKLDlDELgNLSaIPRGSFG 240  
 QY 241 GLMHLQKLWMTQSOIQVTERNAFDNLOSLEINLAHNNLTLLPHDLFTPLHLRIHLHH 300  
 Db 241 glmHlqklWmtqSoiQvTeRnAFdNlOSlEiNlAhNnLTlLpHdLfTPlHlRiHlHh 300  
 QY 301 NPWNCNDIILWLSWIKDMAFSPNTACCARCNTPPNLKGRYIGELDQNYFTCYAPVIVEPP 360  
 Db 301 npwncndiilwlsWIKdMAfSPnTAcCArcNTpPnLKgRYiGElDQnYfTCYApViVEpp 360  
 QY 361 ADLNVTEGMAELKCRASSTLSVSWITPNTGVTVMTHGAYKVRIAVLSOGTLNFTNVTVD 420  
 Db 361 adlNvteGmaElKcraSstLSvSwITpNTGvTVMtHgAYkVriAVlSOGtLNfTNvTVd 420  
 QY 421 TGMVTCVNSVGNVTASATLNVTAAATTPSFYSTVETMETPSODEARTDDNNGVTP 480  
 Db 421 tgmVtCvNsVgnVTaSaTlNvTAAATtPsfYstVeTMeTpsODEaRTdDnNgvTp 480  
 QY 481 VVDWETNTVTSLTTPQSTRTEKFTTIPVTDINSIGIPGIDEVMKTKIIIGCFVAITLMA 540  
 Db 481 vvdWetNtVtSLtTPqSTRtEkFTtIPvTdINsIGiPgIdEvMkTKIIIGcfVaiTlma 540  
 QY 541 AVMLVIFYKKRKQHRQRNHAPTRFVELIINVDDITGDTPMESHLPMPAIEHEHLNHYS 600  
 Db 541 avmlvIfyKmrKqhrqNhApTrtVeLInVddItGdtPmESHlPmpaIEhEhLnHyns 600  
 QY 601 YKSPFNHTTTVTNTINSIHSSVHEPLLIRMNSKDNVQETQI 640  
 Db 601 ykspfnhtttvtntInsiHssVhePlLIRmnsKdNvqEtqi 640  
 XX  
 XX RESULT 2  
 XX AAW85722  
 XX ID AAW85722 standard; Protein; 640 AA.  
 XX  
 XX AC AAW85722;  
 XX  
 XX DT 27-SEP-1999 (first entry)  
 XX  
 XX DE Novel protein (Clone AS209\_1).  
 XX  
 XX KW Polynucleotide; protein; nutrition; cytokine; cell proliferation;  
 XX cell differentiation; immunostimulation; immunosuppression;  
 XX haematopoiesis regulation; tissue growth; activin; inhibin;  
 XX chemotaxis; chemokinesis; haemostasis; thrombolysis; receptor;  
 XX ligand; anti-inflammatory; tumour suppression; gene therapy.  
 XX  
 XX OS Homo sapiens.  
 XX  
 XX PN WO9920644-A1.  
 XX  
 XX PD 29-APR-1999.  
 XX  
 XX PF 16-OCT-1998; 98WO-US22034.  
 XX  
 XX PR 18-OCT-1997; 97US-0955557.  
 XX  
 XX PA (GEMY ) GENETICS INST INC.  
 XX  
 XX PI Agostino MJ, Bowman MR, Evans C, Jacobs K, Lavallie ER;  
 XX McCoy JM, Merberg D, Racie LA, Spaulding V, Treacy M;  
 XX WPI; 1999-288272/24.  
 XX  
 XX DR N-PSDB; AAX08687.  
 XX  
 XX PT New polynucleotides encoding secreted human proteins  
 XX  
 XX PS Claim 26; Page 109-111; 136pp; English.  
 XX  
 XX CC The new human secreted proteins are encoded by polynucleotides  
 XX obtained from human placenta, adult testes, fetal kidney, fetal  
 XX brain, adult brain, adult blood and adult cDNA libraries.  
 XX The polynucleotides and proteins are predicted to have biological

CC activities which would make them suitable for treating, preventing or  
CC ameliorating medical conditions in humans and animals. Suggested  
CC activities include nutritional activity, cytokine and cell  
CC proliferation/differentiation activity, immune stimulating (e.g. as  
CC vaccines) or suppressing activity, haematopoiesis regulating  
CC activity, tissue growth activity, activin/inhibin activity,  
CC chemotactic/chemokinetic activity, haemostatic and thrombolytic  
CC activity, receptor/ligand activity, anti-inflammatory activity,  
CC cadherin/tumour invasion suppressor activity, and tumour inhibition  
CC activity. The polynucleotides are also stated to be useful for gene  
CC therapy. The sequences identified by a secretory leader  
CC sequence motif in the polynucleotide and it is thought that the  
CC encoded proteins have biological activity by virtue of their secreted  
CC nature. This polypeptide was encoded by a clone designated AS209\_1  
CC (See AAX08687).

XX Sequence 640 AA;

Query Match		100.0%; Score 3362; DB 20; Length 640;
Best Local Similarity		100.0%; Pred. No. 2.3e-234;
Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	1	MLNKTLPQIMIGPRNRLFPDLLVLLALQLLVVAGLVRAQTCPSCVCSNQFSKV 60
Db	1	mLnKntLhpqImigprnrfalqdllvllalqlvvaglvraqtcpsvcscnqfskv 60
QY	61	ICVRKRLREVDPGISTNPRLLNLHENQIQIKVNSFKHLRHLLEILQLSRNHRITIEIGAF 120
Db	61	icvrknlrevpvgistnrllnlhenqilqikvnsfkhlrhlleilqlsrnhritleigaf 120
QY	121	NGLANLTLFLDNLRTTIPNGAFVYLSKLKELWLRNPIESIPYAFNRIPSLRRLDLG 180
Db	121	nglanlntlefldnrlttipngafvylskelwlrnnpiesipyanrpslrrldlg 180
QY	181	ELKRLSYISEGAFGLSLNRYLNLAACNLRETPNLTPLIKDELDLSNHLISARPGSFQ 240
Db	181	elkrlyisegafglslnrylnlamcnlreipnltplikdelldlsnhlisaarpgsfq 240
QY	241	GLMHQLKLMIQSQITQVIERNAFNLQSLVEINLAHNNLTLLPHDLFTPLHHLERHLRH 300
Db	241	glmhqlklwmqslqviernafnqlslveinlahnnltllphdlftplhhlrlhlrh 300
QY	301	NPWNCNCDILWSWIKDMASNTACCARNTPPNLKGRIYIGELDQNYFTCYAPVIVEPP 360
Db	301	npwncncdilwswikdmapsntaccarnctppnlkgriyigeidqnyftcyapvivepp 360
QY	361	ADLNVTEGMAAELKCRASLTSTSVSWITPNGTVMTGHGAKVRIAVLSDGTINFTVTQD 420
Db	361	adlnvtegmaaelkcrasltstsvswitpncgvmthgavkryriavlsdgtinfntvtqgd 420
QY	421	TGMVTCMYSVNSVGNVTASATLNVAATTPFSYFTSVTVMERSQDEARTDNNVGTP 480
Db	421	tgmvtcmysvnsvgntasatlnvtaattpfstvtvmersqdeartdnnvgtp 480
QY	481	VVDWETNTVTSLPQSTRTEKFTIPTVDINSIGIPGIDVMTKIIIGCFVAITLMA 540
Db	481	vvdwettntvtsltpqstrtektftiptvdinsigipgidvmtkiiigcfvaitlma 540.
QY	541	AVMLVIFYKMRKHRRHQRHAPTRVETLINVDDETGTPTMESHLPMPAIEHEHLNHNYS 600
Db	541	avmlvifykmrkhrhqrhnaptrveitlinvddetgtptmeshlpmpaiehehlhyns 600
QY	601	YKSPFNHTTNTVNTINSIHSSVHEPILLIRMSKDNVQETQI 640
Db	601	ykspfnhnttntvntinsihssvhepillirmnskdnvqetqi 640

RESULT 3  
ID AAY13394  
XX AAY13394 standard; Protein; 640 AA.  
AC AAY13394;

XX 25-JUN-1999 (first entry)  
DT Amino acid sequence of protein PRO331.  
DE  
XX Secreted protein; transmembrane protein; human; enterocolitis;  
KW Zollinger-Ellison syndrome; gastrointestinal ulceration;  
KW congenital microvillus atrophy; skin disease; cell growth;  
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;  
KW Parkinson's disease; Alzheimer's disease; ALS; neuropathy;  
KW fibromodulin; dermal scarring; Usher Syndrome; Atrophia areata;  
KW anti-thrombotic; wound healing; tissue repair.  
XX Homo sapiens.  
XX WO9914328-A2.  
PN  
XX 25-MAR-1999.  
PD  
XX 16-SEP-1998; 98WO-US19330.  
PF  
XX 25-NOV-1997; 97US-0066840.  
PR 17-SEP-1997; 97US-0059113.  
PR 17-SEP-1997; 97US-0059115.  
PR 17-SEP-1997; 97US-0059117.  
PR 17-SEP-1997; 97US-0059119.  
PR 17-SEP-1997; 97US-0059121.  
PR 17-SEP-1997; 97US-0059122.  
PR 17-SEP-1997; 97US-0059184.  
PR 18-SEP-1997; 97US-0059263.  
PR 18-SEP-1997; 97US-0059266.  
PR 15-OCT-1997; 97US-0062125.  
PR 17-OCT-1997; 97US-0062285.  
PR 17-OCT-1997; 97US-0062287.  
PR 21-OCT-1997; 97US-0063486.  
PR 24-OCT-1997; 97US-0062814.  
PR 24-OCT-1997; 97US-0062816.  
PR 24-OCT-1997; 97US-0063045.  
PR 24-OCT-1997; 97US-0063120.  
PR 24-OCT-1997; 97US-0063121.  
PR 24-OCT-1997; 97US-0063127.  
PR 27-OCT-1997; 97US-0063128.  
PR 27-OCT-1997; 97US-0063329.  
PR 27-OCT-1997; 97US-0063327.  
PR 28-OCT-1997; 97US-0063541.  
PR 28-OCT-1997; 97US-0063542.  
PR 28-OCT-1997; 97US-0063544.  
PR 28-OCT-1997; 97US-0063549.  
PR 28-OCT-1997; 97US-0063550.  
PR 28-OCT-1997; 97US-0063564.  
PR 29-OCT-1997; 97US-0063435.  
PR 29-OCT-1997; 97US-0063704.  
PR 29-OCT-1997; 97US-0063732.  
PR 29-OCT-1997; 97US-0063738.  
PR 29-OCT-1997; 97US-0063734.  
PR 29-OCT-1997; 97US-0064215.  
PR 31-OCT-1997; 97US-0063735.  
PR 31-OCT-1997; 97US-0063870.  
PR 31-OCT-1997; 97US-0064103.  
PR 03-NOV-1997; 97US-0064248.  
PR 07-NOV-1997; 97US-0064809.  
PR 12-NOV-1997; 97US-0065186.  
PR 17-NOV-1997; 97US-0065846.  
PR 18-NOV-1997; 97US-0065693.  
PR 21-NOV-1997; 97US-0066120.  
PR 21-NOV-1997; 97US-0066364.  
PR 24-NOV-1997; 97US-0066772.  
PR 24-NOV-1997; 97US-0066466.  
PR 24-NOV-1997; 97US-0066770.  
PR 24-NOV-1997; 97US-0066511.  
PR 24-NOV-1997; 97US-0066453.  
XX  
XX (GETH ) GENENTECH INC.

Chen J, Goddard A, Gurney AL, Pennica D, Wood WI, Yuan J;  
WPI: 1999-229533/19.  
N-PSDB; AAX52265.  
New isolated human genes and polypeptides used in, e.g. treatment of  
gastrointestinal ulceration  
Claim 12; Fig 104; 320pp; English.  
AAV13344-403 represent secreted and transmembrane human proteins.  
The cDNA sequences are obtained from cDNA libraries, prepared from  
fetal lung, fetal kidney, fetal brain, fetal liver and fetal retina.  
The encoded polypeptides have specific uses based on their homology to  
known polypeptides, e.g. PRO211 and PRO217 can be used for disorders  
associated with the preservation and maintenance of gastrointestinal  
mucosa and the repair of acute and chronic mucosal lesions  
(e.g. enterocolitis, Zollinger-Ellison syndrome, gastrointestinal  
ulceration and congenital microvillus atrophy), skin diseases associated  
with abnormal keratinocyte differentiation (e.g. psoriasis, epithelial  
cancers such as lung squamous cell carcinoma of the vulva and gliomas),  
potent effects on cell growth and development, diseases related to  
growth or survival of nerve cells including Parkinson's disease,  
Alzheimer's disease, ALS, neuropathies or cancer. PRO265 can be used as  
a target for anti-tumor drugs. PRO533 may be used in the treatment  
of Usher Syndrome or Atrophia areata; PRO269 can be used as an  
anti-thrombotic agent; PRO287 polypeptides and portions may have  
therapeutic applications in wound healing and tissue repair; PRO317 can  
be used for treating problems of the kidney, uterus, endometrium, blood  
vessels, or related tissue, e.g. in the heart of genital tract.

Sequence 640 AA;

Query Match 100.0%; Score 3362; DB 20; Length 640;  
Best Local Similarity 100.0%; Pred. No. 2.3e-234;  
Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MLNKLTPHQDITGPRNFALFDPVLVLLALQLLVAGLVRAQTCPSVCSCNQFSKV 60  
DB 1 mLnKmltpqqimqprnfaldfpvlvllalqlvvaglvraqtcpsvcscnqfskv 60  
QY 61 ICVRKNLREVDPGISTNRLNLHENQIQIKVNSFKHLRLEIQLSRNIRTEIGAF 120  
DB 61 icvrknlrevdpgistnrlnlhenqiiqvnsfkhlrlleiqslsrnirteigaf 120  
QY 121 NGLANLTLFDRNLTPNGAFVYLSKLKELWLRNPNIESIPSYAFNRIPSLRLDLG 180  
DB 121 nglanltleifdrnltpngafvylsklkelwlrnnpiesipsyafnrpslrlldlg 180  
QY 181 ELKRLSYISEGAFGLSNLRYLNAMCNLRTPNLTPLIKLDELDSLGNHLSAIRPGSFQ 240  
DB 181 elkrlyisegafglsnlrylnamcnlrtpnltplikdeldslgnhlsairpgsfq 240  
QY 241 GLMHQLKWLMTQSQIOQTVERNAFQNLQSLVEINLAHNNLTLLPHDLFTPLHHLRIHLRH 300  
DB 241 glmhqlkwlmtsqioqtvernafqnlqslveinlahnnltllphdlftplhhlrihlrh 300  
QY 301 NPWNCNCDILWLSWIKDMASNTACCARNTPPNLKGRIYIGELDQNYFTCYAPVIVEPP 360  
DB 301 npwncncdilwlswwikdmassntaccarnppnlkgriyigeldqnyftcyapvivepp 360  
QY 361 ADLNVTEGMAELKCRATSLTSVSWITPNCVTMTHGAYKVRVIAVLSGTLNFTNTVQD 420  
DB 361 adlnvtegmaelkcratsltsvswitpncvtmthgaykvrviavlsdgtlnftntvqd 420  
QY 421 TCWYTCWVSNVGNFTASATLNVTAAATTPFSYFSTVVTWEPESQDEARTDDNNVGTP 480  
DB 421 tgmtycmvsnvgnftasatlnvtaatttfsyfstvtvetmepsqdeartddnnvgtp 480  
QY 481 VDWETTNVNTSLTPQSTRSTEKFTTIPVTDINSIGIPIDEVMKTKIIIGCFVAITLMA 540

Db 481 vdwettnvntsltpqstrstekfttptvtdinsigipidevmktkiiigcfvaitlma 540  
QY 541 AVMLVIFYKMKRKHRRONHAPTRTVELINVDDETGTGTPMESHLPMPAIEHEHLNHYNS 600  
DB 541 avmlvifykmrkhrqnqhapttrtvelinvddeitgtpmeshlmpalenehlnhyns 600  
QY 601 YKSPFNHTTNTVNTINSIHSSVHEPLLIRMSKDNVQETQI 640  
DB 601 ykspfntttvntinsihssvhpepllirmnskdnvqetqi 640

RESULT 4

AAAB24407  
ID AAB24407 standard; Protein; 640 AA.  
XX AAB24407;  
XX AAB24407;  
DT 07-NOV-2000 (first entry)  
DE Human PRO331 protein sequence SEQ ID NO:107.  
KW Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation;  
KW diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;  
KW angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic;  
KW cytostatic; gene therapy; vaccine.  
XX Homo sapiens.  
XX WO200032221-A2.  
XX 08-JUN-2000.  
XX 30-NOV-1999; 99WO-US28313.  
XX 01-DEC-1998; 98WO-US25108.  
XX 16-DEC-1998; 98US-0112850.  
XX 12-JAN-1999; 99US-0115554.  
XX 08-MAR-1999; 99WO-US05028.  
XX 12-MAR-1999; 99US-0123957.  
XX 28-APR-1999; 99US-0131445.  
XX 14-MAY-1999; 99US-0134287.  
XX 02-JUN-1999; 99WO-US12252.  
XX 20-JUL-1999; 99US-0144758.  
XX 26-JUL-1999; 99US-0145698.  
XX 01-SEP-1999; 99WO-US20111.  
XX 08-SEP-1999; 99WO-US20594.  
XX 13-SEP-1999; 99WO-US20944.  
XX 15-SEP-1999; 99WO-US21090.  
XX 05-OCT-1999; 99WO-US21547.  
XX 29-OCT-1999; 99WO-US23089.  
XX 99US-0162506.  
XX (GETH ) GENENTECH INC.  
XX Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ, Goddard A;  
PI Godowski PJ, Gurney AL, Klein RD, Kuo SS, Paoni NF, Smith V;  
PI Watanabe CK, Williams PM, Wood WI;  
XX WPI; 2000-412154/35.  
XX N-PSDB; AAA77596.  
XX Nucleic acids encoding PRO polypeptides useful for preventing,  
PT diagnosing and treating disorders a cardiovascular, endothelial or  
PT angiogenic disorders in mammals -  
XX Claim 72; Fig 40; 315pp; English.  
XX The present invention describes nucleic acids encoding PRO polypeptides  
CC useful for preventing, diagnosing and treating disorders a  
CC cardiovascular, endothelial or angiogenic disorder in mammals by  
CC modulating cell proliferation, angiogenesis and cardiovascularisation,



CC and for identifying agonists and antagonists of these processes. The  
CC nucleic acids and the proteins they encode may be used in the  
CC prevention, treatment and diagnosis of diseases associated with  
CC inappropriate PRO expression such as cardiovascular, endothelial or  
CC angiogenic disorders in mammals (e.g. atherosclerosis, cancers and  
CC cardiac hypertrophy). For example, the nucleic acids (NCs) and vectors  
CC containing them and the PRO polypeptide may be used to treat disorders  
CC associated with decreased PRO expression. AAA77510 to AAA77721 and  
CC AAB24388 to AAB24435 represent nucleotide and protein sequences used in  
CC the exemplification of the present invention.

XX  
SQ Sequence 640 AA;

Query Match 100.0%; Score 3362; DB 21; Length 640;  
Best Local Similarity 100.0%; Pred. No. 2.3e-234;  
Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLNKMTHLPQIMIGPRFNRAFDPLLVLLALQLLVVAGLVRAQTCPSVCSCNQFSKV 60  
Db 1 MLNKMTHLPQIMIGPRFNRAFDPLLVLLALQLLVVAGLVRAQTCPSVCSCNQFSKV 60  
Qy 61 ICVRKNLEVPDGI STNTRLLNLHENQIIKVNFKHLRHLLEIQLSRNHIRIEICAF 120  
Db 61 ICVRKNLEVPDGI STNTRLLNLHENQIIKVNFKHLRHLLEIQLSRNHIRIEICAF 120  
Qy 121 NGLANLTLFDFNRLTIPNGAFVYLSKKELWLRNPNIESIPSNFNRIPSLRRDLG 180  
Db 121 NGLANLTLFDFNRLTIPNGAFVYLSKKELWLRNPNIESIPSNFNRIPSLRRDLG 180  
Qy 181 ELKRLSYISEGAFGLSNRLVNLAMCNLRIPNLTPLIKDELDLSGNHLSAIRPGSFQ 240  
Db 181 ELKRLSYISEGAFGLSNRLVNLAMCNLRIPNLTPLIKDELDLSGNHLSAIRPGSFQ 240  
Qy 241 GLMHLOKLWMIQSOTVTERNAFNQSLVEINLAHNNLTLLPHDLFPLHLERHILHH 300  
Db 241 GLMHLOKLWMIQSOTVTERNAFNQSLVEINLAHNNLTLLPHDLFPLHLERHILHH 300  
Qy 301 NPWNCNDILWSWIKDMAPSNTACCARNTPPNLKGRIYIGELDONFTCYAPVIVEPP 360  
Db 301 NPWNCNDILWSWIKDMAPSNTACCARNTPPNLKGRIYIGELDONFTCYAPVIVEPP 360  
Qy 361 ADLNVTEGMAELKCRASLTLSVSWITPNGTVTHGAYKRVIAVLSGDTLNFNTVQD 420  
Db 361 ADLNVTEGMAELKCRASLTLSVSWITPNGTVTHGAYKRVIAVLSGDTLNFNTVQD 420  
Qy 421 TGMVTCMVSNGVNTASATLNVAATTPFSYFTSVTETMEPSQDEARTDDNNVGTP 480  
Db 421 TGMVTCMVSNGVNTASATLNVAATTPFSYFTSVTETMEPSQDEARTDDNNVGTP 480  
Qy 481 VVDWETTNVTTSLTPQSTRTEKFTTIPVTDINSIGIPGIDEVMKTKIIGCFVAITLMA 540  
Db 481 VVDWETTNVTTSLTPQSTRTEKFTTIPVTDINSIGIPGIDEVMKTKIIGCFVAITLMA 540  
Qy 541 AVMLVIFVKMRKHQRHQRHAPTRVTEIINVDDDETGTPTPESHLPMPAIEHEHLNHVNS 600  
Db 541 AVMLVIFVKMRKHQRHQRHAPTRVTEIINVDDDETGTPTPESHLPMPAIEHEHLNHVNS 600  
Qy 601 YKSPENHTTNTVNTINSIHSSVHEPLLIRMSKDNVQETQI 640  
Db 601 YKSPENHTTNTVNTINSIHSSVHEPLLIRMSKDNVQETQI 640

RESULT 5

ID AAY70673 standard; Protein; 640 AA.

XX AAY70673;

DT 18-JUL-2000 (first entry)

XX Human PRO331 protein.

DE Human PRO331 protein.

XX

PRO331; UNQ292; dermatological; immunosuppressive; antiinflammatory;  
immunostimulant; antiasthmatic; antirheumatic; antiarthritic; virucide;  
antiallergic; haemostatic; hepatotropic; antidiabetic; antianaemic;  
nephrotropic; neuroprotective; anticoagulant; immunological disorder;  
lung; pneumonia; skin; psoriasis; kidney; glomerulonephritis; arthritis;  
spondyloarthropathy; SLE; systemic lupus erythematosus; scleroderma;  
idiopathic inflammatory myopathy; anaemia; thrombocytopenia; diabetes;  
thyroiditis; Grave's disease; demyelinating disease; multiple sclerosis;  
Crohn's disease; hepatobiliary disease; hepatitis; asthma; human;  
graft-versus-host-disease.

XX Homo sapiens.

Key Location/Qualifiers  
Modified-site 40..46 /note= "N-myristoylation site"  
Modified-site 73..79 /note= "N-myristoylation site"  
Modified-site 118..124 /note= "N-myristoylation site"  
Modified-site 183..187 /note= "cAMP and cGMP-dependent protein kinase phosphorylation site"  
Modified-site 191..197 /note= "N-myristoylation site"  
Modified-site 228..234 /note= "N-myristoylation site"  
Modified-site 237..243 /note= "N-myristoylation site"  
Modified-site 268..272 /note= "Casein Kinase II phosphorylation site"  
Modified-site 278..282 /note= "N-glycosylation site"  
Modified-site 364..368 /note= "N-glycosylation site"  
Modified-site 390..394 /note= "N-glycosylation site"  
Modified-site 391..397 /note= "N-myristoylation site"  
Modified-site 412..416 /note= "N-glycosylation site"  
Modified-site 415..419 /note= "N-glycosylation site"  
Modified-site 417..421 /note= "Casein Kinase II phosphorylation site"  
Modified-site 422..428 /note= "N-myristoylation site"  
Modified-site 433..439 /note= "N-myristoylation site"  
Modified-site 434..438 /note= "N-myristoylation site"  
Modified-site 442..446 /note= "N-glycosylation site"  
Modified-site 465..469 /note= "Casein Kinase II phosphorylation site"  
Modified-site 488..492 /note= "N-glycosylation site"  
Modified-site 531..537 /note= "N-myristoylation site"  
Modified-site 579..583 /note= "Casein Kinase II phosphorylation site"  
Modified-site 606..610 /note= "N-glycosylation site"  
Modified-site 620..624 /note= "Casein Kinase II phosphorylation site"

XX WO200015797-A2.

XX 23-MAR-2000.

XX 15-SEP-1999; 99WO-US21547.

XX 17-SEP-1998; 98US-0100858.

XX

PR 17-SEP-1998; 98WO-US19437.  
XX (GETH ) GENENTECH INC.  
XX Fong S, Goddard A, Gurney AL, Tumas D, Wood WI;  
XX WPI; 2000-271435/23.  
DR N-PSDB; AAZ52207.  
XX  
PT Composition for treatment and diagnosis of immune related diseases e.g.  
PT Grave's disease comprises a PRO245, PRO217, PRO301, PRO266, PRO335,  
PT PRO331 or PRO326 polypeptide or its agonists or antagonists (preferably  
PT antibodies) -  
XX  
XX Example 1; Fig 14; 201pp; English.  
XX  
CC The present sequence is the human protein PRO331, encoded by UNQ292 cDNA,  
CC designated as clone DNA40981. It is isolated from human foetal brain  
CC tissue. Portions of PRO331 has homology to the Lig-1 protein.  
CC It enhances or suppresses the infiltration of inflammatory cells into  
CC tissues, proliferation of T-lymphocytes and modulates the immune  
CC response. This sequence is useful for treatment of immune related  
CC disorders, like SLE, rheumatoid/juvenile arthritis, spondyloarthritis,  
CC systemic sclerosis (scleroderma), idiopathic inflammatory myopathies such  
CC as dermatomyositis, Sjogren's syndrome, systemic vasculitis, sarcoidosis,  
CC autoimmune haemolytic anaemia, thrombocytopenia, thyroiditis e.g. Grave's  
CC disease, diabetes mellitus, immune-mediated renal disease e.g.  
CC glomerulonephritis, demyelinating diseases such as multiple sclerosis and  
CC Guillain-Barre syndrome, hepatobiliary diseases like hepatitis and  
CC primary biliary cirrhosis, inflammatory and fibrotic lung diseases such  
CC as inflammatory bowel disease (e.g. Crohn's disease), autoimmune or  
CC immune-mediated skin diseases such as psoriasis, allergies like asthma,  
CC immunological diseases of the lungs such as eosinophilic pneumonia and  
CC transplantation associated diseases such as graft-versus-host-disease.  
XX  
XX Sequence 640 AA;

Query Match 100.0%; Score 3362; DB 21; Length 640;  
Best Local Similarity 100.0%; Pred. No. 2.3e-234;  
Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLNKLTHPQIMGPRNRPDLPLVLLALQLLVVAGLVRAQTCPSCVCSNQSKV 60  
Db 1 mlNkmtlhpgqimgrfnrldfpllvllalqlvvaglvraqtcpsvcscnqfskv 60  
Qy 61 ICVRKNLREVDPGISTNRLNLHENOQIIKVNSEKHLRLLEILQLSRNHRITIEIGAF 120  
Db 61 icvrknlrevdpdgistnrlnlhengoqiiikvnsekhrlleilqlsrnhritieigaf 120  
Qy 121 NGLANLTLFDRNLRTIPNGAFVYLSKELWLRNPNIESIPYAFNRIPSLRRDLG 180  
Db 121 nglanlntleifdrnlrttippngafvylskelwlrnnpiesipynfrlpsrldlg 180  
Qy 181 ELKRLYISEGAFGLSNRLVNLAMCNLRIPNLPLIKLDELDSGNHLSAIRPGSFQ 240  
Db 181 elkrlyisegafglsnrlvnlamcnlrnipnlpllikdelldsgnhlsairpgsfq 240  
Qy 241 GLMHLQKLMWTQSQIQVIERNAFNLQSLVEINLAHNNLTLLPHDLFTPLHLHLRIHLH 300  
Db 241 glmhlqklwmqlsqiqviernaafnlqslveinlahnnltlphdlftplhlhlrihlh 300  
Qy 301 NPWNCNDILWLSWIKMDAPSNFACCARNTPPNLKGRTYTGELDQNYFTCYAPVIVEPP 360  
Db 301 npwncndilwlswwikmdapsnfaccarntpplnkgrytgeldqnyftcyapvivepp 360  
Qy 361 ADLNVTEGMAELKCRASSTLSVSWITPNCVTMTHGAKVRIAYLSDGTINFTNVVQD 420  
Db 361 adlnvtegmaaelkcrasstlsvswitpncvtmthgavkriaylsvdgtlnfntvq 420  
Qy 421 TGMVTCMVSNGVNTASATLNVAATTPPSYFSTVVTETMPSQDEARTDNNVGTPT 480  
Db 421 tgmvtcmvsngvntasatlnvvaattpsfystvtvetmepsqdeartdnnvgtpt 480

Qy 481 VVDWETTNVTTSLTPQSTRSTEKFTIPVTDINSIGIDEVMKTKIIIGCFVAITLMA 540  
Db 481 vdwettnvttsltpqstrstekftipvtdinsigpidevmkttkiiigcfvaitlma 540  
Qy 541 AVMLVIFYKMRKQHRHQRNHAPTRTVEIINVDDETITGTPMESHLPMPAIEHEHLNHNYS 600  
Db 541 avmlvifykmrkqhrrqnhrhaptretveiinvddeitgtpmeshlmpaiehehlnhyns 600  
Qy 601 YKSPFNHHTTNTNTINSIHSSVHEPLLIIRMNSKDNVQETQI 640  
Db 601 ykspfnhhtntntinsihssvheplliirmnsakdnvqetqi 640  
RESULT 6  
AAU12355  
ID AAU12355 standard; Protein; 640 AA.  
XX  
AC AAU12355;  
XX  
DT 24-OCT-2001 (first entry)  
XX  
DE Human PRO331 polypeptide sequence.  
XX  
KW Human secretory and transmembrane; PRO; mammalian; cancer; lung;  
KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;  
KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;  
KW adipocyte; A-peptide; factor VIIA; gene therapy.  
XX  
OS Homo sapiens.  
XX  
XX WO200140466-A2.  
XX PN  
XX 07-JUN-2001.  
XX  
XX 01-DEC-2000; 2000WO-US32678.  
XX  
PR 01-DEC-1999; 99WO-US28301.  
PR 01-DEC-1999; 99WO-US28634.  
PR 02-DEC-1999; 99WO-US28551.  
PR 02-DEC-1999; 99WO-US28564.  
PR 02-DEC-1999; 99WO-US28565.  
PR 09-DEC-1999; 99US-0170262.  
PR 16-DEC-1999; 99WO-US30095.  
PR 20-DEC-1999; 99WO-US30911.  
PR 20-DEC-1999; 99WO-US30999.  
PR 30-DEC-1999; 99WO-US31243.  
PR 06-JAN-2000; 2000WO-US00277.  
PR 06-JAN-2000; 2000WO-US00376.  
PR 11-FEB-2000; 2000WO-US03565.  
PR 18-FEB-2000; 2000WO-US04341.  
PR 18-FEB-2000; 2000WO-US04342.  
PR 22-FEB-2000; 2000WO-US04344.  
PR 24-FEB-2000; 2000WO-US04914.  
PR 24-FEB-2000; 2000WO-US05004.  
PR 01-MAR-2000; 2000WO-US05601.  
PR 20-MAR-2000; 2000WO-US07377.  
PR 21-MAR-2000; 2000WO-US07532.  
PR 30-MAR-2000; 2000WO-US08439.  
PR 17-MAY-2000; 2000WO-US13705.  
PR 22-MAY-2000; 2000WO-US14042.  
PR 30-MAY-2000; 2000WO-US14941.  
PR 02-JUN-2000; 2000WO-US15264.  
PR 10-NOV-2000; 2000WO-US30873.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2001-408281/43.  
XX N-PSDB; AAS21427.

Isolated, secretory and transmembrane PRO polypeptide used to detect other PRO polypeptides, link bioactive molecules to cells expressing PRO polypeptides, and detect the presence of mammalian tumours e.g. lung, breast, prostate, cervical

Claim 12: Fig 368; 813pp; English.

AAU12172-AAU12446 represent novel human secretory and transmembrane PRO polypeptides. The PRO polypeptides are useful to detect other PRO polypeptides, to link bioactive molecules to cells expressing PRO polypeptides, to modulate biological activities of cells expressing PRO polypeptides, and to detect the presence of mammalian lung, colon, breast, prostate, rectal, cervical or liver tumours by comparing PRO polypeptide expression in a cell sample to that in a control sample. Some of the 275 sequences are also useful to stimulate the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or differentiation of chondrocytes, the proliferation or gene expression in pericyte cells, the release of proteoglycans from cartilage, the proliferation of inner ear utricular supporting cells or of T-lymphocytes, the release of a cytokine from peripheral blood monocytes (PBMCs), or the proliferation of endothelial cells. Some of the PRO polypeptides may modulate glucose or free fatty acid uptake by skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide to factor VIIA. The PRO polypeptides can be used in assays to identify molecules involved in binding interactions. The polynucleotides encoding PRO polypeptides can be used to generate probes, antisense RNA/DNA, transgenic or knock out animals and can be used in gene therapy.

Sequence 640 AA;

Query Match 100.0%; Score 3362; DB 22; Length 640;  
Best Local Similarity 100.0%; Pred. No. 2.3e-234;  
Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX	QY	1	MLNKWTLHPQOIMGTPRNRALFDPDLLVLLALQLLVVAGLVRAQTCPVSCSCSNQSKV	60
PT	Db	1		
PT	QY	61	ICVRKNREVDPGISTNFRILNHLNENQIIVKNSFKHLRHLLETIQLSRNHIRTEIGAF	120
PT	Db	61		
QY	QY	121	NGLANLTLLELFDNRKLTPIPGAFVYISKELWLRNPNIESIPSYAFNRPISLRRLDLG	180
Db	Db	121		
QY	QY	181	ELKRLSYISEGAFEGLSNLRVNLNLCWNLREIPNLTPLIKIDELDSGNHLSAIRPGSFQ	240
Db	Db	181		
QY	QY	241	GLMHLOKLWMTQSOIQVTERNAFDNLQSLVEINLAHNLTLLPHDLFTPLHLHRIHLH	300
Db	Db	241		
QY	QY	301	NPWNCNDILWLSMWIKDMAPSNACCARCNTPPNLKGRYIGELDONFTCYAPVIVEPP	360
Db	Db	301		
QY	QY	361	ADLVNTEGMAELKCRASLTLSVSWITPNGVTWTHGAYKRIAVLSDGTLNFTNVTVD	420
Db	Db	361		
QY	QY	421	TGMVTCVMSVNGNTASATLNVAATTPFSYFSTVTVETWEPDSQDEARTDNNVGTP	480
Db	Db	421		
QY	QY	481	VVDWETTNVTLTPQSTRTEKFTTIPVTDINSIGIPGIDVEMTKTKIIIGCFVAITLMA	540
Db	Db	481		
QY	QY	541	AVMLVIFYKMRKQHRONHHAFTRTVEIINVDDTEITGTPMESHLPMPAIEHEHLNHVNS	600

Db	541	avmlvifykmrkqhrgnhhapttrvelinvddteitgtpmeshlpmpaiehehlhyns	600
QY	601	YKSPFNHTTNTTNSIHSSVHPEPLLRMSKDNVQETOI	640
Db	601	YKSPFNHTTNTTNSIHSSVHPEPLLRMSKDNVQETOI	640
RESULT	7		
AAU00826			
ID	AAU00826	standard; Protein; 640 AA.	
XX	AAU00826;		
XX	04-JUL-2001	(first entry)	
XX	Human immune response protein PRO331 (UNQ292).		
XX	Human; PRO331; UNQ292; Immune response; osteoarthritis;		
KW	systemic lupus erythematosus; rheumatoid arthritis; systemic sclerosis;		
KW	juvenile chronic arthritis; spondyloarthropathy; Sjogren's syndrome;		
KW	idiopathic inflammatory myopathy; polymyositis; systemic vasculitis;		
KW	sarcoidosis; autoimmune haemolytic anaemia; immune pancytopenia;		
KW	autoimmune thrombocytopaenia; idiopathic thrombocytopaenic purpura;		
KW	thyroiditis; Grave's disease; Hashimoto's thyroiditis;		
KW	diabetes mellitus; glomerulonephritis; demyelinating disease;		
KW	multiple sclerosis; Guillain-Barre syndrome; hepatobiliary disease;		
KW	chronic inflammatory demyelinating polyneuropathy; infectious hepatitis;		
KW	auto immune chronic active hepatitis; primary biliary cirrhosis;		
KW	granulomatous hepatitis; sclerosing cholangitis; ulcerative colitis;		
KW	inflammatory bowel disease; Crohn's disease; Whipple's disease;		
KW	erythema multiforme; psoriasis; asthma; allergic rhinitis; urticaria;		
KW	food hypersensitivity; eosinophilic pneumonia; graft rejection;		
KW	idiopathic pulmonary fibrosis; graft-versus-host-disease; immunogen;		
XX	antibody.		
XX	Homo sapiens.		
OS			
XX			
FH	Key	Location/Qualifiers	
FT	Peptide	1..44	
FT		/label= Signal_peptide	
FT	Modified-site	40..46	
FT		/note= "Glycine is N-myristoylated"	
FT	Protein	45..640	
FT		/label= Mature_PRO331	
FT	Modified-site	73..79	
FT		/note= "Glycine is N-myristoylated"	
FT	Modified-site	118..124	
FT		/note= "Glycine at 118 is N-myristoylated"	
FT	Region	183..187	
FT		/label= Phosphorylation_site	
FT		/note= "cAMP/cGMP dependent protein kinase phosphorylation site"	
FT	Modified-site	191..197	
FT		/note= "Glycine at 191 is N-myristoylated"	
FT	Modified-site	228..234	
FT		/note= "Glycine is N-myristoylated"	
FT	Modified-site	237..243	
FT		/note= "Glycine is N-myristoylated"	
FT	Modified-site	278..282	
FT		/note= "Asn is N-glycosylated"	
FT	Modified-site	364..368	
FT		/note= "Asn is N-glycosylated"	
FT	Modified-site	390..394	
FT		/note= "Asn is N-glycosylated"	
FT	Modified-site	391..397	
FT		/note= "Glycine at 391 is N-myristoylated"	
FT	Modified-site	412..416	
FT		/note= "Asn is N-glycosylated"	
FT	Modified-site	415..419	
FT		/note= "Asn is N-glycosylated"	
FT	Modified-site	422..428	
FT		/note= "Glycine is N-myristoylated"	
FT			

FT Modified-site 433..439 /note= "Glycine is N-myristoylated"  
 FT Modified-site 434..438 /note= "Asn is N-glycosylated"  
 FT Modified-site 442..446 /note= "Asn is N-glycosylated"  
 FT Modified-site 488..492 /note= "Asn is N-glycosylated"  
 FT Domain 528..543 /label= Transmembrane\_domain  
 FT Modified-site 531..537 /note= "Glycine is N-myristoylated"  
 FT Modified-site 606..610 /note= "Asn is N-glycosylated"  
 XX WO200119991-A1.  
 XX 22-MAR-2001.  
 XX 20-MAR-2000; 2000WO-US07377.  
 XX 15-SEP-1999; 99WO-US21547.  
 XX (GETH ) GENENTECH INC.  
 XX Fong S, Goddard A, Gurney AL, Hillan KJ, Tumas D, Wood WI;  
 XX WPI: 2001-226823/23.  
 XX N-PSDB: AAS00162.  
 XX Composition for diagnosing and treating immune related diseases, e.g.:  
 XX rheumatoid arthritis and diabetes mellitus, comprises a PRO  
 XX polypeptide, agonist, antagonist or fragment -  
 XX Claim 31; Fig 12; 138pp; English.  
 XX The sequence represents Human PRO331 (UNQ292), a protein involved in  
 CC the immune response. PRO polypeptides, and (ant)agonists to them, are  
 CC used in compositions for modulating infiltration of inflammatory cells  
 CC into a tissue, modulating an immune response and modulating proliferation  
 CC of T-lymphocytes in response to an antigen. Immune related diseases can  
 CC be treated with the compositions, such as, systemic lupus erythematosus,  
 CC rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis,  
 CC spondyloarthropathies, systemic sclerosis, idiopathic inflammatory  
 CC myopathies (e.g. polymyositis), Sjogren's syndrome, systemic vasculitis,  
 CC sarcoidosis, autoimmune haemolytic anaemia (e.g. immune pancytopenia),  
 CC autoimmune thrombocytopaenia (e.g. idiopathic thrombocytopaenic purpura),  
 CC thyroiditis (e.g. Grave's disease, Hashimoto's thyroiditis), diabetes  
 CC mellitus, immune-mediated renal disease (e.g. glomerulonephritis),  
 CC demyelinating diseases of the central and peripheral nervous systems e.g.  
 CC multiple sclerosis or Guillain-Barre syndrome, and chronic inflammatory  
 CC demyelinating polyneuropathy, hepatobiliary diseases such as infectious  
 CC hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses),  
 CC auto immune chronic active hepatitis, primary biliary cirrhosis,  
 CC granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel  
 CC disease (ulcerative colitis, Crohn's disease and Whipple's disease),  
 CC autoimmune or immune-mediated skin diseases (e.g. erythema  
 CC multiforme or psoriasis), asthma, allergic rhinitis, urticaria,  
 CC food hypersensitivity, immunologic diseases of the lung such as  
 CC eosinophilic pneumonias, idiopathic pulmonary fibrosis, transplantation  
 CC associated diseases including graft-versus-host-disease and graft  
 CC rejection. PRO polypeptides can be used to diagnose immune related  
 CC diseases, to identify inhibitors, and to stimulate the proliferation of  
 CC T lymphocytes. Anti-PRO antibodies can be used to detect PRO and  
 CC in diagnosis. PRO polypeptides, antibodies and (ant)agonists can be used  
 CC in rational drug design.  
 XX Sequence 640 AA:  
 XX  
 XX Query Match 100.0%; Score 3362; DB 22; Length 640;  
 XX Best Local Similarity 100.0%; Pred. No. 2.3e-234;  
 XX Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX

QY 1 MLNKMTHLPQOIMIGPRENRAFDPDLLVLLALQLLVVAGLVRAQTCPSCVCSNOFSKY 60  
 DB 1 mlnkmtlhppqimigprfnralfdpdllvllalqlvvaglvraqtcpsvcsnqfskv 60  
 QY 61 ICVRKNREVPDGGISTNTRLLNLHENOQIIKVSFKHLRHLLEILQLSRNHRTIEIGAF 120  
 DB 61 icvrknrevpdgistntrllnlhnenqiiikvsnfkhlrhlleilqlsrnhrtieigaf 120  
 QY 121 NGLANLTLELFDNRLTTPNGAFVYLSKLELWLRNPNIESIPSYAFNRPLSLRLDLG 180  
 DB 121 nglanltlelfdnrlttpngafvyisklkelwlrnnpiesipsyafnrpslrrldlg 180  
 QY 181 ELKRLSYISEGAFEGLSNRLYNLWAMCNLREIPLIKDELPLSGNHLISAIRPGSFQ 240  
 DB 181 elkrlsyisegafeglsnrlrynliwamcnlreiplikidelplsgnhsairpgsfq 240  
 QY 241 GLMHLQKLWMTQSQIQVIERNAFDNLQSLVEINLAHNLTLLPHDLFTPLHHLERHLHH 300  
 DB 241 glmhlqklwmiqsgiqvieraafndnlqslveinlahnltllphdlftplhhlhlerihhh 300  
 QY 301 NPWNCNDILWLSWIKDMAPSNTACCACRCNTPPNKLGRYIGELDONVETCYAPVIVEPP 360  
 DB 301 npwncndilwlswwikdmapsntaccacrcntppnlkgryyigeldqnyftcyapvivepp 360  
 QY 361 ADLNVTEGMAELKCRASSTLSVSWITPNGTVMTGHAYKVRIAVLSDGTNLNFTNVTQD 420  
 DB 361 adlnvtegmaaelkcrastsitsvswitpngtvmthgaykvrivavlsdgtlnftnvtqgd 420  
 QY 421 TGMTYCMVSNVSGNTASATNLVTAATTPFSYFSTVTVTMESQDEARTDNNVGTP 480  
 DB 421 tgmtycmvsnvsgntasatnlvtaattppfsyfstvtvtemesqdeartdnnvgtp 480  
 QY 481 VVDWETTNVTTSLTPQSTRSEKTFPIPTVDINSIGICIDEVMKTKIIGCFVAITLMA 540  
 DB 481 vvdwettntvttsltpqstrsektftipvtidnsgipgidevmkctkligcfvaitlma 540  
 QY 541 AVMLVIFYKMRKHRRQNHAPTRTVEINVDDEITGDTPMESHLPMPAIEHEHLNHYNS 600  
 DB 541 avmlvifykmrkqhrrqnhaptrtveinvddeitgdtgtpmeshlpmpaiehehlhnyns 600  
 QY 601 YKSPFNHTTNTVNTINSIHSSVHEPLLRMSKDNVQETQI 640  
 DB 601 ykspfntttvntinsihssvhepllrmskdnvqetqi 640  
 RESULT 8  
 AAB80262 ID AAB80262 standard; Protein; 640 AA.  
 AC AAB80262;  
 XX 24-APR-2001 (first entry)  
 DE Human PRO331 protein.  
 KW Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;  
 KW antiparkinsonian nootropic; neuroprotective; vulnery; cardiac;  
 KW antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;  
 KW antiarthritic; antinfertility; antidiabetic; antiviral; diabetes;  
 KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;  
 KW ischaemia; inflammation.  
 OS Homo sapiens.  
 XX WO200104311-A1.  
 XX 18-JAN-2001.  
 XX 22-FEB-2000; 2000WO-US04414.  
 XX 07-JUL-1999; 99US-0143048.  
 XX 26-JUL-1999; 99US-0145698.



PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;  
 PI Grimaldi CJ, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;  
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WJ;  
 PI Zhang Z;  
 DR WPI: 2001-032160/04.  
 DR N-PSDB: AAF44261.  
 XX PRO polynucleotides used to produce polypeptides used to target  
 PT bioactive molecules such as toxins, radiolabels or antibodies, to  
 PT specific cells, to cause targeted cell death -  
 XX  
 PS Claim 12: Fig 314; 935pp; English.  
 XX  
 CC The present invention describes human secreted and transmembrane PRO  
 CC proteins. The PRO proteins have cytotstatic activity. The PRO proteins  
 CC can be used for targeted delivery of bioactive molecules, such as  
 CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide  
 CC sequences, and their fragments, can be used as hybridisation probes, in  
 CC chromosomal and gene mapping, and in the generation of anti-sense RNA  
 CC and DNA. They may also be used to produce transgenic animals which are  
 CC used to develop and screen therapeutically useful reagents. The PRO  
 CC nucleotide and protein sequence can be used for tissue typing and in  
 CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.  
 CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used  
 CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and  
 CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein  
 CC sequences given in the exemplification of the present invention.  
 XX  
 SQ Sequence 640 AA;

Query Match 100.0%; Score 3362; DB 22; Length 640;  
 Best Local Similarity 100.0%; Pred. No. 2.3e-234;  
 Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLNMTLHPQIMTGPENRNLFPDLVLVLLALQLLVVAGLVRAQTCPSCVCSNQFSKV 60  
 DB 1 mlnkmtlhpgqimgrfnralfpdlvlvllalqlvvaglvraqtcpsvcscnqfskv 60  
 QY 61 ICVRKRLREVDPDGTSTNRLNLHENOITQIFKVSFKHLRLHLEITQLSRNHRITIEGAF 120  
 DB 61 icvrkrlrevdpdgstnrlnlhenoitqifkvsfkhrlhlrlhleiqslsrnhritieigaf 120  
 QY 121 NGLANLTLFELNRLTTPNGAFVYLSKELWLRNPIESIPYAFNRIPSLRRDLG 180  
 DB 121 nglanlntlelfnrltltppngafvylskelwlrnpiessipyafrnripslrrldlg 180  
 QY 181 ELKRLSYISEGAFGLSLNRLYLNLAMCNLRIPNLTPLIKDELDELGNHLSAIRPGSFQ 240  
 DB 181 elkrlsyisegafglslnrllynlamcnlreipnltplikdelidlgngnhlsairpgsfq 240  
 QY 241 GLMHLQKLWMIQSOIQVTERNAFNLQSLVINLAHNLTLLPHDLFTPLHLRIHLH 300  
 DB 241 glmhlqklwmiqsdqivternafnlqslvlnlahnltllphdlftplhlhrlhlh 300  
 QY 301 NPWNCNCDILWSWIKDMAPSNACCARCNTPPNLKGRYIGELDONFTCYAPVIVEPP 360  
 DB 301 npwncncdilwswikdmapsntaccarcntppnlkgrylgieldonfycyapvivepp 360  
 QY 361 ADLNVTEGMAELKCRASTSLTSVTPNGVTMGAYKVRIVLSDGLTNFTNVVQD 420  
 DB 361 adlnvtegmaaelkcrastsltsvtpngvtmgaykvrivlsdgltnftnvvtqd 420  
 QY 421 TGMVTCMVNSVGNVTASATLVNVAATTPPSYFTVTMETPESQDEARTDNNVGTP 480  
 DB 421 tgmvtcmvnsvgnvtasatlvnvaattppsyftvtmetpessqdeartdnnvgtp 480  
 QY 481 VVDWETTNTVTLSPQSTRTEKFTTIPVTDINSIGIPGIDVMTKTKIIIGCFVAITLMA 540  
 DB 481 vvdwettntvltspqstrtektfttvpvtdinsigipgidevmkttkiigcfvaitlma 540  
 QY 541 AVMLVIFYKRRKQHRQNHHAAPTFTVEILNVDDITGDTPMESHLPMPAIEHEHLNHNYS 600

DB 541 avmlvifykrmrkqhrghhapttvtveilnvdditgdtpmeshlpmpaiehehlhnys 600  
 QY 601 YKSPFNHTTTVTNTINSIHSSVHEPLLRMSKDNVQETQI 640  
 DB 601 ykspfnhtttvtntinsihssvhpepllrmskdnvqetqi 640  
 RESULT 10  
 AAB53089  
 ID AAB53089 standard; Protein: 640 AA.  
 XX AC AAB53089;  
 XX DT 28-FEB-2001 (first entry)  
 XX DE Human angiogenesis-associated protein PRO331, SEQ ID NO:137.  
 XX KW Human; angiogenesis-associated protein; PRO; endothelial cell growth;  
 KW cardiac hypertrophy; cardiovascular disorder; endothelial disorder;  
 KW angiogenic disorder; atherosclerosis; osteoporosis; hypertension;  
 KW myocardial infarction; diabetic retinopathy; rheumatoid arthritis;  
 KW Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer;  
 KW Alzheimer's disease; Huntington's disease; stroke; drug screening;  
 KW gene therapy; transgenic animal.  
 XX OS Homo sapiens.  
 XX PN WO200053753-A2.  
 XX PD 14-SEP-2000.  
 XX PF 05-JAN-2000; 2000WO-US00219.  
 XX PR 08-MAR-1999; 99WO-US05028.  
 PR 12-MAR-1999; 99US-0123957.  
 PR 14-MAY-1999; 99US-0134287.  
 PR 02-JUN-1999; 99WO-US12252.  
 PR 23-JUN-1999; 99US-0141037.  
 PR 20-JUL-1999; 99US-0144758.  
 PR 26-JUL-1999; 99US-0145698.  
 PR 01-SEP-1999; 99WO-US20111.  
 PR 08-SEP-1999; 99WO-US20594.  
 PR 13-SEP-1999; 99WO-US21090.  
 PR 15-SEP-1999; 99WO-US21547.  
 PR 05-OCT-1999; 99WO-US23089.  
 PR 30-NOV-1999; 99WO-US28313.  
 PR 30-NOV-1999; 99WO-US28409.  
 PR 02-DEC-1999; 99WO-US28584.  
 PR 02-DEC-1999; 99WO-US28565.  
 XX (GETH ) GENENTECH INC.  
 PA Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Goddard A;  
 PI Godowski PJ, Gurney AL, Hillan KJ, Kuo SS, Mark MR, Marsters SA;  
 PI Paoni NF, Pitti RM, Watanabe CK, Williams PM, Wood WI;  
 DR WPI: 2001-090793/10.  
 DR N-PSDB: AAC97475.  
 XX  
 PT New isolated nucleic acid for producing a PRO polypeptide, analyzing  
 PT genetic disorders and treating cardiovascular, endothelial or  
 PT angiogenic disorders, such as atherosclerosis, wounds or cancer -  
 XX  
 PS Claim 69; Fig 52; 293pp; English.  
 XX  
 CC The invention relates to novel human angiogenesis-associated proteins  
 CC designated PRO proteins (AAB53064-B53097), and to nucleic acids encoding  
 CC PRO proteins. The invention also relates to vectors and host cells  
 CC comprising a PRO nucleic acid, the recombinant production of a PRO  
 CC protein, PRO antibodies specific for a PRO protein, fusion proteins  
 CC comprising a PRO protein, agonists or antagonists of a PRO protein, and  
 CC compounds which inhibit the expression of a PRO gene. The invention









CC sequences. AAC58367 to AAC58396 and AAB24057 to AAB24089 represent human  
CC PRO polynucleotide and protein sequences given in the exemplification of  
CC the present invention.

XX Sequence 653 AA;

Qy Query Match 55.5%; Score 1865; DB 21; Length 653;  
Best Local Similarity 56.4%; Pred. No. 2.8e-126;  
Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;

Qy 29 VLLALQLLVAGLVRA-----QPCPSVCSCNQFSCVICKVRLREVDPGISTNTLLN 82

Db 22 VYLTAQWILCAALAAASAGGQCPCSCNQSFKSVCTRTGLSEVPGGIPSTRYLN 81

Qy 83 LHENQIQIIVKNSPKHLRIEILQLSRNHRTIEIGAFNGLANLTLELFDNRLLTPNG 142

Db 82 lmenniqiadtrfhlhlevqlgrnsrqievgafnglasintlelfdnwlvtipsq 141

Qy 143 AFVYSLKELWLRNNPIESIPSAFNRPSLRDLGELKRLSYISEGAFEGSLNRYL 202

Db 142 afeylsklrelwlrnnpiesipsafnrpslrmldlgelkklleyisegafegiflnikyl 201

Qy 203 NLAACNLREIPNLTPLKLDLDELDSGNHLSAIRPSCFQGLMHLQKLMWISQIOVIERNA 262

Db 202 nlgmcnlkdmplnltplvgleelmsnfhpeirpgrstglsllkklwvmsqvslierna 261

Qy 263 FDNQLSIVEINLAHNNLTLLPHDLFTPLHLERLHLHNPWNCNDILWLSWIKDMAPS 322

Db 262 fdglasiveinlahnnlssphdiftprlyvelhlhmpwncodcllwawlwreiypt 321

Qy 323 NTACACRNPFPNKLGRYIGELDQNYFTCYAPVIVEPPADLNVTGMAELKCRASLT 382

Db 322 nstccgrchaphmrgylyvevdqsfqscapfimdaprdlnisegrmaelkor-tpgms 380

Qy 383 SVSITPNTGTWTHGAKVRITAVLSDDGLTNTVTYODTGMYTCMVNSVCNNTTASATLN 442

Db 381 svkllpntgtvshasrhprlsvlndgtlnfshvllsdgtgyvtmvtvagnsnasayln 440

Qy 443 VTAA--TTTPSYSTVTVMETPESODEARTDNNVPTPVVDWETTNV-----TTSLT 494

Db 441 vstaeltntsnysftttvtvettelspe-d--ttrkykxpv-----ttstgypayttstt 492

Qy 495 P--OSTRSTKTFPIPTVDINSGLPGIDEVMTKTKIIIGCFVAITLMAAVLVIFYKMR 551

Db 493 vliqtr-vpkqavpatdtdtkmqtsldvymkttkiliigcfvavtllaaamlivfyklr 551

Qy 552 KOHHRONHAPTRVEIINVDDEITGDTPM-----ESHLPMPAIEHEHLNHYNS 600

Db 552 krhqrstvttaartveliqvdedipaatsaaataapsvgsgavviptl-hdhlin-ynt 609

Qy 601 YKSPFNHTTTVNTI-NSIH-----SSVHEPLLRIMNSKDNVQETQI 640

Db 610 ykpahgahwtenslgnshlptvtitisepyliiqtthtkdkvqetqi 653

RESULT 13

AAY66694

ID AAY66694 standard; protein; 653 AA.

XX AC AAY66694;

XX DT 05-APR-2000 (first entry)

XX DE Membrane-bound protein PRO1111.

XX KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;  
XX KW pharmaceutical; receptor immunoadhesin; gene mapping.

XX OS Homo sapiens.

XX PN WO9963088-A2.

XX

PD 09-DEC-1999.  
XX PF 02-JUN-1999;  
XX XX 99WO-US12252.  
PR 02-JUN-1998; 98US-0087607.  
PR 02-JUN-1998; 98US-0087609.  
PR 02-JUN-1998; 98US-0087759.  
PR 03-JUN-1998; 98US-0087827.  
PR 04-JUN-1998; 98US-0088021.  
PR 04-JUN-1998; 98US-0088025.  
PR 04-JUN-1998; 98US-0088028.  
PR 04-JUN-1998; 98US-0088029.  
PR 04-JUN-1998; 98US-0088030.  
PR 04-JUN-1998; 98US-0088033.  
PR 04-JUN-1998; 98US-0088326.  
PR 05-JUN-1998; 98US-0088167.  
PR 05-JUN-1998; 98US-0088202.  
PR 05-JUN-1998; 98US-0088212.  
PR 05-JUN-1998; 98US-0088217.  
PR 09-JUN-1998; 98US-0088655.  
PR 10-JUN-1998; 98US-0088722.  
PR 10-JUN-1998; 98US-0088730.  
PR 10-JUN-1998; 98US-0088734.  
PR 10-JUN-1998; 98US-0088738.  
PR 10-JUN-1998; 98US-0088740.  
PR 10-JUN-1998; 98US-0088741.  
PR 10-JUN-1998; 98US-0088742.  
PR 10-JUN-1998; 98US-0088810.  
PR 10-JUN-1998; 98US-0088811.  
PR 10-JUN-1998; 98US-0088824.  
PR 10-JUN-1998; 98US-0088825.  
PR 10-JUN-1998; 98US-0088826.  
PR 11-JUN-1998; 98US-0088858.  
PR 11-JUN-1998; 98US-0088861.  
PR 11-JUN-1998; 98US-0088863.  
PR 11-JUN-1998; 98US-0088876.  
PR 12-JUN-1998; 98US-0089090.  
PR 12-JUN-1998; 98US-0089105.  
PR 16-JUN-1998; 98US-0089440.  
PR 16-JUN-1998; 98US-0089512.  
PR 16-JUN-1998; 98US-0089514.  
PR 17-JUN-1998; 98US-0089532.  
PR 17-JUN-1998; 98US-0089538.  
PR 17-JUN-1998; 98US-0089598.  
PR 17-JUN-1998; 98US-0089599.  
PR 17-JUN-1998; 98US-0089600.  
PR 17-JUN-1998; 98US-0089653.  
PR 18-JUN-1998; 98US-0089801.  
PR 18-JUN-1998; 98US-0089907.  
PR 18-JUN-1998; 98US-0089908.  
PR 19-JUN-1998; 98US-0089947.  
PR 19-JUN-1998; 98US-0089948.  
PR 19-JUN-1998; 98US-0089952.  
PR 22-JUN-1998; 98US-0090246.  
PR 22-JUN-1998; 98US-0090252.  
PR 22-JUN-1998; 98US-0090254.  
PR 23-JUN-1998; 98US-0090349.  
PR 23-JUN-1998; 98US-0090355.  
PR 24-JUN-1998; 98US-0090429.  
PR 24-JUN-1998; 98US-0090431.  
PR 24-JUN-1998; 98US-0090435.  
PR 24-JUN-1998; 98US-0090444.  
PR 24-JUN-1998; 98US-0090445.  
PR 24-JUN-1998; 98US-0090461.  
PR 24-JUN-1998; 98US-0090472.  
PR 24-JUN-1998; 98US-0090535.  
PR 24-JUN-1998; 98US-0090538.  
PR 24-JUN-1998; 98US-0090540.  
PR 24-JUN-1998; 98US-0090557.  
PR 25-JUN-1998; 98US-0090676.  
PR 25-JUN-1998; 98US-0090678.  
PR 25-JUN-1998; 98US-0090688.  
PR 25-JUN-1998; 98US-0090690.

PR	25-JUN-1998;	98US-0090691.	DR	WPI; 2000-072883/06.
PR	25-JUN-1998;	98US-0090694.	DR	N-PSDB; AA265033.
PR	25-JUN-1998;	98US-0090695.	XX	Membrane-bound proteins and related nucleotide sequences
PR	25-JUN-1998;	98US-0090696.	PT	
PR	26-JUN-1998;	98US-0090862.	XX	claim 12; Fig 157; 822pp; English.
PR	26-JUN-1998;	98US-0090863.	PS	
PR	01-JUL-1998;	98US-0091358.	XX	The invention provides membrane-bound PRO polypeptides and
PR	01-JUL-1998;	98US-0091360.	CC	polynucleotides encoding them. The PRO sequences of the invention were
PR	01-JUL-1998;	98US-0091344.	CC	identified based on extracellular domain homology screening. The PRO
PR	02-JUL-1998;	98US-0091478.	CC	sequences have homology with proteins including LDL receptors, TIE
PR	02-JUL-1998;	98US-0091486.	CC	ligands and various enzymes. The membrane-bound proteins and receptor
PR	02-JUL-1998;	98US-0091519.	CC	molecules are useful as pharmaceutical and diagnostic agents. Receptor
PR	02-JUL-1998;	98US-0091626.	CC	immunoadhesins, for instance, can be used as therapeutic agents to block
PR	02-JUL-1998;	98US-0091628.	CC	receptor-ligand interactions. The membrane-bound proteins can also be
PR	02-JUL-1998;	98US-0091633.	CC	employed for screening of potential peptide or small molecule inhibitors
PR	02-JUL-1998;	98US-0091646.	CC	of the relevant receptor/ligand interaction. The PRO encoding sequences
PR	02-JUL-1998;	98US-0091673.	CC	are useful as hybridization probes, in chromosome and gene mapping and in
PR	07-JUL-1998;	98US-0091978.	CC	the generation of antisense RNA and DNA. PRO nucleic acid sequences
PR	07-JUL-1998;	98US-0091982.	CC	will also be useful for the preparation of PRO polypeptides, especially
PR	09-JUL-1998;	98US-0092182.	CC	by recombinant techniques.
PR	10-JUL-1998;	98US-0092472.	XX	
PR	20-JUL-1998;	98US-0093339.	SQ	Sequence 653 AA;
PR	30-JUL-1998;	98US-0094651.		
PR	04-AUG-1998;	98US-0095282.		
PR	04-AUG-1998;	98US-0095285.		
PR	04-AUG-1998;	98US-0095301.		
PR	04-AUG-1998;	98US-0095302.		
PR	04-AUG-1998;	98US-0095318.		
PR	04-AUG-1998;	98US-0095321.		
PR	04-AUG-1998;	98US-0095325.		
PR	10-AUG-1998;	98US-0095916.		
PR	10-AUG-1998;	98US-0095929.		
PR	10-AUG-1998;	98US-0096012.		
PR	11-AUG-1998;	98US-0096143.		
PR	11-AUG-1998;	98US-0096146.		
PR	12-AUG-1998;	98US-0096329.		
PR	17-AUG-1998;	98US-0096757.		
PR	17-AUG-1998;	98US-0096766.		
PR	17-AUG-1998;	98US-0096768.		
PR	17-AUG-1998;	98US-0096773.		
PR	17-AUG-1998;	98US-0096791.		
PR	17-AUG-1998;	98US-0096867.		
PR	17-AUG-1998;	98US-0096891.		
PR	17-AUG-1998;	98US-0096894.		
PR	17-AUG-1998;	98US-0096895.		
PR	17-AUG-1998;	98US-0096897.		
PR	18-AUG-1998;	98US-0096949.		
PR	18-AUG-1998;	98US-0096950.		
PR	18-AUG-1998;	98US-0096959.		
PR	18-AUG-1998;	98US-0096960.		
PR	18-AUG-1998;	98US-0097022.		
PR	19-AUG-1998;	98US-0097141.		
PR	20-AUG-1998;	98US-0097218.		
PR	24-AUG-1998;	98US-0097661.		
PR	26-AUG-1998;	98US-0097951.		
PR	26-AUG-1998;	98US-0097952.		
PR	26-AUG-1998;	98US-0097954.		
PR	26-AUG-1998;	98US-0097955.		
PR	26-AUG-1998;	98US-0097971.		
PR	26-AUG-1998;	98US-0097974.		
PR	26-AUG-1998;	98US-0097978.		
PR	26-AUG-1998;	98US-0097979.		
PR	26-AUG-1998;	98US-0097986.		
PR	26-AUG-1998;	98US-0098014.		
PR	31-AUG-1998;	98US-0098525.		
PR	16-SEP-1998;	98US-0100634.		
PR	12-JAN-1999;	99US-0115565.		
XX				
PA	(GETH ) GENENTECH INC.			
XX	Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;			
PI	Wood WL, Yuan J;			
XX				

```
RESULT 14
AAE09438
ID AAE09438 standard; Protein; 653 AA.
XX
XX AAE09438;
AC
XX
XX 19-NOV-2001 (first entry)
DT
XX
XX Human sbgPRO331a protein.
DE
XX
XX Human; Alzheimer's disease; amyotrophic lateral sclerosis;
KW ALS; Zollinger-Ellison syndrome; immune system disease; schizophrenia;
KW inflammation; haematopoietic disease; anxiety; feeding disorder; aging;
KW anorexia; depression; cardiovascular disease; sleep disorder; seizure;
KW memory alteration; migraine; stroke; asthma; neuropathy; hypoglycaemia;
KW sexual disorder; growth abnormality; infection; autoimmune disease;
KW rheumatoid arthritis; cataractogenesis; angiogenesis; atherosclerosis;
KW cerebral ischaemia; cirrhosis; Huntington's disease; Hodgson's disease;
KW hypercholesterolaemia; headache; amnesia; cardiac arrhythmia; obesity;
KW diabetes mellitus; glomerulonephritis; renovascular hypertension;
KW cancer; vaccine; gene therapy; sbgPRO331a gene.
XX
XX Homo sapiens.
OS
XX
XX WO200160850-A1.
PN
XX
XX 23-AUG-2001.
PD
XX
XX 14-FEB-2001; 2001WO-US04703.
PF
XX
XX 14-FEB-2000; 2000US-0182172.
PR
XX 29-FEB-2000; 2000US-0186084.
PR 18-APR-2000; 2000US-0198583.
PR 04-OCT-2000; 2000US-0237963.
XX
XX (SMIK ) SMITHKLINE BEECHAM CORP.
PA (SMIK ) SMITHKLINE BEECHAM PLC.
PA
XX
XX Agarwal P, Kabnick KS, Murdoch PR, Rizvi SK, Smith RF, Xiang Z;
PI WPI; 2001-536566/59.
XX
XX N-PSDB; AAD16345.
DR
XX
XX New secreted and membrane associated polypeptides for treating
PT Alzheimer's disease, psoriasis, cancer, enterocolitis, sleep and sexual
PT disorders, stroke, and asthma
XX
XX Claim 1; Page 56-58; 94pp; English.
PS
XX
XX The present sequence is a human sbgPRO331a protein,
CC a membrane bound protein of the invention.
CC The invention relates to secreted and membrane associated polypeptides
CC and nucleic acid molecules encoding such polypeptides. Sequences of the
CC invention are useful for treating diseases such as Alzheimer's disease,
CC amyotrophic lateral sclerosis (ALS), Zollinger-Ellison syndrome, diseases
CC of the immune system, haematopoietic disease, inflammation, anxiety,
CC schizophrenia, feeding disorders, anorexia, depression, social, sexual
CC and rewarded behaviour, cardiovascular disease, sleep disorder, learning
CC and memory alteration and altered immune response, seizure, migraine,
CC cancer, stroke, asthma, neuropathy, aging, sexual disorders, treatment
CC of transsexuals, growth abnormalities, obesity, infections, autoimmune
CC diseases (e.g. rheumatoid arthritis), cataractogenesis, angiogenesis,
CC disorders associated with healthy maintenance of gastric mucosa and
CC repair of acute and chronic mucosal lesion, lung carcinoma, cerebral
CC ischaemia, atherosclerosis, cirrhosis, Huntington's disease, headache,
CC amnesia, multiple sclerosis, Hodgson's disease, dilated cardiomyopathy,
CC congestive heart failure, cardiac arrhythmias, hypercholesterolaemia,
CC viral and non-viral hepatitis, type I and type II diabetes mellitus,
CC glomerulonephritis, renovascular hypertension, hypoglycaemia, periodic
CC paralyses, tendinitis and malignant hyperthermia. Polypeptides of the
CC invention are used to identify membrane bound and soluble receptors.
CC They are also useful as vaccines for inducing an immunological response
CC
```

```
CC in a mammal. Polynucleotides of the invention are used in gene therapy.
CC They are also valuable for chromosome localisation studies and tissue
CC expression studies.
XX
XX Sequence 653 AA;
SQ
Query Match 55.5%; Score 1865; DB 22; Length 653;
Best Local Similarity 56.4%; Pred. No. 2.8e-126;
Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;
QY 29 VLLALQLLVVAGLVRA-----QTCPSVCSCSNQFSKVICVRKNLRVPPDGISTNTLLN 82
DB 22 VYTAGVWILCAALAAASAGPQCPCSCSNQFSKVCVTRRGLSEVPDGIPSNTRYLN 81
QY 83 LHENOQIIKVNSEFKLHLRLLEILQLSRNHRTTEIGAFNGLANLLELEFDRNLTTPNG 142
DB 82 LMENNIMQIADFRHHLHLEVLQGRNSIRQIEVGFNGLASINTLELFDNWLTVPSG 141
QY 143 AFVYLSKLKELWLRNNPIESPSYAFNRIPSLRRLDLGELKRLSYISEGAFEGLSNRYL 202
DB 142 AFEYLSKLRLWLRNPISPSYAFNRVPSLMRLDLGELKKLEYISGAFEGIFNLKYL 201
QY 203 NLAMCNLRREIPNLPLIKLDELQSLGNHLSAIRPGSQGLMLHQLKLMQIOSQIOVIERN 262
DB 202 NLGMCNIKMPNITPLVGLLEEMSGNHFPETRPGSLMRDLGELKKLEYISGAFEGIFNLK 261
QY 263 FDNLOSLEINLAHNLTLLPHDLFTPLHLHLRLHLHHPNWCNCDILWLSWTKDMAPS 322
DB 262 FDGLASIVEINLHNNLSSLPDFTPLRYLVEHLHHPNWCNCDILWLSWTKDMAPS 321
QY 323 NTACCARCNTPPNLKGRYIGELQDNYFYAPVIVEPPADLNVTGMAELKCRASLTSLT 382
DB 322 NSTCCGRCHAPMBMRGYLVEVDQASFGCSAPFIMDAPRDLINISGMAELKCR-TPPMS 380
QY 383 SVSWIRPNGTVMHGAAYKVRIVLSDGTLNFTNTVVDGTGMYTCMVNSVNTTASATLN 442
DB 381 SVKWLIPNGTVLHNSRHRISVINDGTLNFTSHVILSDGTGMYTCMVNSVNTTASATLN 440
QY 443 VTAA--TTTTFVSFTVTETMPSQDEARTNNVPTVPVDMETTNV-----TTSLT 494
DB 441 VSTAEINTSNYSFFTTVTETTEISPED---TTRKYKVP-----TSTGYQPAYTSTT 492
QY 495 P--QSTRSTKTKTIPVTDINSGL-PCIDEVMTKTKIIIGCFVAITLMAAVMLVIFYKMR 551
DB 493 VLIQTR-VPKQVAVPATDITDKMTSLDEVMKTKIIGCFVAVTILAAAMLVIFYKLR 551
QY 552 KOHHRQNHAPTRTVEIINVDDEITGDTPM-----ESHLPMPATEHEHLNHYNS 600
DB 552 KRHQGRSTVTAARTVEIIGVDEDIPAAATSAATAAPSGVSGEGAVIPTI-HDHN-YN 609
QY 601 YKSPFNHTTNTI-NSIH---SSVHEPLLRMNSKDNVOETQI 640
DB 610 YKPAHGAWHTENSIGNSLHPTVTTISEPYIIQHTKDKVQETQL 653
RESULT 15
AAU12390
ID AAU12390 standard; Protein; 653 AA.
XX
XX AAU12390;
AC
XX
XX 24-OCT-2001 (first entry)
DT
XX
XX Human PRO1111 polypeptide sequence.
DE
XX
XX Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW adipocyte; A-peptide; factor VITA; gene therapy.
XX
XX Homo sapiens.
XX
```







GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 26, 2002, 15:39:27 ; Search time 20.98 seconds  
(without alignments)  
2931.228 Million cell updates/sec

Title: US-09-905-056-292  
Perfect score: 3362  
Sequence: 1 MLNKMTHPQIMIGPRNR.....VHEPLLIRMNSKDNVQETQI 640

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283138 seqs, 96089334 residues

Total number of hits satisfying chosen parameters: 283138

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR\_71.\*  
1: pir1.\*  
2: pir2.\*  
3: pir3.\*  
4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1376.5	40.9	421	2 T46266	hypothetical prote
2	417.5	12.4	1091	2 A58532	glial cell membran
3	410.5	12.2	361	2 A53860	chondroadherin pre
4	406	12.1	707	2 JC7763	neuronal leucine-r
5	399	11.9	1531	2 T42218	slit-1 protein hom
6	374.5	11.1	1523	2 T13953	MEGF5 protein - ra
7	350	10.4	1469	2 B36665	slit protein 2 pre
8	350	10.4	1480	2 A36665	slit protein 1 pre
9	348.5	10.4	789	2 T28714	hypothetical prote
10	348.5	10.4	1355	2 T28715	hypothetical prote
11	344.5	10.2	1025	2 T42626	secreted leucine-r
12	337.5	10.0	1535	2 S46224	peroxidase - frui
13	335	10.0	605	2 JC5239	insulin-like growt
14	329.5	9.8	560	2 A60164	platelet membrane
15	320	9.5	605	2 A41915	insulin-like growt
16	312	9.3	603	2 JC1282	insulin-like growt
17	311	9.3	603	2 JC6128	insulin-like growt
18	302	9.0	359	1 NBHUC8	decorin precursor
19	296.5	8.8	594	2 T23801	hypothetical prote
20	296.5	8.8	626	1 NBHUIA	platelet glycoprot
21	293	8.7	357	2 S24317	decorin precursor
22	293	8.7	360	2 S06280	decorin precursor
23	293	8.7	360	2 T47020	decorin - rabbit
24	290	8.6	354	2 A55454	decorin precursor
25	289	8.6	907	2 JG0193	G protein-coupled
26	287.5	8.6	536	2 A34901	lysine carboxypept
27	287.5	8.6	610	2 T23836	hypothetical prote
28	287	8.5	354	2 S29145	decorin precursor
29	286	8.5	420	2 A53531	oncofetal trophobl

30	286	8.5	603	2 T24315	hypothetical prote
31	283.5	8.4	907	2 JE0176	orphan G protein-c
32	281.5	8.4	1389	2 T13852	gene wheeler prote
33	276.5	8.2	1385	2 T13887	tlr protein - frui
34	275.5	8.2	853	2 T25194	hypothetical prote
35	275.5	8.2	680	2 T19939	hypothetical prote
36	271.5	8.1	368	1 BGHUN	biglycan precursor
37	270.5	8.0	369	2 S20811	proteoglycan I - m
38	270.5	8.0	369	2 S32793	biglycan precursor
39	269.5	8.0	369	2 S32559	biglycan precursor
40	264.5	7.9	458	2 T19941	hypothetical prote
41	262	7.8	1066	2 T15864	hypothetical prote
42	258.5	7.7	562	2 T34319	hypothetical prote
43	257.5	7.7	1134	1 A29944	chaoptin precursor
44	252	7.5	575	2 T29972	hypothetical prote
45	250.5	7.5	382	2 I39068	proline- arginine-

ALIGNMENTS

RESULT 1

T46266

hypothetical protein DKFzp761A179.1 - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 04-Feb-2000 #sequence\_revision 04-Feb-2000 #text\_change 04-Feb-2000

C:Accession: T46266

R:Blum, H.; Bauersachs, S.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.

submitted to the Protein Sequence Database, January 2000

A:Reference number: Z23034

A:Accession: T46266

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-421 <AAA>

A:Cross-references: EMBL:AL137451

A:Experimental source: adult amygdala; clone DKFzp761A179

C:Genetics:

A:Note: DKFzp761A179.1

Query Match 40.9%; Score 1376.5; DB 2; Length 421;  
Best Local Similarity 62.6%; Pred. No. 8.5e-83;  
Matches 256; Conservative 56; Mismatches 58; Indels 39; Gaps 6;

QY 206 MCNLEIPNLPTLIKDELDSGNHLSAIRPGSQGLMHLQKLMWISQIOVIERNAPDN 265

Db 1 MCNLIKDPNLTALVRLLEELELSGNRLDLIRPGSQGLTSLRKLWLMHAQVATIERNAFDD 60

QY 266 LQSLVEINLAHNLTLLPHDLFTPLHLERHLHNPWNCNCDILWLSWIKDMAPNTA 325

Db 61 LKSLLEELNLSHNLSLPHDLFTPLHLERVHLNHPWNCNCDVLSWMLKETVPSNTT 120

QY 326 CCARCNTPPNLKGRYIGELDQNYETCYAPVIVPEPPADLVNTEGMAAEKCRASLSLTSVS 385

Db 121 CCARCHAPAGLKRGYIGELDQSHFTCYAPVIVEPTDLNVTGMAAEKCRGTGSMTSVN 180

QY 386 WITPNGVTMTHGAYKVRIVAVLSLSDGTNFTNVQDTGMTCWNSVSGNTTASATLVNTA 445

Db 181 WLTPNGTLMTHGSRVRSVLSVLHDGTNFTNVQDTGQTCMVNTSAGNTTASATLVNSA 240

QY 446 ATTPP-----FSYFSTVTVETME--PSQD--EARTTDNN-VG 477

Db 241 VDPVAAGGTGGGGGGGGGGGGGGYFTVTVETLETQPGEEALQPRGTEKEPPG 300

QY 478 PTPVVDW-----ETNVTTSLTPQSTRSTEKFTIPVTDI-NSGIPGIDEVMTKT 526

Db 301 PTTDGVWGGGRPGDAAAGPASSSTTAPAPRSSRPTKFTVPTDVTENALKDLDDVMKTT 360

QY 527 KIIIGCFVAITLMAAVMLVIFYKMKRQHHNHONHAPTRTVEIINVDDEI 575

Db 361 KIIIGCFVAITFMAAVMLVAFYKLRKQHLKHGPTFTVEIINVEDEL 409





A:Title: Rat neuronal leucine-rich repeat protein-3: Cloning and regulation of the gene  
A:Reference number: JC7763; PMID:11549284  
A:Contents: Fibrosarcoma cells  
A:Accession: JC7763  
A:Molecule type: mRNA  
A:Residues: 1-707 <FUK>  
A:Cross-references: GB:AF291437  
C:Comment: This protein, a new member of the neuronal leucine-rich repeat protein family in protein-protein interaction and functions as a cell adhesion molecule or soluble ligand.  
C:Genetics:  
A:Gene: nlr-3  
C:Keywords: cell adhesion

```
Query Match      12.1%   Score 406;  DB 2;  Length 707;
Best Local Similarity 23.9%;  Pred. No. 6.8e-19;
Matches 154;  Conservative 98;  Mismatches 239;  Indels 154;  Gaps 20;

Qy  31 LALQLLVVAGLVRAQTCPSCVSCS-----NQFSKVICVRKNLREVPDGLSTNTR 79
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  14 LAITLVQAGDKVD-CPLQCTCEIRPWFTPRSIYMEASTVDCNDGLNFPARLPADTQ 72
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  80 LLNLHENOIQIILK-----VNSFKHLRHLLEILQLSR-----NHIRTIE 116
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  73 ILLQTNIAIRIEHSTDPVNLTLGLDLSQNNLSVTINVOKMQLLSVLYLEENKLTPEL 132
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  117 IGAENGLANLTLFNDRLTTPINGAFVYLSKELKELWRNPIESIPSYAFNRIPSRLR 176
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  133 EKCLYGLSLQELVYHNHLLSAISPGAFVGLHLLRLHLNLSNRLQIMKWFALPNLEI 192
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  177 LDGLGKLKLSYISGAFGLGNLRYLNAMCNLRIP-----NLT 216
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  193 LMLGD-NPLIRKIDMNFQPLKRLSLVLAGINLTVDPDGLVLENLESISFYDNRLNKV 251
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  217 PLIKLDE-----LDLSGNHLSAIRPGSQFGLMHLOKLWM-----IQS 253
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  252 FOVALQKAVNLKFLDLNKNPNIIRRGDFSNMLHLKELGGINNMPPELVSIDSLAVDNL 311
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  254 -----QIOVERNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHHLERTHLHNPWN 304
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  312 RKIEATNPRLSYIHPNAFFRLPKLESMLNSALSALYHGHTIESLPNLKESISHSNPIR 371
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  305 NCNDTLWLSW---WIKDMAPNTACCRCNTPPNKLKRYIGELD-QNYFTCYAPVIVPEP- 359
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  372 CDCVIRWINMKNKTIRFNEPDSLEFCV---DPPEFGQGNVRQVHFRDMEICLPIAPES 427
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  360 -PADLVNTEGMAAEKLCRASTS-LTSVSWITPNCVTMTHGAKYVRIAVLSDGLNFTNVT 417
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  428 FPSILDVADSVSLHCRATAEPOEIIWITPSGKRLLPNTLREKFVYHSEGLDIRGIT 487
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  418 VQDTGMVTCMVSNVSGNTTAS-----ATLNV-----TAA 446
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  488 PREGGLYTCIATNLVAGDLKSMIKVGFVPQDNNGLNLIKIRDIRANSVLVSMKANSKI 547
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  447 TTPPSYFSTVVTETMPSQDEARTD-----NNVGPTPVDM-----ETT 487
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  548 LKSSVKWTAFKWTEDSQAASARIPSDVKVYNLHLKPSYKICIDIPTIYQSRKQCV 607
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  488 NVTTSLTPQSTRSTKTTIPVTDINSIGPIDEVKMTTKIIGC 532
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  608 NVTTKSLSHDGENKSHTEVFACV-GGLLGIIGVM-----CLFGC 647
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
```

RESULT 5  
T42218  
slit-1 protein homolog - rat  
N:Alternate names: MEGF4 protein  
C:Species: Rattus norvegicus (Norway rat)  
C:Date: 03-Dec-1999 #sequence\_revision 03-Dec-1999 #text\_change 21-Jul-2000  
C:Accession: T42218  
R:Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O.  
Genomics 51, 27-34, 1998  
A:Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs

A:Reference number: Z14126; MUID:98360089  
A:Accession: T42218  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-1531 <NAK>  
A:Cross-references: EMBL:AB011530; NID:g3449289; PIDN:BAA32460.1; PID:g3449290  
A:Experimental source: strain Sprague-Dawley; brain  
C:Genetics:  
A:Gene: MEGF4

```
Query Match      11.9%   Score 399;  DB 2;  Length 1531;
Best Local Similarity 22.7%;  Pred. No. 5.4e-18;
Matches 156;  Conservative 101;  Mismatches 235;  Indels 194;  Gaps 18;

Qy  31 LALQLLVVAGLVRAQTCPSCVSCSNOFSKVICVRKNLREVPDGLSTNRLNLHENQIQI 90
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  18 LWLLWAAANRWLGATACPALCTCTG--TTVCHGTGLQAIKPNIPRTERLELGNNTIR 75
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  91 IKVNSFKHLRHLLEILQLSRNHRTIEIGAFN----- 121
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  76 IHKNDFAGLKQLRVLQLMENQIGAVERGAFDDMKELERLNRNQLQVLPPELLFONQAL 135
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  122 -----GLANLTLELFDNRLTTINGAFVYLSKELKELWRNPIES 162
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  136 SRLDLSNSLAQVPRKAFRGATDLKNLQLDKNQISCIEEGAFRALRGLEVTLLNNNTT 195
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  163 IPSVAFNRIPSRL--RLDLGEL---KRLSYISE-----GAF---EGLSNLRYLNL-- 204
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  196 IPVSFNPMPKLRFLRHLNHLFCDCHLAWLSQWLQRPTIGLFTQCSPASLRLGNVAE 255
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  205 -----AMCN----- 208
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  256 VOKSEFSCSGGGAQVPACTLSSGSCPAMCSCSNGIVDCRGKGLTAIPANLPETWTEIR 315
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  209 -----LRIP--NLTPLIKDELDSGNHLSAIRPGSQGLMH----- 244
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  316 LELNGIKSIPPGAFSPYRKLRRIDLSNNQIAIAPAFQGLRSLNSLVLYGNKIIDLPRG 375
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  245 -----LOKLWMIQSQIOVIERNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHHLERH 297
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  376 VFGGLYTLQLLLNANKINCIRPDFAQLQNLSSLSDNKLQSLAKGTTFTSLRAIQTLLH 435
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  298 LHHPNWNCNDILWMLWIKDMAPNTACCRCNTPPNKLKRYIGELDQNYFTC----- 351
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  436 LAQNPFIQDCNKLKWLADFLRTNPDIETTG--ARCASPRRLANKRIGQIKSKKFRCSAKEQ 493
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  352 YAPVIVEPADLVNTEGMAAEKLCRASTSLSVSWI-----TPNGT----- 392
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  494 FIPGTEDYHLNSECTSDVACPHKCRCEASVVECSGLKLSKIPERIPQSTTELRLNNEIS 553
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  393 -VMTHGAYKVRIVLSDGLTNFTNVVDTCMYTCMVSNVSGNTTASATLVNTAATTPF 451
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  554 ILEATGLFK-KLSHLKKLNLSNNKRVSEIDEGTFEGATSVSELHLTANQLESVRSGNFG 612
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  452 SYFSTVTVETMEPS--QDEARTDNNVGPTPVDMETNVTTSPTQSTRSTKTTFTIPV 509
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  613 DGLRTLMLRNRNRSICIHNDSTGLNRVLLSLYD---NHITISPGAFDTLQALSTLNL 668
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Qy  510 T-----DINSIGPIDEVKMTTKIIG 531
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  669 LANPFCNCQLAWLGDWLRKRKIIVTG 694
   ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
```

RESULT 6  
T13953  
MEGF5 protein - rat  
N:Alternate names: slit protein homolog  
C:Species: Rattus norvegicus (Norway rat)  
C:Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 21-Jul-2000  
C:Accession: T13953  
R:Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O.  
Genomics 51, 27-34, 1998

A:Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs  
A:Reference number: 214126; MUID:98360089

A:Accession: T13953

A:Molecule type: mRNA

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Residues: 1-1523 <NAK>

C:Genetics: references: EMBL:AB011531; NID:g3449291; PIDN:BAA32461.1; PID:g3449292

A:Gene: MEGF5

Query Match 11.1%; Score 374.5; DB 2; Length 1523;  
Best Local Similarity 25.4%; Pred. No. 2.2e-16;  
Matches 120; Conservative 49; Mismatches 147; Indels 157; Gaps 9;

Qy 31 LALQLLVAGLVRAQCPSCVCSNQSKVICVRKNLREVPDGIISTRTNLNLHENQIQI 90

Db 18 LALALSLSGPPAAACPTKTCSS--AASVDCHGLGRLAVRPGIPRNAERLDLDRNNITR 75

Qy 91 IKVNSFKHLRHLLEILQLSRNHRTIEIGAFNGLANLTLELFDNRLTTPNGAFVYLSKL 150

Db 76 LTKMDFGLKRLVHLLEDNQSVIERGAFODLQALERLRLNKNKQLVLPPELLFQSTPKL 135

Qy 151 KELWRNPIESISYAFNRTPSLRRDLGELKRLSYISEGAFGLSNLRYNL----- 204

Db 136 TRLDLSENIQIOPKAPRGVGTGVKNLQL-DNNHISCIEDGAFRALRDLLEITLNNNIS 194

Qy 205 ----- 204

Db 195 RILVTSFNHMPKIRTLRLSHNLYCDCHLAWLSDWLQRRTIGQFTLCMAPVHLRGFSA 254

Qy 205 -----AMCN-----LREIP-NLTPLI----- 219

Db 255 DVQKKEYVCPGHPSEAPACNANSLSCPSACSCSNIVDCRGKGLTEIPANLPEGIVEIRL 314

Qy 220 -----KLDELDSGNHLSAIRPGSQ----- 240

Db 315 BONSISIPAGAFQYQKLRIDISKNOISDIADPAFOGLKSLTSLVLYGNKITEIPKGL 374

Qy 241 --GLMHQLQKLMWIOSQIOVIERNAFDNLQSLVEINLAHNNTLLPHDLFTPLHLHLRIHL 298

Db 375 FDGLVSLQLLLNANKINCLRVNFTODLONLNLSLYDNKLOTISKGLFAPLQSTQTLHL 434

Qy 299 HHNPWNCNDILWLSWTKDMAPNTACCACRCNTPPNLKGRYIGELDONQYTC 351

Db 435 AQNPFCVCDHLKWLADYLOD-NPIETS-GARCSSPRLANKRISQIKSKKPRC 485

RESULT 7

B3665

C:Species: Drosophila melanogaster

C:Date: 30-Apr-1991 #sequence\_revision 30-Apr-1991 #text\_change 19-May-2000

C:Accession: B3665

R:Rothberg, J.M.; Jacobs, J.R.; Goodman, C.S.; Artavanis-Tsakonas, S.

Genes Dev. 4, 2169-2187, 1990

A:Title: slit: an extracellular protein necessary for development of midline glia and co

A:Reference number: A36665; MUID:91099665

A:Accession: B3665

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-1469 <ROT>

A:Cross-references: GB:X53959

C:Genetics:

A:Gene: FlyBase:slit

C:Cross-references: FlyBase:FBgn0003425

C:Superfamily: unassigned EGF-related proteins; EGF homology; leucine-rich alpha-2-glyco

F:66-91/Domain: proteoglycan amino-terminal homology <PAH2>

F:101-124/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>

F:125-148/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>

F:149-172/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>

F:173-196/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>

F:197-220/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>

F:228-272/Domain: proteoglycan carboxyl-terminal homology <PCS1>

F:288-313/Domain: proteoglycan amino-terminal homology <PAH2>

F:323-346/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>

F:347-370/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>

F:371-394/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>

F:395-418/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>

F:419-442/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>

F:450-494/Domain: proteoglycan carboxyl-terminal homology <PCS2>

F:512-537/Domain: proteoglycan amino-terminal homology <PAH3>

F:547-571/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>

F:572-595/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR12>

F:596-619/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR13>

F:620-643/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR14>

F:651-695/Domain: proteoglycan carboxyl-terminal homology <PCS3>

F:708-733/Domain: proteoglycan amino-terminal homology <PAH4>

F:743-766/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR15>

F:767-790/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR16>

F:846-890/Domain: proteoglycan carboxyl-terminal homology <PCS4>

F:1028-1061/Domain: EGF homology <EGF>

F:1068-1093/Domain: EGF homology <EGF2>

F:1115-1148/Domain: EGF homology <EGF1>

Query Match 10.4%; Score 350; DB 2; Length 1469;

Best Local Similarity 23.9%; Pred. No. 8.4e-15;

Matches 109; Conservative 65; Mismatches 152; Indels 130; Gaps 9;

Qy 46 TPCSVCSNQSKVICVRKNLREVPDGIISTRTNLNLHENQIQIIVKNSFKHLRLHLIL 105

Db 294 SCPHPCADGI--VDCREKSLTSPVTVLPDDTTDVRLEQNFITELPKPSSFRRLRI 351

Qy 106 QLSRNHIRTIEIGAFNGLANLTLELFDNRLTTPNGAFVYLSKLKELWLRNPNIESIPS 165

Db 352 DLSNNISRIADHSLGKQLTTLVLYGNKIKDLPSPGVFKGLSLRLLLNANEISCIK 411

Qy 166 YAFNRISLRDLGELKRLSYISEGAFGLSNLRYNLAM-----CNLR----- 210

Db 412 DAFRDLHSLSLSLSD-LNIIQSLANGTFDAMKSMKTVHLAKNPFITCDNLRMLADYLHN 470

Qy 211 ----- 210

Db 471 PIETSGARCESPKRMHRRRIESLREKFKCSWGLRMKLSGECRMDSDCPAMCHCEGTV 530

Qy 211 -----EIPNLTP-----TKLD-----ELDLSGNHLSAIRPGS 238

Db 531 DCTGRLKEIPRDIPTLHTTELLNDNELGRISDGLFGRLPHLVKLELKRNLQGTIEPNA 590

Qy 239 FQGLMHQLQKLMWIOSQIOVIERNAFDNLQSLVEINLAHNNTLLPHDLFTPLHLHLRIHL 298

Db 591 FEGASHIQELQIENKKEISNKMPLGLHQLKTLNLYDNQISCVMPGSEHLSLTSNL 650

Qy 299 HHNPWNCNDILWLSWTKDMAPNTACCACRCNTPPNLKGRYIGELDONQYTCYAPVIVE 358

Db 651 ASNPFNCNCHLAWAEVCVRKKSNGGA--ARCGAPSKVRDVQIKDLPHSEFKCSS----- 703

Qy 359 PPADLVNTEGMAELKCRASLTSLTSVSWITNGVTM 394

Db 704 -----ENSEGLGDGYCPCPCTCT-----GTVV 726

RESULT 8

A3665

C:Species: Drosophila melanogaster

C:Date: 30-Apr-1991 #sequence\_revision 30-Apr-1991 #text\_change 17-Nov-2000

C:Accession: A36665; A31640; S13523

R:Rothberg, J.M.; Jacobs, J.R.; Goodman, C.S.; Artavanis-Tsakonas, S.

Genes Dev. 4, 2169-2187, 1990

A:Title: slit: an extracellular protein necessary for development of midline glia and

A:Reference number: A36665; MUID:91099665

A:Accession: A36665

A:Status: preliminary

A:Molecule type: mRNA

A;Residues: 1-1480 <R0T>  
A;Cross-references: GB:X53959; NID:g8614; PIDN:CAA37910.1; PID:g8615  
R;Rothberg, J.M.; Hartley, D.A.; Walther, Z.; Artavanis-Tsakonas, S.  
Cell 55, 1047-1059, 1988  
A;Title: slit: An EGF-homologous locus of D. melanogaster involved in the development of  
A;Reference number: A31640; MUID:89077533  
A;Accession: A31640  
A;Molecule type: DNA  
A;Residues: 881-1182, 'G', 1185-1404, 'GT', 1463-1464, 'YHA', <R0>  
A;Cross-references: GB:M23543; NID:g340939; PID:g514357  
C;Genetics:  
A;Gene: FlyBase:slit  
A;Cross-references: FlyBase:FBgn0003425  
A;Introns: 1351/3  
C;Superfamily: unassigned EGF-related proteins; EGF homology; leucine-rich alpha-2-glyco  
F;66-91/Domain: proteoglycan amino-terminal homology <PAH1>  
F;101-124/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>  
F;125-148/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>  
F;149-172/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>  
F;173-196/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>  
F;197-220/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>  
F;228-272/Domain: proteoglycan carboxyl-terminal homology <PCS1>  
F;288-313/Domain: proteoglycan amino-terminal homology <PAH2>  
F;323-346/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>  
F;347-370/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>  
F;371-394/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>  
F;395-418/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>  
F;419-442/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>  
F;450-494/Domain: proteoglycan carboxyl-terminal homology <PCS2>  
F;512-537/Domain: proteoglycan amino-terminal homology <PAH3>  
F;547-571/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>  
F;572-595/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR12>  
F;596-619/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR13>  
F;620-643/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR14>  
F;651-695/Domain: proteoglycan carboxyl-terminal homology <PCS3>  
F;708-733/Domain: proteoglycan amino-terminal homology <PAH4>  
F;743-766/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR15>  
F;767-790/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR16>  
F;791-814/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR17>  
F;815-838/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR18>  
F;846-890/Domain: proteoglycan carboxyl-terminal homology <PCS4>  
F;1028-1061/Domain: EGF homology <EGF>  
F;1068-1099/Domain: EGF homology <EGF2>  
F;1115-1148/Domain: EGF homology <EGF1>

Db 591 FEGASHIQEQLQGENKIKEISNMFLGLHQLKLTNLNDNOISCVMPGSEFHLNLSLNL 650  
Qy 299 HHNPWNCNCIDILWSMWIKDWPASNTACCARCNTPPNPKRGYIGELDONFTCYAPVIVE 358  
Db 651 ASNPFNCNCHLAWFAECVRKKSLLNGGA--ARCGAPSKVRDVOIKDLPHSEKCSS----- 703  
Qy 359 PPADLVNTEGMAAEELKCRASLTSLTSVSWITPNGTVM 394  
Db 704 -----ENSEGLGDGCPYSCCTCT-----GTVV 726  
RESULT 9  
T28714  
hypothetical protein T21D12.9a - Caenorhabditis elegans  
C;Species: Caenorhabditis elegans  
C;Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 29-Oct-1999  
C;Accession: T28714  
R;Moessner, J.  
submitted to the EMBL Data Library, August 1997  
A;Description: The sequence of C. elegans cosmid T21D12.  
A;Reference number: Z20514  
A;Accession: T28714  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-789 <MOE>  
A;Cross-references: EMBL:AF016687; PIDN:AAC48096.1; GSPDB:GN00022; CESP:T21D12.9a  
A;Experimental source: strain Bristol N2; clone T21D12  
C;Genetics:  
A;Gene: CESP:T21D12.9a  
A;Map position: 4  
A;Introns: 38/2; 84/2; 132/2; 204/2; 275/2; 351/2; 519/3; 615/1; 714/1; 758/2

Query Match 10.4%; Score 348.5; DB 2; Length 789;  
Best Local Similarity 24.3%; Pred. No. 4.6e-15;  
Matches 131; Conservative 85; Mismatches 233; Indels 89; Gaps 19;  
Qy 75 STNTRL-LNLHENOIQIKVNSFKHLRHLLEQLSLNRHIRTIEIGAFNGLANLTLEFD 133  
Db 101 SFNTLVTLKLARNHITTLNFSRLKRLKESLDLTRNIREVRLAFNQLPQLQNVSLAR 160  
Qy 134 NRLTTPNGAFVILSKLKLWLRNPIESIP-----SYAFNRI----- 171  
Db 161 NDVRLDDGMFYACEGLKHLNLTSTNRVOAVTEGWMFGLTSLVLDLSYNOQSFISSWS 220  
Qy 172 --PSLRRLDLGELKRLSYISEGAPEGLSNRLYNLNCMLNREIPN--LTPLIKLDELDSL 227  
Db 221 HTPKLKWLSL-HSNRIQSLPSGSRVLRQLLELILSANSIDSLHKFALVGMSSLHKLDLS 279  
Qy 228 GNHLIS-AIRPGSF--OGLMHLQKLWMIQSQIOVIERNAFDNLSLVEINLAHNNLTLLP 283  
Db 280 SNTLAVCVEDGAVLYNTSMPPFLRSRLRTNNLRVTPKRAFERFALBELDLDNPIATIH 339  
Qy 284 HDLFTPLHLHLRIHLHNPWNCNCIDILWSMWIKDWPASNTACCARCNTPPNPKRGYIGE 343  
Db 340 PEAEPTL-ELKRLWSSSSILDCQISWLASWIYRLKLDSSIIAKCSYPPPLADLYVVA 398  
Qy 344 LDQNYFTCY----APVIVEPADLVNTEGMAAEELKCRSA-STSLTSVSW----- 386  
Db 399 IDTANLTCNDSPRAKIVRQPVVESTLIGEKARETCNVYGASPLSIEWRMVMEQPRVLV 458  
Qy 387 -----TTPNGTVMTHGAYKVRIAVLSGTLNFTNVTVDQFGMYTCMVNSVGNWTASAT 440  
Db 459 QDSATFLSINRTAVVNGTFDER--ELAAAEILLDNVAMTONSEYQCQVARNRFG-SDFSTH 515  
Qy 441 LNVTAATTTTFSYFTVIVETM-----EPSQDEARTTNNVGPPTPVVDWETNTTSLTP 495  
Db 516 VKLOVYQAPKFTY----TPEDMPLLVGQTAKFCAATGT---PRPEIKWAFEQI-----P 563  
Qy 496 QSTRSTKTFPTPTVDINSIGIPGIDEVMTKIIIGCF-----VAITLMAAVMLVIF 547  
Db 564 FPAEAERLRYTPND-----HIYIMNVTKEQOGAYTCHATVACOTQASANLIVF 614

Query Match 10.4%; Score 350; DB 2; Length 1480;  
Best Local Similarity 23.9%; Pred. No. 8.5e-15;  
Matches 109; Conservative 65; Mismatches 152; Indels 130; Gaps 9;

Qy 46 TCPVSCSNQFSKVICVRKNLRVDPDGISTNTRLLNLHENQIQIKVNSFKHLRHLLEIL 105  
Db 294 SCPPHRCADGI--VDCREKSLTSPVTPLPDDTTDVRLEQNFITELPKSFSSFRRLRI 351  
Qy 106 QLSNRHIRTIEIGAFNGLANLTLEFDNRLTTTPNGAFVILSKLKLWLRNPIESIPS 165  
Db 352 DLNNNISRIAHDAISGLKQLTTLVLYGNKIKDLPVGFGLSLRLLLNANEISCIK 411  
Qy 166 YAFNRIPSLRLDLGELKRLSYISEGAPEGLSNRLYNLNCMLNREIPN--LTPLIKLDELDSL 210  
Db 412 DAFRLHLSLLSLYD--NNTOSLANGTFDAMKSMKTVHLAKNPICDNLRLADLYLHK 470  
Qy 211 -----EIPNLTP-----IKLD-----ELDSGNHLSAIRPGS 238  
Db 531 DCTGRRLKEIPRLPLHTTELLNDNELGRITSDGLFGRPLHLVKLKRNLQTGIEPNA 590  
Qy 239 FOGLMHLQKLWMIQSQIOVIERNAFDNLSLVEINLAHNNLTLLPHDLFTPLHLHLRIHL 298  
Db 547

RESULT 10  
T28715  
hypothetical protein T21D12.9b - Caenorhabditis elegans  
C:Species: Caenorhabditis elegans  
C>Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 29-Oct-1999  
C:Accession: T28715  
R:Woessner, J.  
submitted to the EMBL Data Library, August 1997  
A:Description: The sequence of C. elegans cosmid T21D12.  
A:Reference number: Z20514  
A:Accession: T28715  
A>Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: DNA  
A:Residues: 1-1355 <WOE>  
A:Cross-references: EMBL:AF016687; PIDN:AAC48095.1; GSPDB:GN00022; CESP:T21D12.9b  
A:Experimental source: strain Bristol N2; clone T21D12  
C:Genetics:  
A:Gene: CESP:T21D12.9b  
A:Map position: 4  
A:Introns: 38/2; 84/2; 132/2; 204/2; 275/2; 351/2; 519/3; 615/1; 714/1; 758/2; 786/3; 84/2

Query Match 10.4%; Score 348.5; DB 2; Length 1355;  
Best Local Similarity 24.3%; Pred. No. 9.5e-15;  
Matches 131; Conservative 85; Mismatches 233; Indels 89; Gaps 19;  
QY 75 STNTRL-LNLHENOIQIKVNSFKHLRHLLETLQLSRHHRTIEIGAFNGLANLNTLELF<sup>133</sup>  
Db 101 SFNTLVTLKLARNHITLNFQSFRLRKLESOLDTRNMIREVRLAFNPQLPSLQNSLAR 160  
QY 134 NRTLTTPNGAFVYLSKLKELWRNPNIESIP-----SYAFNRT----- 171  
Db 161 NDVRLDDGEYACEGLKHLNLSNRQAVTEGWMFGLSLEVLDSYVNSIQOSPHISSWS 220  
QY 172 --PSLRDLGELKRLSYISEGAFEGLSNRYLNLMCNLRIPN--LTPLIKLDELDS 227  
Db 221 HTPKLKWLSL-HSNRIQSLPSGSRVLRQLEELTILSANSIDSLHKFALVGMSLHKLDLS 279  
QY 228 GNHLS-AIRPGSF--QGLMHLQKLMWIOSIOVIERNAPDNLOSLSVEINLAHNHNLTP 283  
Db 280 SNTLAVCEDGAVLYNTSMFLRSRLRTNNQLRVIPRAFERFPALELOLTDNPATIH 339  
QY 284 HDLFTPLHLERLHLHNPWCNCDILWSWIKDMAPSNTACCARGTTPNKLGRYIGE 343  
Db 340 PEAPEPL-ELKRLVWSSSILCDQISWLASWIVRLKDKSIIIAKCSYPPPLADLYVA 398  
QY 344 LDQNYFCY----APVIVEPPADLVNTEGMAELKRA-STSLTSVSW----- 386  
Db 399 IDTANLCHNDSPRAKIVRQPEVSTLIGEKAREFTCNVYGASPLSIEWRMENGOQPRVLV 458  
QY 387 -----TPNGVTMTHGAYKVRIVASLDGTLNFTNTVQDTGMVTCMVNSVGNNTTASAT 440  
Db 459 QDSATFSLINRTAVNGTDFER--ELAAEALLDNVAMTNSQVQVARNRFG-SDFSTH 515  
QY 441 LNVTAATTTFFSYSTVVTETM-----EPSQDEARTDNNVGPVVDVETNVTTSITLP 495  
Db 516 VKLOVQAPKFTY---TPEDMPLLVQGTAKFLCAATGT---PRPEIKWAFEQI-----P 563  
QY 496 QSTRSTKFTIPVTDNSGIPGIDVWYKTKIIIGCF-----VAITLMAAVMLVIF 547  
Db 564 FPAAEARRLVYTPND-----HIYIMNVTKEDOGAYTCHATNVAGTQOASANLIVF 614

RESULT 11  
T42626  
secreted leucine-rich repeat-containing protein SLIT2 - mouse (fragment)  
N:Alternate names: neurogenic extracellular slit protein  
C:Species: Mus musculus (house mouse)  
C>Date: 11-Jan-2000 #sequence\_revision 11-Jan-2000 #text\_change 11-Jan-2000  
C:Accession: T42626  
R:Holmes, G.P.; Negus, K.; Burridge, L.; Raman, S.; Algar, E.; Yamada, T.; Little, M.H.  
Mech. Dev. 79, 57-72, 1998

A:Title: Distinct but overlapping expression patterns of two vertebrate slit homologs  
A:Reference number: Z22177; MUID:99279238  
A:Accession: T42626  
A>Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-1025 <HOL>  
A:Cross-references: EMBL:AF074960; NID:g4151258; PID:g4151259; PIDN:AAD04345.1  
C:Genetics:  
A:Gene: Slit2

Query Match 10.2%; Score 344.5; DB 2; Length 1025;  
Best Local Similarity 24.3%; Pred. No. 1.2e-14;  
Matches 102; Conservative 62; Mismatches 149; Indels 107; Gaps 8;  
QY 47 CPSVCSNCSNFSKVICVRKNLREVDPDGISNTNRLNLHENOIQIKVNS-FKHLRHLLEIL 105  
Db 2 CPEKCRCEG--TTVDCSNQRLNKIPDHIPQYTAEELNNNEFTLEATGIFKKLPQURXI 59  
QY 106 QLSRNHIRTIEIGAFNGLANLNTLEFDNRLTTPNGAFVYLSKLKELWRNPNIESIPS 165  
Db 60 NFSNKKITDIEGAFEGAGSGVNEILLTSNRLNENYQHKMFGLSKLTMLRSNRISCVGN 119  
QY 166 YAFNRIPSLRRLDGLGELKRLSYISEGAFEGLSNRYLNLM-----CN----- 208  
Db 120 DSFTGLGSRLLSLYD-NQITVAPGAFDXLHLSLSTLNLNLANPENCNCHLAWLGEWLRRK 178  
QY 209 -----LREIP-----NLTPLIK----- 220  
Db 179 RIVTGNPRCKPKYFLKEIPIQDVAIQDFTCDGNDNDNSCPLSRCPSECTCLDTXVRCSN 238  
QY 221 -----LDELDSGNHLSAIRPGSFQGLMH 244  
Db 239 KGLKVLPGKIPKDVTELYLDGNQFTLVLPKELSNYKHLTLIDLNNRISTLSNQFENMTQ 298  
QY 245 LQKUMVTSQIQVIERNAFNLQSLVEINLAHNLTLLPHDLFTPLHLERLHLHNPWN 304  
Db 299 LLTILSYNRLURCIPPTFDGLKSLRLSLHSGNDISVVPEGAFNDLSALSLHAIGANPLY 358  
QY 305 CNCIDILWSLWIKDMAPSNTACCARGTTPNKLGRYIGELDONVETCYAPVIVEPPADLN 364  
Db 359 CDCNNQWLSDMVK--SEYKEPGIARCAGPGEMADKLLTTPSKKFTCOGPMIDITQAKCN 416

RESULT 12  
S46224  
peroxidase - fruit fly (Drosophila sp.)  
C:Species: Drosophila sp.  
C>Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 24-Oct-2000  
C:Accession: S46224  
R:Nelson, R.E.; Fessler, L.I.; Takagi, Y.; Blumberg, B.; Keene, D.R.; Olson, P.F.; Pa  
EMBO J. 13, 3438-3447, 1994  
A:Title: Peroxidase: a novel enzyme-matrix protein of Drosophila development.  
A:Reference number: S46224; MUID:94341255  
A:Accession: S46224  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-1535 <NEL>  
A:Cross-references: GB:U11052; NID:g531384; PID:AAA61568.1; PID:g531385  
C:Superfamily: peroxidase; myeloperoxidase homology; proteoglycan amino-terminal hom  
F:19-44/Domain: proteoglycan amino-terminal homology <PAH4>  
F:661-1350/Domain: myeloperoxidase homology <MPX>

Query Match 10.0%; Score 337.5; DB 2; Length 1535;  
Best Local Similarity 25.6%; Pred. No. 5.9e-14;  
Matches 106; Conservative 58; Mismatches 141; Indels 109; Gaps 13;  
QY 26 LLVYLLALQLLVAGLVRATQCPSCVCSNQFSKVICVRKNLREVDPDGISNTNRLNLH 85  
Db 6 LMQLQLGL-LLLLAGGVQSVYCPAGCTCLER--TVRIRAKLSAVP----- 48  
QY 86 NQIOIKVNSFKHLRHLLEILQLSRHHRTIEIGAFNGLANLNTLELFDNRLTTPNGAFV 145











GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 26, 2002, 15:41:28 ; Search time 13.57 Seconds  
(without alignments)  
1826.125 Million cell updates/sec

Title: US-09-905-056-292  
Perfect score: 3362  
Sequence: 1 MLNRMTHLPHQIMIGPRFNR.....VHEPLLIRMSKDNVQETQI 640

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 105224 seqs, 38719550 residues

Total number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : SwissProt\_40:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	438.5	13.0	713	1 GAC1_HUMAN	O75325 homo sapien
2	411.5	12.2	361	1 CHAD_BOVIN	Q27972 bos taurus
3	369.5	11.0	567	1 GPV_MOUSE	O08742 mus musculu
4	361.5	10.8	567	1 GPV_RAT	O08770 rattus norv
5	350	10.4	1480	1 SLIT_DROME	P24014 drosophila
6	335	10.0	605	1 ALS_PAPHA	O02833 papio hamad
7	329.5	9.8	560	1 GPV_HUMAN	P40197 homo sapien
8	320	9.5	605	1 ALS_HUMAN	P35858 homo sapien
9	312	9.3	603	1 ALS_RAT	P35859 rattus norv
10	311	9.3	603	1 ALS_MOUSE	P70389 mus musculu
11	302	9.0	359	1 PGS2_HUMAN	P07585 homo sapien
12	299	8.9	360	1 PGS2_HORSE	O46542 equus cabal
13	296.5	8.8	626	1 GPBA_HUMAN	P07359 homo sapien
14	295	8.8	360	1 PGS2_CANFA	Q29333 canis fami
15	295	8.8	360	1 PGS2_PIG	Q9xsd9 sus scrofa
16	293	8.7	357	1 PGS2_CHICK	P28675 gallus gall
17	293	8.7	360	1 PGS2_BOVIN	P21793 bos taurus
18	293	8.7	360	1 PGS2_RABIT	Q28888 oryctolagus
19	290	8.6	354	1 PGS2_MOUSE	P28654 mus musculu
20	287.5	8.5	536	1 CBP8_HUMAN	P22792 homo sapien
21	287	8.5	354	1 PGS2_RAT	Q01129 rattus norv
22	276	8.2	353	1 KERA_COTJA	Q9de66 coturnix co
23	276	8.2	966	1 Y918_HUMAN	O94991 homo sapien
24	274.5	8.2	331	1 PLIB_AGKBL	O93233 agkistrodon
25	274	8.1	353	1 KERA_CHICK	O42235 gallus gall
26	271.5	8.1	368	1 PGS1_HUMAN	P21810 homo sapien
27	271.5	8.1	369	1 PGS1_CANFA	O02678 canis fami
28	271.5	8.1	372	1 PGS1_HORSE	O46403 equus cabal
29	270.5	8.0	369	1 PGS1_MOUSE	P28653 mus musculu
30	270.5	8.0	369	1 PGS1_RAT	P47853 rattus norv
31	269.5	8.0	369	1 PGS1_SHEEP	O46390 ovis aries
32	268.5	8.0	369	1 PGS1_BOVIN	P21809 bos taurus
33	268	8.0	423	1 OMD_RAT	Q9z1s7 rattus norv

ALIGNMENTS

RESULT 1	GAC1_HUMAN	STANDARD;	PRT;	713 AA.
ID	GAC1_HUMAN	STANDARD;	PRT;	713 AA.
AC	O75325;			
DT	16-OCT-2001 (Rel. 40, Created)			
DT	16-OCT-2001 (Rel. 40, Last sequence update)			
DT	01-MAR-2002 (Rel. 41, Last annotation update)			
DE	Glioma amplified on chromosome 1 protein precursor.			
GN	GAC1.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Glial tumor;			
RX	MEDLINE=98324709; PubMed=9662332;			
RA	Malfoy B., Almeida A., Zhu X.X., Vogt N., Tyagi R., Muleris M.,			
RA	Dutrillaux A.-M., Dutrillaux B., Ross D., Hanash S.;			
RT	*GAC1, a new member of the leucine-rich repeat superfamily on			
RT	chromosome band 1q32.1, is amplified and overexpressed in malignant			
RT	gliomas.";			
RL	Oncogene 16:2997-3002(1998).			
CC	-1- SUBCELLULAR LOCATION: Type I membrane protein (Potential).			
CC	-1- TISSUE SPECIFICITY: OVERAMPLIFIED IN MALIGNANT GLIOMAS.			
CC	-1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.			
CC	-1- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAIN.			
CC	-1- SIMILARITY: CONTAINS 11 LEUCINE-RICH REPEATS (LRR).			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (see <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a>			
CC	or send an email to <a href="mailto:license@isb-sib.ch">license@isb-sib.ch</a> ).			
CC	-----			
DR	EMBL; AF030435; AAC39792.1;			
DR	MIN; 605492;			
DR	InterPro; IPR003598; Iq_c2.			
DR	InterPro; IPR001611; LRR.			
DR	InterPro; IPR000483; LRR_Cterm.			
DR	InterPro; IPR000372; LRR_Nterm.			
DR	InterPro; IPR003592; LRR_out.			
DR	InterPro; IPR003591; LRR_typ.			
DR	Pfam; PF00047; Iq; 1.			
DR	Pfam; PF00560; LRR; 10.			
DR	Pfam; PF01463; LRRCT; 1.			
DR	Pfam; PF01462; LRRNT; 1.			
DR	PRINTS; PR00019; LEURICHRPT.			
DR	SMART; SM00408; IGC2; 1.			
DR	SMART; SM00370; LRR; 6.			
DR	SMART; SM00082; LRRCT; 1.			
DR	SMART; SM00013; LRRNT; 1.			
DR	SMART; SM00369; LRR_TYP; 2.			

P82963 tribolium c  
O99mb1 mus musculu  
P12024 drosophila  
O9nyk1 homo sapien  
O94933 homo sapien  
P51888 homo sapien  
O15455 homo sapien  
P58681 mus musculu  
O62702 bos taurus  
O35103 mus musculu  
O60938 homo sapien  
P23515 homo sapien

KW Immunoglobulin domain; Transmembrane; Glycoprotein; Repeat;  
KW Leucine-rich repeat; Signal.

FT SIGNAL 1 18 POTENTIAL.  
FT CHAIN 19 713 GLIOMA AMPLIFIED ON CHROMOSOME 1 PROTEIN.  
FT DOMAIN 19 630 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 631 651 POTENTIAL.  
FT DOMAIN 652 713 CYTOPLASMIC (POTENTIAL).  
FT REPEAT 92 115 LRR 1.  
FT REPEAT 116 139 LRR 2.  
FT REPEAT 140 163 LRR 3.  
FT REPEAT 165 187 LRR 4.  
FT REPEAT 188 211 LRR 5.  
FT REPEAT 213 235 LRR 6.  
FT REPEAT 236 259 LRR 7.  
FT REPEAT 261 283 LRR 8.  
FT REPEAT 309 333 LRR 9.  
FT REPEAT 334 357 LRR 10.  
FT REPEAT 359 385 LRR 11.  
FT DOMAIN 438 504 IG-LIKE C2-TYPE DOMAIN.  
FT DISULFID 445 497 BY SIMILARITY.  
FT CARBOHYD 94 94 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 381 381 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 555 555 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 583 583 N-LINKED (GLCNAC. . .) (POTENTIAL).  
SQ SEQUENCE 713 AA; 78798 MW; EC8BC0FD240C9396 CRC64;

Query Match 13.0%; Score 438.5; DB 1; Length 713;  
Best Local Similarity 25.2%; Pred. No. 2.3e-22;  
Matches 147; Conservative 86; Mismatches 228; Indels 123; Gaps 12;

QY 20 RALFDPDLVLLALQLVLVAGLVRAQTCPSVCSCS-----NQFSKVICVRKNLR 68  
DB 2 RLLVAPLLAAVACATAAPVPPVPHVPCPCQACQIRPWTPRSSYREATTVDNCLFLT 61  
QY 69 EYPDGISTNTPLLNHENOQIIKVNSEFKHLRHEILQLSRNHRTRTEIGAFNGLANT 128  
DB 62 AVPPALPAGTQTLQLQNSIVRVDSGLYLANETELDSLSONSFSDARDCDFHALPQLLS 121  
QY 129 LEFDNRLLTPNGAFVYLSKELKELNRRNPPIESIPVAFNRIPSLRLDLGE----- 181  
DB 122 LHLEENQLTREDSHFSAGLASQLQELYNHNLQYRIAPRFGSLNLLRLHLSNLLRAID 181  
QY 182 -----LKRSLYISEGA-----FEGLSNRLRYLNLANCNRLEIPN----- 214  
DB 182 SRWFEMLPNLEILMIGGNKVDAILDMNFRPLANERSLVLAGMNLREISDYALEGLQSLES 241  
QY 215 -----LPLIKLDELDSGNHLSAIRPGSFGQMLHQLKLNWIOSQ----- 254  
DB 242 LSFYDNLARVPRRALBOVPGKFLDKLNKPLQRVGPGDFANMLHLKELGLNNMEELVSI 301  
QY 255 -----IQVIERNAFDNQLQSLVEINLAHNHNLTLPLHDLFTPLHL 293  
DB 302 DKFALVNLPELTKLDITNNPLSLFIHPRAFHHLPMQETMLNNSALHQQTVESLPNL 361  
QY 294 ERIHLHNPNWNCIDILWLS---HWIKDAPSNTACCARCNTPNLKGRIYIGELDQNYFT 350  
DB 362 QEVGLHGNPIRCDVCIRWANATGTRVRFEIPEQSTLCA-----EPDQLRQLPVREVPFREM 417  
QY 351 CYAPVIVPEP---PADLNVTEGMAELKRA-STSLTSVSWITPNTGVTWTHGAYKVRTAVL 406  
DB 418 DHCLPLISPRFSPSLQVAGESMVLCHRALAEPEIYVWTPAGLRLTPAHAGRRRCRV 477  
QY 407 SDGTLNFTNTVQDTGMVTCVNSVGNVTASATLNTVTAATTPFSYFSTVVTETMEPSQ 466  
DB 478 PEGTLELRRVTAEGAGLYCTCAQNLGVADTKVSVVVGRA-----LLQPGR 523  
QY 467 DEATTNNNGVTP-----VVDWETNTVTSLSLTPQSTRSTKFT 506  
DB 524 DEGOGLERVOETHPYHLLSW-----VTPDNTVSTNLTWS 559

RESULT 2

CHAD\_BOVIN STANDARD; PRT; 361 AA.  
ID Q27972;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 30-MAY-2000 (Rel. 39, Last annotation update)  
DE Chondroadherin precursor (Cartilage leucine-rich protein) (38 kDa bone  
DE protein).  
GN CHAD  
OS Bos taurus (Bovine).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;  
OC Bovidae; Bovinae; Bos.  
OX NCBI\_TaxID=9913;  
RN [1]  
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.  
RC TISSUE=Cartilage;  
RX MEDLINE=9434341; PubMed=8063792;  
RA Name P.J., Sommarin Y., Boynton R.E., Heinigaard D.;  
RT "The structure of a 38-kDa leucine-rich protein (chondroadherin)  
RT isolated from bovine cartilage.";  
RL J. Biol. Chem. 269:21547-21554(1994).  
RN [2]  
RP SEQUENCE OF 25-55 AND 77-97.  
RC TISSUE=Bone;  
RX MEDLINE=95113864; PubMed=7814406;  
RA Hu B., Coulson L., Moyer B., Price P.A.;  
RT "Isolation and molecular cloning of a novel bone phosphoprotein  
RT related in sequence to the cystatin family of thiol protease  
RT inhibitors.";  
RL J. Biol. Chem. 270:431-436(1995).  
CC -----  
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
CC or send an email to license@isb-sib.ch).  
CC -----  
CC EMBL: U08018; AAA21330.1;  
DR InterPro; IPR001611; LRR.  
DR InterPro; IPR000483; LRR\_Cterm.  
DR InterPro; IPR000372; LRR\_Nterm.  
DR InterPro; IPR003591; LRR\_Typ.  
DR Pfam; PF00560; LRR; 10.  
DR Pfam; PF01463; LRRCT; 1.  
DR Pfam; PF01482; LRRNT; 1.  
DR SMART; SM00082; LRRCT; 1.  
DR SMART; SM00013; LRRNT; 1.  
DR SMART; SM00369; LRR\_Typ; 5.  
KW Repeat; Signal.  
FT SIGNAL 1 24 OR 23 (IN SOME ISOFORM(S)).  
FT CHAIN 25 361 CHONDROADHERIN.  
FT CHAIN 25 352 CHONDROADHERIN, MINOR FORM.  
FT DOMAIN 79 317 10 X 24 AA LEUCINE-RICH TANDEM REPEATS.  
FT REPEAT 79 102 1.  
FT REPEAT 103 126 2.  
FT REPEAT 127 150 3.  
FT REPEAT 151 174 4.  
FT REPEAT 175 198 5.  
FT REPEAT 199 222 6.  
FT REPEAT 223 246 7.  
FT REPEAT 248 271 8.  
FT REPEAT 272 293 9.  
FT REPEAT 294 317 10.  
FT DISULFID 306 348  
FT DISULFID 308 328  
FT CONFLICT 25 25 C -> Y (IN REF. 2).  
FT CONFLICT 29 29 C -> W (IN REF. 2).  
FT CONFLICT 31 31 C -> H (IN REF. 2).  
FT CONFLICT 40 40 C -> L (IN REF. 2).  
FT CONFLICT 52 52 S -> R (IN REF. 2).

DR	InterPro:	IPR001611;	LRR.
DR	InterPro:	IPR000483;	LRR_Cterm.
DR	InterPro:	IPR000372;	LRR_Nterm.
DR	InterPro:	IPR003592;	LRR_Out.
DR	InterPro:	IPR003591;	LRR_Typ.
DR	Pfam:	PF00560;	LRR_13.
DR	Pfam:	PF01463;	LRRCT; 1.
DR	PRINTS:	PR00019;	LEURICHRPT.
DR	SMART:	SM00370;	LRR; 1.
DR	SMART:	SM00082;	LRRCT; 1.
DR	SMART:	SM00013;	LRRNT; 1.
DR	SMART:	SM00369;	LRR_Typ; 10.
KW	Platelet;	Transmembrane;	Glycoprotein; Blood coagulation;
KW	Repeat;	Leucine-rich repeat;	Cell adhesion; Signal.
FT	SIGNAL	1	POTENTIAL.
FT	CHAIN	17	PLATELET GLYCOPROTEIN V.
FT	DOMAIN	17	EXTRACELLULAR (POTENTIAL).
FT	TRANSMEM	523	POTENTIAL.
FT	DOMAIN	544	CYTOPLASMIC (POTENTIAL).
FT	REPEAT	73	LRR 1.
FT	REPEAT	97	LRR 2.
FT	REPEAT	122	LRR 3.
FT	REPEAT	145	LRR 4.
FT	REPEAT	170	LRR 5.
FT	REPEAT	194	LRR 6.
FT	REPEAT	217	LRR 7.
FT	REPEAT	241	LRR 8.
FT	REPEAT	266	LRR 9.
FT	REPEAT	289	LRR 10.
FT	REPEAT	314	LRR 11.
FT	REPEAT	338	LRR 12.
FT	REPEAT	362	LRR 13.
FT	REPEAT	386	LRR 14.
FT	CARBOHYD	51	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	67	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	181	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	243	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	298	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	312	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD	385	N-LINKED (GLCNAC. .) (POTENTIAL).
SQ	SEQUENCE	567 AA;	C48643AA73967A7D C6C64;

Query Match 11.0%; Score 369.5; DB 1; Length 567;  
 Best Local Similarity 30.1%; Pred. No. 8e-18;  
 Matches 119; Conservative 63; Mismatches 166; Indels 47; Gaps

Qy	1	M L N K W T L H P Q O I M G P R E N A L D P L L V L L A L Q L L V V A G L V R A Q T C -- P S V C S C S N Q F 57
Dd	117	I L D K M V L - L G O L F D H N A L R D L D Q N L F Q Q U R N L Q E L --- G L N Q N Q S L F P A N L F S S U R E L 172
Qy	58	S K Y I C V R K N L R E V P D G I --- S T N T R L N L H E N Q I T I K V N S F K H R L H L E I L Q L S R N H I R T 114
Dd	173	K L I D L S R N N L T H L P K G L L G A Q V K L E K L L L Y S N Q L T S V D S G L L S N I G A L T E L R L E R N H L R S 232
Qy	115	I E T G A F N G L A N L T F L E F D N R L T T I P N G A F V Y L S K U K E L M W R N N P T E S I P S Y A F N R I P S L 174
Dd	233	V A P G A F D R L G N L S L T S G N L L E S L P P A L F H V S S V S R L T F E N P L E E L P D V L F G M A G L 292
Qy	175	R R L D L G E L K R L S Y I S E A F E G L S N L R Y L N L A M C N L R E I P N L T P L I K ----- L D E L D S G N 229
Dd	293	R E L W I N G - T H L S T L P A A A F R N L S G I Q T L G T ----- R N P R S A L P R G V F O G L R E L R V I G L 346
Qy	230	H --- L S A I R P G S F Q G L M H L Q K L M M I O S Q I O V I E R N A F D N L Q S L V E I N A H N N L T L L P H D L 286
Dd	347	H T N A L E A R D A L R G L G H L R Q V S L R H N R A L P R T L F R N L S S L E S V Q L E H N Q L E T L P G D V 406
Qy	287	F T P L H L E R I H L H N P N C N C D I L W L S W L K D N A P S N T A C C A R C N T P P N L K G R Y I G E L Q 346
Dd	407	F A A L P Q L T Q V L L G H N P W L C D G L W R F L Q W L R H ----- H P D I L G R - - D E P P O 450
Qy	347	N Y F T C Y A P V I E P A D L N V T E G M A A E L K C R A S T S L 381

Db 451 ----CRGP----EPRASLFWELQGDWCPDPRSL 478

## RESULT 4

GPV\_RAT ID GPV\_RAT STANDARD: PRT; 567 AA.

AC O08770;  
DT 15-JUL-1998 (Rel. 36, Created)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Platelet glycoprotein V precursor (GPV) (CD42b).  
GN GPS.

OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]

RP SEQUENCE FROM N.A.  
RC STRAIN=WISTAR; TISSUE=Liver;  
RX MEDLINE=97275136; PubMed=9129030;  
RA Ravanat C., Morales M., Azorsa D.O., Moog S., Schuhler S.,  
RA Grunert P., Loew D., van Dorsselaer A., Cazenave J.-P., Lanza F.;  
RT "Gene cloning of rat and mouse platelet glycoprotein V;  
RT identification of megakaryocyte-specific promoters and demonstration  
RT of functional thrombin cleavage.";  
RL Blood 89:3253-3262(1997).

CC -!- FUNCTION: THE GPIB-V-IX COMPLEX FUNCTIONS AS THE VON WILLEBRAND  
CC FACTOR RECEPTOR AND MEDIATES VON WILLEBRAND FACTOR-DEPENDENT  
CC PLATELET ADHESION TO BLOOD VESSELS. THE ADHESION OF PLATELETS TO  
CC INJURED VASCULAR SURFACES IN THE ARTERIAL CIRCULATION IS A  
CC CRITICAL INITIATING EVENT IN HEMOSTASIS (BY SIMILARITY).  
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.  
CC -!- SIMILARITY: CONTAINS 14 LEUCINE-RICH REPEATS (LRR).  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC -----

CC EMBL; Z69594; CAA93440.1; -;  
CC InterPro; IPR001611; LRR.  
CC InterPro; IPR000483; LRR\_Cterm.  
CC InterPro; IPR000372; LRR\_Nterm.  
CC InterPro; IPR003592; LRR\_out.  
CC InterPro; IPR003591; LRR\_typ.  
CC Pfam; PF00560; LRR; 14.  
CC Pfam; PF01463; LRRCT; 1.  
CC PRINTS; PR00019; LEURICHRPT.  
CC SMART; SM00370; LRR; 2.  
CC SMART; SM00082; LRRCT; 1.  
CC SMART; SM00013; LRRNT; 1.  
CC SMART; SM00369; LRR\_TTP; 10.

CC Platelet; Transmembrane; Glycoprotein; Blood coagulation;  
CC Repeat; Leucine-rich repeat; Cell adhesion; Signal.  
CC SIGNAL 1 16  
CC CHAIN 17 567  
CC DOMAIN 17 522  
CC TRANSMEM 523 543  
CC POTENTIAL.

CC PLATELET GLYCOPROTEIN V.  
CC EXTRACELLULAR (POTENTIAL).  
CC POTENTIAL.

CC CHAIN 17 567  
CC DOMAIN 17 522  
CC TRANSMEM 523 543  
CC POTENTIAL.

CC PLATELET GLYCOPROTEIN V.  
CC EXTRACELLULAR (POTENTIAL).  
CC POTENTIAL.

CC CHAIN 17 567  
CC DOMAIN 17 522  
CC TRANSMEM 523 543  
CC POTENTIAL.

CC PLATELET GLYCOPROTEIN V.  
CC EXTRACELLULAR (POTENTIAL).  
CC POTENTIAL.

CC CHAIN 17 567  
CC DOMAIN 17 522  
CC TRANSMEM 523 543  
CC POTENTIAL.

CC PLATELET GLYCOPROTEIN V.  
CC EXTRACELLULAR (POTENTIAL).  
CC POTENTIAL.

CC CHAIN 17 567  
CC DOMAIN 17 522  
CC TRANSMEM 523 543  
CC POTENTIAL.

CC PLATELET GLYCOPROTEIN V.  
CC EXTRACELLULAR (POTENTIAL).  
CC POTENTIAL.

CC CHAIN 17 567  
CC DOMAIN 17 522  
CC TRANSMEM 523 543  
CC POTENTIAL.

CC PLATELET GLYCOPROTEIN V.  
CC EXTRACELLULAR (POTENTIAL).  
CC POTENTIAL.

CC CHAIN 17 567  
CC DOMAIN 17 522  
CC TRANSMEM 523 543  
CC POTENTIAL.

CC PLATELET GLYCOPROTEIN V.  
CC EXTRACELLULAR (POTENTIAL).  
CC POTENTIAL.

CC CHAIN 17 567  
CC DOMAIN 17 522  
CC TRANSMEM 523 543  
CC POTENTIAL.

FT REPEAT 338 361 LRR 12.  
FT REPEAT 362 385 LRR 13.  
FT REPEAT 387 409 LRR 14.  
FT CARBOHYD 51  
FT CARBOHYD 181 181 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 243 243 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 298 298 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 312 312 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 385 385 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 498 498 N-LINKED (GLCNAC. . .) (POTENTIAL).  
SQ SEQUENCE 567 AA; 63344 MW; CAL0708E0D03707F CRC64;

Query Match 10.8%; Score 361.5; DB 1; Length 567;  
Best Local Similarity 29.0%; Pred. No. 2.8e-17;  
Matches 121; Conservative 59; Mismatches 180; Indels 57; Gaps 11;

Qy 1 MNKMTLHPQOIMIGPFRNRAFDPLLVLLALQLLVVLVAGLVRAQTCPSCVSCSQNFS-- 58  
Db 117 ILDKMVL-LEQLFLDHNAIRDLDQNLFOKLENL- - - - -DLCLNQQLSFL 161

Qy 59 - - - - -KVICV-RKNLREVPDGI- - - - -STNTRLLNLHENOIQIITKVNSEKHLRLE 103  
Db 162 PANLFSSLGKUKVLDLSRNNLTHLPQGLGGAQIKLEKULLYSNRULMSDLSGLLANZGALT 221

Qy 104 ILQLSRNHRTIEGAFNGLANLNTLEFDRNLTPGPAFVYLSKELMLRNPIESI 163  
Db 222 ELRLERNHLRSIAPGAFDSLGNLSTLTLSGNLLESPPALFLHYSWLTTLFENPLEEL 281

Qy 164 PSYAFNIPSRRLDGLGELKRLSYISGAFGLSMLRYNLAMCMLEIPNLT- - - - -L 218  
Db 282 PEVLFGEMAGRLWNLG-THLRTLPAFAAFNLGLQTLGLTRNPL- - -LSALPGMFHGL 338

Qy 219 IKLDELDSGNHLSAIRPGSFGMLHQLKAMIOSIQIOVIERNADFNLQSLVEINLANN 278  
Db 339 TELRLVAVHTNALBELPEDALRGGLRQVSLRHNRRLALPTRLFRNLSLVTVLEHNQ 398

Qy 279 LTLPLHDLFTPLHLERLTHLHNPNWNCNDILWLSWI- - - - -KDMAPSNTACCARC 330  
Db 339 LKTLPGDVFALPOLTRVLLGHNPWLCDCGLWPFLOWLRHLELLGRDEPP- - - - -QC 451

Qy 331 NTPNPKGRYIGELDONFTCYAPVIVPEPPADLVNTEGMAAELKCRASTSLTSVSI 387  
Db 452 NGPESRASLTFWELQGDQWC- - -PSSRGLPDPPTTENALKAPDPTQRPNSQSWAW 506

RESULT 5  
SLIT\_DROME ID SLIT\_DROME STANDARD: PRT; 1480 AA.

AC P24014;  
DT 01-MAR-1992 (Rel. 21, Created)  
DT 01-MAR-1992 (Rel. 21, Last sequence update)  
DT 01-MAR-2002 (Rel. 41, Last annotation update)  
DE Slit protein precursor.

GN SLI.  
OS Drosophila melanogaster (Fruit fly).  
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;  
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
OC Ephydroidea; Drosophilidae; Drosophila.

OX NCBI\_TaxID=7227;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=91099665; PubMed=2176636;  
RA Rothberg J.M., Jacobs J.R., Goodman C.S., Artavanis-Tsakonas S.;  
RT "Slit: an extracellular protein necessary for development of midline  
RT glia and commissural axon pathways contains both EGF and LRR  
RT domains.";  
RL Genes Dev. 4:2169-2187(1990).

CC -!- FUNCTION: NECESSARY FOR DEVELOPMENT OF MIDLINE GLIA AND  
CC COMMISSURAL AXON PATHWAYS. SLIT MAY INTERACT WITH EXTRACELLULAR  
CC MATRIX MOLECULES.  
CC -!- ALTERNATIVE PRODUCTS: 2 ISOFORMS; A LONG FORM (SHOWN HERE) AND A  
CC SHORT FORM; ARE PRODUCED BY ALTERNATIVE SPLICING.



```
Qy 211 -----EIPNLTP-----TKLD-----ELDSGNHLSAIRPGS 238
Db 471 PIETSGARCESPKRMHRRRIEBSLREKFKCSWGLRMKLSGECRMDSDCPAMCHCEGTVV 530
Qy 211 -----EIPNLTP-----TKLD-----ELDSGNHLSAIRPGS 238
Db 531 DCTGRLKEIPDIPLHTTELLNDNELGRISDGLFGLRPLHLVKLELKRNLQTGIEPNA 590
Qy 239 FQGLMHLOKLMWISOQIOVIERNADFNQSLQSLVEINLAHNNLTLLPHDLFTPLHLERHL 298
Db 591 FEGASHIQELQGENKTEISNKMFLGHLQKLTNLNDNQISCVMPGSEFHLNLSLNL 650
Qy 299 HNPWNCNDLILWLSWIKDMAPSNTACCRNTPPNLKGRIYIGELDONVFTCYAPVIVE 358
Db 651 ASNFNCNCHLAWFAECVRKKSNGGA--ARCGAPSKVRDVOIKDLPHSEFKCSS----- 703
Qy 359 PPADLVTEGMAELKCRASLTSLTSVSWITPNTVM 394
Db 704 -----ENSEGCLGDGYPSPCTCT-----GTWV 726

RESULT 6
ALS_PAPHA ID ALS_PAPHA STANDARD; PRT; 605 AA.
AC 002833;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE Insulin-like growth factor binding protein complex acid labile chain
DE precursor (ALS).
GN IGFALS OR ALS.
OS Papio hamadryas (Hamadryas baboon).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
OC Cercopithecoidea; Papio.
OX NCBI_TaxID=9557;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Liver;
RX MEDLINE=97040714; PubMed=8886027;
RA Delhanty P.; Baxter R.C.;
RT "The cloning and expression of the baboon acid-labile subunit of the
RT insulin-like growth factor binding protein complex.";
RL Biochem. Biophys. Res. Commun. 227:897-902(1996).
CC -!- FUNCTION: INVOLVED IN PROTEIN-PROTEIN INTERACTIONS THAT RESULT
CC IN PROTEIN COMPLEXES, RECEPTOR-LIGAND BINDING OR CELL ADHESION.
CC -!- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 kDa WITH
CC IGF-I OR IGF-II AND IGF-BP-3 (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Extracellular.
CC -!- SIMILARITY: CONTAINS 20 LEUCINE-RICH REPEATS (LRR).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; S83462; .. NOT_ANNOTATED_CDS.
CC HSSP; P23945; 1XUN.
CC InterPro; IPR001611; LRR.
CC InterPro; IPR000483; LRR_Nterm.
CC InterPro; IPR000372; LRR_Nterm.
CC InterPro; IPR003592; LRR_out.
CC InterPro; IPR003591; LRR_typ.
CC Pfam; PF00560; LRR; 19.
CC Pfam; PF01463; LRRCT; 1.
CC PRINTS; PR00019; LEURICHRPT.
CC SMART; SM00370; LRR; 2.
CC SMART; SM00082; LRRCT; 1.
```

```
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_Typ; 11.
KW Glycoprotein; Leucine-rich repeat; Repeat; Signal.
FT SIGNAL 1 27 BY SIMILARITY.
FT CHAIN 28 605 INSULIN-LIKE GROWTH FACTOR BINDING
FT PROTEIN COMPLEX ACID LABILE CHAIN.
FT REPEAT 53 73 LRR 1.
FT REPEAT 74 96 LRR 2.
FT REPEAT 98 120 LRR 3.
FT REPEAT 121 144 LRR 4.
FT REPEAT 146 168 LRR 5.
FT REPEAT 169 192 LRR 6.
FT REPEAT 194 216 LRR 7.
FT REPEAT 217 240 LRR 8.
FT REPEAT 242 264 LRR 9.
FT REPEAT 265 288 LRR 10.
FT REPEAT 289 312 LRR 11.
FT REPEAT 313 336 LRR 12.
FT REPEAT 338 360 LRR 13.
FT REPEAT 361 384 LRR 14.
FT REPEAT 386 408 LRR 15.
FT REPEAT 409 432 LRR 16.
FT REPEAT 433 456 LRR 17.
FT REPEAT 458 480 LRR 18.
FT REPEAT 482 504 LRR 19.
FT REPEAT 505 530 LRR 20.
FT CARBOHYD 64 64 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 85 85 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 96 96 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 368 368 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 515 515 N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 580 580 N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 605 AA; 66110 MW; 9D71994625F23652 CRC64;
```

Query Match 10.0%; Score 335; DB 1; Length 605;

Best Local Similarity 20.8%; Pred. No. 1.9e-15;

Matches 125; Conservative 64; Mismatches 125; Indels 286; Gaps 13;

```
Qy 31 LALQLLVVA-----GLVRAQTCPSCVSCS-----NOFSVICVKKRLR 68
Db 8 LALALLLSWALGPRSLGAEPTGGEAGPACATCATCSDYDEVNELS-VFCSSRLT 66
Qy 69 EVDGISTNTRL-----
Db 67 RLPDGIPTGTOALWLDSDNNLSIPPAFRNLSSLAFLNLQGGQLSGLEPQALLGLENLCH 126
Qy 81 LNLHENQIQIKVNSFKHLRHLLEILQLSRNHRTIEICAFNGLANLNTLELFDNRLTTP 140
Db 127 LHLERNQLRSVAVGTFTAYTPALALLGLSNRLSRLEDFEGGLGNLDNLGNWSLAVLP 186
Qy 141 NGAF-----VY-----LSKLKELMLRNNPIESIPSYAFNRIPSRLR 176
Db 187 DAAEFGGLRELVLGNRLAYLQPALEFGLAELRELDLSRNALRAIKANVPAQLPRLOK 246
Qy 177 L-----
Db 247 LYLDRLTAAVAPGAFGLKALRWLDLSHNRVAGLLEDFPCLLGLRLVRLSHNIAASLR 306
Qy 178 -----DLGELK-----RLSYISGGAPEGLSLRY 201
Db 307 PRTEDLHLFLEELQIGHNRIQLAERSPEGLQGLEVLTDHNLQGVKVGAFGLTNVAV 366
Qy 202 LNLAMCNLRIPN--LTPLIKLDELDSLGNHLSAIRPGSFQGLMHLOKLMWISOQIOVIE 259
Db 367 MNLSCNLRNLPEQVFRGLGKLSLHLESGSLGRIRPHTFAGLSGLRLFLKDKNLGVIE 426
Qy 260 RNAFDNQSLVEINLAHNNLTLLPHDLFTPL-----
Db 427 EQSLWGLAELLEDLTSNQLTHLPHQLFQGLKLEKLYLLSHNRLAELPADALGPLQRAFW 486
Qy 291 ---HH-----LERHLHHPNMCNDILW 311
```

Db 487 LDVSHNLEALPSGLIASLGRLYLRLNNSLRFTFPQPLERLRLWLEGNWPCSLKA 546,  
QY 312 LSWIKMDAPNTACCAR-----CNTPPNLKGRYIGELDONF 349,  
Db 547 L-----RDFALONFSAVPRFVQACEGDCOPVYNNITCASPPVAGLDLRLDGEAHF 602

RESULT 7  
GPV\_HUMAN STANDARD; PRT; 560 AA.  
AC P40197;  
DT 01-FEB-1995 (Rel. 31, Created)  
DT 01-FEB-1995 (Rel. 31, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Platelet glycoprotein V precursor (GPV) (CD42D).  
GN GP5.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Lung;  
RX MEDLINE=93391348; PubMed=7690959;  
RA Hickey M.J., Hagen F.S., Yagi M., Roth G.J.;  
RT "Human platelet glycoprotein V: characterization of the polypeptide  
and the related ib-v-ix receptor system of adhesive, leucine-rich  
glycoproteins.";  
RL Proc. Natl. Acad. Sci. U.S.A. 90:8327-8331(1993).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC TISSUE=platelet;  
RX MEDLINE=94012616; PubMed=8407908;  
RA Lanza F., Morales M., de la Salle C., Cazenave J.-P., Clemetson K.J.,  
RT Shimomura T., Phillips D.R.;  
RT "Cloning and characterization of the gene encoding the human platelet  
glycoprotein V. A member of the leucine-rich glycoprotein family  
cleaved during thrombin-induced platelet activation.";  
RL J. Biol. Chem. 268:20801-20807(1993).  
RN [3]  
RP PARTIAL SEQUENCE.  
RC TISSUE=platelet;  
RX MEDLINE=90275263; PubMed=2350580;  
RA Shimomura T., Fujimura K., Maehama S., Takemoto M., Oda K.,  
RA Fujimoto T., Oyama R., Suzuki M., Ichiara-Tanaka K., Titani K.,  
RA Kuramoto A.;  
RT "Rapid purification and characterization of human platelet  
glycoprotein V: the amino acid sequence contains leucine-rich  
repetitive modules as in glycoprotein Ib.";  
RL Blood 75:2349-2356(1990).  
RN [4]  
RP PARTIAL SEQUENCE.  
RC TISSUE=platelet;  
RX MEDLINE=90321220; PubMed=2372284;  
RA Roth G.J., Church T.A., McMullen B.A., Williams S.A.;  
RT "Human platelet glycoprotein V: a surface leucine-rich glycoprotein  
related to adhesin.";  
RL Biochem. Biophys. Res. Commun. 170:153-161(1990).  
CC -!- FUNCTION: THE GPIB-V-IX COMPLEX FUNCTIONS AS THE VON WILLEBRAND  
FACTOR RECEPTOR AND MEDIATES VON WILLEBRAND FACTOR-DEPENDENT  
PLATELET ADHESION TO BLOOD VESSELS. THE ADHESION OF PLATELETS TO  
INJURED VASCULAR SURFACES IN THE ARTERIAL CIRCULATION IS A  
CRITICAL INITIATING EVENT IN HEMOSTASIS.  
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.  
CC -!- TISSUE SPECIFICITY: PLATELETS AND MEGAKARYOCYTES.  
CC -!- PTM: THE N-TERMINUS IS BLOCKED.  
CC -!- SIMILARITY: CONTAINS 14 LEUCINE-RICH REPEATS (LRR).  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL: L11238; AAA03069.1; -;  
CC EMBL: Z23091; CAA80637.1; -;  
CC HSSP: P16473; IXUM.  
CC MIM: 173511; -;  
CC InterPro: IPR001611; LRR.  
CC InterPro: IPR000483; LRR\_Cterm.  
CC InterPro: IPR000372; LRR\_Nterm.  
CC InterPro: IPR003592; LRR\_Out.  
CC InterPro: IPR003591; LRR\_Typ.  
CC Pfam: PF00560; LRR; 14.  
CC Pfam: PF01463; LRRCT; 1.  
CC PRINTS: PR00019; LEURICHRPT.  
CC SMART: SM00370; LRR; 1.  
CC SMART: SM00082; LRRCT; 1.  
CC SMART: SM00013; LRRNT; 1.  
CC SMART: SM00369; LRR\_Typ; 9.  
CC Platelet; Transmembrane; Glycoprotein; Blood coagulation;  
KW Repeat; Leucine-rich repeat; Cell adhesion; Signal.  
FT SIGNAL 1 16  
FT CHAIN 17 560 PLATELET GLYCOPROTEIN V.  
FT DOMAIN 17 523 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 524 544 POTENTIAL.  
FT DOMAIN 545 560 CYTOPLASMIC (POTENTIAL).  
FT REPEAT 73 96 LRR 1.  
FT REPEAT 97 120 LRR 2.  
FT REPEAT 122 144 LRR 3.  
FT REPEAT 145 168 LRR 4.  
FT REPEAT 169 192 LRR 5.  
FT REPEAT 194 216 LRR 6.  
FT REPEAT 217 240 LRR 7.  
FT REPEAT 241 264 LRR 8.  
FT REPEAT 266 288 LRR 9.  
FT REPEAT 289 312 LRR 10.  
FT REPEAT 314 337 LRR 11.  
FT REPEAT 338 361 LRR 12.  
FT REPEAT 362 385 LRR 13.  
FT REPEAT 386 409 LRR 14.  
FT CARBOHYD 51 51 N-LINKED (GLCNAC. . .).  
FT CARBOHYD 181 181 N-LINKED (GLCNAC. . .).  
FT CARBOHYD 243 243 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 267 267 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 298 298 N-LINKED (GLCNAC. . .).  
FT CARBOHYD 312 312 N-LINKED (GLCNAC. . .).  
FT CARBOHYD 385 385 N-LINKED (GLCNAC. . .).  
FT CARBOHYD 499 499 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CONFLICT 73 74 MT -> TK (IN REF. 2).  
FT CONFLICT 109 109 K -> T (IN REF. 2).  
FT CONFLICT 130 130 D -> W (IN REF. 3).  
FT CONFLICT 136 138 GID -> PGG (IN REF. 3).  
FT CONFLICT 209 209 L -> I (IN REF. 2).  
FT CONFLICT 267 267 N -> H (IN REF. 3).  
FT CONFLICT 327 327 L -> I (IN REF. 2).  
FT CONFLICT 478 478 P -> G (IN REF. 2).  
FT CONFLICT 509 509 P -> D (IN REF. 2).  
SQ SEQUENCE 560 AA; 60959 MW; BICDB04AF8AF7115 CRC64;

Query Match 9.8%; Score 329.5; DB 1; Length 560;  
Best Local Similarity 29.7%; Pred. No. 4e-15;  
Matches 83; Conservative 43; Mismatches 104; Indels 49; Gaps 3;  
QY 66 NLREVDPG-----ISTNTRLLN-----LHENQIQLKVNSEFKH 98  
Db 181 NLTHLPKGLLGAQAKLERLLHSHNRLVSLDGLNLSGALTELOFHRNHSIAPGAEDR 240  
QY 99 LRHEILQLSRNHRTTEIGAGLANLNTLEFDNRLLTTPNGAFVYLSKLKELWLRNN 158  
Db 241 LPNLSSTLSNRHLAFIPSAFLSHNLTLLTFENPLAEIPGVLFGEIMGGLQELWLRNT 300  
QY 159 PIESIPSYAFNRIPSLRRRLDGLKRLSYISEGAFEGLSNRLYLNLAMCNLRIPNLTP 218

```
Db 301 QLRTPAAAFNRNLSRLRYGLVTSPLRSALPQAFQGLGELQV-----343
QY 219 IKLDELDSGNHLSAIRPGSQFGLMHLQKLMWISQIOVIERNAPDNQSLVEINLAHNN 278
Db 344 -----LALHNSGLTLPDGLLGLGKLRQVSLRRNRRLRALPRALFRNLSSLESVOLDHNO 398
QY 279 LTLPHDLFTPLHDLERHHLHNPWNCNDILWLSWLIK 317
Db 399 LETLPDGVFGALPRLTVEVLGHNSWRCDGGLGPFGLGNLR 437

RESULT 8
ALS_HUMAN
AC 35858;
DT 01-JUN-1994 (Rel. 29, Created)
DT 01-JUN-1994 (Rel. 29, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE Insulin-like growth factor binding protein complex acid labile chain
DE precursor (ALS).
GN IGFALS OR ALS.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RC SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RP TISSUE=Liver;
RX MEDLINE=92357025; PubMed=1379671;
RT Leong S.R., Baxter R.C., Camerato T., Dai J., Wood W.I.;
RT "Structure and functional expression of the acid-labile subunit of
RT the insulin-like growth factor-binding protein complex.";
RN [2]
RN Mol. Endocrinol. 6:870-876(1992).
RP SEQUENCE FROM N.A.
RA Frankland J.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RN SEQUENCE OF 28-35.
RX MEDLINE=9308584; PubMed=2473065;
RA Baxter R.C., Martin J.L., Beniac V.A.;
RT "High molecular weight insulin-like growth factor binding protein
RT complex. Purification and properties of the acid-labile subunit from
RT human serum.";
RN [1]
RN J. Biol. Chem. 264:11843-11848(1989).
CC -1- FUNCTION: INVOLVED IN PROTEIN-PROTEIN INTERACTIONS THAT RESULT
CC IN PROTEIN COMPLEXES, RECEPTOR-LIGAND BINDING OR CELL ADHESION.
CC -1- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 kDa WITH
CC IGF-I OR IGF-II AND IGFBP-3.
CC -1- SUBCELLULAR LOCATION: Extracellular.
CC -1- TISSUE SPECIFICITY: PLASMA.
CC -1- SIMILARITY: CONTAINS 20 LEUCINE-RICH REPEATS (LRR).
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/annouce/
CC or send an email to license@isb-sib.ch).
```

```
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01462; LRRNT; 1.
DR PRINTS; PR00019; LEURICHRPT.
DR SMART; SM00370; LRR; 2.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_TYP; 11.
KW Glycoprotein; Leucine-rich repeat; Repeat; Signal.
FT SIGNAL 1 27
FT CHAIN 28 605
FT REPEAT 53 73
FT REPEAT 74 96
FT REPEAT 98 120
FT REPEAT 121 144
FT REPEAT 145 168
FT REPEAT 170 192
FT REPEAT 193 216
FT REPEAT 217 240
FT REPEAT 242 264
FT REPEAT 265 288
FT REPEAT 289 312
FT REPEAT 313 336
FT REPEAT 337 360
FT REPEAT 361 384
FT REPEAT 386 408
FT REPEAT 409 432
FT REPEAT 433 456
FT REPEAT 458 480
FT REPEAT 482 504
FT REPEAT 505 530
FT REPEAT 64 64
FT CARBOHYD 64 64
FT CARBOHYD 85 85
FT CARBOHYD 96 96
FT CARBOHYD 368 368
FT CARBOHYD 515 515
FT CARBOHYD 580 580
FT SEQUENCE 605 AA; 66034 MW; F6562A23CBE918F6 CRC64;
SQ
Query Match 9.58; Score 320; DB 1; Length 605;
Best Local Similarity 29.8%; Pred. No. 2e-14;
Matches 95; Conservative 50; Mismatches 124; Indels 50; Gaps 6;
QY 31 LALQLLVVA-----GLVRAQTCPSCVSCS-----NOFSKVICVRKNLR 68
Db 8 LALALLLSWALGPRSLGADPGTGEAGPACPAACVCSYDDADELS-VFCSSRLT 66
QY 69 EYPDGISTNTLLNLHENQIOIIRVNSFKHLRHLI-----104
Db 67 RLDPGVPGGTQALWLDGNLSSVPPAFAQNLSSGLFLNLQGGQLGSLRPOALLGLENLCH 126
QY 105 LQLSNRHRTIEICAFNGLANLNTLELPDNLRTIPNGAFVYLSKLELWLRNPISIP 164
Db 127 LHLENRQLRSALGTFAHTPALASGLSNRSLRLEDGLFEGLSLWDLNLGWSLAVLP 186
QY 165 SYAFNRPLSLRDLGELKRLSYSEGAFCGLSNRLYLNLAMCNLRIPN--LPLIKLD 222
Db 187 DAAPFGLSRELVLG--NRLAYLQPALFSGLAELRELDLSNRNALRAIKANVFOLPRQ 245
QY 223 ELDSGNHLSAIRPGSQFGLMHLQKLMWISQIOVIERNAPDNQSLVEINLAHNNLTLL 282
Db 246 KLYLDRNLIAAVAPGAFGLGKALRWLDLSHNRVAGLLEDTFPGLLGLRLVLRSHNAIASL 305
QY 283 PHDLFTPLHLERLHLHNN 301
Db 306 RPRTFKDLHFLLEELQLGHN 324
RESULT 9
ALS_RAT
ID ALS_RAT
AC P35859;
STANDARD; PRT; 603 AA.
```



01-JUN-1994 (Rel. 29, Created)  
 01-JUN-1994 (Rel. 29, Last sequence update)  
 16-OCT-2001 (Rel. 40, Last annotation update)  
 Insulin-like growth factor binding protein complex acid labile chain precursor (ALS).  
 IGFALS OR ALS.  
 Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 NCBI\_TaxID=10116;  
 [1]  
 SEQUENCE FROM N.A.  
 RP TISSUE=Liver;  
 RC MEDLINE=93038676; PubMed=1384485;  
 RX Dai J., Baxter R.C.;  
 RA "Molecular cloning of the acid-labile subunit of the rat insulin-like growth factor binding protein complex."  
 RT Blochem. Biophys. Res. Commun. 188:304-309(1992).  
 RL [2]  
 RP SEQUENCE OF 24-44, AND CHARACTERIZATION.  
 RC STRAIN=Wistar; TISSUE=Serum;  
 RX MEDLINE=94130835; PubMed=7507839;  
 RA Baxter R.C., Dai J.;  
 RT "Purification and characterization of the acid-labile subunit of rat serum insulin-like growth factor binding protein complex."  
 RL Endocrinology 134:848-852(1994).  
 CC -!- FUNCTION: MAY HAVE AN IMPORTANT ROLE IN REGULATING THE ACCESS OF CIRCULATING IGFs TO THE TISSUES.  
 CC -!- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 kDa WITH IGF-I OR IGF-II AND IGFBP-3.  
 CC -!- SUBCELLULAR LOCATION: Extracellular.  
 CC -!- TISSUE SPECIFICITY: BRAIN, KIDNEY, LUNG, HEART, SPLEEN, MUSCLE AND LIVER.  
 CC -!- SIMILARITY: CONTAINS 21 LEUCINE-RICH REPEATS (LRR).  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL; S46785; AAB23770.2; -  
 CC PIR; JC1282; JC1282.  
 CC HSSP; P23945; 1XUN.  
 CC InterPro; IPR001611; LRR.  
 CC InterPro; IPR000483; LRR\_Cterm.  
 CC InterPro; IPR000372; LRR\_Nterm.  
 CC InterPro; IPR003592; LRR\_out.  
 CC InterPro; IPR003591; LRR\_typ.  
 CC Pfam; PF00560; LRR; 19.  
 CC Pfam; PF01463; LRRCT; 1.  
 CC Pfam; PF01462; LRRNT; 1.  
 CC PRINTS; PR00019; LEURICRPT.  
 CC SMART; SM00370; LRR; 5.  
 CC SMART; SM00082; LRRCT; 1.  
 CC SMART; SM00013; LRRNT; 1.  
 CC SMART; SM00369; LRR\_TYP; 9.  
 KW Glycoprotein; Leucine-rich repeat; Repeat; Signal.  
 FT SIGNAL 1 23  
 FT CHAIN 24 603  
 FT REPEAT 52 73  
 FT REPEAT 74 96  
 FT REPEAT 98 120  
 FT REPEAT 121 144  
 FT REPEAT 146 168  
 FT REPEAT 169 192  
 FT REPEAT 194 216  
 FT REPEAT 217 240  
 FT REPEAT 242 264  
 FT REPEAT 266 288

FT REPEAT 289 312 LRR 11.  
 FT REPEAT 313 336 LRR 12.  
 FT REPEAT 337 360 LRR 13.  
 FT REPEAT 361 384 LRR 14.  
 FT REPEAT 386 408 LRR 15.  
 FT REPEAT 409 432 LRR 16.  
 FT REPEAT 433 456 LRR 17.  
 FT REPEAT 458 478 LRR 18.  
 FT REPEAT 479 504 LRR 19.  
 FT REPEAT 506 529 LRR 20.  
 FT REPEAT 543 566 LRR 21.  
 FT CARBOHYD 64 64 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 85 85 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 96 96 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 368 368 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 515 515 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 578 578 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 586 586 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 SQ SEQUENCE 603 AA; 66811 MW; DCD7637D94A5037C CRC64;  
 Query Match 9.3%; Score 312; DB 1; Length 603;  
 Best Local Similarity 30.0%; Pred. No. 6.8e-14;  
 Matches 95, Conservative 46; Mismatches 136; Indels 40; Gaps 5;  
 Qy 25 PLLVLLALQLLV-----VAGLVRAQTCPSCVCSN-----QFSKVICVRKNLRE 69  
 Db 8 PALVLLAFVWALGCHLQGTDPGASADAEGPQCPVACTCSHDDYTDLSVFCSSKNLTH 67  
 Qy 70 VPDGISTWTRLLHENOIQIKVNSFKHLRHLTQLSRNHIRTEIGAFNGLANLNTL 129  
 Db 68 LPDDIPVSTRALWLDGNNLSSIPSAFQNLSSLDLFLNQGSLRSLRLEPQALLGLQNLVYL 127  
 Qy 130 ELFDNRLTTPNGAFVYLKELWLRNNPTIESIPSYAFNIPSLRRLDLG----- 180  
 Db 128 HLERNLNLAVGLTHPTPSLASLSLNNLGRLEEGFLQGLSHLDNLGNLSLVLPD 187  
 Qy 181 -----EL-----KRLSYISEGAFEGLSNRLYNLNCMLNREIPN--LTPLIKLDEL 224  
 Db 188 TVFGGLGNLHELVLVAGNLTVLPALFCGLGELRELDLSRNALRSVKANFVHLPRQLK 247  
 Qy 225 DLSGNHLSAIRPGSQGLMHLOKLMWIOSQIOVIERNADFNLQSLVEINLANNLTLLPH 284  
 Db 248 YLDNRLITAVAPGAFGLMKALRWLDLSHNRVAGLMEDTFPGLLGLHLVRLAHNAIASLRP 307  
 Qy 285 DLFTPLHLERLHLHN 301  
 Db 308 RTFRDLHFLLEQLQGHN 324  
 PRT; 603 AA.  
 RESULT 10  
 ALS\_MOUSE STANDARD; PRT; 603 AA.  
 ID ALS\_MOUSE  
 AC P70389;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 01-MAR-2002 (Rel. 41, Last annotation update)  
 DE Insulin-like growth factor binding protein complex acid labile chain precursor (ALS).  
 DE IGFALS OR ALS OR ALBS.  
 GN Mus musculus (Mouse).  
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 NCBI\_TaxID=10090;  
 [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=129/SV;  
 RX MEDLINE=96413591; PubMed=8816745;  
 RA Boicclair Y.R., Seto D., Hsieh S., Hurst K.R., Ooi G.T.;  
 RT "Organization and chromosomal localization of the gene encoding the mouse acid labile subunit of the insulin-like growth factor binding protein complex."  
 RT Proc. Natl. Acad. Sci. U.S.A. 93:10028-10033(1996).



"Purification and partial characterization of small proteoglycans I and II, bone statorproteins I and II, and osteonectin from the mineral compartment of developing human bone.";  
J. Biol. Chem. 262:9702-9708(1987).  
-I- FUNCTION: BINDS TO TYPE I AND TYPE II COLLAGEN AND AFFECTS THE RATE OF FIBRILS FORMATION. ALSO BINDS TO FIBRONECTIN AND TGF-BETA.  
-II- PTM: THE GLYCOSAMINOGLYCAN CHAIN ATTACHED TO DECORIN CAN BE EITHER CHONDROITIN SULFATE OR DERMATAN SULFATE DEPENDING UPON THE TISSUE OF ORIGIN.  
-III- ALTERNATIVE PRODUCTS: 5 isoforms; A (shown here), B, C, D and E; are produced by alternative splicing.  
-IV- SIMILARITY: BELONGS TO THE SMALL INTERSTITIAL PROTEOGLYCANS FAMILY.  
-V- SIMILARITY: CONTAINS 10 LEUCINE-RICH REPEATS (LRR).  
  
THIS SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to licensese@isb-sib.ch).  
  
EMBL; M14219; AAB00774.1; -  
DR EMBL; L01131; AAA52301.1; ALT SEQ.  
DR EMBL; L01125; AAA52301.1; JOINED.  
DR EMBL; L01126; AAA52301.1; JOINED.  
DR EMBL; L01127; AAA52301.1; JOINED.  
DR EMBL; L01129; AAA52301.1; JOINED.  
DR EMBL; L01130; AAA52301.1; JOINED.  
DR EMBL; M98262; AAB60901.1; -  
DR EMBL; AF138300; AAD44713.1; -  
DR EMBL; AF138301; AAF61437.1; -  
DR EMBL; AF138302; AAD44714.1; -  
DR EMBL; AF138303; AAF61438.1; -  
DR EMBL; AF138304; AAD44715.1; -  
DR PIR; A26476; NBHUCB.  
DR PIR; S05640; S05640.  
DR PIR; B28457; B28457.  
DR PIR; A45016; A45016.  
DR MIM; 125255; -  
DR InterPro; IPR001611; LRR.  
DR InterPro; IPR000372; LRR\_Nterm.  
DR InterPro; IPR003592; LRR\_Out.  
DR InterPro; IPR003591; LRR\_Typ.  
DR Pfam; PF00560; LRR; 9.  
DR Pfam; PF01462; LRRNT; 1.  
DR SMART; SM00370; LRR; 3.  
DR SMART; SM00013; LRNT; 1.  
DR SMART; SM00369; LRR\_ITP; 1.  
KW Glycoprotein; Connective tissue; Extracellular matrix; Proteoglycan;  
KW Repeat; Leucine-rich repeat; Signal; Alternative splicing;  
KW Polymorphism.  
FT SIGNAL 1 16  
FT FT FT 17 30 POTENTIAL.  
FT FT FT 31 359 BONE PROTEOGLYCAN II.  
FT REPEAT 77 98 LRR 1.  
FT REPEAT 99 122 LRR 2.  
FT REPEAT 123 145 LRR 3.  
FT REPEAT 146 167 LRR 4.  
FT REPEAT 168 193 LRR 5.  
FT REPEAT 194 217 LRR 6.  
FT REPEAT 218 238 LRR 7.  
FT REPEAT 239 262 LRR 8.  
FT REPEAT 263 285 LRR 9.  
FT REPEAT 286 308 LRR 10.  
FT CARBOHYD 34 34 O-LINKED (GLYCOSAMINOGLYCAN).  
FT CARBOHYD 211 211 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT CARBOHYD 262 262 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT CARBOHYD 303 303 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT DISULFID 54 67 BY SIMILARITY.  
FT FT 313 346

entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

```
CC EMBL; AF038127; AAB92652.1; -
CC InterPro; IPR001611; LRR;
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003592; LRR_out.
DR Pfam; PF00560; LRR; 9.
DR SMART; SM001462; LRRNT; 1.
DR SMART; SM00370; LRR; 3.
DR SMART; SM00013; LRRNT; 1.
KW Glycoprotein; Connective tissue; Extracellular matrix; Proteoglycan;
KW Repeat; Leucine-rich repeat; Signal.
FT SIGNAL 1 16
FT PROPEP 17 30
FT CHAIN 31 360
FT REPEAT 78 99
FT REPEAT 100 123
FT REPEAT 124 146
FT REPEAT 147 168
FT REPEAT 169 194
FT REPEAT 195 218
FT REPEAT 219 239
FT REPEAT 240 263
FT REPEAT 264 286
FT REPEAT 287 309
FT CARBOHYD 34 34
FT FT
FT CARBOHYD 190 190
FT FT
FT CARBOHYD 212 212
FT CARBOHYD 263 263
FT CARBOHYD 304 304
FT DISULFID 55 68
FT DISULFID 314 347
FT SEQUENCE 360 AA; 39939 MW; 2DAE97CDE16F7C45 CRC64;

Query Match 8.9%; Score 299; DB 1; Length 360;
Best Local Similarity 29.4%; Pred. No. 2.7e-13;
Matches 107; Conservative 47; Mismatches 150; Indels 60; Gaps 13;

QY 15 GPRENRLFDPLL- - - - - VLLALQLLVAGLVRAQTCPSCVSCSNQFSKVI 61
Dy 17 GPFOQGLDFMDEASGIGPEDRIHEVLDLEPL- - - - - GPVCPFCQC--HLRVVQ 67
QY 62 CVRNLRVDPGISTNRLNLHENOIQIKVNSFKHLRHLLEILQLSRNRHRTIEICAFN 121
Dy 68 CSDLGLKVPKDLPPDTLLDLQNNKITEIKDGFKNLKNLHALLVNNKISKISPGFT 127
QY 122 GLANLTLELFDNRLLTPINGAFYLSKLELWLRNPIESIPSYAFNRIPSLRRLDLG- 180
Dy 128 PLVKLERLYLSKNHLKELPE- - - - - KMPKTLQELRVHENEITKVRKAVFNGLNQIMVVELGT 184
QY 181 -ELKRLSYISEGAFEGLSNLYLNLACNLRREI-PNUTPLIKDELDSGNHLSAIRPGS 238
Dy 185 NPLKS-SCIENGAFQGMKLSYIRIADNTITPPGLP--SLTELHDGNNKITKVDAA 241
QY 239 FQGLHMLQKLMQISOQVTERNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHLRIHL 298
Dy 242 LRGLNNLAKGLSFNSISAVDNGSLATPHRLHLLDNKKLKVPGGL-ADHKYIVQV 300
QY 299 HNPWNCNDILWLSWIKDKMAPSNTACCARCNTPPNLKGRYIG- - - - - ELDQN 347
Dy 301 HNN--NISA- - - - - VGSNDRCPPGYNFK- - - - - KASYSGVLSFNPVQWWEIOPS 343
QY 348 YFTC 351
Dy 344 TFRC 347

RESULT 13
GPBA_HUMAN
```

```
ID GPBA_HUMAN STANDARD; PRT; 626 AA.
AC P07359;
DT 01-APR-1988 (Rel. 07, Created)
DT 01-APR-1988 (Rel. 07, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE Platelet glycoprotein IB alpha chain precursor (GP-IB alpha) (GP1BA)
DE (CD42B-alpha) (CD42B) [Contains: Glycocalicin].
GN GP1BA.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
MEDLINE=87289655; PubMed=3303030;
RA Lopez J.A., Chung D.W., Fujikawa K., Hagen F.S., Papayannopoulou T.,
RA Roth G.J.;
RT "Cloning of the alpha chain of human platelet glycoprotein Ib: a
RT transmembrane protein with homology to leucine-rich alpha 2-
RT glycoprotein."
RL Proc. Natl. Acad. Sci. U.S.A. 84:5615-5619(1987).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=89025874; PubMed=2845978;
RA Wenger R.H., Kieffer N., Wicki A.N., Clemetson K.J.;
RT "Structure of the human blood platelet membrane glycoprotein Ib alpha
RT gene."
RL Biochem. Biophys. Res. Commun. 156:389-395(1988).
RN [3]
RP SEQUENCE OF 17-315.
RX MEDLINE=87289654; PubMed=3497398;
RA Titani K., Takio K., Handa M., Ruggeri Z.M.;
RT "Amino acid sequence of the von Willebrand factor-binding domain of
RT platelet membrane glycoprotein Ib."
RL Proc. Natl. Acad. Sci. U.S.A. 84:5610-5614(1987).
RN [4]
RP DISULFIDE BONDS.
RX MEDLINE=91301149; PubMed=2070794;
RA Hess D., Schaller J., Rickli E.E., Clemetson K.J.;
RT "Identification of the disulphide bonds in human platelet
RT glycoalbumin."
RL Eur. J. Biochem. 199:389-393(1991).
RN [5]
RP VARIANT SIBA.
RX MEDLINE=92265982; PubMed=1586750;
RA Murata M., Furihata K., Ishida F., Russell S.R., Ware J.,
RA Ruggeri Z.M.;
RT "Genetic and structural characterization of an amino acid dimorphism
RT in glycoprotein Ib alpha involved in platelet transfusion
RT refractoriness."
RL Blood 79:3086-3090(1992).
RN [6]
RP VARIANT BSS PHE-73.
RX MEDLINE=92110577; PubMed=1730088;
RA Miller J.L., Lyle V.A., Cunningham D.;
RT "Mutation of leucine-57 to phenylalanine in a platelet glycoprotein
RT Ib alpha leucine tandem repeat occurring in patients with an
RT autosomal dominant variant of Bernard-Soulier disease."
RL Blood 79:433-446(1992).
RN [7]
RP VARIANT BSS VAL-172.
RX MEDLINE=93388831; PubMed=7690774;
RA Ware J., Russell S.R., Marchese P., Murata M., Mazzucato M.,
RA de Marco L., Ruggeri Z.M.;
RT "Point mutation in a leucine-rich repeat of platelet glycoprotein Ib
RT alpha resulting in the Bernard-Soulier syndrome."
RL J. Clin. Invest. 92:1213-1220(1993).
RN [8]
RP VARIANT BSS SER-225.
RX MEDLINE=95118882; PubMed=7819107;
RA Simsek S., Noris P., Lozano M., Pico M., von Dem Borne A.E.G.K.,
RA Ribera A., Gallardo D.;
RT "Cys209 Ser mutation in the platelet membrane glycoprotein Ib alpha
```



Db 140 GELQELYLKGNELKTLPLGLLTPTPKLEKLSLANNLTLPAGLNGL-----187  
Qy 255 IQVIERNAFDNLQSLVEINLAHNLTLLPHDLFTPLHLERHLHHPWNCNCDILWSW 314  
Db 188 -----ENLDLL-----LQENSLYITPKGFFGS-HLLPFAFLHGNPWCNCEILYFRR 234  
Qy 315 WIKDMA-----PSNTACCARCANTPPLKGRYIG-----ELDONVFTC 351  
Db 235 WLQDANVYVWKQGVKAMTSNVASVQCDNSDKFPVYKPGKCPPLGDEGDTLDYD 294  
Qy 352 YAPVIVEPADLNTVEGMAELKRASTLSLTS-----VSWIT-----PNG 391  
Db 295 Y-----PEED-----KVRATRVVVKFTKAHTTWPGLFYFMSSTASLDSQMESS 341  
Qy 392 TVMTHGAYKVRIAVLSDCTLNF-----NVTVDGTGWTGCVNSVGNNTAS-----438  
Db 342 LHPTQESTKEOTTPPRWTPNFTLHMSITFSKTPKSTTEPTPS--PTSEPVPEPAPNM 399  
Qy 439 ATLNVTAATTFPFYSFSTVVTETMPSODEARTDNNVGPVVDWET-----NVITSL 493  
Db 400 TLEPTSPPTTP-----EPTSEPA-PSPTTPEPTPIATISPTILYSATSLI 446  
Qy 494 TPQSTRSTEKFTIPVTDINS---GIPGIDEVMKTKIIIG-----CFV 534  
Db 447 TP-----KSTFLFTTPVLSLESTKTKTIPELDQPPKLGVLQGHLESSRNDPFLHPDFCCLL 508  
Qy 535 AI-----TLMAAVMLVI 546  
Db 504 PLGFVVLGLFWLLFASVVLIL 524  
RESULT 14  
PGS2\_CANFA  
ID PGS2\_CANFA STANDARD; PRT; 360 AA.  
AC Q29393;  
DT 15-JUL-1998 (Rel. 36, Created)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Bone proteoglycan II precursor (PG-S2) (Decorin).  
GN CAN OR DCNIC.  
OS Canis familiaris (Dog).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.  
OX NCBI\_TaxID:9615;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Glant T.T.;  
RL Submitted (DEC-1996) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE OF 244-259 FROM N.A.  
RA Venta P.J., Brouillette J.A., Yuzbasiyan-Gurkan V., Brewer G.J.;  
RL Submitted (APR-1996) to the EMBL/GenBank/DBJ databases.  
CC -1- FUNCTION: BINDS TO TYPE I AND TYPE II COLLAGEN AND AFFECTS THE  
CC RATE OF FIBRILS FORMATION. ALSO BINDS TO FIBRONECTIN AND TGF-  
CC BETA (BY SIMILARITY).  
CC -1- PWM: THE GLYCOSAMINOGLYCAN CHAIN ATTACHED TO DECORIN CAN BE EITHER  
CC CHONDROITIN SULFATE OR DERMATAN SULFATE DEPENDING UPON THE  
CC TISSUE OF ORIGIN (BY SIMILARITY).  
CC -1- SIMILARITY: BELONGS TO THE SMALL INTERSTITIAL PROTEOGLYCANS  
CC FAMILY.  
CC -1- SIMILARITY: CONTAINS 10 LEUCINE-RICH REPEATS (LRR).  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL: U83141; AAB51245.1; -;  
DR EMBL: L77684; AAA98062.1; -;  
DR InterPro: IPR001611; LRR.

DR InterPro: IPR000372; LRR\_Nterm.  
DR InterPro: IPR003592; LRR\_out.  
DR InterPro: IPR003591; LRR\_typ.  
DR Pfam: PF00560; LRR; 9.  
DR Pfam: PF01462; LRRNT; 1.  
DR SMART: SM00370; LRR; 2.  
DR SMART: SM00013; LRRNT; 1.  
DR SMART: SM00369; LRR\_TYP; 1.  
KW Glycoprotein; Connective tissue; Extracellular matrix; Proteoglycan;  
KW Repeat; Leucine-rich repeat; Signal.  
FT SIGNAL 1 16  
FT PROPEP 17 30  
FT CHAIN 31 360  
FT REPEAT 78 99  
FT REPEAT 100 123  
FT REPEAT 124 146  
FT REPEAT 147 168  
FT REPEAT 169 194  
FT REPEAT 195 218  
FT REPEAT 219 239  
FT REPEAT 240 263  
FT REPEAT 264 286  
FT REPEAT 287 309  
FT CARBOHYD 34 34  
FT CARBOHYD 212 212  
FT CARBOHYD 263 263  
FT CARBOHYD 304 304  
FT DISULFID 55 68  
FT DISULFID 314 347  
SQ SEQUENCE 360 AA; 99880 MW; 998E11A9C812906 CRC64;  
Query Match 8.8; Score 295; DB 1; Length 360;  
Best Local Similarity 29.2; Pred. No. 5e-13;  
Matches 106; Conservative 45; Mismatches 154; Indels 58; Gaps 12;  
Qy 15 GPFRNALFDPLL-----VVLLALQLLVVAGLVRAQTCPSCVCSNQFSKVI 61  
Db 17 GPFQQRGLDFMLEASGIGPEDRAPDMPDLELL-----GPVCPFCOC--HLRVVQ 67  
Qy 62 CVRNKLRVDPGISTNTRLLNHNQIIVKNSFKHLRHLRLEILQLSNRHRTTEIGAFN 121  
Db 68 CSDLGLDKVPKDLPPDPTLLDQNNKITEIKDGFKNLKNLHTLTVNKKISKISPGFT 127  
Qy 122 GLANLTLELFDNRLTTIPNGAFVLSKLKELWLRNPNIESIPSVAFNRIPSLRDLIG- 180  
Db 128 PLLKLERLYLSKNHLKELPE---KMPKTLQELRAHENEITVKRAVFNGLNQMVIVELGT 184  
Qy 181 -ELKRLSYISEGAFEGLSNRLNLCNREIPNLTPLIKDELQSLGNSHLSAIRPGSF 239  
Db 185 NPLKS-SGIENGAFQGMKLSYIRIADNTITTIPOGLP-PSLTELHLEGNKITKVDASSL 242  
Qy 240 QGLMHLQKLMQIQOIVIERNAFDNLQSLVEINLAHNLTLLPHDLFTPLHLERHLH 299  
Db 243 KGLNLAKLGLSFSISAVDNGTLANTPLHRELHLDNNKLRVPGGL-AEHKVIQVYVLH 301  
Qy 300 HNPWNCIDILWSWIKDMAPSNTACCARCNTPPNKLGRYIG-----ELDONV 348  
Db 302 NN--NISA-----VGSNDFCPGYNK---KASISGVSLSPNPVQYWEIQPST 344  
Qy 349 FTC 351  
Db 345 FRC 347  
RESULT 15  
PGS2\_PIG  
ID PGS2\_PIG STANDARD; PRT; 360 AA.  
AC Q9XSD9; Q9XSH4;  
DT 30-MAY-2000 (Rel. 39, Created)  
DT 30-MAY-2000 (Rel. 39, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)

DE Bone proteoglycan II precursor (PG-S2) (Decorin).  
GN DCN.  
OS Sus scrofa (Pig).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.  
OX NCBI\_TaxID=9822;  
RN [1]  
RP SEQUENCE FROM N.A. (LONG FORM).  
RC STRAIN=YORKSHIRE;  
RA Stephenson S., Schnoke M., Vesely I.;  
RT "Cloning of the porcine decorin gene";  
RL Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A. (SHORT FORM).  
RC STRAIN=YORKSHIRE; TISSUE=Aorta;  
RA Stephenson S., Schnoke M., Vesely I.;  
RT "Alternatively spliced version of the porcine decorin gene";  
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.  
CC -1- FUNCTION: BINDS TO TYPE I AND TYPE II COLLAGEN AND AFFECTS THE  
CC RATE OF FIBRIL FORMATION. ALSO BINDS TO FIBRONECTIN AND TGF-  
CC BETA (BY SIMILARITY).  
CC -1- P-TM: THE GLYCOSAMINOGLYCAN CHAIN ATTACHED TO DECORIN CAN BE EITHER  
CC CHONDROITIN SULFATE OR DERMATAN SULFATE DEPENDING UPON THE  
CC TISSUE OF ORIGIN.  
CC -1- SIMILARITY: BELONGS TO THE SMALL INTERSTITIAL PROTEOGLYCANS  
CC FAMILY.  
CC -1- SIMILARITY: CONTAINS 10 LEUCINE-RICH REPEATS (LRR).  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; AF125537; AAD23578.1; -  
DR EMBL; AF140270; AAD33862.1; -  
DR InterPro; IPR001611; LRR.  
DR InterPro; IPR00372; LRR\_Nterm.  
DR InterPro; IPR003592; LRR\_Out.  
DR InterPro; IPR003591; LRR\_Typ.  
DR Pfam; PF00560; LRR\_9.  
DR Pfam; PF01462; LRRNT; 1.  
DR SMART; SM00370; LRR; 1.  
DR SMART; SM00013; LRRNT; 1.  
DR SMART; SM00369; LRR\_Typ; 2.  
KW Glycoprotein; Connective tissue; Extracellular matrix; Proteoglycan;  
KW Repeat; Leucine-rich repeat; Signal; Alternative splicing.  
FT SIGNAL 1 16  
FT PROPEP 17 30  
FT CHAIN 31 360  
FT REPEAT 78 99  
FT REPEAT 100 123  
FT REPEAT 124 146  
FT REPEAT 147 168  
FT REPEAT 169 194  
FT REPEAT 195 218  
FT REPEAT 219 239  
FT REPEAT 240 263  
FT REPEAT 264 286  
FT REPEAT 287 309  
FT CARBOHYD 34  
FT O-LINKED (GLYCOSAMINOGLYCAN) (BY  
FT SIMILARITY).  
FT CARBOHYD 212 212  
FT CARBOHYD 263 263  
FT CARBOHYD 304 304  
FT DISULFID 55 68  
FT DISULFID 314 347  
FT VARSPLIC 281 318  
FT VARSPLIC 318 318  
SQ SEQUENCE 360 AA; 39899 MW; 8573DE8DEBA7509 CRC64;

Query Match 8.8%; Score 295; DB 1; Length 360;  
Best Local Similarity 30.5%; Pred. No. 5e-13;  
Matches 97; Conservative 44; Mismatches 139; Indels 38; Gaps 10;  
QY 47 CPSVCSGNSQFSKVICVRKNLREVDPDGISNTRLLNHNQIOIKVNSFKHLRHLLEIQ 106  
DB 55 CPFRQCQ--HLRVVQCSDLGLDKVPKLPDPDTALLDLQNNKITEIKDGFKNLKNLHTLI 112  
QY 107 LSRNHRTIETGAENGLANLNTLELNFONRLTTPNGAFVYLSKLKELWLRNNTIESIPSY 166  
DB 113 LINNKISKISPGAFAPLVKLERLYLSKNQKELPE---KMPKTLOELRVHENEITKVRKA 169  
QY 167 AFNRIPSLRRDLG--ELKRLSYISEGAFGLSNLYLNLMWLNAMCNLRIPNITPILIKLDEL 224  
DB 170 VFNGLNQIMVVELGTNPLKS-SGIENGAFOGMMKLSYIRIADTNTITTPQGLP-PSLTEL 227  
QY 225 DLSNHLISAIRPGSFOGLMHLOKLMWIOSQIOVIERNAFQNLQSLVEINLAHNLTLLPH 284  
DB 228 HLDGNKISKYDAAASKGLNNLAKLGLGFNSISTVDNGSLANTPHLRHLNKNLKNKVP 287  
QY 285 DLFTPLHHLERIHLLHNPWNCNCDILWSWIKDMAPSNTACCACNTPPNKLKRYIG-- 342  
DB 288 GL-AEHKVIQVYVYLHN--NISA-----VGSNDFCPCPYNTK---KASYSGVS 329  
QY 343 -----ELDONYFTC 351  
DB 330 LFSNPVQYWEIQPSTFRC 347

Search completed: August 26, 2002, 15:45:35  
Job time: 247 sec





GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 26, 2002, 15:41:03 ; Search time 34.22 Seconds  
(without alignments)  
3235.440 Million cell updates/sec

Title: US-09-905-056-292  
Perfect score: 3362  
Sequence: 1 MLNKMTHLPOQIMIGPRNR.....VHEPLLIRMSKDNVQETQI 640

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 562222 seqs, 17994929 residues

Total number of hits satisfying chosen parameters: 562222

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL\_19.\*

1: sp\_archaea.\*

2: sp\_bacteria.\*

3: sp\_fungi.\*

4: sp\_human.\*

5: sp\_invertebrate.\*

6: sp\_mammal.\*

7: sp\_mhc.\*

8: sp\_organelle.\*

9: sp\_phase.\*

10: sp\_plant.\*

11: sp\_rodent.\*

12: sp\_virus.\*

13: sp\_vertebrate.\*

14: sp\_unclassified.\*

15: sp\_rvivirus.\*

16: sp\_bacteriap.\*

17: sp\_archaeap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3362	100.0	640	Q9HCJ2	Q9hcj2 homo sapien
2	1865	55.5	653	Q9HBW1	Q9hbw1 homo sapien
3	1840	54.7	649	Q96A85	Q96a85 homo sapien
4	1376.5	40.9	422	Q9NT99	Q9nt99 homo sapien
5	1153	34.3	441	Q99PH1	Q99ph1 mus musculus
6	583.5	17.4	614	Q96FE5	Q96fe5 homo sapien
7	578.5	17.2	614	Q9N008	Q9n008 macaca fasc
8	577.5	17.2	614	Q9D1T0	Q9d1t0 mus musculus
9	575	17.1	606	Q9BZ20	Q9bz20 homo sapien
10	480.5	14.3	719	Q96N16	Q96ni6 homo sapien
11	466	13.9	1021	Q9V430	Q9v430 drosophila
12	442.5	13.2	832	Q9ULH4	Q9ulh4 homo sapien
13	437.5	13.0	789	Q9BE71	Q9be71 macaca fasc
14	432	12.8	705	O43377	O43377 homo sapien
15	432	12.8	708	Q9H3W5	Q9h3w5 homo sapien
16	431.5	12.8	492	Q99KT6	Q99kt6 mus musculus

ALIGNMENTS

RESULT 1

Q9HCJ2 ID Q9HCJ2 PRELIMINARY; PRT; 640 AA.

AC Q9HCJ2; 01-MAR-2001 (TrEMBLrel. 16, Created)

DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)

DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)

DE KIAA1580 PROTEIN (FRAGMENT).

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI\_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=20450683; PubMed=10997877;

RA Nagase T., Kikuno R., Nakayama M., Hirotsawa M., Ohara O.;

RT "Prediction of the coding sequences of unidentified human genes.

RT XVIII. The complete sequences of 100 new cDNA clones from brain which

code for large proteins in vitro."

RL DNA Res. 7:273-281(2000).

DR EMBL; AB046800; BAB13406.1;

DR HSSP; P22888; 11UT.

DR InterPro; IPR003599; Iq.

DR InterPro; IPR003598; Iq\_c2.

DR InterPro; IPR003600; Iq\_like.

DR InterPro; IPR003006; Iq\_MHC.

DR InterPro; IPR001611; LRR.

DR InterPro; IPR000483; LRR\_Cterm.

DR InterPro; IPR000372; LRR\_Nterm.

DR InterPro; IPR003592; LRR\_out.

DR InterPro; IPR003591; LRR\_typ.

Pfam; PF00047; Iq; 1.

Pfam; PF000560; LRR; 9.

Pfam; PF01463; LRRCT; 1.

Pfam; PF01462; LRRNT; 1.

PRINTS; PR00019; LEURICHRPT.

SMART; SM00409; IG; 1.

SMART; SM00408; IGC2; 1.

```
DR SMART; SM00410; IG_like; 1.
DR SMART; SM00370; LRR; 6.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_TYP; 8.
KW Immunoglobulin domain.
FT NON_TER 1
SQ SEQUENCE 640 AA; 71949 MW; 6058974872636838 CRC64;

Query Match 100.0%; Score 3362; DB 4; Length 640;
Best Local Similarity 100.0%; Pred. No. 2.3e-240;
Matches 640; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLNKMTHLPQIMIGPREFNRLFDPLLVLLALQLLVVAGLVRAQTCPVSCSCSNQFSKV 60
Db 1 MLNKMTHLPQIMIGPREFNRLFDPLLVLLALQLLVVAGLVRAQTCPVSCSCSNQFSKV 60

Qy 61 ICVRKNREVDPGISTNTRLLNHNHQIIVKNSFKHLRHLLEILOLSRNHIRTIEIGAF 120
Db 61 ICVRKNREVDPGISTNTRLLNHNHQIIVKNSFKHLRHLLEILOLSRNHIRTIEIGAF 120

Qy 121 NGLANLTLLEFDRNLRTIPNGAFVYLSKELKELMLRNPNPIESIPSYAFNRIPSLRRLDLG 180
Db 121 NGLANLTLLEFDRNLRTIPNGAFVYLSKELKELMLRNPNPIESIPSYAFNRIPSLRRLDLG 180

Qy 181 ELKRLSYISEGAFGLSLNRLYLNLAMCNLRIPNLTPLIKDELDSLGNHLSAIRPGSFQ 240
Db 181 ELKRLSYISEGAFGLSLNRLYLNLAMCNLRIPNLTPLIKDELDSLGNHLSAIRPGSFQ 240

Qy 241 GLMHQLKWMTSQIOVIERNAFNLQSLVEINLAHNHNLTLPLPHDLFTPLHHLERHLHH 300
Db 241 GLMHQLKWMTSQIOVIERNAFNLQSLVEINLAHNHNLTLPLPHDLFTPLHHLERHLHH 300

Qy 301 NPWNCNDILWLSWIKMDAPSNACCARNTPNLRKGRYIGELDONVETCYAPVIVEPP 360
Db 301 NPWNCNDILWLSWIKMDAPSNACCARNTPNLRKGRYIGELDONVETCYAPVIVEPP 360

Qy 361 ADLVNTEGMAELKCRASTSLTSVSWITPNCVTMGAYKVRVIAVLSDLGTLNFTNVQD 420
Db 361 ADLVNTEGMAELKCRASTSLTSVSWITPNCVTMGAYKVRVIAVLSDLGTLNFTNVQD 420

Qy 421 TGMVTCVNSVGNVTASATLNVTAATTPFSYFSTVTVETMPSQDEARTDNNVGTP 480
Db 421 TGMVTCVNSVGNVTASATLNVTAATTPFSYFSTVTVETMPSQDEARTDNNVGTP 480

Qy 481 VVDWETTNVTLSPQSTRTEKFTTIPVTDINSIGIPGIDEVMKTKIIIGCFVAITLMA 540
Db 481 VVDWETTNVTLSPQSTRTEKFTTIPVTDINSIGIPGIDEVMKTKIIIGCFVAITLMA 540

Qy 541 AVMLVIFYKMRKHRRQNHHAAPTVEIINVDDITGDTPMESHLPMPAIEHEHLNHYNS 600
Db 541 AVMLVIFYKMRKHRRQNHHAAPTVEIINVDDITGDTPMESHLPMPAIEHEHLNHYNS 600

Qy 601 YKSPFNHTTNTVNTSHSSVHEPPLLIRMSKDNVQETQI 640
Db 601 YKSPFNHTTNTVNTSHSSVHEPPLLIRMSKDNVQETQI 640

RESULT 2
Q9HBW1 PRELIMINARY; PRT; 653 AA.
AC Q9HBW1;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-OCT-2001 (TrEMBLrel. 18, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE BRAIN TUMOR ASSOCIATED PROTEIN NAG14.
GN NAG14.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
```

```
RP SEQUENCE FROM N.A.
RA Wang J., Bin L., Jiang N., Li G.;
RT "Homo sapiens brain-specific gene (BAG), downregulated in brain tumor,
RT mRNA.";
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF196976; AAC28019.2;
DR HSSP; P23945; 1XUN.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR003598; Ig_c2.
DR InterPro; IPR003600; Ig_like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_out.
DR InterPro; IPR003592; LRR_Typ.
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF00047; Ig; 1.
DR Pfam; PF00560; LRR; 8.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01462; LRRNT; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00408; IGc2; 1.
DR SMART; SM00410; IG_like; 1.
DR SMART; SM00370; LRR; 3.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_TYP; 7.
KW Immunoglobulin domain.
SQ SEQUENCE 653 AA; 72717 MW; 38159C81F6850E37 CRC64;

Query Match 55.5%; Score 1865; DB 4; Length 653;
Best Local Similarity 56.4%; Pred. No. 1.2e-129;
Matches 363; Conservative 107; Mismatches 130; Indels 44; Gaps 14;

Qy 29 VLLALQLLVAGLVRA-----QTCPSVCSNQSFKVICVKNRNLREVPDGISTNTRLN 82
Db 22 VYLAQVWILCAATAAASAGPQNCPSVCSNQSFKVYCTRRGLSEYPOGIPSNTRYLN 81

Qy 83 LHENOIQIIVKNSFKHLRHLLEILOLSRNHIRTIEIGAFNGLANLTLLEFDRNLRTIPNG 142
Db 82 LMENNIQIQADTFRHLHLEVLQGRNSIRQIEVGAENGLASLNTLEFDRNLRTIPNG 141

Qy 143 AFVYLSKLKELWLRNPNPIESIPSYAFNRIPSLRRLDLGELKRLSYISEGAFGLSLNRYL 202
Db 142 AFEVLSKLRELWLRNPNPIESIPSYAFNRVPSLMRLDLGELKKLEYISEGAFGLNLYL 201

Qy 203 NLAMCNLRIPNLPLIKDELDSLGNHLSAIRPGSFOGLMHLOKLMWISQIQVIERNA 262
Db 202 NLGMCNKDMPNLPLVGLLEELMSGNHFPPIRPGSFHGLSLKKLWYMNQVSLIERNA 261

Qy 263 FDNQLSLVEINLAHNHNLTLPLHDLFTPLHHLERHLHHPNWCNCDILWLSWIKMDAPS 322
Db 262 FDGLASVELNLAHNHNLTLPLHDLFTPLRYLVLEHLHHPNWCNCDILWLAWLREYIPT 321

Qy 323 NTACCARNCTPPNLKGRYIGELDONVETCYAPVIVEPPADLVNTEGMAELKCRASTSLT 382
Db 322 NSTCCGRCHAPMHMRGRYLVVEVDQASFCQSAPPFIAMDAPDLNISGRMAELKCR-TPPMS 380

Qy 383 SVSWITPNCVTMGAYKVRVIAVLSDLGTLNFTNVQDTGMVTCVNSVGNVTASATL 442
Db 381 SVKWLPLNGTVLSHARRPRISVLDNGDTLNFSHVLLSDTGYVTCVMTNVAGNSASAYLN 440

Qy 443 VTAA--TTTPFSYFSTVTVETMPSQDEARTDNNVGTPPVVDWETTNV-----TTSLT 494
Db 441 VSTAELNTSNYSFTTIVTETTESPED---TTRKYKPPV-----TTSQGPAYTSTTT 492

Qy 495 P--QSTRSTKTEFTIPVTDINSIGI-PGIDEVMKTKIIIGCFVAITLMAAVLVIFYKMR 551
Db 493 VLIQITR-VPKQVAVPATDITDKMQTSLDEVMKTKIIIGCFVAVTLAAAMLVIFYKLR 551

Qy 552 KOHRRQNHHAAPTVEIINVDDITGDTPM-----ESHLPMPAIEHEHLNHYNS 600
Db 552 KOHRRQNHHAAPTVEIINVDDITGDTPM-----ESHLPMPAIEHEHLNHYNS 600
```





```

Db 540 ATV-PEP-FDIKTLIIATMGFIS-----F 562
QY 534 VAITLMAAVMLVIFY--KMRKQHRQNHAPTRVELINVDDEITGTPMESHLP 587
Db 563 LGVVLFLVLFLWSRGKGNTHKNIETIYVPRKSDAGIS-----SADAPRKFNMKM 613

RESULT 7
Q9N008 ID Q9N008 PRELIMINARY; PRT; 614 AA.
AC Q9N008;
DT 01-OCT-2000 (Tremblrel. 15, Created)
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)
DE HYPOTHETICAL 69.2 KDA PROTEIN.
OS Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
OC Cercopithecinae; Macaca.
OX NCBI_TaxID=9541;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=CEREBELLUM CORTEX;
RA Osada N., Hida M., Kusuda J., Tanuma R., Iseki K., Hirai M., Terao K.,
RA Suzuki Y., Sugano S., Hashimoto K.;
RT "Isolation of full-length cDNA clones from macaque brain cDNA
RT libraries."
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB046639; BAB03557.1; -
DR HSSP; P23945; IXUN.
DR InterPro; IPR003598; Ig_C2.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Cterm.
DR InterPro; IPR003592; LRR_Out.
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF00047; Ig; 1.
DR Pfam; PF00560; LRR; 9.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01462; LRRNT; 1.
DR Pfam; PF00408; IGC2; 1.
DR SMART; SM00370; LRR; 5.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_Typ; 1.
KW Hypothetical protein; Immunoglobulin domain.
SQ SEQUENCE 614 AA; 69187 MW; BA6C8BC7C993BE9A CRC64;

Query Match 17.2%; Score 578.5; DB 6; Length 614;
Best Local Similarity 27.6%; Pred. No. 1.6e-34;
Matches 181; Conservative 96; Mismatches 242; Indels 137; Gaps 16;

QY 20 RALEPDLVLLALQLLVAGLV--RAQTCPSCVCSNQFSKVICVRKNLREVPDGISTN 77
Db 7 RMSPEPLACQWPTILLVLGSLGSGATGCPPRCECSAQDRAVLCHRRFVAVPEGIPTE 66
QY 78 TRLLNLHENQIITKVNFKHLRHLLEIQLSRNHIRFIEIGAFNGLNLTLELFDNRLT 137
Db 67 TRLLDLGKNRIKTLNQDEFASFPHLEELNENIVSAVEFGAFNGLNLTLELGRSLRK 126
QY 138 TIPNGAFVYLSKELKELWLNRPNIPSPYAFNRIPSLRRLDLGLKRLSYISGAFEGLS 197
Db 127 LIPGVGTGLSNLTKLIDISENKIVILLDYMFQDLYNLSKLEVG-DNLVYISHRAFGSLN 185
QY 198 NLRVNLAMCNLRIP----- 213
Db 186 SLEQLTLEKCNLTSTIPTEALSHLGLVLRHLNLINAIRDSYFKRLYRUKLVLEISHWPY 245
QY 214 -----NLT-----LIKLDLGLSNLSAIRPGSFGLM 243

```

```

Db 246 LDTMTPNCLYGLNLTSLSTHICNLNTAVPYLAVRHLVYLRFLNLNLSYNPISTIEGSMHELL 305
QY 244 HLOKLWIOSIOIIVERNAPDNLOSILVEINLAHNLTLLPHDLTPLHLHRIHLHNPW 303
Db 306 RLQEIQLVGGOLAMVEPYAFRLNLYLRVLNVSNGNLTLEESVFHSVGNLTLLDLSNPL 365
QY 304 NCNCIDIWL---SWWIKDMAPSNTACCARCNTPPNLKGRYIGE-----LDQNYFYCYADPI 356
Db 366 ADCRLLWVFRRLNFRNQPT-----CATPEVQVQKEKDFPDVLLPNYFCRRARI 420
QY 357 VEPPA-DLNVTEGMAAELKCR-STSLSVSWITPNTGVTMTHGAYKVRIAVLSOGTLNFT 414
Db 421 RDRKAQVFEVDEGHTVQVFCRADGDPPIAILWSPRKLVS-AKSNGLRTVFPDGTLEVR 479
QY 415 NTVQDTGMVTCMVNSVNGNTASATLNVA-ATTTPSYSTVTVTMPSQDEARTTD 473
Db 480 YAVQVDNGTYLCIAANAGGNDMPAHLHVRYSYSPDWPHPKNTFAFIPNQGEGEANSTR 539
QY 474 NNVGTPVVDWETTNVTSLTPQSTRTKFTTIPVTDINSIGPIDEVMKTKIIIGCF 533
Db 540 ATV-PEP-FDIKTLIIATMGFIS-----F 562
QY 534 VAITLMAAVMLVIFY--KMRKQHRQNHAPTRVEIINVDDEITGTPMESHLP 587
Db 563 LGVVLFLVLFLWSRGKGNTHKNIETIYVPRKSDAGIS-----SADAPRKFNMKM 613

RESULT 8
Q9D1T0 ID Q9D1T0 PRELIMINARY; PRT; 614 AA.
AC Q9D1T0;
DT 01-JUN-2001 (Tremblrel. 17, Created)
DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)
DT 01-DEC-2001 (Tremblrel. 19, Last annotation update)
DE ADULT MALE TESTIS CDNA, RIKEN FULL-LENGTH ENRICHED LIBRARY,
DE CLONE:4930471K13, FULL INSERT SEQUENCE.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=TESTIS;
RX MEDLINE=21085660; PubMed=11217851;
RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamataka I.,
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schriml L.M., Straubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohtsuki S.,
RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection."
RL Nature 409:685-690(2001).
DR EMBL; AK027262; BAB32403.1; -
DR HSSP; P23945; IXUN.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR003598; Ig_C2.
DR InterPro; IPR003600; Ig_Like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Term.

```

```
DR InterPro: IPR003591; LRR_typ.
DR Pfam: PF00047; Ig: 1.
DR Pfam: PF00560; LRR: 9.
DR Pfam: PF01463; LRRCT; 1.
DR Pfam: PF01462; LRRNT; 1.
DR SMART: SM00409; IG; 1.
DR SMART: SM00408; IGG2; 1.
DR SMART: SM00410; IG.Like; 1.
DR SMART: SM00082; LRRCT; 1.
DR SMART: SM00013; LRRNT; 1.
DR SMART: SM00369; LRR_TYP; 9.
KW Immunoglobulin domain.
SQ SEQUENCE 614 AA; 69100 MW; 41CFP40C21335681 CRC64;

Query Match 17.28; Score 577.5; DB 11; Length 614;
Best Local Similarity 27.68; Pred. No. 1.9e-34;
Matches 181; Conservative 95; Mismatches 243; Indels 137; Gaps 16;

QY 20 RALDPLVLVLLALQLLVAGLV--RAQTCPSCVSCSNQFVKVCRKNLREVDPGISTN 77
DB 7 RSMSPLLACWQPTILLVLGSLGVSATGCPCECSAQDRAVLCHRRKFVAVPEGIPT 66
QY 78 TRLLNLHENQIIKIVNSFKHLRHLLEILQLSRNHRTIEIGAFNGLANLTLFDRNLT 137
DB 67 TRLLDLGNRIKTLNQDEFASFPHLELELNELNIVSAVEPGAFNNLFLNRLTGLRSNRLK 126
QY 138 TIPGAFVYLSKLKELWLRNPIESIPSYAFNRIPSLRLDLGELKRLSYISEGAFEGLS 197
DB 127 LIPLGVFTGLSGLNFKLDISENKIVILLDYMFQDLNKLSEVGD-NDLVYISHRAFSGLN 185
QY 198 NLRVLNLAACMLRETP----- 213
DB 186 SLEQLTLEKCNLTSTPTALSHLGLVLRHLNLNAINARDYSFKRLYRLKVLISHWPY 245
QY 214 -----NTP-----LIKDELDSLGNLSATRPGSGFLM 243
DB 246 LDTWTPNCLYGLNLTSLTICHTNLTAVPYLAVRHLVYLRFLNLSYNPITGTEGSMHELL 305
QY 244 HLQKLWMTQSOIOVERNAFNLQSLVEINLAHNNLTLPHDLFTPLHLHRIHLHNPW 303
DB 306 RLQELIQLVGGQAVPEYAFGLNLYRLVNLVSGNQLTTLESAPHSVGNLTLILDSNPL 365
QY 304 NCNCDILWL-----SMWIKDMAPSNACCARCNTPNLKGRIYGE-----LDQNYFTCYAPVI 356
DB 366 ADCRKLWVRRRLNFRNQPT-----CATPEFVQGEKDFPDVLLPNYFTCRAHI 420
QY 357 VEPPA-DLNVTEGMAELKCR-STSLSVSWITPNGVTWTHGAYKVRIVLSLDTLNT 414
DB 421 RDRKAQVYFVDEGHTVQVCRADGPPPAIWLSPRKLVS-AKSNGLTVPFDPGTLEVR 479
QY 415 NVTVQDTGMYTCVNSVGNNTASATNLNVA-ATTTPSYESTVVTETPESQDEARTD 473
DB 480 YAQVQDNGTYLCIAANAGGNDSPFAHLHVRYSYSPDHPQPKTFAFISNQGEGEANSTR 539
QY 474 NNVGTPVVDWETNTVTSLPQSTRSTEKTFITPVTDINSIGPIDEVMKTKIILGCF 533
DB 540 ATV-PEP-FDIKTLIATMTGFI-----F 562
QY 534 VAILMAAVMLVIFY--KMRQKHQRHQRHATPRTVEIINVDDEITGTPMESHLP 587
DB 563 LGVVLFCVLVLLFLWSRGKNTKHNIEIYVPRKSDAGIS-----SADAPRKFNMKM 613

RESULT 9
Q9B220 PRELIMINARY; PRT; 606 AA.
AC Q9B220;
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE BA43823.1 (NEURONAL LEUCINE-RICH REPEAT PROTEIN) (CDNA FLJ31810 FIS,
CLONE NT2R12009289, WEAKLY SIMILAR TO CARBOXYPEPTIDASE N 83 KDA
```

```
DE CHAIN).
GN BA43823.1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Babbage A.;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Ishibashi T., Kanehori K., Yosida M., Watanabe S., Ishida S., Ono Y.,
RA Hotuta T., Hiraoka S., Murakawa K., Takiguchi S., Kusano J.,
RA Watanabe M., Fujimori K., Tanai H., Ishida M., Yamashita H., Chiba Y.,
RA Sugiyama T., Irie R., Otsuki T., Sato H., Wakamatsu A., Ishii S.,
RA Yamamoto J., Isono Y., Kawai-Hio Y., Saito K., Nishikawa T.,
RA Kimura K., Matsuo K., Nakamura Y., Sekine M., Kikuchi H., Kanda K.,
RA Wagatsuma M., Takahashi-Fujii A., Oshima A., Sugiyama A., Kawakami B.,
RA Suzuki Y., Sugano S., Nagahari K., Masuho Y., Nagai K., Isogai T.;
RT "NEDO human cDNA sequencing project.";
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL353746; CAC22713.1; -.
DR EMBL; AK056372; BAB71167.1; -.
DR InterPro: IPR003599; Ig.
DR InterPro: IPR003598; Ig_C2.
DR InterPro: IPR003600; Ig_Like.
DR InterPro: IPR003006; Ig_MHC.
DR InterPro: IPR001611; LRR.
DR InterPro: IPR000483; LRR_Cterm.
DR InterPro: IPR000372; LRR_Nterm.
DR InterPro: IPR003591; LRR_typ.
DR Pfam: PF00047; Ig: 1.
DR Pfam: PF00560; LRR: 11.
DR Pfam: PF01463; LRRCT; 1.
DR Pfam: PF01462; LRRNT; 1.
DR PRINTS; PR00019; LEURICHREP.
DR SMART; SM00409; IG; 1.
DR SMART; SM00408; IGG2; 1.
DR SMART; SM00410; IG.Like; 1.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_TYP; 10.
KW Immunoglobulin domain.
SQ SEQUENCE 606 AA; 68065 MW; CB608E281B066B9D CRC64;

Query Match 17.18; Score 575; DB 4; Length 606;
Best Local Similarity 26.98; Pred. No. 2.8e-34;
Matches 172; Conservative 95; Mismatches 224; Indels 148; Gaps 16;

QY 31 LALQLLVVAGLVRAQTCPSCVSCSNQFVKVCRKNLREVDPGISTNRLNLHENQIQI 90
DB 15 LAVVLIPMGSTI---GCPARCECAQNKSVCRRRLIAIEGPIETKILDSLKNRLKS 71
QY 91 IKVNSFKHLRHLLEILQLSRNHRTIEIGAFNGLANLTLFDRNLTTPINGAFVYLSKL 150
DB 72 VNPEEFISYPLEETDLSLDNIIANVEPGAFNNLFLNLSRLKGNRLKLVPLGVFTGLSNL 131
QY 151 KELWLRNPIESIPSYAFNRIPSLRLDLGELKRLSYISEGAFEGLSNLRVLNLAACMLR 210
DB 132 TKLDISENKIVILLDYMFQDLNKLSEVGD-NDLVYISHRAFSGLSLEQLTLEKCNLT 190
QY 211 EIP-----N 214
DB 191 AVPTALSHLRLSLHLKHLNINNMPPVAFKRLFLKHLKLEIDYWPDLDMPPANSLYGLN 250
QY 215 LTP-----LIKDELDSLGNLSATRPGSGFLMHLQKLWMTQSOIQ 256
DB 251 LTLSTVNTNLSTVTPVFLAFKHLVLTLLNLSYNPTSTTEAGMFSDLIRLQELHIVGAQLR 310
QY 257 VIERNAFDNLOSLEINLAHNNLTLPHDLFTPLHLHRIHLHNPWCNCDILWL----- 312
DB 312
```

```

Db 311 TIEPHSFOGLRFLRVNLVNSQNLLETLEBNVSPRALEVLISNNNNPLACDRLILWILQRO 370
Qy 313 -SWIKMAPNTACCARCNTPPNLKGRYIGELDON-----YFTCYAPVIVEPPAD-LNVT 366
Db 371 PTLQGGQOP-----MCAGPDITERSPKDFHSTALSFFYFTCKPKIKREKKLQHLVLD 423
Qy 367 EGMARELCRASTSLTSV-SWITPENG-----TWMTGAYKVRZAVLSGDGTLNFTNTVQDTG 422
Db 424 EGQTVQLECSADGDPQPVISWVTPRRRFTITKSNG-----RATVLGDDGTLEIRFAQDDQSG 479
Qy 423 MYTCWNSVGNNTASATLNVTAATTPFSYFSTVVTETMEPSQDEARTDNNVGPPTPV 482
Db 480 MYVCIASNAAGNDFTASLTGKFSRDLFANRTPMTDSNDSITNGTAN-----TFSL 536
Qy 483 DWETNTVTSLTPOSTRSTKFTTIPVTDINSIGIPIDEVMKTKIIIGCFVAITLMAAV 542
Db 537 DLKTLVSTAM-----GCTFLGVVLF 559
Qy 543 MLVIFYMR-KQHURON---HHATRVVEIINVDDEITG 577
Db 560 FLLLFVWSRGKHKHNSIDLEYVPRKNGAV-VEGEVAG 597

RESULT 10
Q96NI6
ID Q96NI6 PRELIMINARY; PRT; 719 AA.
AC Q96NI6;
DT 01-DEC-2001 (TREMBlrel. 19, Created)
DT 01-DEC-2001 (TREMBlrel. 19, Last sequence update)
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)
DE CDNA FLJ30803 FIS, CLONE FEBRA2001245, WEAKLY SIMILAR TO NAG14.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE-BRAIN;
RA Nishimura K., Wagatsuma M., Kanda K., Kondo H., Yokoi T., Kodaira H.,
RA Furuya T., Takahashi M., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Sugiyama T., Irie R.,
RA Otsuki T., Sato H., Wakamatsu A., Ishii S., Yamamoto J., Isono Y.,
RA Kawai-Hio Y., Saito K., Nishikawa T., Kimura K., Yamashita H.,
RA Matsuo K., Nakamura Y., Sekine M., Kikuchi H., Murakawa K.,
RA Kanehori K., Takahashi-Fujii A., Oshima A., Sugiyama A., Kawakami B.,
RA Suzuki Y., Sugano S., Nagahari K., Masuho Y., Nagai K., Isogai T.;
RT "NEDO human cDNA sequencing project.";
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK055365; BAB70910.1; -.
SQ SEQUENCE 719 AA; 79472 MW; CE301F219705FF4B CRC64;

Query Match 14.3%; Score 480.5; DB 4; Length 719;
Best Local Similarity 25.5%; Pred. No. 3.5e-27;
Matches 169; Conservative 78; Mismatches 249; Indels 167; Gaps 16;

Qy 29 VLLALQLDLVAGLVRAQTPCVSCS---NPFSCVICKVRNLEVPDGTSTNRLNLNEN 86
Db 4 ILVFLFLGIA--VKAQICPRVCQILSPNLATLCAKGLLFFPPNDRITVELRLADN 61
Qy 87 QIQIKVNSFKLRLHLQLSRNHIETIEGAPNGLANLTLEFDRNLTTPINGAPVY 146
Db 62 FVTNKKRDFANMTSLVDLTLSRNTISPITPAFADLNLRLALHNSNRLTKITNMFSG 121
Qy 147 LSKLKEMLWRNPTESIPSYAFNRIPSLRRLDGLGKRLSYISECAFGLSNLRYLNAM 206
Db 122 LSNLHLILNNQTLISSTAFDDV----- 146
Qy 207 CNLREIPNLPLIKDELDSNLSAIFRPGSFGQLMHLQKLMWITQSOIQUIERNAFDNL 266
Db 147 -----FALEELDSLNNLETIPWDAVEKMSVLSHTLSLDHNNIDNIPKGTFSHL 194
Qy 267 QSLVEINLAHNNLPLPHDLTPLHLERI-----HLHNNPWNCCNCDILWL 312

```

```

Db 195 HKMTRLDVTSNKLOKLPPD---PLFORAQVLATSGIISPSTFALSFGNPLNCCELLWL 251
Qy 313 SWIKMAPNTACCARCNTPPNLKGRYIGELDONFYFTCYAPVIVEPPADLNVTGMAAE 372
Db 252 -----RLKSREDDLETCASPLLTGRYFWSIPEEFCEPPLITRHTHEMRKVLGQAR 305
Qy 373 LKCRATSLTSLSVSWITPENGVTMTHGAYKVRZAVLSGDGTLNFTNTVQDTGMYTCWNS 431
Db 306 LRKARGDPEPAIHWSPEGLISNA---TRSLVVDNGTLDLITTVKDTGAFTCIASNP 362
Qy 432 VGNNTASA-----TLNVTAATTPFSYFSTVVTETMEPSQDEARTDNNVGPPTPV 482
Db 363 AGEATQIVDLHIIKPLHLLNSTNIHEPDGSSDSTSTKSGNSTSSNGDTKLSDQKIV 422
Qy 483 DWETNTVTSLTPOSTRSTKFTTIPVTDINSIGIPIDEVMKTKIIIGCFVAITLMAAV 542
Db 423 VAEATSTALLKFNQIRNIPGIRFQIQYNGTYDDTLVYRMIPPTSKFLL---VNNLAGT 480
Qy 517 -----PGIDEVMKT-----TKIII--GCFVAI 536
Db 481 MYDLCLVLAIVDDGTSLTATRVVGCIOFTTBDYVRCHEMQSQFLGGTMIIGIIVAS 540
Qy 537 TLMRAVMLVIFYMRKQHRONHHAPTRTVELINVDDEITGTPMESHLPMP-----AI 590
Db 541 VLVFIILIRYKV-----CNNNGQHVKTVKSVNSYSGTNGAQIQGCSVTLPQSVSKOAV 594
Qy 591 EHE 593
Db 595 GHE 597

RESULT 11
Q9V430
ID Q9V430 PRELIMINARY; PRT; 1021 AA.
AC Q9V430;
DT 01-MAY-2000 (TREMBlrel. 13, Created)
DT 01-MAY-2000 (TREMBlrel. 13, Last sequence update)
DT 01-DEC-2001 (TREMBlrel. 19, Last annotation update)
DE KEK3 PROTEIN.
GN KEK3 OR BG:DS04862.1 OR CG4192.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BERKELEY;
RX MEDLINE=20196006; PubMed=10731132;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Ananides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blazer R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA Abrell J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA Balley R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,
RA Burkova K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferrier S., Fleischmann W.,
RA Folsler C., Gabriellian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Helman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,

```







```
Db 535 ILVIGGIIVATPLVILVMRYKV-----CNHEAPSKMAAAVSNVYSQTNGAQP----- 584
Qy 585 LPMPA 589
Db 585 -PPPS 588

RESULT 14
O43377
ID O43377 PRELIMINARY; PRT; 705 AA.
AC O43377;
DT 01-JUN-1998 (TrEMBLrel. 06, Created)
DT 01-JUN-1998 (TrEMBLrel. 05, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE PROBABLE LEUCINE-RICH REPEAT PROTEIN.
GN RGL18D07.1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=FIBROBLAST;
RA Murray J., Langston Y., Clarke C.;
RL Submitted (FEB-1998) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC004142; AAC02752.1; -.
DR InterPro; IPR003961; FN_III.
DR InterPro; IPR003598; Ig_c2.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003592; LRR_Out.
DR InterPro; IPR003591; LRR_typ.
DR Pfam; PF00041; fn3; 1.
DR Pfam; PF00047; ig; 1.
DR Pfam; PF00560; LRR; 9.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01462; LRRNT; 1.
DR PRINTS; PR00019; LEURICHRPT.
DR SMART; SM00408; IGC2; 1.
DR SMART; SM00370; LRR; 4.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_Typ; 1.
KW Immunoglobulin domain.
SQ SEQUENCE 705 AA; 97049 MW; 9B46066693F4BC1A CRC64;

Query Match 12.8%; Score 432; DB 4; Length 705;
Best Local Similarity 24.0%; Pred. No. 1.3e-23;
Matches 166; Conservative 104; Mismatches 250; Indels 172; Gaps 21;

Qy 25 PLLV-VLLAQL-LVAVGLVRAQTPCSVCSCS-----NQFSKVICVRKNLRVYP 71
Db 2 PLRHLVLLGLAITLVQAVDKVDCPRCTCEIRPWTTPRSIYMEASTVDCNDLGLLTFP 61
Qy 72 DGISTNRLNLHENQIOLK-----VN-----SFKHLRHLLEILQLS,108
Db 62 ARLPANTQILLQNTAKIEYSTDFPVNLTGLDSQNNLSSVTNINVKMPQLLSVYLE 121
Qy 109 RNHRTIEGAFNGLANLNTLEFDNRLTTPNGAFVYLSKLELWLRNPIESIPSYAF 168
Db 122 ENKLTPEKCLSELSNLQELYINHLLSTISPGAFGLNLLRLHLNSRLQWINSKWP 181
Qy 169 NRIPSLRRLDGLKRLSYISEGAFGLSNLRLYLNLAMCNLRTEIPN----- 214
Db 182 DALPNLEILMIGE-NPIIRIKDMNFKPLNLSLVIAGINLTETPDNALVLENLESISF 240
Qy 215 -----LTPFLKLELDLSGNHLSAIRPGSQGLMHLOKLMW-----IQS- 253
Db 241 YDNRLLIKVPHVALQKVVNLFKLDLKNKPNIRKRGDFSNMLHLKELGINNNPELISDLS 300
```

```
Qy 254 -----QIOVIERNAFDNQLQSLVEINLAHNNLTLLPHDLFTPLHHLERI 296
Db 301 AVDNLPDLRKIEATNNPRLSYIHPNAPFRLPKLESMLNSALSALYHGTTIESPLNKEI 360
Qy 297 HLHHPNWCNCDILWSW---WIKDMAPSNATACARCNTPPNLKRGYIGELD-QNYFTCY 352
Db 361 SIHNPIRCDCVIRWMNMNKTNIREFMEPDSLFCV---DPPEFOGQNVQVHFDRDMEIC 416
Qy 353 APVIVEP--PADLVNTEGMAAEKCRASTS--LTSVSWITPNTGTVMTGAYKVRITAVLSDG 409
Db 417 LPLIAPESFPLNVEAGSYVSFHCRAETAEQPPEIYWTSPGSKLLPNTLTDKRYVHSEG 476
Qy 410 TLNFTNTVTDGTMYTCWNSVSGNTTASATPLNVTAAATTTTPESTVSTVTVETMPSODEA 469
Db 477 TLDINGVTPKEGGLYTCIATNLVGLADLKSVMIKV-----DGS 513
Qy 470 RTTDNNVGPVPVDMETNTVTTSLTPQSTRSTEKTFPTPTVDINSIGIPGIDEVMTTKII 529
Db 514 FPQDNN-----GSLNKKIRDIQA-----NSVLVSKWA- 540
Qy 530 IGCFAVITLAAVMLVIFYKMRKQHRQNHHPATPTVEIINVDDEITGDTPMESHLPMPA 589
Db 541 -----SSKILSSVKWTAFVKTENSHAAOSARIPS-DVKVYNL-THLNPSTYEKICIDIPT 594
Qy 590 IEHEHLN-----HNSYKSPFNHTTV 611
Db 595 IYQNRKKCVNTTKGLHPDQKEYEKNNTTTL 626

RESULT 15
Q9H3W5
ID Q9H3W5 PRELIMINARY; PRT; 708 AA.
AC Q9H3W5;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE HYPOTHETICAL 79.4 KDA PROTEIN (NEURONAL LEUCINE-RICH REPEAT
DE PROTEIN-3).
GN DKFZP761K242 OR NLRR-3.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=AMYGDALA;
RA Bioecker H., Boecker M., Brandt P., Mewes H.W., Weil B., Wiemann S.;
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA Hamano S., Inuzuka H., Morohashi A., Ohira M., Nakagawara A.;
RT "Human neuronal leucine-rich repeat protein-3(NLRR-3).";
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL442092; CAC09450.1; -.
DR EMBL; AB060967; BAB47184.1; -.
DR InterPro; IPR003961; FN_III.
DR InterPro; IPR003595; Ig.
DR InterPro; IPR003598; Ig_c2.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003592; LRR_Out.
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF00041; fn3; 1.
DR Pfam; PF00047; ig; 1.
DR Pfam; PF00560; LRR; 9.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01462; LRRNT; 1.
DR PRINTS; PR00019; LEURICHRPT.
DR SMART; SM00060; FN3; 1.
DR SMART; SM00409; IG; 1.
```







Db 304 AVDNLPLRKTATNPNRLSYIHPNAPFRPLKLESLMLNSNALSALYHGHTIESLPNLKEI 363  
Qy 297 HLHNPWNCDDILWLSW---WIKDMAPSNTACCARCNTPPNLKGRYIGELD-QNYETCY 352  
Db 364 SIHNPTRCDDIVIRMMNMKNTRIFMEPDSLFCV---DPPEFQGNQVQVHFRDMMEIC 419  
Qy 353 APVTVEP---PADLNVTEGMAAELKCRASTS-LTSVSWITTPNGTVMTHGAYKVRIVLSDG 409  
Db 420 LPLAPESFPNVLNVEAGSYVFFHCRTAEPQPEIYWIITPSGOKLLPNTLTKYVHSEG 479  
Qy 410 TLNFTNTVQDTGMVTCMVNSVNSGNTASATLNTAATTPPFVSFTVVTMETPESQDEA 469  
Db 480 TLDINGVTPKEGGLYTCTIATNLVGLADKSVMIK-----DGS 516  
Qy 470 RTTNNVGPVVDWEITNTVTSLTPOQSTREKTFPIPTVDINSIPGIDEVMKTKII 529  
Db 517 PQDNN-----GSLNKKIRDIQA-----NSVLVSWKA- 543  
Qy 530 IGCFAITLMAAVMLVIFKMKRQHRRHONHAPRTVEIINVDDDEITGDTPMESHLPMPA 589  
Db 544 ---SSKILSSVKWTAFVKTENSAAQSARIPS-DVKVYNL-THLNPSTEYKICIDIPT 597  
Qy 590 IEHEHLN-----HNSYKSPFNHTTV 611  
Db 598 IYQNRKCKVNVTKGLHPDQKEYEKNNTTL 629

## RESULT 2

US-08-986-485-5  
; Sequence 5, Application US/08986485  
; Patent No. 6046030  
; GENERAL INFORMATION:  
; APPLICANT: WU, SHUJIAN  
; APPLICANT: SWEET, RAYMOND  
; APPLICANT: TRUNEH, ALEMSEGED  
; TITLE OF INVENTION: A HUMAN LIG-1 HOMOLOG (HLIG-1)  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: RATNER & PRESTIA  
; STREET: P.O. BOX 980  
; CITY: VALLEY FORGE  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19482  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FASTSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/986,485  
; FILING DATE: 08-DEC-1997  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/059,448  
; FILING DATE: 22-SEP-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: PRESTIA, PAUL F  
; REGISTRATION NUMBER: 23,031  
; REFERENCE/DOCKET NUMBER: GH-70264  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 610-407-0700  
; TELEFAX: 610-407-0701  
; TELEX: 846169  
; INFORMATION FOR SEQ ID NO: 5:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1091 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-986-485-5

Query Match 12.4%; Score 417.5; DB 3; Length 1091;  
Best Local Similarity 23.1%; Pred. No. 5.3e-27;  
Matches 156; Conservative 87; Mismatches 208; Indels 223; Gaps 19;  
Qy 81 LNLHENOQIIKVSFKHLRHLLEILQLSRNHRTIEIGAFNGLANLNTLELDFNRLTTP 140  
Db 218 LDLNRRIRLIEGLTFQGLDSLEVLRLQRNNISRLTDCAFWGLSKMHLVHLEYSNLSEVN 277  
Qy 141 NGAFVYLSKLKELWLRNPNIESIPS-----YAFNRIPSLRRLDLGELKRL-- 185  
Db 278 SGSLYGLTALHQLHLSSNRSIORQDGSFCQKLHELILSFNNLRLDEESLAELSSLSI 337  
Qy 186 -----SYISEGAFEGLSNLRVNLNLMCNLRREPNLTPLIKLDELDSLNSHLSAIRPG 237  
Db 338 LRLSHNAISHAEGAFKGLKSLRVL-----LDHNEISTIEDT--SG 378  
Qy 238 SFQGLMHLQKLMWIOSQIVIERNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHHLERIH 297  
Db 379 AFTGLDNLKSLTLFGNKIKSVAKRAFSGLSLEHLNLGENAIRSVQFDAFAKMKNLKELY 438  
Qy 298 LHHNPWNCDDILWLSWI---KDMAPSNTACCARCNTPPNLKGRYI-GELQNY----- 348  
Db 439 ISSSEFLCDCQLKWLPPMLMGRMLQAFVTATCAH---PESLKGOSIFSVLPDSFVCDPFP 495  
Qy 349 -----FTCYA----- 353  
Db 496 KPQIITQPTTMVVGKDIRFTCSAASSSSSPMTFAMKKDNEVLNADNMFVHRAQDG 555  
Qy 354 -----PVIVEPPADLNVTEG 368  
Db 556 EMVEYTTILHLRVHTEGHEGRYQCIITNHFGSTVSHKARLTNVNVLPSFTKIPHDIAIRTG 615  
Qy 369 MAELKCRASLT-SVSWITTPNGTVMTHGAYKVRIVLSDGTLNF-TNVTQDTGMVTC 426  
Db 616 TTRLECAATGHPNPQIAWQKDGDTDF-AARERMMHVMPPDDVFFITDVKIDDMGVYSVC 674  
Qy 427 MVSNSVGNNTASATLNVTAATTPFSVFTVTMETPESQDEARTDNNV-----GP 478  
Db 675 TAQNSAGSVSANATLVLE-----TPSLAVPLEDRVVTVGETVAFQCKATGSP 722  
Qy 479 TPVVDWETNTVTSLT-----PQSTRSTEKTTI 507  
Db 723 TPRTWLKGGRPPLSLTERHHFTPGNQLLVQNVNMDAGRYTCMSNPLGTERAHSQLSI 782  
Qy 508 PVTDSINGIPGIDEVMKTKII-IGCFVAITLMAAVMLVIFVKMKRQHRRHONHAPRTTV 566  
Db 783 LPT-----PCRKDGTIVGIFTIAVVCISIVLTSVLVWVCIYQTRK---KSEKSVTWTND 833  
Qy 567 EIIINVDDDEITGDT 580  
Db 834 ETI-----VPPDVP 842

## RESULT 3

US-08-986-485-2  
; Sequence 2, Application US/08986485  
; Patent No. 6046030  
; GENERAL INFORMATION:  
; APPLICANT: WU, SHUJIAN  
; APPLICANT: SWEET, RAYMOND  
; APPLICANT: TRUNEH, ALEMSEGED  
; TITLE OF INVENTION: A HUMAN LIG-1 HOMOLOG (HLIG-1)  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: RATNER & PRESTIA  
; STREET: P.O. BOX 980  
; CITY: VALLEY FORGE  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19482  
; COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/986,485  
FILING DATE: 08-DEC-1997  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/059,448  
FILING DATE: 22-SEP-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: PRESTIA, PAUL F  
REGISTRATION NUMBER: 23,031  
REFERENCE/DOCKET NUMBER: GH-70264  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 610-407-0700  
TELEFAX: 610-407-0701  
TELEX: 846169  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1101 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
us-08-986-485-2

Query Match 11.98; Score 401; DB 3; Length 1101;  
Best Local Similarity 22.08; Pred. No. 1.4e-25;  
Matches 172; Conservative 111; Mismatches 265; Indels 234; Gaps 27;  
Qy 26 LVLVLLAQLLVAGLVRAQTCPSCVCSNQ-----FSKVICVRKNLREVDPDGISTNRL 80  
Db 21 LWWLLRLLEPVTAAGPRA-PCAACTCAGDPTCAGDSLCCGGRGLAALPGDLPSWTRS 79  
Qy 81 LNL-----HE----- 85  
Db 80 LNLSYNKLAEIDPAGFEDLPNLQEVYLNHHELTAVASLGAGSSQVVALFLOQQQNRSLDG 139  
Qy 86 -----NQIIKIVNSFKHLRHLLEILQLSRNHIETIEGAFNGLA-NLNT 128  
Db 140 SOLKAYLSLEVLDDLNNITEVRNTYFPHGPPKELNLAGNRIGLELGAEDGSLRSLLT 199  
Qy 129 LEFDNRLLTTPNGAFVYLSKLKELWLRNNPIESIPSYAFNRIPSLRLDLGELKRLSYI 188  
Db 200 LRLSKNRITQLPVRAF-KLPRLTOLDLNRNRLIEGLTFQGLNSLVKL-QRNNISKL 257  
Qy 189 SEGAFGLSNRLYMLAMCNLEI----- 212  
Db 258 TDGAFWGLSKMHVHLHLEVDLSLEVNSGLYGLTALHQLHLSNNSIARIHRKGWSPCKLH 317  
Qy 213 -----PNLPLIKLDELDSLGNHLSAIRPGSFQGLMHLO----- 246  
Db 318 ELVLSFNLLRLDEESLAESSLVLRUSHNSISHIAGKAFKGLSLRVLDDLHNEISGT 377  
Qy 247 -----KLWIIQSQIQTIERNAFDNLQSLVEINLAHNNLTLLPHDLFTPL 290  
Db 378 LEDTSGAFSGLEFGHSKLTGKNTKSVAKRAFSGLEGLHNLGNGNAIRSVOFDFAVKM 437  
Qy 291 HLEIRIHLHHPNWCNDIILMSWI--KDMAPSNTACCARNTPPNLKGRYIGELDON 348  
Db 438 KNLKELHSSDSFLCDCKLQWLPPLMGLMQLQAFVATCAH---PESLKGQSIFSVPPES 494  
Qy 349 FTC---YAPVIVEPPADLVNTEGMAELKCRASSTLS---VSWITPNTGVTMTHGAYKVR 402  
Db 495 FVCDFLKPKIITQPETTMAMVGKDIFRTCSAAASSSSPMTFAWKDN-EVLTNADMENF 553  
Qy 403 IAV-LSDG-----TLNFTNVVTDGTGMYTCMVNSVNGT---TASATLVNTAA-TTTP 450  
Db 554 VHVHADGEVMEYITILHLRQVTFGHEGRYOCYVITNHFHGSTYSHKARLTNVNLPSTFKTP 613

Qy 451 FSYFSTVTVETMEPSQDEARTDDNNVGPTPVVDMETTNVTTSLTPQSTRSTEKTFIP-- 508  
Db 614 HD-----ITRTTVARLECAATH---PNQIAMKDGTDPPAARERR-----MHVMPDD 662  
Qy 509 -----VTDINSIPGIDE-VMKTTKIIICCFVAITLMAAVMLVIFYKMKRQHRRQHHAPT 563  
Db 663 DVFFITDVKIDDAGVYSCTAQNSAGSISANATLTVLETPSLVPLEDR----- 710  
Qy 564 RTVEIINVDDEI-----TGDTT-----MESHLPAPTEHEHNLHNYNSKSPFNHTTVN 612  
Db 711 -----VSVGETVALOCKATGNPPRITWFKGDRPLSLTERHHL-----TPDNQLLVQ 759  
Qy 613 TI 614  
Db 760 NV 761  
RESULT 4  
US-09-191-647-2  
Sequence 2, Application US/09191647  
Patent No. 6046015  
GENERAL INFORMATION:  
APPLICANT: Goodman, Corey  
APPLICANT: Kid, Thomas  
APPLICANT: Brose, Katja  
APPLICANT: Tessier-Lavigne, Marc  
TITLE OF INVENTION: Modulating Robo: Ligand Interactions  
FILE REFERENCE: B98-031-3  
CURRENT APPLICATION NUMBER: US/09/191,647  
CURRENT FILING DATE: 1998-11-13  
EARLIER APPLICATION NUMBER: 60/065,544  
EARLIER FILING DATE: 1997-11-14  
EARLIER APPLICATION NUMBER: 60/081,057  
EARLIER FILING DATE: 1998-04-07  
NUMBER OF SEQ ID NOS: 14  
SOFTWARE: Patentin Ver. 2.0  
SEQ ID NO 2  
LENGTH: 1525  
TYPE: PRT  
ORGANISM: human  
US-09-191-647-2

Query Match 11.88; Score 395.5; DB 3; Length 1525;  
Best Local Similarity 25.18; Pred. No. 6.7e-25;  
Matches 129; Conservative 51; Mismatches 171; Indels 163; Gaps 9;  
Qy 30 LLALQL---LVVAGLVRAQTCPSCVCSNQFSKVICVRKNLREVDPDGISTNRLNLHEN 86  
Db 8 MLUSLGLVLAILNKNVAPQACPAQCSCG--STVDCHGLALRSVPRNIPRNTERLDLNGN 65  
Qy 87 QTOIIVKNSFKHLRHLLEILQLSRNHIETIEGAFNGLANLNTLELFDNRLLTTPNGAFVY 146  
Db 66 NITRITKDFACLRHLRVLQMLMENKISTIERGAFODLELRLLNRNHLQFLPELLFIG 125  
Qy 147 LSKLKLWLRNNPIESIPSYAFNRIPSLRLDLGELKRLSYISEGAFGLSNRLYNL-- 204  
Db 126 TAKLYRLDLSENOIAIPKAPRGAVDIKNLQL-DYNOISCIEDGAFRALRDLEVLTLNN 184  
Qy 205 ----- 204  
Db 185 NNITRLSVASFNNHMPKLRTRLHNSNLYCDCHLAWLSDWLRKRPRVGLYTCMGPSHLRG 244  
Qy 205 -----AMC-----NLREIPN----- 214  
Db 245 HNAVEQKREFVCSDEECHOFSMAPSCSVLHCPACTCSNNIVDCRKGKGLTEIPTNLPE 304  
Qy 215 -----LTPLIKDELDSLGNHLSAIRPGSFQ----- 240  
Db 305 TITEIRLEQNTIKVIPPQGAFFPKKLRRLDLSNNQISELAPDAFQGLRSLNSILVYGNKI 364  
Qy 241 -----GLMHLOKLMWIOSQIOVIERNAPDNLOSLVEINLAHNNLTLLPHDLFTPLH 291

Db 365 TELPKSLEFGLSLQLLLNANKINCLRVDAFQDLHNLNLLSLYDNKLTQIAKGTFSPLR 424  
Qy 292 HLERIHLHNPNWNCNDILWLSWIKDMAPSNNTACCARCNTPPNKLGRYIGELDONYETC 351  
Db 425 AQTQTHLAQNPICDCHLKLWADYL-HTNPIETS-GARCTSPRLANKRIGQIKSKKFC 482  
Qy 352 YAPVIVEPPADLVNTEGMAELKCRASSTLSVTS 385  
Db 483 SGTEYRSKLSGDCDFADLACPEKCRCEGTTVDCS 516

RESULT 5  
US-09-540-245A-2  
; Sequence 2, Application US/09540245A  
; Patent No. 6270984  
; GENERAL INFORMATION:  
; APPLICANT: Goodman, Corey  
; APPLICANT: Kid, Thomas  
; APPLICANT: Brose, Katja  
; APPLICANT: Tessier-Lavigne, Marc  
; TITLE OF INVENTION: Modulating Robo: Ligand Interactions  
; FILE REFERENCE: B98-031-3  
; CURRENT APPLICATION NUMBER: US/09/540,245A  
; CURRENT FILING DATE: 2000-03-31  
; PRIOR APPLICATION NUMBER: 60/065,544  
; PRIOR FILING DATE: 1997-11-14  
; PRIOR APPLICATION NUMBER: 60/081,057  
; PRIOR FILING DATE: 1998-04-07  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 1525  
; TYPE: PRT  
; ORGANISM: human  
US-09-540-245A-2

Query Match 11.8%; Score 395.5; DB 4; Length 1525;  
Best Local Similarity 25.1%; Pred. No. 6.7e-25;  
Matches 129; Conservative 51; Mismatches 171; Indels 163; Gaps 9;  
Qy 30 LLALQL---LVVAGLVRAQTCPSCVSCSNQPSKVCVRKNLREVDPDGISTNTRLLNLHEN 86  
Db 8 MLSLSGLVLVLAITNKAPOACPAQCSG--STVDCHGLAHSVRPNIPNTERLDLNGN 65  
Qy 87 QTIQIKVANSFKHLRLEILQLSRNHIRTIEIGAFNGLANLNTLELFDNRLTTPNGAFVY 146  
Db 66 NITRTKTDFAGLRHLRVLQLMENKISTIERGAFODLKELERLNRNHLQLFPELLFLG 125  
Qy 147 LSKKELMWRNPNIBSIPYAFNRIPSLRRDLGELKRLSYISEGAFGLSNRLYNL-- 204  
Db 126 TAKLYRLDLSNQIAIPKAPRGAVDIKNLQ-L-DYNQISCTIEDGAFRALRDLEVLTLNN 184  
Qy 205 ----- 204  
Db 185 NNITRLSVASFNHMPKLTFRHLNHNLYCDCHLAWLSDWLRKRPRVGLYTQCMGFSHLRG 244  
Qy 205 -----AMC-----NLREIPN----- 214  
Db 245 HNVAEQKREFVCSDEEBCHOSFMAPSCSVLHCPAACTCSNNIVDCRGKGLTEIPTNLPE 304  
Qy 215 -----LTPLIKDELJDSGNHLSAIRGFSQ----- 240  
Db 305 TITEIRLEQNTIKVPPGAFSPYKKLRRLDLSNNQISELAPDAFOGLRSLNSLVLYGNKI 364  
Qy 241 -----GLMHLOKLMQISOQIOVERNAFDNLQSLVEINLHNNLTLLPHDLFTPLH 291  
Db 365 TELPKSLEFGLSLQLLLNANKINCLRVDAFQDLHNLNLLSLYDNKLTQIAKGTFSPLR 424  
Qy 292 HLERIHLHNPNWNCNDILWLSWIKDMAPSNNTACCARCNTPPNKLGRYIGELDONYETC 351  
Db 425 AQTQTHLAQNPICDCHLKLWADYL-HTNPIETS-GARCTSPRLANKRIGQIKSKKFC 482

Qy 352 YAPVIVEPPADLVNTEGMAELKCRASSTLSVTS 385  
Db 483 SGTEYRSKLSGDCDFADLACPEKCRCEGTTVDCS 516  
RESULT 6  
US-09-540-153-2  
; Sequence 2, Application US/09540153  
; Patent No. 6270995  
; GENERAL INFORMATION:  
; APPLICANT: Goodman, Corey  
; APPLICANT: Kid, Thomas  
; APPLICANT: Brose, Katja  
; APPLICANT: Tessier-Lavigne, Marc  
; TITLE OF INVENTION: Modulating Robo: Ligand Interactions  
; FILE REFERENCE: B98-031-3  
; CURRENT APPLICATION NUMBER: US/09/540,153  
; CURRENT FILING DATE: 2000-03-31  
; PRIOR APPLICATION NUMBER: 09/191,647  
; PRIOR FILING DATE: 1998-11-13  
; PRIOR APPLICATION NUMBER: 60/081,057  
; PRIOR FILING DATE: 1998-04-07  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 1525  
; TYPE: PRT  
; ORGANISM: human  
US-09-540-153-2

Query Match 11.8%; Score 395.5; DB 4; Length 1525;  
Best Local Similarity 25.1%; Pred. No. 6.7e-25;  
Matches 129; Conservative 51; Mismatches 171; Indels 163; Gaps 9;  
Qy 30 LLALQL---LVVAGLVRAQTCPSCVSCSNQPSKVCVRKNLREVDPDGISTNTRLLNLHEN 86  
Db 8 MLSLSGLVLVLAITNKAPOACPAQCSG--STVDCHGLAHSVRPNIPNTERLDLNGN 65  
Qy 87 QTIQIKVANSFKHLRLEILQLSRNHIRTIEIGAFNGLANLNTLELFDNRLTTPNGAFVY 146  
Db 66 NITRTKTDFAGLRHLRVLQLMENKISTIERGAFODLKELERLNRNHLQLFPELLFLG 125  
Qy 147 LSKKELMWRNPNIBSIPYAFNRIPSLRRDLGELKRLSYISEGAFGLSNRLYNL-- 204  
Db 126 TAKLYRLDLSNQIAIPKAPRGAVDIKNLQ-L-DYNQISCTIEDGAFRALRDLEVLTLNN 184  
Qy 205 ----- 204  
Db 185 NNITRLSVASFNHMPKLTFRHLNHNLYCDCHLAWLSDWLRKRPRVGLYTQCMGFSHLRG 244  
Qy 205 -----AMC-----NLREIPN----- 214  
Db 245 HNVAEQKREFVCSDEEBCHOSFMAPSCSVLHCPAACTCSNNIVDCRGKGLTEIPTNLPE 304  
Qy 215 -----LTPLIKDELJDSGNHLSAIRGFSQ----- 240  
Db 305 TITEIRLEQNTIKVPPGAFSPYKKLRRLDLSNNQISELAPDAFOGLRSLNSLVLYGNKI 364  
Qy 241 -----GLMHLOKLMQISOQIOVERNAFDNLQSLVEINLHNNLTLLPHDLFTPLH 291  
Db 365 TELPKSLEFGLSLQLLLNANKINCLRVDAFQDLHNLNLLSLYDNKLTQIAKGTFSPLR 424  
Qy 292 HLERIHLHNPNWNCNDILWLSWIKDMAPSNNTACCARCNTPPNKLGRYIGELDONYETC 351  
Db 425 AQTQTHLAQNPICDCHLKLWADYL-HTNPIETS-GARCTSPRLANKRIGQIKSKKFC 482  
Qy 352 YAPVIVEPPADLVNTEGMAELKCRASSTLSVTS 385  
Db 483 SGTEYRSKLSGDCDFADLACPEKCRCEGTTVDCS 516  
RESULT 7







QY 46 TPCSVCSNQSFCVCRKRLNREVPDGIISNTNRLNLHENQIQIKVNSFKHLRHLEIL 105  
Db 294 SCPPHRCADGI--VDCREKSLTSPVTPDPTDTRVLEQNFITELPKFSFRRRLRI 351  
QY 106 QLSRNRHRTTEIGAFNGLANLNTLEFDNRLLTTPNGAFVYLSKLKELWLRNPNIESIPS 165  
Db 352 DLSNNISRTAHDALSGKQLTTLVLYGNKIKDLPVGFGLGSLRLRLNANEISCIK 411  
QY 166 YAFNRIPSLRRLDGLKRLSYISEGAFEGLSNRLYNLNM-----CNLR----- 210  
Db 412 DAFRDLHSLLSLYD--NNIQSLANGTFDAMKSMKTVHLAKNPFICDNCNRLWLADYHLHN 470  
QY 211 -----EIPNLTP-----TKLD-----ELDLSGNHLSAIRPGS 238  
Db 471 PIETSGARCESPKRMHRRRIEESLREKFKCSWGLRMLKSGECRMDSDCPAMCHCEGTV 530  
QY 211 -----EIPNLTP-----TKLD-----ELDLSGNHLSAIRPGS 238  
Db 531 DCTGRRLKEIPRDIPLHTTELLNDNLGRISDGLFGRPLHLVKLEKRLNQLTGIEPNA 590  
QY 239 FQGLMHLOKLMWIOSQIOVIERNAPDNLOSIVEINLAHNNLTLLPHDLFTPLHHLERHL 298  
Db 591 FEGASHIOELQGENKIKEISNKMFLGLHQLKTLNLYDNQISCVMPGSEFHLNLSLNL 650  
QY 299 HHNPWNCNDILWLSWIKDMAPNTACARCNTPPNKLKGRYIGELDONFTCYAPVIVE 358  
Db 651 ASNPFNCNCHLAWFAECVRKSLNGGA--ARCGAPSKVRDVOIKDLPHESEFKCSS----- 703  
QY 359 PPADLVNTEGMAAEKLCRASTSLTSVSWITPNGTVM 394  
Db 704 -----ENSEGCLGDBGYCPPTCT-----GTVV 726

## RESULT 12

US-09-540-153-7  
; Sequence 7, Application US/09540153  
; Patent No. 627095  
; GENERAL INFORMATION:  
; APPLICANT: Goodman, Corey  
; APPLICANT: Kid, Thomas  
; APPLICANT: Brose, Katja  
; APPLICANT: Tessier-Lavigne, Marc  
; TITLE OF INVENTION: Modulating Robo: Ligand Interactions  
; FILE REFERENCE: B98-031-3  
; CURRENT APPLICATION NUMBER: US/09/540,153  
; PRIOR FILING DATE: 2000-03-31  
; PRIOR APPLICATION NUMBER: 09/191,647  
; PRIOR FILING DATE: 1998-11-13  
; PRIOR APPLICATION NUMBER: 60/081,057  
; PRIOR FILING DATE: 1998-04-07  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: Patent In Ver. 2.0  
; SEQ ID NO 7  
; LENGTH: 1480  
; TYPE: PRT  
; ORGANISM: Drosophila melanogaster  
US-09-540-153-7

Query Match 10.4%; Score 350; DB 4; Length 1480;  
Best Local Similarity 23.9%; Pred. No. 5.1e-21;  
Matches 109; Conservative 65; Mismatches 152; Indels 130; Gaps 9;  
QY 46 TPCSVCSNQSFCVCRKRLNREVPDGIISNTNRLNLHENQIQIKVNSFKHLRHLEIL 105  
Db 294 SCPPHRCADGI--VDCREKSLTSPVTPDPTDTRVLEQNFITELPKFSFRRRLRI 351  
QY 106 QLSRNRHRTTEIGAFNGLANLNTLEFDNRLLTTPNGAFVYLSKLKELWLRNPNIESIPS 165  
Db 352 DLSNNISRTAHDALSGKQLTTLVLYGNKIKDLPVGFGLGSLRLRLNANEISCIK 411  
QY 166 YAFNRIPSLRRLDGLKRLSYISEGAFEGLSNRLYNLNM-----CNLR----- 210

Db 412 DAFRDLHSLLSLYD--NNIQSLANGTFDAMKSMKTVHLAKNPFICDNCNRLWLADYHLHN 470  
QY 211 -----EIPNLTP-----TKLD-----ELDLSGNHLSAIRPGS 238  
Db 471 PIETSGARCESPKRMHRRRIEESLREKFKCSWGLRMLKSGECRMDSDCPAMCHCEGTV 530  
QY 211 -----EIPNLTP-----TKLD-----ELDLSGNHLSAIRPGS 238  
Db 531 DCTGRRLKEIPRDIPLHTTELLNDNLGRISDGLFGRPLHLVKLEKRLNQLTGIEPNA 590  
QY 239 FQGLMHLOKLMWIOSQIOVIERNAPDNLOSIVEINLAHNNLTLLPHDLFTPLHHLERHL 298  
Db 591 FEGASHIOELQGENKIKEISNKMFLGLHQLKTLNLYDNQISCVMPGSEFHLNLSLNL 650  
QY 299 HHNPWNCNDILWLSWIKDMAPNTACARCNTPPNKLKGRYIGELDONFTCYAPVIVE 358  
Db 651 ASNPFNCNCHLAWFAECVRKSLNGGA--ARCGAPSKVRDVOIKDLPHESEFKCSS----- 703  
QY 359 PPADLVNTEGMAAEKLCRASTSLTSVSWITPNGTVM 394  
Db 704 -----ENSEGCLGDBGYCPPTCT-----GTVV 726

## RESULT 13

PCT-US91-09055-2  
; Sequence 2, Application PC/TUS9109055  
; GENERAL INFORMATION:  
; APPLICANT: Rothberg, Jonathan Marc and Artavanis-Tsakonas, Spyridon  
; TITLE OF INVENTION: Purified SLIT protein and Sequence Elements Thereof  
; NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Yale University  
; ADDRESSEE: Office of Cooperative Research  
; STREET: 246 Church Street  
; STREET: Suite 401  
; CITY: New Haven,  
; STATE: Connecticut  
; COUNTRY: USA  
; ZIP: 06510  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage  
; COMPUTER: Apple Macintosh  
; OPERATING SYSTEM: Macintosh 6.0.5  
; SOFTWARE: Microsoft Word 4.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US91/09055  
; FILING DATE: 19911127  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/07/624,135  
; FILING DATE: 7-DEC-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Barth, Richard J.  
; REGISTRATION NUMBER: 28,180  
; REFERENCE/DOCKET NUMBER: 900964/RSB  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 972-1400  
; TELEFAX: (212) 370-1622  
; TELEX: 236268  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1480 amino acids  
; TYPE: AMINO ACIDS  
; TOPOLOGY: Linear  
; MOLECULE TYPE: protein  
; FEATURE:  
; NAME/KEY: signal sequence  
; LOCATION: 1 to 36  
; IDENTIFICATION METHOD: similarity to other signal  
; OTHER INFORMATION: Directs Export  
; NAME/KEY: Four Flank-LRR-Flank domains  
; LOCATION: 37 to 910  
; IDENTIFICATION METHOD: Array of Flank-LRR-Flank

```
; OTHER INFORMATION: mediates adhesive events
; NAME/KEY: Tandem EGF-like repeats
; LOCATION: 911 to 1150
; IDENTIFICATION METHOD: similarity to tandem EGF-like
; OTHER INFORMATION: protein-protein interactions
; NAME/KEY: 7th EGF-like repeat
; LOCATION: 1353 to 1393
; IDENTIFICATION METHOD: similarity to epidermal growth
; OTHER INFORMATION: involvement in receptor-ligand
; NAME/KEY: Alternative splice segment
; LOCATION: 1394 to 1404
; IDENTIFICATION METHOD: experimental
; OTHER INFORMATION: developmentally regulated
; NAME/KEY: COOH-terminal region
; LOCATION: 1405 to 1480
; IDENTIFICATION METHOD: experimental
; PCT-US91-09055-2

Query Match      10.4%; Score 350; DB 5; Length 1480;
Best Local Similarity 23.9%; Pred. No. 5.1e-21;
Matches 109; Conservative 65; Mismatches 152; Indels 130; Gaps 9;

QY 46 TCPVSCSNQFVKVCRNLRVDPGISTNTRLLNLHENQIOIKVNSFKHLRHL 105
Db 294 SCPPHRCADGI--VDCREKSLTSVPVTLDDTDDVRLQNFITELPKKSFSPRLRRI 351
QY 106 QLSRNHIRTIEIGAFNGLANLTLEFDNRLTTPNGAFVYLSKLKELWLRNNPIESIPS 165
Db 352 DLSNNISRIAHDAISGLKQLTTLVLYGNKIKDLPVGFGLGSLRLLNLANEISCIRK 411
QY 166 YAFNRIPSLRRLDGLKRLSYISEGAFEGLSNLRYLNLAM-----CNLR----- 210
Db 412 DAFRDLHSLSLSYD--NNIQSLANGTFDAMKSMKTVHLAKNPFCDCNLRWLADYLHN 470
QY 211 ----- 210
Db 471 PIETSGARCESPKRMHRRRIESLREERFKCSWGLRMKLSGECRMDSDCPAMCHCEGTV 530
QY 211 -----EIPNLTP-----IKLD-----ELDLSGNHLSAIRPGS 238
Db 531 DCTGRRRLKEIPRDLPHLTTELLNDNLGRISDGLFGRPLHLVKLEKRNQLTGIEPNA 590
QY 239 FQGLHMLQKLMWIOSQIQVIERNADNLQSLVEINLAHNNLTLLPHDLFTPLHHLRIHL 298
Db 591 FEGASHIQELQNGENKIKEISNKMFLGLHQLKTLNLYDNQISCVMPGSFEHLNLSLNL 650
QY 299 HHNPWNCNDILWLSWIKDAPNTACCARCNTPPNKGRIYIGELDONFTCYAPVIVE 358
Db 651 ASNPFCNCHLAWFAECVRKKSLNGA--ARCGAPSKVRDQVQIKDLPHSEFKCSS----- 703
QY 359 PPADLVNTEGMAAEKCRASLTLSVSMTPTNGTVM 394
Db 704 -----ENSEGCLGCGYPPSCTCT-----GTVV 726

RESULT 14
US-09-182-024A-5
; Sequence 5, Application US/09182024A
; Patent No. 6342370
; GENERAL INFORMATION:
; APPLICANT: Connolly, Timothy
; APPLICANT: Rajput, Bhanu
; TITLE OF INVENTION: Human Slit Polypeptide and Polynucleotides Encoding
; TITLE OF INVENTION: Same
; FILE REFERENCE: 640100-271
; CURRENT APPLICATION NUMBER: US/09/182,024A
; CURRENT FILING DATE: 1998-10-29
; PRIOR APPLICATION NUMBER: 60/063,946
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/096,420
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 5
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 1480
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; US-09-182-024A-5

Query Match      10.3%; Score 347; DB 4; Length 1480;
Best Local Similarity 23.9%; Pred. No. 9.2e-21;
Matches 109; Conservative 65; Mismatches 152; Indels 130; Gaps 9;

QY 46 TCPVSCSNQFVKVCRNLRVDPGISTNTRLLNLHENQIOIKVNSFKHLRHL 105
Db 294 SCPPHRCADGI--VDCREKSLTSVPVTLDDTDDVRLQNFITELPKKSFSPRLRRI 351
QY 106 QLSRNHIRTIEIGAFNGLANLTLEFDNRLTTPNGAFVYLSKLKELWLRNNPIESIPS 165
Db 352 DLSNNISRIAHDAISGLKQLTTLVLYGNKIKDLPVGFGLGSLRLLNLANEISCIRK 411
QY 166 YAFNRIPSLRRLDGLKRLSYISEGAFEGLSNLRYLNLAM-----CNLR----- 210
Db 412 DAFRDLHSLSLSYD--NNIQSLANGTFDAMKSMKTVHLAKNPFCDCNLRWLADYLHN 470
QY 211 ----- 210
Db 471 PIETSGARCESPKRMHRRRIESLREERFKCSWGLRMKLSGECRMDSDCPAMCHCEGTV 530
QY 211 -----EIPNLTP-----IKLD-----ELDLSGNHLSAIRPGS 238
Db 531 DCTGRRRLKEIPRDLPHLTTELLNDNLGRISDGLFGRPLHLVKLEKRNQLTGIEPNA 590
QY 239 FQGLHMLQKLMWIOSQIQVIERNADNLQSLVEINLAHNNLTLLPHDLFTPLHHLRIHL 298
Db 591 FEGASHIQELQNGENKIKEISNKMFLGLHQLKTLNLYDNQISCVMPGSFEHLNLSLNL 650
QY 299 HHNPWNCNDILWLSWIKDAPNTACCARCNTPPNKGRIYIGELDONFTCYAPVIVE 358
Db 651 ASNPFCNCHLAWFAECVRKKSLNGA--ARCGAPSKVRDQVQIKDLPHSEFKCSS----- 703
QY 359 PPADLVNTEGMAAEKCRASLTLSVSMTPTNGTVM 394
Db 704 -----ENSEGCLGCGYPPSCTCT-----GTVV 726

RESULT 15
US-09-063-950-5
; Sequence 5, Application US/09063950C
; Patent No. 6225085
; GENERAL INFORMATION:
; APPLICANT: Holtzman, Douglas A.
; TITLE OF INVENTION: NOVEL LRSG PROTEIN AND NUCLEIC ACID MOLECULES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: MEI-019
; CURRENT APPLICATION NUMBER: US/09/063,950C
; CURRENT FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 605
; TYPE: PRT
; ORGANISM: Papilio hamadryas
; US-09-063-950-5

Query Match      10.0%; Score 335; DB 4; Length 605;
Best Local Similarity 20.8%; Pred. No. 2.5e-20;
Matches 125; Conservative 64; Mismatches 125; Indels 286; Gaps 13;

QY 31 LALQLLVVA-----GLVRAQTCPSCVSCS-----NOFSKVICVRKNLR 68
Db 8 LALALLLSVWALGPRSLRLEGAEPTGAEAGPACATCATCACSDDDEVNELS-VFCSRNLT 66
```





GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 26, 2002, 15:41:53 ; Search time 31.57 Seconds

(without alignments)

1681.764 Million cell updates/sec

Title: US-09-905-056-292\_COPY\_45\_522

Perfect score: 2524

Sequence: 1 QTCPSVCSNQFSKVICVR.....KTFTPTVDINSIGIPIDEV 478

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A\_Geneseq\_032802.\*

```

1: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/AA2001.DAT.*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2524	100.0	640	20 AAY08100	Human PRO331 prote
2	2524	100.0	640	20 AAW85722	Novel protein (Clo
3	2524	100.0	640	20 AAY13394	Amino acid sequenc
4	2524	100.0	640	21 AAB24407	Human PRO331 prote
5	2524	100.0	640	21 AAY70673	Human PRO331 prote
6	2524	100.0	640	22 AAU12355	Human PRO331 polyp
7	2524	100.0	640	22 AAU00826	Human immune respo
8	2524	100.0	640	22 AAB80262	Human PRO331 prote
9	2524	100.0	640	22 AAB65292	Human PRO331 prote
10	2524	100.0	640	22 AAB53089	Human angiogenesis
11	1793.5	71.1	713	22 AAE13006	Human leucine-rich

12	1581.5	62.7	653	20 AAY28806	cc359_4 secreted p
13	1581.5	62.7	653	21 AAB24073	Human PRO1111 prot
14	1581.5	62.7	653	21 AAY66694	Membrane-bound pro
15	1581.5	62.7	653	22 AAE09438	Human sbgPRO331a p
16	1581.5	62.7	653	22 AAU12390	Human PRO1111 poly
17	1581.5	62.7	653	22 AAB65217	Human PRO1111 (UNQ
18	1561.5	61.9	448	21 AAE23044	Human SLIT protein
19	1560.5	61.8	606	22 AAU18035	Human immunoglobul
20	1548.5	61.4	590	21 AAB23034	Human SLIT protein
21	1548.5	61.4	694	21 AAB23033	Human SLIT protein
22	1356.5	53.7	553	22 ABB10349	Human CDNA SEQ ID
23	971	38.5	302	21 AAY87066	Human secreted pro
24	971	38.5	302	22 AAE06043	Human gene 3 encod
25	886.5	35.1	441	21 AAB43091	Human ORFX ORF2855
26	845.5	33.5	281	22 ABB10522	Human CDNA SEQ ID
27	845.5	33.5	281	22 AAU18084	Human immunoglobul
28	685	27.1	224	21 AAY87135	Human secreted pro
29	685	27.1	224	22 AAE06112	Human gene 3 encod
30	568.5	22.5	614	20 AAW84596	Amino acid sequenc
31	565.5	22.4	579	22 AAE06804	Mature human neuro
32	565.5	22.4	606	22 AAE06799	Human neuronal gui
33	565.5	22.4	620	22 AAB74705	Human membrane ass
34	556.5	22.0	620	20 AAY13357	Amino acid sequenc
35	556.5	22.0	620	22 AAU12333	Human PRO227 polyp
36	556.5	22.0	620	22 AAB80225	Human PRO227 prote
37	522.5	20.7	592	22 AAE09437	Human sbgTangog79a
38	477.5	18.9	548	22 AAB31161	Amino acid sequenc
39	453	17.9	766	22 AAG67505	Amino acid sequenc
40	443.5	17.6	1021	22 ABB60162	Drosophila melanog
41	430.5	17.1	713	20 AAY13385	Amino acid sequenc
42	430.5	17.1	713	22 AAB80253	Human PRO293 prote
43	422.5	16.7	707	20 AAY02379	Polypeptide identi
44	421	16.7	705	21 AAB42513	Human ORFX ORF2277
45	421	16.7	705	22 AAM78823	Human protein SEQ

#### ALIGNMENTS

```

RESULT 1
AAY08100
ID AAY08100 standard; Protein; 640 AA.
XX
AC AAY08100;
XX
DT 11-SEP-2000 (first entry)
XX
DE Human PRO331 protein.
XX

```

Inflammatory cell infiltration; immune response; T cell proliferation;  
 anti-inflammatory; anti-autoimmune; anti-diabetic; spondyloarthritis;  
 T cell-mediated disease; spondyloarthritis; sclerosis; renal disease;  
 inflammatory myopathy; hemolytic anemia; thrombocytopenia; thyroiditis;  
 diabetes mellitus; demyelinating polyneuropathy; Gullain-Barre syndrome;  
 multiple sclerosis; polyneuropathy; hepatitis; cirrhosis; enteropathy;  
 sclerosing cholangitis; inflammatory bowel disease; Whipple's disease;  
 skin disease; dermatitis; psoriasis; asthma; allergic rhinitis; tumor;  
 food hypersensitivity; urticaria; eosinophilic pneumonia; transplant;  
 idiopathic pulmonary fibrosis; graft rejection; PRO245; human;  
 PRO331.

```

XX Homo sapiens.
XX
XX WO9914241-A2.
XX
XX 25-MAR-1999.
XX
XX 17-SEP-1998; 98WO-US19437.
XX
XX 17-SEP-1997; 97US-0059119.
XX
XX 18-SEP-1997; 97US-0059263.
XX
XX 28-OCT-1997; 97US-0063550.
XX
XX 12-NOV-1997; 97US-0065186.

```

PR 21-NOV-1997; 97US-0066364.  
 PR 24-NOV-1997; 97US-0066770.  
 PR 04-JUN-1998; 98US-0088026.  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Fong S, Goddard A, Gurney AL, Tumas D, Wood WI;  
 XX WPI; 1999-229499/19.  
 DR N-PSDB; AAX37738.  
 XX  
 XX Composition containing novel polypeptide PRO245, its agonist or  
 FT antagonist -  
 XX  
 PS Example 1; Fig 33; 177pp; English.  
 XX  
 CC This invention describes a novel composition containing (apart from a  
 CC carrier or excipient), a novel PRO245 polypeptide (I), its agonist or  
 CC antagonist, or their fragments, for modulating: (i) infiltration of  
 CC inflammatory cells into tissue; (ii) an immune response; or (iii) T cell  
 CC proliferation. The composition increases or decreases any of the effects  
 CC (i)-(iii). The products of the invention have anti-inflammatory,  
 CC anti-autoimmune and anti-diabetic activity. (I), and its (ant)agonists  
 CC and their fragments, are used to treat immune-related diseases,  
 CC particularly T cell-mediated diseases. The diseases treated include  
 CC systemic lupus erythematosus, rheumatoid arthritis, juvenile chronic  
 CC arthritis, spondyloarthropathies, systemic sclerosis (scleroderma),  
 CC idiopathic inflammatory myopathies (dermatomyositis, polymyositis),  
 CC Sjogren's syndrome, systemic vasculitis (dermatomyositis, polymyositis),  
 CC hemolytic anemia (immune pancytopenia, paroxysmal nocturnal  
 CC hemoglobinuria), autoimmune thrombocytopenia (idiopathic thrombocytopenic  
 CC purpura immune-mediated thrombocytopenia), thyroiditis (Grave's disease,  
 CC Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic  
 CC thyroiditis), diabetes mellitus, immune-mediated renal disease  
 CC (glomerulonephritis, tubulointerstitial nephritis), multiple sclerosis,  
 CC idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome, chronic  
 CC inflammatory demyelinating polyneuropathy, infectious hepatitis  
 CC (hepatitis A, B, C, D, E and other non-hepatotropic viruses), autoimmune  
 CC chronic active hepatitis, primary biliary cirrhosis, granulomatous  
 CC hepatitis, and sclerosing cholangitis, inflammatory bowel disease  
 CC (ulcerative colitis; Crohn's disease), gluten-sensitive enteropathy, and  
 CC Whipple's disease. Autoimmune or immune-mediated skin diseases including  
 CC bullous skin diseases, erythema multiforme, contact dermatitis, psoriasis,  
 CC asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity,  
 CC urticaria, eosinophilic pneumonia, idiopathic pulmonary fibrosis,  
 CC hypersensitivity pneumonitis, and transplantation associated diseases  
 CC (graft rejection, and graft-versus-host-disease). (I), its (ant)agonists  
 CC or fragment can also be used as an adjuvant in treatment of tumors.  
 CC Antibodies against (I) can also be used for diagnosing such diseases.  
 CC This sequence represents the human PRO331 protein which is described in  
 CC the method of the invention.  
 XX  
 SQ Sequence 640 AA;

Query Match 100.0%; Score 2524; DB 20; Length 640;  
 Best Local Similarity 100.0%; Pred. No. 2.4e-177;  
 Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 QTCPSVCSNSQFSKVCVRKRLREVPDGISTNRLNLHENQIQIKVNSFKHLRLEI 60  
 Db 45 qtcpvscsnqfskvcvrkrlrevpdgiistnrlnlhenqikvnsfkhlrlei 104  
 QY 61 LQLSRNHRTIEGAFNGLANLTLEFDNRLTIPNGAFVYLSKLKELWRNPPIESIP 120  
 Db 105 lqlsrnhrtiegfnglanltlefdnrltippngafvylskelwlrnpiesip 164  
 QY 121 SYANRNPISRLRDLGELKRLSYISEGAFEGLSNRLYNLAMCNLREIPNTPLIKDEL 180  
 Db 165 syanrnpisrlrdlgelkrlsyisegafeglsnrlynlamcnlreipnltplikidel 224  
 QY 181 DLSGNHLSAIRPGSFGQHLHKLQKWLWIOSQIQVTERNAFNLQSLVLEINLHNNLTLLPH 240  
 XX

Db 225 dlsghnhsairpgsfqglmhklqkwmqsgiqviernafndnlgsiveinlahnnltllph 284  
 QY 241 DLFTPLHLHLRIHLHNPWNCNCDILWLSWIKOMAPSNATACCARNTPPNLKGRIYIGEL 300  
 Db 285 dlftplhlhlerihhnpwncncdillwlswikmapsentaccarcncppnlkgryigel 344  
 QY 301 DQNYFTCYAPVIVPEPPADLNVTEGMAAEKCRASSTLSVSWITPNGVTMTHGAYKVRIA 360  
 Db 345 dqnyftcyapviveppadlnvtegmaaeekcrasstlsvswitpntgvmthgaykvria 404  
 QY 361 VLSGTLNFTNVTVDGMYTCMVNSVGNVTASATLNVTAATTPPFSYFSTVVTMEP 420  
 Db 405 vlsdgtlnftnvtvgdgmtycmvnsvgnvtasatlnvtaatttptfsyfstvtvetnep 464  
 QY 421 SODEARTDNNVGPVVDWETTNVTTSLTPQSTRSTEKTTIPVTDNSGIPGIDEV 478  
 Db 465 sqdeartdnnvgpvpvvdwettnttsltbpqstrstekttipvtdnsgipgidev 522  
 XX  
 XX RESULT 2  
 XX AAW85722  
 XX ID AAW85722 standard; Protein; 640 AA.  
 XX AC AAW85722;  
 XX DT 27-SEP-1999 (first entry)  
 XX DE Novel protein (Clone AS209\_1).  
 XX KW Polynucleotide; protein; nutrition; cytokine; cell proliferation;  
 KW cell differentiation; immunostimulation; immunosuppression;  
 KW hematopoiesis regulation; tissue growth; activin; inhibin;  
 KW chemotaxis; chemokinesis; haemostasis; thrombolysis; receptor;  
 KW ligand; anti-inflammatory; tumour suppression; gene therapy.  
 XX OS Homo sapiens.  
 XX PN WO9920644-A1.  
 XX PD 29-APR-1999.  
 XX PF 16-OCT-1998; 98WO-US22034.  
 XX PR 18-OCT-1997; 97US-0955557.  
 XX PA (GEMY ) GENETICS INST INC.  
 XX PI Agostino MJ, Bowman MR, Evans C, Jacobs K, Lavallie ER;  
 PI McCoy JM, Merberg D, Racie LA, Spaulding V, Treacy M;  
 XX WPI; 1999-288272/24.  
 XX DR N-PSDB; AAX08687.  
 XX PT New polynucleotides encoding secreted human proteins  
 XX Claim 26; Page 109-111; 136pp; English.  
 XX The new human secreted proteins are encoded by polynucleotides  
 CC obtained from human placenta, adult testes, fetal kidney, fetal  
 CC brain, adult brain, adult brain and adult blood cDNA libraries.  
 CC The polynucleotides and proteins are predicted to have biological  
 CC activities which would make them suitable for treating, preventing or  
 CC ameliorating medical conditions in humans and animals. Suggested  
 CC activities include nutritional activity, cytokine and cell  
 CC proliferation/differentiation activity, immune stimulating (e.g. as  
 CC vaccines) or suppressing activity, haematopoiesis regulating  
 CC activity, tissue growth activity, activin/inhibin activity,  
 CC chemotactic/chemokinetic activity, haemostatic and thrombolytic  
 CC activity, receptor/ligand activity, anti-inflammatory activity,  
 CC cadherin/tumour invasion suppressor activity, and tumour inhibition  
 CC activity. The polynucleotides are also stated to be useful for gene  
 CC therapy. The sequences identified by a secretory leader  
 CC sequence motif in the polynucleotide and it is thought that the



CC encoded proteins have biological activity by virtue of their secreted nature. This polypeptide was encoded by a clone designated AS209\_1 (See AAX08687).

XX Sequence 640 AA;

Query Match 100.0%; Score 2524; DB 20; Length 640;  
Best Local Similarity 100.0%; Pred. No. 2.4e-177;  
Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QTCPSVCSCNQSKVICVRKNLREVPDGIISTNRLNLHENOIQIKVNSFHLRHLEI 60  
DB 45 qtcpvcscsnqskvicvrknirevpdgiistnrlnlhendqikvnsfkhrlhleI 104  
QY 61 LQLSNRHIRTIEGAFNGLANLTLEFDNRLTTPNGAFVYLSKLEWLRNPNIESIP 120  
DB 105 lqlsnrhirtieigafnglanltlefdnrltppngafvyskikewlwrnnpiesip 164  
QY 121 SYAFNRIPSLRRDLGELKRLSYISEGAFGLSNLRYLNLMCNLREIPNLTLPLIKIDEL 180  
DB 165 syafnrslrrldlgelkrlsyisegafglslnrllylnlmcnltreipnltplikidel 224  
QY 181 DLSONHLASIRPGSFQGLMHLQKLWIKQSIQVIERNAFDNLSLVEINLAHNNLLPLPH 240  
DB 225 dlsgnhlasirpgsfqglmhlqklwmiqsiqviernafdnlsveinlahnnllplph 284  
QY 241 DLFTPLHLERIRLHHPWNCNDILWLSWIKDMAPSNACCARCNTPPNLKGRYIGEL 300  
DB 285 dlftplhlerrlhhpwnncndilwlswwikdmapsnaccarcntppnlkgriygel 344  
QY 301 DQNYFTCYAPVIEPPADLNVTEGMAELKCRASSTLSITSVITPVTGTHGAYKVRIA 360  
DB 345 dqnyftcyapvieppadlnvtegmaelkcrasstlsitsvtpvtgthgaykvria 404  
QY 361 VLSGTLNFTNVVQDTGWTCHVNSVGNVTASALNVTAATTPPSYFSTVVTWMEP 420  
DB 405 vlsdgtlnftnvtvqdtgwtcmvnsvgnttasatlnvtaattppsfystvtwmetp 464  
QY 421 SQDEARTDNNVGPVVDWETTNVTTSLPQSTRSTEKFTTIPVTDINSIGIPIDEV 478  
DB 465 sqdeartdnnvgpvpvdwettntvttsltpqstrstekfttvpvtdinsgipidev 522

RESULT 3

AAV13394  
ID AAY13394 standard; Protein; 640 AA.

AC AAY13394;

XX 25-JUN-1999 (first entry)

XX Amino acid sequence of protein PRO331.

XX Secreted protein; transmembrane protein; human; enterocolitis;  
KW Zollinger-Ellison syndrome; gastrointestinal ulceration;  
KW congenital microvillus atrophy; skin disease; cell growth;  
KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;  
KW Parkinson's disease; Alzheimer's disease; ALS; neuropathy;  
KW fibromodulin; dermal scarring; Usher Syndrome; Atrophia areata;  
KW anti-thrombotic; wound healing; tissue repair.

XX Homo sapiens.

XX W09914328-A2.

XX 25-MAR-1999.

XX 16-SEP-1998; 98WO-US19330.

XX 25-NOV-1997; 97US-0066840.

XX 17-SEP-1997; 97US-0059113.

XX 17-SEP-1997; 97US-0059115.

PR 17-SEP-1997; 97US-0059117.  
PR 17-SEP-1997; 97US-0059119.  
PR 17-SEP-1997; 97US-0059121.  
PR 17-SEP-1997; 97US-0059122.  
PR 17-SEP-1997; 97US-0059184.  
PR 18-SEP-1997; 97US-0059263.  
PR 18-SEP-1997; 97US-0059266.  
PR 15-OCT-1997; 97US-0062125.  
PR 17-OCT-1997; 97US-0062285.  
PR 17-OCT-1997; 97US-0062287.  
PR 21-OCT-1997; 97US-0063486.  
PR 24-OCT-1997; 97US-0062814.  
PR 24-OCT-1997; 97US-0062816.  
PR 24-OCT-1997; 97US-0063045.  
PR 24-OCT-1997; 97US-0063120.  
PR 24-OCT-1997; 97US-0063121.  
PR 24-OCT-1997; 97US-0063127.  
PR 24-OCT-1997; 97US-0063128.  
PR 27-OCT-1997; 97US-0063329.  
PR 27-OCT-1997; 97US-0063327.  
PR 28-OCT-1997; 97US-0063541.  
PR 28-OCT-1997; 97US-0063542.  
PR 28-OCT-1997; 97US-0063544.  
PR 28-OCT-1997; 97US-0063549.  
PR 28-OCT-1997; 97US-0063550.  
PR 28-OCT-1997; 97US-0063564.  
PR 29-OCT-1997; 97US-0063435.  
PR 29-OCT-1997; 97US-0063704.  
PR 29-OCT-1997; 97US-0063732.  
PR 29-OCT-1997; 97US-0063738.  
PR 29-OCT-1997; 97US-0063734.  
PR 29-OCT-1997; 97US-0064215.  
PR 31-OCT-1997; 97US-0063735.  
PR 31-OCT-1997; 97US-0063870.  
PR 31-OCT-1997; 97US-0064103.  
PR 03-NOV-1997; 97US-0064248.  
PR 07-NOV-1997; 97US-0064809.  
PR 12-NOV-1997; 97US-0065186.  
PR 17-NOV-1997; 97US-0065846.  
PR 18-NOV-1997; 97US-0065693.  
PR 21-NOV-1997; 97US-0066120.  
PR 21-NOV-1997; 97US-0066364.  
PR 24-NOV-1997; 97US-0066772.  
PR 24-NOV-1997; 97US-0066466.  
PR 24-NOV-1997; 97US-0066770.  
PR 24-NOV-1997; 97US-0066511.  
PR 24-NOV-1997; 97US-0066453.

(GETH ) GENENTECH INC.

Chen J, Goddard A, Gurney AL, Pennica D, Wood WI, Yuan J;

WPI; 1999-229533/19.

N-PSDB; AAX52265.

New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration

Claim 12; Fig 104; 320pp; English.

AAV13344-403 represent secreted and transmembrane human proteins.

The cDNA sequences are obtained from cDNA libraries, prepared from fetal lung, fetal kidney, fetal brain, fetal liver and fetal retina. The encoded polypeptides have specific uses based on their homology to known polypeptides, e.g. PRO211 and PRO217 can be used for disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions (e.g. enterocolitis, Zollinger-Ellison syndrome, gastrointestinal ulceration and congenital microvillus atrophy), skin diseases associated with abnormal keratinocyte differentiation (e.g. psoriasis, epithelial cancers such as lung squamous cell carcinoma of the vulva and gliomas), potent effects on cell growth and development, diseases related to growth or survival of nerve cells including Parkinson's disease,

CC Alzheimer's disease, ALS, neuropathies or cancer. PRO265 can be used as  
CC for fibromodulin, e.g. for reducing dermal scarring. PRO264 can be used  
CC as a target for anti-tumor drugs. PRO533 may be used in the treatment  
CC of Usher Syndrome or Atrophia areata; PRO269 can be used as an  
CC anti-thrombotic agent; PRO287 polypeptides and portions may have  
CC therapeutic applications in wound healing and tissue repair; PRO317 can  
CC be used for treating problems of the kidney, uterus, endometrium, blood  
CC vessels, or related tissue, e.g. in the heart of genital tract.

XX Sequence 640 AA;

Query Match 100.0%; Score 2524; DB 20; Length 640;  
Best Local Similarity 100.0%; Pred. No. 2.4e-177;  
Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QTCPSVCSNQSFKVTCVRKNLREVPDGI STNTRLLNHNHQI I KVN SFKHLRHEI 60  
DB 45 qtcpsvcsnqfskvcvcrknrlrevpdg istntrllnhnq i kvn sfkhlr hlei 104  
QY 61 LQLSRNHIRTIEGAFNGLANLTLELFDNRLTTPNGAFVYLSKELWLRNPIESIP 120  
DB 105 lqlsrnhirtieigafnglanltlelfdnrlt tipngafv ylskelwlrnp iesip 164  
QY 121 SYAFNRIPSLRRDLGELKRLSYISEGAFEGLSNRLYNLAMCNLREIPNLTPLIKDEL 180  
DB 165 syafnr ipslrrdl gelkrlsy isegafegls nrl ynla mcnlre ipnltp likdel 224  
QY 181 DLGNHLSAIRPGSFQGLMHLQKLMWIOSQIQTIERNAFNLQSLVEINLAHNLTLLPH 240  
DB 225 dlgnhlsairpgsfqglmhlqklmwiosqi qtier na fnlqslve inla hnltp lph 284  
QY 241 DLFTPLHLERIHLPNPNWNCNCDILWLSWIKDMASNTACCRCNTPPNKLGRYIGEL 300  
DB 285 dlftplhl erihlpnpn wncncd ilwls w i k d m a s n t a c c r c n t p p n k l g r y i g e l 344  
QY 301 DQNTFTYAPVIVPEPADLNVTEGMAELKCRASSTLSVSWITPNGTVMTHGAYKRIA 360  
DB 345 dqntft yapv ivpe padlnv te gmael kcras ts lsv switp ng tvm thg ayk ria 404  
QY 361 VLSGDTNFTNVTQDGMVTCMVSNGVNTASATLNVTAAATTPFSYSTVVTWMEP 420  
DB 405 vls gdt nft nvt qd gm vtc mvs n g v n t a s a t l n v t a a t t p f s y s t v v t w m e p 464  
QY 421 SQDEARTDNNVGPVVDVETTNVTTSLTPQSTRSTEKFTTIPVTDINSIGIPIDEV 478  
DB 465 sqdeart dnnv g p v v d v e t t n v t t s l t p q s t r s t e k f t t i p v t d i n s i g i p i d e v 522

RESULT 4

AAB24407  
ID AAB24407 standard; Protein; 640 AA.  
XX  
AC AAB24407;  
XX  
DT 07-NOV-2000 (first entry)  
DE Human PRO331 protein sequence SEQ ID NO:107.  
XX  
KW Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation;  
KW diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;  
KW angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic;  
KW cytostatic; gene therapy; vaccine.  
XX  
OS Homo sapiens.  
XX  
PN WO200032221-A2.  
XX  
PD 08-JUN-2000.  
XX  
PF 30-NOV-1999; 99WO-US28313.  
XX  
PR 01-DEC-1998; 98WO-US25108.

PR 16-DEC-1998; 98US-0112850.  
PR 12-JAN-1999; 99US-0115554.  
PR 08-MAR-1999; 99WO-US05028.  
PR 12-MAR-1999; 99US-0123957.  
PR 28-APR-1999; 99US-0131445.  
PR 14-MAY-1999; 99US-0134287.  
PR 02-JUN-1999; 99WO-US12252.  
PR 23-JUN-1999; 99US-0141037.  
PR 20-JUL-1999; 99US-0144758.  
PR 26-JUL-1999; 99US-0145698.  
PR 01-SEP-1999; 99WO-US20111.  
PR 08-SEP-1999; 99WO-US20594.  
PR 13-SEP-1999; 99WO-US20944.  
PR 15-SEP-1999; 99WO-US21090.  
PR 15-SEP-1999; 99WO-US21547.  
PR 03-OCT-1999; 99WO-US23089.  
PR 29-OCT-1999; 99US-0162506.

(GETH ) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ, Goddard A;  
XX Godowski PJ, Gurney AL, Klein RD, Kuo SS, Paoni NF, Smith V;  
XX Watanabe CK, Williams PM, Wood WI;

XX WPI: 2000-412154/35.

XX N-PSDB; AAA77596.

XX Nucleic acids encoding PRO polypeptides useful for preventing,  
XX diagnosing and treating disorders in mammals -  
XX PT angio-genic disorders in mammals -

XX PS Claim 72; Fig 40; 315pp; English.

XX The present invention describes nucleic acids encoding PRO polypeptides  
XX useful for preventing, diagnosing and treating disorders in mammals by  
XX cardiovascular, endothelial or angiogenic disorder in mammals by  
XX modulating cell proliferation, angiogenesis and cardiovascularisation,  
XX and for identifying agonists and antagonists of these processes. The  
XX nucleic acids and the proteins they encode may be used in the  
XX prevention, treatment and diagnosis of diseases associated with  
XX inappropriate PRO expression such as cardiovascular, endothelial or  
XX angiogenic disorders in mammals (e.g. atherosclerosis, cancers and  
XX cardiac hypertrophy). For example, the nucleic acids (NAs) and vectors  
XX containing them and the PRO polypeptide may be used to treat disorders  
XX associated with decreased PRO expression. AAA77510 to AAA77721 and  
XX AAB24388 to AAB24435 represent nucleotide and protein sequences used in  
XX the exemplification of the present invention.

XX Sequence 640 AA;

Query Match 100.0%; Score 2524; DB 21; Length 640;  
Best Local Similarity 100.0%; Pred. No. 2.4e-177;  
Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QTCPSVCSNQSFKVTCVRKNLREVPDGI STNTRLLNHNHQI I KVN SFKHLRHEI 60  
DB 45 qtcpsvcsnqfskvcvcrknrlrevpdg istntrllnhnq i kvn sfkhlr hlei 104  
QY 61 LQLSRNHIRTIEGAFNGLANLTLELFDNRLTTPNGAFVYLSKELWLRNPIESIP 120  
DB 105 lqlsrnhirtieigafnglanltlelfdnrlt tipngafv ylskelwlrnp iesip 164  
QY 121 SYAFNRIPSLRRDLGELKRLSYISEGAFEGLSNRLYNLAMCNLREIPNLTPLIKDEL 180  
DB 165 syafnr ipslrrdl gelkrlsy isegafegls nrl ynla mcnlre ipnltp likdel 224  
QY 181 DLGNHLSAIRPGSFQGLMHLQKLMWIOSQIQTIERNAFNLQSLVEINLAHNLTLLPH 240  
DB 225 dlgnhlsairpgsfqglmhlqklmwiosqi qtier na fnlqslve inla hnltp lph 284  
QY 241 DLFTPLHLERIHLPNPNWNCNCDILWLSWIKDMASNTACCRCNTPPNKLGRYIGEL 300



Db 105 lqlsrnhrtieigafnglanlntlelfdnrlttipngafvyskkelwlrnnpiesip 164  
QY 121 SYAFNRIPSLRRDLGKRLSYISEGAFGLSNLRYLNAMCNLREIPNLTPLIKLDEL 180  
Db 165 syafnrpslrrldlgelkrlsyisegafeglsnrlinlancnrlreipnltplikidel 224  
QY 181 DLGNHLSAIRPGSFGQIMHQLKRLSYISQIQIERNAFDNLQSLVEINLAHNLTLLPH 240  
Db 225 dlsgnhlsairpgsfqglmlhqlkrlsyisegafeglsnrlinlancnrlreipnltplikidel 284  
QY 241 DLFTPLHLRIHLHNPWNCNDILWLSWIKDMPSTACCACTPPNPKRGYIGEL 300  
Db 285 dlftplhlhlerihlhnnpwncndilwlswwikdmpstaccarctppnlgryigel 344  
QY 301 DQNYFTCYAPVIVEPPADLNVTGMAELKCRASSTLSVSWITPNCVTMTHGAYKVRIA 360  
Db 345 dqnyftcyapviveppadlnvtgmaaelkcraststsvswitpncvmtghaykvria 404  
QY 361 VLSGTLNFTNVTVDGMYTCMVSNVGNVTASATLNVTAAATTPFSYFTVTMETMEP 420  
Db 405 vlsdgtlnftnvtvdgmytcmvsnvsgnttasatlnvtatattptfsyfstvtmetme 464  
QY 421 SQDEARTDNNVGPVVDHETNVTLSLPQSTRTEKFTTIPVTDINSIGIDIV 478  
Db 465 sqdeartdnnvgtpvvdhettntvtsltpqstrstekfttptvtdinsigpidev 522  
  
RESULT 6  
AAU12355  
ID AAU12355 standard; Protein; 640 AA.  
XX  
AC AAU12355;  
XX  
DT 24-OCT-2001 (first entry)  
XX  
DE Human PRO331 polypeptide sequence.  
XX  
KW Human secretory and transmembrane; PRO; mammalian; cancer; lung;  
KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;  
KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;  
KW adipocyte; A-peptide; factor VIIA; gene therapy.  
XX  
OS Homo sapiens.  
XX  
PN WO20010466-A2.  
XX  
PD 07-JUN-2001.  
XX  
PF 01-DEC-2000; 2000WO-US32678.  
XX  
PR 01-DEC-1999; 99WO-US28301.  
PR 01-DEC-1999; 99WO-US28634.  
PR 02-DEC-1999; 99WO-US28551.  
PR 02-DEC-1999; 99WO-US28564.  
PR 02-DEC-1999; 99WO-US28565.  
PR 09-DEC-1999; 99US-0170262.  
PR 16-DEC-1999; 99WO-US30095.  
PR 20-DEC-1999; 99WO-US30911.  
PR 20-DEC-1999; 99WO-US30999.  
PR 30-DEC-1999; 99WO-US31243.  
PR 06-JAN-2000; 2000WO-US00277.  
PR 06-JAN-2000; 2000WO-US00376.  
PR 11-FEB-2000; 2000WO-US03565.  
PR 18-FEB-2000; 2000WO-US04341.  
PR 18-FEB-2000; 2000WO-US04342.  
PR 22-FEB-2000; 2000WO-US04414.  
PR 24-FEB-2000; 2000WO-US04914.  
PR 24-FEB-2000; 2000WO-US05004.  
PR 01-MAR-2000; 2000WO-US05601.  
PR 20-MAR-2000; 2000WO-US07377.  
PR 21-MAR-2000; 2000WO-US07532.  
PR 30-MAR-2000; 2000WO-US08439.  
PR 17-MAY-2000; 2000WO-US13705.

PR 22-MAY-2000; 2000WO-US14042.  
PR 30-MAY-2000; 2000WO-US14941.  
PR 02-JUN-2000; 2000WO-US15264.  
PR 10-NOV-2000; 2000WO-US30873.  
XX  
PA (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2001-408281/43.  
DR N-PSDB; AAS21427.  
XX  
XX Isolated, secretory and transmembrane PRO polypeptide used to detect  
PT other PRO polypeptides, link bioactive molecules to cells expressing  
PT PRO polypeptides, and detect the presence of mammalian tumours e.g.  
PT lung, breast, prostate, cervical  
XX  
XX Clalim 12; Fig 368; 813pp; English.  
XX  
XX AAU12172-AAU12446 represent novel human secretory and transmembrane  
CC PRO polypeptides. The PRO polypeptides are useful to detect other  
CC PRO polypeptides, to link bioactive molecules to cells expressing  
CC PRO polypeptides, to modulate biological activities of cells expressing  
CC PRO polypeptides, and to detect the presence of mammalian lung, colon,  
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO  
CC polypeptide expression in a cell sample to that in a control sample.  
CC Some of the 275 sequences are also useful to stimulate the release of  
CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the  
CC proliferation or differentiation of chondrocytes, the proliferation or  
CC gene expression in pericyte cells, the release of proteoglycans from  
CC cartilage, the proliferation of inner ear utricular supporting cells or  
CC of T-lymphocytes, the release of a cytokine from peripheral blood  
CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of  
CC the PRO polypeptides may modulate glucose or free fatty acid uptake by  
CC skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide  
CC to factor VIIA. The PRO polypeptides can be used in assays to identify  
CC molecules involved in binding interactions. The polynucleotides encoding  
CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,  
CC transgenic or knock out animals and can be used in gene therapy.  
XX  
SQ Sequence 640 AA;  
  
Query Match 100.0%; Score 2524; DB 22; Length 640;  
Best Local Similarity 100.0%; Pred. No. 2.4e-177; Indels 0; Gaps 0;  
Matches 478; Conservative 0; Mismatches 0;  
  
QY 1 QTCPSVCSCSNQFSKVICVRKRLREVPDGIETNTRRLNLHENQIQIKVNSFKHLRLEI 60  
Db 45 qtcpsvcscsnqfskvicvrkrlrevpdgistntrlnlhengdiqikvnsfkhlrlei 104  
QY 61 LQLSRNHRTIEIGAFNGLANLTLELFDNRLTTPNGAFVYLSKLELWLRNNPESIP 120  
Db 105 lqlsrnhrtieigafnglanlntlelfdnrlttipngafvyskkelwlrnnpiesip 164  
QY 121 SYAFNRIPSLRRDLGKRLSYISEGAFGLSNLRYLNAMCNLREIPNLTPLIKLDEL 180  
Db 165 syafnrpslrrldlgelkrlsyisegafeglsnrlinlancnrlreipnltplikidel 224  
QY 181 DLGNHLSAIRPGSFGQIMHQLKRLSYISQIQIERNAFDNLQSLVEINLAHNLTLLPH 240  
Db 225 dlsgnhlsairpgsfqglmlhqlkrlsyisegafeglsnrlinlancnrlreipnltplikidel 284  
QY 241 DLFTPLHLRIHLHNPWNCNDILWLSWIKDMPSTACCACTPPNPKRGYIGEL 300  
Db 285 dlftplhlhlerihlhnnpwncndilwlswwikdmpstaccarctppnlgryigel 344  
QY 301 DQNYFTCYAPVIVEPPADLNVTGMAELKCRASSTLSVSWITPNCVTMTHGAYKVRIA 360  
Db 345 dqnyftcyapviveppadlnvtgmaaelkcraststsvswitpncvmtghaykvria 404

QY 361 VLSGTLNFTNVTQDGMVTCMVSNSVGNNTASATLNVAATTPRSYFSTVETMEP 420  
 Db 405 VLSGTLNFTNVTQDGMVTCMVSNSVGNNTASATLNVAATTPRSYFSTVETMEP 464  
 QY 421 SQDEARTDNNVGPVVDWETNNTVTSLSLPQSTRSTEKTFPTVTDINSIGIPGIDEV 478  
 Db 465 sqdeartdnnvgpvdvwetnntvtsltpqstrstektfptvtdinsigipgidev 522

RESULT 7  
 AAU00826  
 ID AAU00826 standard; Protein; 640 AA.  
 XX  
 AC AAU00826;  
 XX  
 DT 04-JUL-2001 (first entry)  
 XX  
 DE Human immune response protein PRO331 (UNQ292).  
 XX  
 KW Human; PRO331; UNQ292; immune response; osteoarthritis;  
 KW systemic lupus erythematosus; rheumatoid arthritis; systemic sclerosis;  
 KW juvenile chronic arthritis; spondyloarthropathy; Sjogren's syndrome;  
 KW idiopathic inflammatory myopathy; polymyositis; systemic vasculitis;  
 KW sarcoidosis; autoimmune haemolytic anaemia; immune pancytopenia;  
 KW autoimmune thrombocytopaenia; idiopathic thrombocytopaenic purpura;  
 KW thyroiditis; Grave's disease; Hashimoto's thyroiditis;  
 KW diabetes mellitus; glomerulonephritis; demyelinating disease;  
 KW multiple sclerosis; Guillain-Barre syndrome; hepatobiliary disease;  
 KW chronic inflammatory demyelinating polyneuropathy; infectious hepatitis;  
 KW auto immune chronic active hepatitis; primary biliary cirrhosis;  
 KW granulomatous hepatitis; sclerosing cholangitis; ulcerative colitis;  
 KW inflammatory bowel disease; Crohn's disease; Whipple's disease;  
 KW erythema multiforme; psoriasis; asthma; allergic rhinitis; urticaria;  
 KW food hypersensitivity; eosinophilic pneumonia; graft rejection;  
 KW idiopathic pulmonary fibrosis; graft-versus-host-disease; immunogen;  
 KW antibody.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key  
 FT Peptide  
 FT 1..44  
 FT /label= Signal\_peptide  
 FT Modified-site 40..46  
 FT /note= "Glycine is N-myristoylated"  
 FT Protein 45..640  
 FT /label= Mature\_PRO331  
 FT Modified-site 73..79  
 FT /note= "Glycine is N-myristoylated"  
 FT Modified-site 118..124  
 FT /note= "Glycine at 118 is N-myristoylated"  
 FT Region 183..187  
 FT /label= Phosphorylation\_site  
 FT /note= "CAMP/cGMP dependent protein kinase phosphorylation site"  
 FT Modified-site 191..197  
 FT /note= "Glycine at 191 is N-myristoylated"  
 FT Modified-site 228..234  
 FT /note= "Glycine is N-myristoylated"  
 FT Modified-site 237..243  
 FT /note= "Glycine is N-myristoylated"  
 FT Modified-site 278..282  
 FT /note= "Asn is N-glycosylated"  
 FT Modified-site 364..368  
 FT /note= "Asn is N-glycosylated"  
 FT Modified-site 390..394  
 FT /note= "Asn is N-glycosylated"  
 FT Modified-site 391..397  
 FT /note= "Glycine at 391 is N-myristoylated"  
 FT Modified-site 412..416  
 FT /note= "Asn is N-glycosylated"  
 FT Modified-site 415..419  
 FT /note= "Asn is N-glycosylated"  
 FT Modified-site 422..428

FT /note= "Glycine is N-myristoylated"  
 FT Modified-site 433..439  
 FT /note= "Glycine is N-myristoylated"  
 FT Modified-site 434..438  
 FT /note= "Asn is N-glycosylated"  
 FT Modified-site 442..446  
 FT /note= "Asn is N-glycosylated"  
 FT Modified-site 488..492  
 FT /note= "Asn is N-glycosylated"  
 FT Domain 528..543  
 FT /label= Transmembrane\_domain  
 FT Modified-site 531..537  
 FT /note= "Glycine is N-myristoylated"  
 FT Modified-site 606..610  
 FT /note= "Asn is N-glycosylated"  
 XX  
 PN WO200119991-A1.  
 XX  
 PD 22-MAR-2001.  
 XX  
 PF 20-MAR-2000; 2000WO-US07377.  
 XX  
 PR 15-SEP-1999; 99WO-US21547.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Fong S, Goddard A, Gurney AL, Hillan KJ, Tumas D, Wood WI;  
 XX WPI; 2001-226823/23.  
 DR N-PSDB; AAS00162.  
 XX  
 PT Composition for diagnosing and treating immune related diseases, e.g.  
 PT rheumatoid arthritis and diabetes mellitus, comprises a PRO  
 PT polypeptide, agonist, antagonist or fragment -  
 XX  
 PS Claim 31; Fig 12; 138pp; English.  
 XX  
 CC The sequence represents Human PRO331 (UNQ292), a protein involved in  
 CC the immune response. PRO polypeptides, and (ant)agonists to them, are  
 CC used in compositions for modulating infiltration of inflammatory cells  
 CC into a tissue, modulating an immune response and modulating proliferation  
 CC of T-lymphocytes in response to an antigen. Immune related diseases can  
 CC be treated with the compositions, such as, systemic lupus erythematosus,  
 CC rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis,  
 CC spondyloarthropathies, systemic sclerosis, idiopathic inflammatory  
 CC myopathies (e.g. polymyositis), Sjogren's syndrome, systemic vasculitis,  
 CC sarcoidosis, autoimmune haemolytic anaemia (e.g. immune pancytopenia),  
 CC autoimmune thrombocytopaenia (e.g. idiopathic thrombocytopaenic purpura),  
 CC thyroiditis (e.g. Grave's disease, Hashimoto's thyroiditis), diabetes  
 CC mellitus, immune-mediated renal disease (e.g. glomerulonephritis),  
 CC demyelinating diseases of the central and peripheral nervous systems e.g.  
 CC multiple sclerosis or Guillain-Barre syndrome, and chronic inflammatory  
 CC demyelinating polyneuropathy, hepatobiliary diseases such as infectious  
 CC hepatitis (hepatitis A, B, C, D, E and other non-hepatotropic viruses),  
 CC auto immune chronic active hepatitis, primary biliary cirrhosis,  
 CC granulomatous hepatitis, and sclerosing cholangitis, inflammatory bowel  
 CC disease (ulcerative colitis, Crohn's disease and Whipple's disease),  
 CC autoimmune or immune-mediated skin diseases (e.g. erythema  
 CC multiforme and psoriasis), asthma, allergic rhinitis, urticaria,  
 CC food hypersensitivity, immunologic diseases of the lung such as  
 CC eosinophilic pneumonias, idiopathic pulmonary fibrosis, transplantation  
 CC associated diseases including graft-versus-host-disease and graft  
 CC rejection. PRO polypeptides can be used to diagnose immune related  
 CC diseases, to identify inhibitors, and to stimulate the proliferation of  
 CC T lymphocytes. Anti-PRO antibodies can be used to detect PRO and  
 CC in diagnosis. PRO polypeptides, antibodies and (ant)agonists can be used  
 CC in rational drug design.  
 XX  
 SQ Sequence 640 AA;

Query Match 100.0%; Score 2524; DB 22; Length 640;  
 Best Local Similarity 100.0%; Pred. No. 2.4e-177;

Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	QTCPSVCSNQFSKVICVRKNLEVPDGI	STNRLNLHNLHENQIQIIVKNSFKHLRLEI 60
Db	45	qtcpvscsnqfskvicvrknlevpdgi	stnrlnlhnlhenqiiqvnsfkhlrllei 104
QY	61	LQSRNHRTIEIGAFNGLANLTLF	DNRLTTPNGAFVYLSKLKELWLRNPIESIP 120
Db	105	lqlsrnhrtieigafnglanlntlel	fdnrltttngafvylsklkelwlrnpiiesip 164
QY	121	SYAFNRIPSLRRLDGLGELKRLSY	ISEGAFGLSNLRYLNAMCNLREIPNLTPLIKIDEL 180
Db	165	syafnrripslrldgelkrlsyisega	fglslnrylnlamcnlreipnltplikidel 224
QY	181	DLSGNHLISAIRPGSFGQGLMHQ	LKLMWIOSQIQVIERNAFNLQSLVEINLAHNLTLLPH 240
Db	225	dlsghnhsairpgsfqglmhqlkml	wiqsqvliernafndlqslveinlahnltllph 284
QY	241	DLFTPLHHLERIHLLHNPWCNC	DILWSWIKDMAPSNNTACCARCNTPPNKGRIYIGEL 300
Db	285	dlftplhhlერიhllhnpwncncdil	lswwikdmapsntaccarcntppnkgryigel 344
QY	301	DQNYFTCYAPVIVEPPADLNVT	EGMAAELKCRASSTLSVSWITPNGTVMTGHYKVRIA 360
Db	345	dqnyftcyapviveppadlnvte	gmaaelkcrastsitsvswitpngtvmthgykvrria 404
QY	361	VLSDGTLNFTNVTVDGTGMVTC	WVNSVGNVTASATLNVTAAATTPESYFSTVVTMEP 420
Db	405	vlsdgtlnftnvtvqdtgmytcwv	nsvgntasatlntvtaatttpefsyfstvvtmep 464
QY	421	SQDEARTDNNVGPVVDWETT	NVTTSLTPQSTRSTEKFTTIPVTDINSIGPIDEV 478
Db	465	sqdeartdnnvgptpvdwettnt	vttsltpqstrstekfttippvtdinsigpidev 522

RESULT 8

AAB80262	AAB80262 standard; Protein: 640 AA.		
XX	AC	AAB80262;	
XX	DT	24-APR-2001 (first entry)	
XX	DE	Human PRO331 protein.	
XX	KW	Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;	
XX	KW	antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;	
XX	KW	antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;	
XX	KW	antiarthritic; antinfertility; antidiabetic; antiviral; diabetes;	
XX	KW	ophthalmological; gene therapy; skin disease; gastrointestinal disorder;	
XX	KW	ischaemia; inflammation.	
XX	OS	Homo sapiens.	
XX	PN	WO200104311-A1.	
XX	PD	18-JAN-2001.	
XX	PF	22-FEB-2000; 2000WO-US04414.	
XX	PR	07-JUL-1999; 99US-0143048.	
XX	PR	26-JUL-1999; 99US-0145698.	
XX	PR	28-JUL-1999; 99US-0146222.	
XX	PR	08-SEP-1999; 99WO-US20594.	
XX	PR	13-SEP-1999; 99WO-US20944.	
XX	PR	15-SEP-1999; 99WO-US21090.	
XX	PR	15-SEP-1999; 99WO-US21547.	
XX	PR	05-OCT-1999; 99WO-US23089.	
XX	PR	29-NOV-1999; 99WO-US28214.	
XX	PR	30-NOV-1999; 99WO-US28313.	
XX	PR	16-DEC-1999; 99WO-US30095.	
XX	PR	20-DEC-1999; 99WO-US30911.	
XX	PR	20-DEC-1999; 99WO-US30999.	

PR	05-JAN-2000;	99WO-US00219.	
XX	(GETH ) GENENTECH INC.		
PA	Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;		
XX	Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;		
PI	Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IG;		
PI	Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;		
PI	Williams PM, Wood WI;		
XX	WPI: 2001-081051/09.		
DR	N-PSDB; AAF72423.		
XX	Sixty one nucleic acids encoding PRO polypeptides which are useful in		
PT	the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung		
PT	squamous cell carcinoma) and neurodegenerative diseases (e.g.		
PT	Alzheimer's disease) -		
XX	Claim 1; Fig 104; 393pp; English.		
PS	The present sequence is one of sixty one novel secreted and		
PS	transmembrane PRO polypeptides. The PRO polypeptides are		
CC	useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung		
CC	squamous cell carcinoma), gastrointestinal disorders (e.g.		
CC	enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,		
CC	Parkinson's disease), wound repair, cardiovascular disorders (e.g.		
CC	endometrial bleeding angiogenesis, ischaemias such as coronary		
CC	ischaemia, atherosclerosis), inflammatory disorders (e.g. asthma,		
CC	rheumatoid arthritis, multiple sclerosis), infertility, AIDS and		
CC	diabetes and retinal disorders such as retinitis pigmentosum.		
CC	The PRO nucleic acids have applications in molecular biology, including		
CC	use as hybridization probes, and in chromosome and gene mapping.		
XX	Sequence 640 AA;		
QY	Query Match 100.0%; Score 2524; DB 22; Length 640;		
Db	Best Local Similarity 100.0%; Pred. No. 2.4e-177;		
XX	Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	1	QTCPSVCSNQFSKVICVRKNLEVPDGI	STNRLNLHNLHENQIQIIVKNSFKHLRLEI 60
Db	45	qtcpvscsnqfskvicvrknlevpdgi	stnrlnlhnlhenqiiqvnsfkhlrllei 104
QY	61	LQSRNHRTIEIGAFNGLANLTLF	DNRLTTPNGAFVYLSKLKELWLRNPIESIP 120
Db	105	lqlsrnhrtieigafnglanlntlel	fdnrltttngafvylsklkelwlrnpiiesip 164
QY	121	SYAFNRIPSLRRLDGLGELKRLSY	ISEGAFGLSNLRYLNAMCNLREIPNLTPLIKIDEL 180
Db	165	syafnrripslrldgelkrlsyisega	fglslnrylnlamcnlreipnltplikidel 224
QY	181	DLSGNHLISAIRPGSFGQGLMHQ	LKLMWIOSQIQVIERNAFNLQSLVEINLAHNLTLLPH 240
Db	225	dlsghnhsairpgsfqglmhqlkml	wiqsqvliernafndlqslveinlahnltllph 284
QY	241	DLFTPLHHLERIHLLHNPWCNC	DILWSWIKDMAPSNNTACCARCNTPPNKGRIYIGEL 300
Db	285	dlftplhhlერიhllhnpwncncdil	lswwikdmapsntaccarcntppnkgryigel 344
QY	301	DQNYFTCYAPVIVEPPADLNVT	EGMAAELKCRASSTLSVSWITPNGTVMTGHYKVRIA 360
Db	345	dqnyftcyapviveppadlnvte	gmaaelkcrastsitsvswitpngtvmthgykvrria 404
QY	361	VLSDGTLNFTNVTVDGTGMVTC	WVNSVGNVTASATLNVTAAATTPESYFSTVVTMEP 420
Db	405	vlsdgtlnftnvtvqdtgmytcwv	nsvgntasatlntvtaatttpefsyfstvvtmep 464
QY	421	SQDEARTDNNVGPVVDWETT	NVTTSLTPQSTRSTEKFTTIPVTDINSIGPIDEV 478
Db	465	sqdeartdnnvgptpvdwettnt	vttsltpqstrstekfttippvtdinsigpidev 522

```
RESULT 9
AAB65292
ID AAB65292 standard; Protein; 640 AA.
AC
AC AAB65292;
XX
DT 02-APR-2001 (first entry)
XX
DE Human PRO331 protein sequence SEQ ID NO:501.
XX
DE
XX Human; secreted and transmembrane protein; PRO; cytostatic;
KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW diagnostic assay.
XX
OS Homo sapiens.
XX
PN WO200073454-A1.
XX
PD 07-DEC-2000.
XX
PF 30-MAR-2000; 2000WO-US08439.
XX
PR 02-JUN-1999; 99WO-US12252.
PR 23-JUN-1999; 99US-0141037.
PR 07-JUL-1999; 99US-0143048.
PR 20-JUL-1999; 99US-0144758.
PR 26-JUL-1999; 99US-0145698.
PR 28-JUL-1999; 99US-0146222.
PR 17-AUG-1999; 99US-0149396.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 08-OCT-1999; 99US-0158663.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 03-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
XX
XX (GETH ) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi CJ, Gurney AL, Kijavini LJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WP1; 2001-032160/04.
DR N-PSDB; AAF44261.
XX
XX PRO polynucleotides used to produce polypeptides used to target
XX bioactive molecules such as toxins, radiolabels or antibodies, to
XX PT specific cells, to cause targeted cell death -
XX
XX Claim 12; Fig 314; 935pp; English.
XX
XX The present invention describes human secreted and transmembrane PRO
XX proteins. The PRO proteins have cytostatic activity. The PRO proteins
XX can be used for targeted delivery of bioactive molecules, such as
XX toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
XX sequences, and their fragments, can be used as hybridisation probes, in
XX chromosomal and gene mapping, and in the generation of anti-sense RNA
XX and DNA. They may also be used to produce transgenic animals which are
XX used to develop and screen therapeutically useful reagents. The PRO
XX nucleotide and protein sequence can be used for tissue typing and in
```

```
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC sequences given in the exemplification of the present invention.
XX
SQ Sequence 640 AA;
Query Match 100.0%; Score 2524; DB 22; Length 640;
Best Local Similarity 100.0%; Pred. No. 2.4e-177;
Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QTCPSVCSNQSFKVCRKLNREVPGISTNRLNLNLHENQIQIKVNSFKHLRHLLEI 60
DB 45 qtcpsvcsnqsfkvicvrknrevpdgistnrlnlhenqikvnsfkhlrhllei 104
QY 61 LQJSRNHIRTIEIGAFNGLANLTLFELFDNRLTIPNGAFVYLSKLKELWLRNPIESIP 120
DB 105 lqjsrnhirtieigafnglanlntclelfdnrlttipngafvylskklkelwlrnpiiesip 164
QY 121 SYAFNRIPSLRLDLGELKRLSYISEGAFGLSNLRVNLNLAACNLREIPNLTPLIKLDEL 180
DB 165 syafnrpslrrldlgelkrlsyisegafeglsnlrylnlamcnlreipnltplikidel 224
QY 181 DLGNHLSAIRPGSFOGLMHLQKLMWIOSQIQVIERNAFDNLQSLVEINLAHNNLTLLPH 240
DB 225 dlsgnhlsairpgsfqglmhlqklwmqsgqlqviernafndlqslveinlahnnltllph 284
QY 241 DLFTPLHHLERIHLLHNPWNCNDILWLSWIKDMAPSNLTACCARCNTPPNKGRIYIGEL 300
DB 285 dlftplhhlerihlhnwpwncndilwlswwikdmapsnltaccarcntppnkgriyigel 344
QY 301 DQNYFTCYAPVIVEPPADLNVTGMAAELKCRASLTLSVSWITPNCVTMTHGAYKVRIA 360
DB 345 dqnyftcyapviveppadlnvtgmaaelkcrasltlsvswitpncvtmthgaykvria 404
QY 361 VLSGDTLNFNTVQDTGMYTCMVSNVGNFTASATLNVTAAATTPFSYFSTVVTMEP 420
DB 405 vlsdgtlnfntvqdtgmytcmvsnvgnftasatlnvtaatttfsyfstvtvetmep 464
QY 421 SQDEARTDNNVGTPPVVDWETTNVTTSLTPQSTRTEKFTTIPVTDINSIGPIDEV 478
DB 465 sqdeartdnnvgtpvvdwettntvttsltpqstrstekfttipvtdinsigpidev 522
RESULT 10
AAB53089
ID AAB53089 standard; Protein; 640 AA.
XX
AC AAB53089;
XX
DT 28-FEB-2001 (first entry)
XX
DE Human angiogenesis-associated protein PRO331, SEQ ID NO:137.
XX
DE
XX Human; angiogenesis-associated protein; PRO; endothelial cell growth;
KW cardiac hypertrophy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; atherosclerosis; osteoporosis; hypertension;
KW myocardial infarction; diabetic retinopathy; rheumatoid arthritis;
KW Crohn's disease; psoriasis; endometriosis; ulcer; wound healing; cancer;
KW Alzheimer's disease; Huntington's disease; stroke; drug screening;
KW gene therapy; transgenic animal.
XX
XX Homo sapiens.
OS
XX WO200053753-A2.
XX
XX 14-SEP-2000.
PD
XX 05-JAN-2000; 2000WO-US00219.
PF
XX 08-MAR-1999; 99WO-US05028.
PR
```









PT adult brain, human fetal brain, human fetal kidney, and human adult  
XX blood cDNA libraries -  
PS Claim 1; Page 97-99; 122pp; English.  
XX  
CC The present sequence is the cc359\_4 secreted protein encoded by the cDNA  
CC clone cc359\_4. cc359\_4 was isolated from a human adult brain cDNA library  
CC using methods specific for secreted protein cDNAs. The leader sequence or  
CC signal peptide acts as a transmembrane domain due to its hydrophobic  
CC nature. The TopPredII computer program predicts five potential  
CC transmembrane domains centered around amino acids 20, 410, 490, 530 and  
CC 590. This protein has a leucine zipper motif. The polynucleotide and  
CC protein may effect nutritional activity, cytokine and cell proliferation,  
CC immune stimulation or suppression, hematopoiesis regulation, tissue  
CC growth, tumour inhibition etc.  
XX  
SQ Sequence 653 AA;

Query Match 62.7%; Score 1581.5; DB 20; Length 653;  
Best Local Similarity 60.9%; Pred. No. 5.le-108;  
Matches 298; Conservative 77; Mismatches 93; Indels 21; Gaps 8;

Qy 1 QTCPSVCSNQSFKVICVRKLNREVPGISTNTLLNHNQIQIKVNSFKHLRHLLEI 60  
Dy 44 qncpsvcsnqsfkvctrrglsevpqgipnsnrylnlmenniqmiquadtrfhlhlev 103  
Qy 61 LQLSNRHTRTEIGAFNGLANLNTLEFDNRLTTPNGAFVYLSKLELWLRNPNIESIP 120  
Dy 104 lqgrnsrlqevafnglasintlelfdnwtlvpqafeylskirelwrnnpiesip 163  
Qy 121 SYAFNRPLSRRLDGLKRLSYISEGAFEGLSNRLRYLNAMCNLRTEIPNLTPIKLDL 180  
Dy 164 syafnrpslmlrdlglkrlsyisegafeglnkylngmcnkdmnpnlplvgleel 223  
Qy 181 DLSGNHLSAIRPFSFGQHLHOKLWMIOSQIQVIERNAFDNLQSLVEINLAHNLTLLPH 240  
Dy 224 emsgnhfpeirpghfghlsslklwvmsqvsliernafdglsalveinlahnlsip 283  
Qy 241 DLFTPLHLERLHLHNPWCNCDLTLMSWIKDAPSNATACCARPPLNKGRIYIGEL 300  
Dy 284 dlftplylvelhlnhpwncdclilawlwrelyptnscgcrcphamrgrylvev 343  
Qy 301 DONFTCYAPVIVPEPPADLVTEGMAELKCRSTLSFVSIVTPNGVMTGHAYKVRIA 360  
Dy 344 dqasfcsaptmdaprdlnlsegmaelkcr-tpmssvkwllpngtvlshashrpris 402  
Qy 361 VLSGDTLNFNTVQDTGMYTCWYSNSVGNNTASATLNVTA--TTTPFSFSTVVTETM 418  
Dy 403 vlngdtlnfshvldstgvtcmvtnvagnsnasaylnvstaelsntsfyftvtvett 462  
Qy 419 EPSQDEARTTNNVGPVPVDWETNV-----TTSLTP--QSTRSEKTKFTTIPVTDINS 470  
Dy 463 elsped---trkykypv-----tstgyqpaytstvtllqtr-vpkqvavpatdtd 513  
Qy 471 GI-PGIDEV 478  
Dy 514 kmqtsldev 522

RESULT 13  
AAB24073  
ID AAB24073 standard; Protein; 653 AA.  
XX  
AC AAB24073;  
XX  
DI 29-JAN-2001 (first entry)  
XX  
DE Human PRO1111 protein sequence SEQ ID NO:46.  
XX  
KW Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;  
KW proliferation; tumorigenesis; identification; cancer; cytostatic;  
KW neutrotic; neuroprotective; antinflammatory; immunosuppressive;

immunostimulant; antiangiogenic; leukaemia; lymphoid malignancy;  
neural disorder; glial disorder; astrocytal disorder; angiogenic;  
hypothalamic disorder; glandular disorder; macrophagal disorder;  
epithelial disorder; stromal disorder; blastocoelec disorder;  
inflammatory disorder; immunologic disorder.

Homo sapiens.  
WO200053755-A2.  
14-SEP-2000.  
06-JAN-2000; 2000WO-US00376.  
08-MAR-1999; 99WO-US05028.  
02-JUN-1999; 99WO-US12252.  
23-JUN-1999; 99US-0141037.  
07-JUL-1999; 99US-0143048.  
26-JUL-1999; 99US-0145698.  
30-NOV-1999; 99WO-US28313.  
20-DEC-1999; 99WO-US30911.  
05-JAN-2000; 2000WO-US00219.  
(GETH ) GENENTECH INC.  
Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hillan KJ, Roy MA;  
Watanabe CK, Wood WI;  
WPI; 2000-572270/53.  
N-PSDB; AAC58383.

Thirty PRO polynucleotides encoding PRO polypeptides, useful in the  
treatment, diagnosis and prevention of cancer -  
Claim 61; Fig 34; 286pp; English.  
The present invention describes an isolated antibody that binds to  
one of the human PRO proteins designated PRO212, PRO290, PRO341, PRO535,  
PRO619, PRO717, PRO809, PRO830, PRO848, PRO943, PRO1005, PRO1009,  
PRO1025, PRO1030, PRO1097, PRO1107, PRO1111, PRO1153, PRO1182, PRO1184,  
PRO1187, PRO1281, PRO23, PRO39, PRO834, PRO1317, PRO1710, PRO2094, cell  
PRO2145 OR PRO2198. PRO antagonists can be used to inhibit tumour cell  
growth. The PRO polypeptides and nucleotides are useful in the  
treatment, diagnosis and prevention of cancer. The antibodies and other  
anti-tumour compounds may be used to treat various conditions, including  
those characterised by overexpression and/or activation of the amplified  
PRO genes. Exemplary conditions or disorders to be treated with such  
antibodies and other compounds include benign or malignant tumours  
(e.g., renal, liver, kidney, bladder, breast, gastric, ovarian,  
colorectal, prostate, pancreatic, lung, vulva, thyroid, hepatic  
carcinomas, sarcomas, glioblastomas, and various head and neck tumours),  
leukaemias and lymphoid malignancies, other disorders such as neuronal,  
glial, astrocytal, hypothalamic and other glandular, macrophagal,  
epithelial, stromal and blastocoelec disorders, and inflammatory,  
CC angiogenic and immunologic disorders. AAC58242 to AAC58366 represent PCR  
CC primers and hybridisation probes used in the isolation of the human PRO  
CC sequences. AAC58367 to AAC58396 and AAB24057 to AAB24089 represent human  
CC PRO polynucleotide and protein sequences given in the exemplification of  
CC the present invention.

Query Match 62.7%; Score 1581.5; DB 21; Length 653;  
Best Local Similarity 60.9%; Pred. No. 5.le-108;  
Matches 298; Conservative 77; Mismatches 93; Indels 21; Gaps 8;  
Qy 1 QTCPSVCSNQSFKVICVRKLNREVPGISTNTLLNHNQIQIKVNSFKHLRHLLEI 60  
Dy 44 qncpsvcsnqsfkvctrrglsevpqgipnsnrylnlmenniqmiquadtrfhlhlev 103  
Qy 61 LQLSNRHTRTEIGAFNGLANLNTLEFDNRLTTPNGAFVYLSKLELWLRNPNIESIP 120  
Dy 104 lqgrnsrlqevafnglasintlelfdnwtlvpqafeylskirelwrnnpiesip 163

98US-0088741.  
98US-0088742.  
98US-0088810.  
98US-0088811.  
98US-0088812.  
98US-0088824.  
98US-0088825.  
98US-0088826.  
98US-0088836.  
98US-0088861.  
98US-0088863.  
98US-0088876.  
98US-0088900.  
98US-0089105.  
98US-0089440.  
98US-0089512.  
98US-0089514.  
98US-0089532.  
98US-0089538.  
98US-0089598.  
98US-0089599.  
98US-0089600.  
98US-0089653.  
98US-0089801.  
98US-0089807.  
98US-0089908.  
98US-0089947.  
98US-0089948.  
98US-0089952.  
98US-0090246.  
98US-0090252.  
98US-0090254.  
98US-0090349.  
98US-0090355.  
98US-0090359.  
98US-0090421.  
98US-0090445.  
98US-0090446.  
98US-0090455.  
98US-0090461.  
98US-0090472.  
98US-0090732.  
98US-0090755.  
98US-0090938.  
98US-0090940.  
98US-0090957.  
98US-0090966.  
98US-0090678.  
98US-0090688.  
98US-0090690.  
98US-0090691.  
98US-0090694.  
98US-0090695.  
98US-0090696.  
98US-0090862.  
98US-0090863.  
98US-0091358.  
98US-0091360.  
98US-0091544.  
98US-0091478.  
98US-0091486.  
98US-0091519.  
98US-0091626.  
98US-0091628.  
98US-0091633.  
98US-0091646.  
98US-0091673.  
98US-0091978.  
98US-0092182.  
98US-0092183.  
98US-0092472.  
98US-0093339.  
98US-0093451.  
98US-0093582.  
98US-0093585.  
98US-0093585.

04-AUG-1998; 98US-0095301.  
04-AUG-1998; 98US-0095302.  
04-AUG-1998; 98US-0095318.  
04-AUG-1998; 98US-0095321.  
04-AUG-1998; 98US-0095325.  
10-AUG-1998; 98US-0095916.  
10-AUG-1998; 98US-0095929.  
10-AUG-1998; 98US-0096012.  
11-AUG-1998; 98US-0096143.  
11-AUG-1998; 98US-0096146.  
12-AUG-1998; 98US-0096329.  
12-AUG-1998; 98US-0096757.  
17-AUG-1998; 98US-0096766.  
17-AUG-1998; 98US-0096768.  
17-AUG-1998; 98US-0096773.  
17-AUG-1998; 98US-0096791.  
17-AUG-1998; 98US-0096867.  
17-AUG-1998; 98US-0096891.  
17-AUG-1998; 98US-0096894.  
17-AUG-1998; 98US-0096895.  
17-AUG-1998; 98US-0096897.  
18-AUG-1998; 98US-0096949.  
18-AUG-1998; 98US-0096950.  
18-AUG-1998; 98US-0096959.  
18-AUG-1998; 98US-0096960.  
18-AUG-1998; 98US-0097022.  
19-AUG-1998; 98US-0097141.  
20-AUG-1998; 98US-0097218.  
20-AUG-1998; 98US-0097261.  
26-AUG-1998; 98US-0097951.  
26-AUG-1998; 98US-0097952.  
26-AUG-1998; 98US-0097954.  
26-AUG-1998; 98US-0097955.  
26-AUG-1998; 98US-0097971.  
26-AUG-1998; 98US-0097974.  
26-AUG-1998; 98US-0097978.  
26-AUG-1998; 98US-0097979.  
26-AUG-1998; 98US-0097986.  
26-AUG-1998; 98US-0098014.  
31-AUG-1998; 98US-0098525.  
16-SEP-1998; 98US-0100634.  
12-JAN-1999; 99US-0115565.

(GETH ) GENENTECH INC.  
Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;  
Wood WJ, Yuan J;  
WPI; 2000-072883/06.  
N-PSDB; AAZ65033.  
Membrane-bound proteins and related nucleotide sequences  
claim 12; Fig 157; 822pp; English.  
The invention provides membrane-bound PRO polypeptides and polynucleotides encoding them. The PRO sequences of the invention were identified based on extracellular domain homology screening. The PRO sequences have homology with proteins including LDL receptors, TIE ligands and various enzymes. The membrane-bound proteins and receptor molecules are useful as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be used as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The PRO encoding sequences are useful as hybridization probes, in chromosome and gene mapping and in the generation of antisense RNA and DNA. PRO nucleic acid sequences will also be useful for the preparation of PRO polypeptides, especially by recombinant techniques.

SQ Sequence 653 AA;

Query Match 62.7%; Score 1581.5; DB 21; Length 653;  
Best Local Similarity 60.9%; Pred. No. 5.1e-108;  
Matches 298; Conservative 77; Mismatches 93; Indels 21; Gaps 8;  
Qy 1 QTCPSVSCSNQFSKVICVRKNLREVDPGISTNTLLMLHENQIOIKVNSFKHRLHLEI 60  
Db 44 qncpsvcscsnqfskvctrrglsevpqgipnsntrlylmennlqmqadttrfhlhlev 103  
Qy 61 LQSRNHRTTETGAFNGLANLTLELFDNRLTTPNGAFVYLSKLKELWLNNDTIESP 120  
Db 104 lqlgrnsirqlievgainglasintlielfdnwltvlpagafeylskirelwnrnplesip 163  
Qy 121 SYAFNRIPRLRLDLGELKRLSYISEGAFEGLSNLRYLNLAMCNLREIPNLTPLIKLDEL 180  
Db 164 syafnrpvlmrldlgelkklkleyisegafeglnfkylnlgmcnikdnpnltpvgleel 223  
Qy 181 DLSGNHLSAIRPGSQGLMHLOKLMWIOSQIOVIERNADFNLQSLVEINLAHNNTLLPH 240  
Db 224 emsgnhfpeirpgsfhglsslkklwmsqvsaliernafdglsaveinlahnnlssiph 283  
Qy 241 DLFTHLHLERHHLHNPNCNCDILWLSWIKDMAPSNACCARCNTPPNLLKGRYIGEL 300  
Db 284 dlftprlyivelhlnhnpwncddilwawlrreypcnstccgrchpmmrgylvev 343  
Qy 301 DQNYFTCYAPVIVEPPADLNVTEGMAELKCRASLTLSVSWITPNGTVMTHGAYKVRIA 360  
Db 344 dqasfqcscapfimdprdlinssegmaelkcr-tpmssvkwllpngtvlshasrhrpis 402  
Qy 361 VLSGDTLNFTNVTQDTGMYTCWNSVGNVTASATLNVTA--TTTFESFSTVVTETM 418  
Db 403 vlngdtlnfshvllsdtgvytcmtvnagnsnassylnvstaelnysffttvtvett 462  
Qy 419 EPSODEARTDNNGVPTPVDWETNV-----TTSLP--QSTRSTEKTFPTIDINS 470  
Db 463 eisped---trkykvp-----ttstgypayttsttvlqtr-vpkqvavpatdtd 513  
Qy 471 GI-PGIDEV 478  
Db 514 kmqtsldev 522  
RESULT 15  
AAE09438  
ID AAE09438 standard; Protein; 653 AA.  
XX AC AAE09438;  
XX AC AAE09438;  
DT 19-NOV-2001 (first entry)  
XX DE Human sbgPRO331a protein.  
XX KW Human; Alzheimer's disease; amyotrophic lateral sclerosis;  
KW ALS; Zollinger-Ellison syndrome; immune system disease; schizophrenia;  
KW inflammation; haematopoietic disease; anxiety; feeding disorder; aging;  
KW anorexia; depression; cardiovascular disease; sleep disorder; seizure;  
KW memory alteration; migraine; stroke; asthma; neuropathy; hypoglycaemia;  
KW sexual disorder; growth abnormality; infection; autoimmune disease;  
KW rheumatoid arthritis; cataractogenesis; angiogenesis; atherosclerosis;  
KW cerebral ischaemia; cirrhosis; Huntington's disease; Hodgson's disease;  
KW hypercholesterolaemia; headache; amnesia; cardiac arrhythmia; obesity;  
KW diabetes mellitus; glomerulonephritis; renovascular hypertension;  
KW cancer; vaccine; gene therapy; sbgPRO331a gene.  
XX OS Homo sapiens.  
XX XX  
XX PN WO200160850-A1.  
XX XX  
XX PD 23-AUG-2001.  
XX XX  
XX PF 14-FEB-2001; 2001WO-US04703.  
XX XX  
XX PR 14-FEB-2000; 2000US-0182172.  
XX PR 29-FEB-2000; 2000US-0186084.







C;Date: 11-Apr-1997 #sequence\_revision 11-Apr-1997 #text\_change 05-Nov-1999

C;Accession: A58532

R;Suzuki, Y.; Sato, N.; Tohyama, M.; Wanaka, A.; Takagi, T.

J. Biol. Chem. 271, 22522-22527, 1996

A;Title: cDNA cloning of a novel membrane glycoprotein that is expressed specifically in

A;Reference number: A58532; MUID:96394313

A;Accession: A58532

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: mRNA

A;Residues: 1-1091 <SUZ>

A;Cross-references: GB:D78572; NID:g1545806; PIDN:BAAL1416.1; PID:g1545807

C;Superfamily: leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan amino-ter

F;36-61/Domain: leucine-rich alpha-2-glycoprotein repeat homology <PAH>

F;95-117/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>

F;118-141/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>

F;142-165/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>

F;166-189/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>

F;191-213/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>

F;214-237/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>

F;238-261/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>

F;262-285/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>

F;286-309/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>

F;310-333/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>

F;334-357/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>

F;358-381/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR12>

F;385-408/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR13>

F;409-432/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR14>

F;440-485/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR15>

F;440-485/Domain: proteoglycan carboxyl-terminal homology <PCH>

Query Match 15.9%; Score 402.5; DB 2; Length 1091;

Best Local Similarity 24.1%; Pred. No. 7.5e-20;

Matches 134; Conservative 77; Mismatches 168; Indels 177; Gaps 14;

QY 37 LNLHENQIITKVSFKHLRLHLEILQLSRNHRITETGAFNGLANLTLELFDNRLTIP 36

Db 218 LNLNRRIRLLEGTFOGLDSEVLRLQRNNISRLTDGAFGLSKMHLVHLEYSLEV 277

QY 97 NGAFVYLSKELMLRLNPIESIPS-----YAFNRIPSLRRDLGELKRL-- 141

Db 278 SGSLYGLTALHQLHLSNNSISRIQDGSFCOKLHELILSFNNLTRDEESLSSLSI 337

QY 142 -----SYTSEGAPEGLSNRLYNLAMCNLRPEINLTPIKIDELDSNHLSATRPG 193

Db 338 LRLSHNAISHTAEGAFGLKSLRVL-----LDHNEISGTIEDT--SG 378

QY 194 SFOGLMHLQKLMWTOSQIOVTERNAFQNLQSLVEINLAHNNLTLLPHDLFTPLHLERIH 253

Db 379 AFTGLDNLSKLTFLGNKIKSVAKRAFGSLSEHLNLNGENAIRSVQDFAFKMLNKELY 438

QY 254 LHHNPWNCNDILMSLWMI--KDMAPSNATACCARCNTPPNPKGRYI--GELDONY----- 304

Db 439 ISSSEFLCDCKLWLPWLMGRMLQAFVATCAH--PESLKGOSIFSLVPDSFVCDFF 495

QY 305 -----FTCYA----- 309

Db 496 KPQIITPETTMVAVGKDIRFTCSAASSSSPMTFANKKNEVLANADMFHVAHQDG 555

QY 310 -----PVIVEPPADLNVTG 324

Db 556 EVMEYTTILHURHVTFGHEGRYQCIINHFSGTYSYSHKARLVNVLPSFTKIPHDIAIRTG 615

QY 325 MAELKCRASLSLT--SVSWITPNGVTMTHGAYKVRIAVLSGDTLNF--TNVTVDQTMVTC 382

Db 616 TTABLECAATGHPNPQATQWQDGTDP--AARERMHVMPDDVFFITDVKIDDMGVYSC 674

QY 383 MYSNSVGNNTASATLVNTAATTPFSYFSTVTVMPEFSQDEARTDNV-----GP 434

Db 675 TAQNSAGSVSANATLTLE-----TPSLAVPLEDRVVTVGTVAFOCKATGSP 722

QY 435 TPVVDWETNTVTSIT 450

Db 723 TPRITWLKGGRRPLSLT 738

RESULT 3

JC7763

neuronal leucine-rich repeat protein-3 - rat

C;Species: Rattus norvegicus (Norway rat)

C;Date: 01-Feb-2002 #sequence\_revision 01-Feb-2002 #text\_change 01-Feb-2002

C;Accession: JC7763

R;Fukanachi, K.; Matsuoka, Y.; Kitanaka, C.; Kuchino, Y.; Tsuda, H.

Biochem. Biophys. Res. Commun. 287, 257-263, 2001

A;Title: Rat neuronal leucine-rich repeat protein-3: Cloning and regulation of the ge

A;Reference number: JC7763; PMID:11549284

A;Contents: Fibrosarcoma cells

A;Accession: JC7763

A;Molecule type: mRNA

A;Residues: 1-707 <FUK>

A;Cross-references: GB:AF291437

C;Comment: This protein, a new member of the neuronal leucine-rich repeat protein fam

in protein-protein interaction and functions as a cell adhesion molecule or soluble l

C;Genetics:

A;Gene: nlrr-3

C;Keywords: cell adhesion

Query Match 15.7%; Score 396; DB 2; Length 707;

Best Local Similarity 25.9%; Pred. No. 1.2e-19;

Matches 127; Conservative 79; Mismatches 166; Indels 98; Gaps 13;

QY 3 CPVSCSCS-----NOFSKVICVRKNLREVPGDGIISNTNRLNHNHQIILK--- 48

Db 29 CPOLCTCEIRPWFPTRSIYMEATVDCNDLGLNFPARLPADTQILLQTNNIARIEHST 88

QY 49 -----VNSFKHLRHLLEILQLSR-----NHRTIEIGAFNGLANLTLELF 88

Db 89 DFPVNLGTGLDSQNNLSSVTNINVKMSQLLSVLEENKLTPELKEKGLYGLSNLQELIYN 148

QY 89 DNRLTTPNGAFVYLSKELMLRLNPIESIPSYAFNRIPSLRRDLGELKRLSYISEGA 148

Db 149 HNLLSATSPGAFVGLHNLRLHLNLSNRLQMINSKWFEALPNLEILMLGD--NPILRIKDMN 207

QY 149 FEGLSNRLYNLAMCNLRPEI-----NLTPLIKLE-----LDL 182

Db 208 FQPLKLRSLVIAGINTETVEPDDALVGLNLESTISFYDNRLNKPQVALQKAVNLKFLD 267

QY 183 SGNHLSATRPGSFOGLMHLQKLMW-----IQS-----QIQVTER 216

Db 268 NKNINRIRRGDFSNMHLKELGINNMPPELVSDSLAVDNLPLDKRIEATNPRLSYIHP 327

QY 217 NAFNQLQSLVEINLAHNNLTLLPHDLFTPLHLHLRIHLHNPWNCNDILMSW---WIK 273

Db 328 NAFFRLPKLESILMNSNALSALYHGTIESLPNLKEISHSNPIRCDVIRWINMKNKTNR 387

QY 274 DMAFSNTACCARCNTPPNPKGRYIGELD--QNYFTCYAPVIVEP--PADLNVTGMAAEK 330

Db 388 FMEPDSLFCV---DPPEFQGNVRQVFRDMWEICLPLIAPESFPSTLDEADSVSLH 443

QY 331 CRAGTS--LTSVSWITPNGVTMTHGAYKVRIAVLSGDTLNF--TNVTVDQTMVSNVSG 389

Db 444 CRATAEPOPEYIWTIPSGKRLLPNTLRKFKYVHSEGLDIRGITPKEGGLTYCIATNLVG 503

QY 390 NTTASATLVN 399

Db 504 ADLKSIMIKV 513

RESULT 4

A53860

chondroadherin precursor - bovine

N;Alternate names: 38K leucine-rich protein

C;Species: Bos primigenius taurus (cattle)

C;Date: 07-Oct-1994 #sequence\_revision 07-Oct-1994 #text\_change 05-Nov-1999

C;Accession: A53860



R; Neame, P. J.; Sommarin, Y.; Boynton, R. E.; Heinegard, D. J. Biol. Chem. 269, 21547-21554, 1994

A; Title: The structure of a 38-kDa leucine-rich protein (chondroadherin) isolated from b

A; Reference number: A53860; MUID: 94342341

A:Accession: A53860  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-361 <NEA>  
A:Cross-references: GB:U08018; PIDN:AAA21330.1; PID: g470672  
C:Superfamily: leucine-rich alpha-2-glycoprotein repeat homology; proteoglycan carboxyl-terminal homology <PCH>  
C:Keywords: disulfide bond  
F:300-346/Domain: proteoglycan carboxyl-terminal homology <PCH>

Query Match 15.6%; Score 394; DB 2; Length 361;  
Best Local Similarity 31.9%; Pred. No. 6.9e-20;  
Matches 104; Conservative 49; Mismatches 139; Indels 34; Gaps 8;

QY 3 CPSVCSNQSFKVICVRKNLREVPDGI STNTRLLNLHENQIQIIKVNSFK-----H 54

db 25 CPONCHCHSDLOHVICDVKVGLQTPK-VSEKTIJINIOBNNEPVIATNSERAMPNI VSIH 83

20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050

QY 55 LRHLEI-----LQLSRNHRTIEIGAFNGLANLTLELFDNRLTTPNG 98

Db 84 LQHCQIREVAAGAFGLKQLIYLYLSHNDIRVLRAGAFDDLTELTYLYLDHNKVTLP 14

0v 99 AFVVISKI KEIWRNNPTESIPSYAFNRIDSPBPIDICETIKPI SVTSECAFECSNI DVT 15

QY 99 AFVLSKRELWLRNNPFIETSPISAFNRPSPRLRDLGELKRLSYISEGAFGLSNRLYL ISE

Db 144 LLSPLVNLFIQLNNKIRELRSQAFQKDLRWLYLSE-NSLSLQPGALDDVENLAKF 20

QY 159 NLAMCNLREIPN - - LTPLIKLDELDSLGNHLSAIRPGSFQGL-MHLQKLWMIQSQIQVIE 21

db 203 YIDBNOLSSVPSAALSKI RVVVEELKLSHNDIKSTDDNAFOSECRPI FETIMJ DNNTNI EVES 26

DD 203 IEDRANQJESSIFSAAUSLRKRVVEELKJESANPLASTFDUNAFQSFGRYDEETLWLDNINLERKS 20

QY 216 RNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHLERIHLLHNPWNCNCDILLWSWIKDM 277

Db 263 DGAFLGVTTLKHVHLENNRLHQLPSNF--PFDSLETLTLTNPWKCTCQLRGLRRWLEAK 322

Qv 276 APSNTACCARCNTPPNKKGRYIGELD 301

QY Z/O AFSNIACCARCNTFPNENAGRIIGELD 301  
| | | : | : | : |  
| | | : | : | : |

Db 321 TSRPDATCA --- SPAKFRGQHIRDTD 343

RESULT 5  
T42218

142210 slit-1 protein homolog - rat

N; Alternate names: MEGF4 protein  
C; Species: *Pattug norvegicus* (Norway rat)

C;Species: Rattus norvegicus (Norway rat)  
C;Date: 03-Dec-1999 #sequence\_revision 03-Dec-1999 #text\_change 21-Jul-2001

C;Accession: T42218

R; Nakajima, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O.  
Genomics 51, 27-34, 1998

A;Title: Identification of high-molecular-weight proteins with multiple E

A;Reference number: Z14126; MUID:98360089  
A;Accession: T42218

A; Status: preliminary; translated from GB/EMBL/DDBJ

A; Molecule type: mRNA  
A; Residues: 1-1531 <NAK>

A;Cross-references: EMBL:AB011530; NID:g3449289; PIDN:BAA32460.1; PID:g3449289.1  
A:Experimental source: strain Sorague-DuLac, bacillus

A; Experimental source: strain Sprague-Dawley; brain  
C; Genetics:

**A; Gene: MEGF4**

Query Match	Score	DB 1	DB 2	Length
15.4%	389.5	DB 1	DB 2	1531
24.0%	389.5	DB 1	DB 2	1531
24.0%	389.5	DB 1	DB 2	1531

Best Local Similarity 24.9%; Pred. No. 9.3e-19;  
Matches 124; Conservative 65; Mismatches 146; Indels 163; Gaps

[illegible]

QY 3 CPSVCSCSNQFSKVICVRKNLREVPDGI STNRLNLHENQIQI IKVNSFKHLRHLEILQ 62

Db 34 CPALCTCTG--TTVDCHGTGLQAIKPKNIPNTERLELNGNNITRIHKNDFAGLKQLRVLQ 91

Qv	63	LSNHIPTIEGAFN	-----	77
----	----	---------------	-------	----

33

Db 271 PACNANSLSCPSACSCSNNIVDCRGKGLTEIPANLPEGIVEIRLEQNSIKSIPAGAFIOY 330  
Qy 176 -KLDELDSGNHLSAIRPSFQ-----GLMHQKLMWIOSQ 210  
Db 331 KKLKRIDISKNOISDIADAFQGLKLSLSVLYGNKITEIPKGFDFGLVLSQLLLLNANK 390  
Qy 211 IQVIERNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHLHLRIHNNPWNCCDILWLSW 270  
Db 391 INCLAVNTFQDLQNLNLSLYDNKLTQTSKGLFAPLQSIQTLHLAQNFVCDCHLKWLAD 450  
Qy 271 WIKDMAPNTACCARNTPPNLKGRYIGELDONVFTC 307  
Db 451 YLQD-NPIETS-GARCSSPRRLANKRISQIKSKFR 485

RESULT 7  
B36665  
slit protein 2 precursor - fruit fly (Drosophila melanogaster)  
C:Species: Drosophila melanogaster  
C:Date: 30-Apr-1991 #sequence\_revision 30-Apr-1991 #text\_change 19-May-2000  
C:Accession: B36665  
R:Rothberg, J.M.; Jacobs, J.R.; Goodman, C.S.; Artavanis-Tsakonas, S.  
Genes Dev. 4, 2169-2187, 1990  
A:Title: slit: an extracellular protein necessary for development of midline glia and co  
A:Reference number: A36665; MUID:91099665  
A:Accession: B36665  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-1469 <ROT>  
A:Cross-references: GB:X53959  
C:Genetics:  
A:Gene: FlyBase:sli  
A:Cross-references: FlyBase:FBgn0003425  
C:Superfamily: unassigned EGF-related proteins; EGF homology; leucine-rich alpha-2-glyco  
F:66-91/Domain: proteoglycan amino-terminal homology <PAH1>  
F:101-124/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>  
F:125-148/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>  
F:149-172/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>  
F:173-196/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>  
F:197-220/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>  
F:228-272/Domain: proteoglycan carboxyl-terminal homology <PCS1>  
F:288-313/Domain: proteoglycan amino-terminal homology <PAH2>  
F:323-346/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>  
F:347-370/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>  
F:371-394/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>  
F:395-418/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>  
F:419-442/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>  
F:450-494/Domain: proteoglycan carboxyl-terminal homology <PCS2>  
F:512-537/Domain: proteoglycan amino-terminal homology <PAH3>  
F:547-571/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>  
F:572-595/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR12>  
F:596-619/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR13>  
F:620-643/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR14>  
F:651-695/Domain: proteoglycan carboxyl-terminal homology <PCS3>  
F:708-733/Domain: proteoglycan amino-terminal homology <PAH4>  
F:743-766/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR15>  
F:767-790/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR16>  
F:846-890/Domain: proteoglycan carboxyl-terminal homology <PCS4>  
F:1028-1061/Domain: EGF homology <EGF>  
F:1068-1099/Domain: EGF homology <EGF>  
F:1115-1148/Domain: EGF homology <EGF1>

Query Match 13.98; Score 350; DB 2; Length 1469;  
Best Local Similarity 23.98; Pred. No. 4.8e-16;  
Matches 109; Conservative 65; Mismatches 152; Indels 130; Gaps 9;  
Qy 2 TCPVSCSNFQSVKVICVRKRLNPEVPCDSTNRLNLENQIQIKVNSFKHLRHLRIL 61  
Db 294 SCPHPCRCADGI--VDCREKSLTSVPVLPDDTTDLRLEQNFITLPPKPSFSSFRRLRI 351  
Qy 62 QLSRNIHTIEIGAPNGLANLTLELFDNRLTTPNGAFVYLSKLKELWLRNNPIESIPS 121

Db 352 DLSNNSIRIAHDALSGLKQLTTLVLYGNKIKDLPVSGVFKGLSLRLLLNANETSCIRK 411  
Qy 122 YAFNRIPSLRLDLGELKRLSYISEGAPEGLSNRYLNLAM-----CNLR----- 166  
Db 412 DAFRDLHSLSLSLYD-NNIQLANGTFDAMKSMKTVHLAKNPFCDNLRWLADYLHN 470  
Qy 167 ----- 166  
Db 471 PIETSGARCESPKRMHRRRIEESLREEKFKCSWGLRMKLSGECRMDSDCPAMCHCEGTV 530  
Qy 167 -----EIPNLTP-----IKLD-----ELDSGNHLSAIRGS 194  
Db 531 DCTGRRLEIPIRDIPLHTTELLANDNELGRISSDGLFGRPLHLVLEKLRNQLTGIEPNA 590  
Qy 195 FOGLMHQKLMWIOSQIOVIERNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHLHLRTHL 254  
Db 591 FEGASHIOELQELQENKIKESNKMPFLGHLQKLTLLNQJSCVMPGSFEHLNLSLNL 650  
Qy 255 HNPWNCNDILWLSWIKDMAPNTACCARNTPPNLKGRYIGELDONVFTCYAPVIVE 314  
Db 651 ASNPENCNCHLAWFAECYRKSLNGA--ARCGAPSKYRDVQIKDLPHSEFKCSS----- 703  
Qy 315 PPADLVNTEGMAELKCRASSTLSVSWITNGVTM 350  
Db 704 -----ENSEGCLGDGVCPPSCTCT-----GTVV 726  
RESULT 8  
A36665  
slit protein 1 precursor - fruit fly (Drosophila melanogaster)  
C:Species: Drosophila melanogaster  
C:Date: 30-Apr-1991 #sequence\_revision 30-Apr-1991 #text\_change 17-Nov-2000  
C:Accession: A36665; A31640; S13523  
R:Rothberg, J.M.; Jacobs, J.R.; Goodman, C.S.; Artavanis-Tsakonas, S.  
Genes Dev. 4, 2169-2187, 1990  
A:Title: slit: an extracellular protein necessary for development of midline glia and  
A:Reference number: A36665; MUID:91099665  
A:Accession: A36665  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-1480 <ROT>  
A:Cross-references: GB:X53959; NID:g8614; PIDN:CAA37910.1; PID:g8615  
R:Rothberg, J.M.; Hartley, D.A.; Walther, Z.; Artavanis-Tsakonas, S.  
Cell 55, 1047-1059, 1988  
A:Title: slit: An EGF-homologous locus of D. melanogaster involved in the development  
A:Reference number: A31640; MUID:89077533  
A:Accession: A31640  
A:Molecule type: DNA  
A:Residues: 881-1182, 'G', 1185-1404, 'GT', 1463-1464, 'YHA' <RO2>  
A:Cross-references: GB:M23543; NID:g340939; PID:g514357  
C:Genetics:  
A:Gene: FlyBase:sli  
A:Cross-references: FlyBase:FBgn0003425  
A:Introns: 1351/3  
C:Superfamily: unassigned EGF-related proteins; EGF homology; leucine-rich alpha-2-gl  
C:Keywords: alternative splicing; growth factor  
F:66-91/Domain: proteoglycan amino-terminal homology <PAH1>  
F:101-124/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>  
F:125-148/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>  
F:149-172/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>  
F:173-196/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>  
F:197-220/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>  
F:228-272/Domain: proteoglycan carboxyl-terminal homology <PCS1>  
F:288-313/Domain: proteoglycan amino-terminal homology <PAH2>  
F:323-346/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>  
F:347-370/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>  
F:371-394/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>  
F:395-418/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>  
F:419-442/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>  
F:450-494/Domain: proteoglycan carboxyl-terminal homology <PCS2>  
F:512-537/Domain: proteoglycan amino-terminal homology <PAH3>  
F:547-571/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>

QY 184 GNHLS-AIRPGSF---QGLMHLQKLWMIQSQIQVIERNAFDNLQSLVEINLAHNNTLLP 2399

Db 280 SNTLAVCEDGAVLYNTSMPELRSRLFTNNQLRVPKRAFEPFALEELDTDNPIATIH 339  
Qy 240 HDLFTPLHLHRIHLHNPWCNCDIWLWSWIKDMAPSNTACCARQNTPPNKLGRVIGE 299  
Db 340 PEAFEPPL-ELKRLVMSSSIICDCQISWLASWIIYRLKDKSIIIAKGSYPPPLADLYVVA 398  
Qy 300 LDQNVFCY----APVIVEPPADLVNTEGMAAELKCA-STSLTSVSW----- 342  
Db 399 IDTANLCHNDSPRAKIVRQVPEVSTLIGEKARTCNVYGASPLSIEMRWENQOPRVLV 458  
Qy 343 -----ITPNGTVMTHGAYKVIARVADSGTLNFTNVVQDGTGMTVCVMSVGN 390  
Db 459 QDSATELSINRTAVVNGTFDER--ELAAAEELLDNVAMTDNSEYQCVARNRFGS 510

RESULT 11  
T42626  
secreted leucine-rich repeat-containing protein SLIT2 - mouse (fragment)  
N:Alternate names: neurogenic extracellular slit protein  
C:Species: Mus musculus (house mouse)  
C:Date: 11-Jan-2000 #sequence\_revision 11-Jan-2000 #text\_change 11-Jan-2000  
C:Accession: T42626  
R:Holmes, G.P.; Negus, K.; Burridge, L.; Raman, S.; Algar, E.; Yamada, T.; Little, M.H.  
Mech. Dev. 79, 57-72, 1998  
A:Title: Distinct but overlapping expression patterns of two vertebrate slit homologs in  
A:Reference number: 222177; MUID:99279238  
A:Accession: T42626  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-1025 <HOL>  
A:Cross-references: EMBL:AF074960; NID:g4151258; PID:g4151259; PIDN:AAD04345.1  
C:Genetics:  
A:Gene: Slit2

Query Match 13.6%; Score 344.5; DB 2; Length 1025;  
Best Local Similarity 24.3%; Pred. No. 7.1e-16;  
Matches 102; Conservative 62; Mismatches 149; Indels 107; Gaps 8;

Qy 3 CPVSCSNQFSKVICYKRNLRVDPGISTNTRLLNLHENQIQIKVNS-FKHLRHLLEL 61  
Db 2 CPEKCRCEG--TTVDCSNORLNKIPDHIPQVTAELRNNEFTVLEATGIFKLPQLRXI 59  
Qy 62 QLSNRHIRTIBIGAFNGLANLTLELFDNRLTIPNGAFVYLSKLKELWLRNPNIESIPS 121  
Db 60 NFSNKKITDIEGAFEGAGSGVNEILLTSNRLENVQHMKFGLESUKTLMLSNRISCVGN 119  
Qy 122 YAFNRPSLRRLDGLKRLSYISEGAFEGLSNRLRYNLAM-----CN----- 164  
Db 120 DSFTGLGSRLLSLYD-NQITVAPGAFDXLHLSLTNLNLPNCNCHLAWLGELRRK 178  
Qy 165 -----LREIP-----NLTPLIK----- 176  
Db 179 RIVTGNPRCKPYELKEIPIQDVAIQDFTCDGNDNDCSPLSRCPSECCLDTFYVRCN 238  
Qy 177 -----LDELDSGNHLSAIRPGSFQGLMH 200  
Db 239 KGLVLPKGPVDELYLDGNQFTLPKELSNYKHLTLIDLNSNRISTLSNQXFSNWTQ 298  
Qy 201 LQKLMWTQSQIQVTERNAFNQLSELVEINLAHNNLTLLPHDLFTPLHLHLHHHPWN 260  
Db 299 LTLTILSYNRLRCIPPTFDGLKSLRLSLHGNDISVVPECAFNDLSALSHLAIGANPLY 348  
Qy 261 CNCIDILMSWIKDMAPSNTACCARCTPPNKLKRYIGELDONVFTCYAVVIEPPADLN 320  
Db 359 CDCNQWLSDDWK--SEYKEPGTARCAGPGEMADKLLLTTPSKKFTCGGPMDTIIQACN 416

RESULT 12  
A60164  
platelet membrane glycoprotein V precursor - human  
C:Species: Homo sapiens (man)

C:Date: 12-Jan-1993 #sequence\_revision 24-Feb-1994 #text\_change 05-Nov-1999  
C:Accession: A48030; A60164; A35483; B35483; C35483; A60432; A47507; S34329  
R:Lanzan, E.; Morales, M.; de la Salle, C.; Cazenave, J.P.; Clemetson, K.J.; Shimomura  
J. Biol. Chem. 268, 20801-20807, 1993  
A:Title: Cloning and characterization of the gene encoding the human platelet glycoprotein  
A:Reference number: A48030; MUID:94012616  
A:Accession: A48030  
A:Molecule type: DNA  
A:Residues: 1-560 <LA2>  
R:Shimomura, T.; Fujimura, K.; Maehama, S.; Takemoto, M.; Oda, K.; Fujimoto, T.; Oyam  
Blood 75, 2349-2356, 1990  
A:Title: Rapid purification and characterization of human platelet glycoprotein V: th  
A:Reference number: A60164; MUID:90275263  
A:Accession: A60164  
A:Molecule type: protein  
A:Residues: 365-384, 'X', 392-395, 'X', 397, 188-208, 'I', 210, 27-50, 'X', 52-53, 1  
, 'XX', 108, 'T', 161-72, 'TK', 75-77, 'V', 56-57, 'G', 479-487, 'X', 489-496, 'X', 500, 'X', 502-503,  
R:Roth, G.J.; Church, T.A.; McMullen, B.A.; Williams, S.A.  
Biochem. Biophys. Res. Commun. 170, 153-161, 1990  
A:Title: Human platelet glycoprotein V: a surface leucine-rich glycoprotein related t  
A:Reference number: A35483; MUID:90321220  
A:Accession: A35483  
A:Molecule type: protein  
A:Residues: 145-166, 'I', 168-169, 'X', 171-172 <ROT>  
A:Note: this proteolytic fragment was designated peptide M392  
A:Accession: B35483  
A:Molecule type: protein  
A:Residues: 121-129, 'W', 131-135, 466-468, 'X', 470 <RO2>  
A:Note: this material was designated peptide M393 but may contain two peptides  
A:Accession: C35483  
A:Molecule type: protein  
A:Residues: 252-266, 'H', 268-272, 'X', 274-279, 'I', 281-284, 'I', 286 <RO3>  
A:Note: this proteolytic fragment was designated peptide M401  
R:Zafar, R.S.; Walz, D.A.  
Thromb. Res. 53, 31-44, 1989  
A:Title: Platelet membrane glycoprotein V: characterization of the thrombin-sensitive  
A:Reference number: A60432; MUID:89162331  
A:Accession: A60432  
A:Molecule type: protein  
A:Residues: 477-478, 'FX', 481-485, 'E', 487, 'V', 489-492, 'NQ', 495, 'E', 497-498 <ZAF>  
R:Hickey, M.J.; Hagen, F.S.; Yagci, M.; Roth, G.J.  
Proc. Natl. Acad. Sci. U.S.A. 90, 8327-8331, 1993  
A:Title: Human platelet glycoprotein V: characterization of the polypeptide and the r  
A:Reference number: A47507; MUID:93391348  
A:Accession: A47507  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-560 <RES>  
A:Cross-references: GDB:L11238; NID:g388759; PIDN:AAA03069.1; PID:g388760  
C:Comment: This platelet membrane protein is a substrate for thrombin.  
C:Comment: The amino end of the intact protein is blocked.  
C:Comment: This protein is absent in Bernard-Soulier syndrome.  
C:Genetics:  
A:Gene: GDB:GP5  
A:Cross-references: GDB:230236; OMIM:173511  
A:Map position: 5pter-5qter  
C:Superfamily: leucine-rich alpha-2-glycoprotein repeat homology  
C:Keywords: blocked amino end; glycoprotein; platelet; tandem repeat; transmembrane p

Query Match 13.1%; Score 329.5; DB 2; Length 560;  
Best Local Similarity 29.7%; Pred. No. 3.5e-15;  
Matches 83; Conservative 43; Mismatches 104; Indels 49; Gaps 3;

Qy 22 NLREVDPG-----ISTNTRLLN-----LHENQIQIKVNSFKH 54  
Db 181 NLTHPLGGLLGAQAKLERLLHNSRLSLDGLSLGALTLEQFHRNHRISTAPGAFDR 240  
Qy 55 LRHLEILQLSRNHRITTEIGAFNGLANLTLELFDNRLTIPNGAFVYLSKLKELWLRN 114  
Db 241 LPNLSLTLNRNHLAFLPSALFLHSHNLTLLTFENPLAELPGVLFGEMLGQLDELNRT 300

QY 115 PIESIPYAFNRIPISURRLDLGELKRLSYISEGAFGLSNLRYLNAMCNLRIPNLTP 174  
Db 301 QLRLTFAAFNRISLRILGVTLSPLSALPOGAFQGLQV----- 343  
QY 175 IKLELDLSGNHLSATRPGSFQGLMHLOKLMWISOIOVTERNAFDNLQSLVEINLAHNN 234  
Db 344 -----LALHNSGTLALPDGLLRLGLKRLQVSLRRNRRLRALFRNLSSLESVQLDHNQ 398  
QY 235 LTLPHDLFTPLHLHLRIHLHHNPNWNCNCDILWLSWIK 273  
Db 399 LETLPDGVGALPRLTEVLLGHNSWRCDCGLGPFGLWLR 437  
RESULT 13  
JC5239  
insulin-like growth factor acid-labile chain - baboon  
C:Species: Papio sp. (baboon)  
C:Date: 17-Apr-1997 #sequence\_revision 09-May-1997 #text\_change 09-May-1997  
C:Accession: JC5239  
R:Delhanty, P.; Baxter, R.C.  
Biochem. Biophys. Res. Commun. 227, 897-902, 1996  
A:Title: The cloning and expression of the baboon acid-labile subunit of the insulin-like  
A:Reference number: JC5239; MUID:97040714  
A:Contents: liver  
A:Accession: JC5239  
A:Molecule type: mRNA  
A:Residues: 1-605 <DEL>  
C:Comment: This factor is structurally related to proinsulin and have insulin-like meta

Query Match 13.1%; Score 329.5; DB 2; Length 605;  
Best Local Similarity 21.0%; Pred. No. 3.9e-15;  
Matches 119; Conservative 61; Mismatches 118; Indels 269; Gaps. 12;  
QY 3 CPVSCS-----NOFSKVIVCRKNLRVDPDGISTNTRL----- 36  
Db 41 CPATCACSYYDVENLS-VFCSSRNLRTPDGPVGGTQALWLDNSLSSIPPAFRNLSS 99  
QY 37 -----LNHENOIQIIVKNSPKHLRHLFIQLSLNRHIR 69  
Db 100 LAFNLQGGQGLSLEPQALLGLENLCHLHLERNQLRSLAVGTTPALALLGLSNRLS 159  
QY 70 TIEGAFNGLANLTLEFDNRLTTPNGAF-----VY-----LSK 105  
Db 160 RLEDGLFEGGLNLDNLGNSLAVLPDAAFRGLGLRELVLVAGNRLAYLPALFSGLA 219  
QY 106 LKELWLRNNPIESIPSYAFNRIPSLRRL----- 133  
Db 220 LRELDLSRNALRAKANVFQALPRLQKLYLDRNLIAAVAPGAFGLKALRWLDLSHRVA 279  
QY 134 -----DLGE 137  
Db 280 GLLLEDTPGLGLRLVRLSHNATSLRPTFEDLHLEELQGLHNRIRQLAERSFEGLGQ 339  
QY 138 LK-----RLSYISEGAFGLSNLRYLNAMCNLRIPN--LTPLIKDELDELGSNHLS 188  
Db 340 LEVLTLDHNLQLEKVGAFGLTNVAVMNLSGNCLRNLPQVFRGLGKLSHLEGSCLG 399  
QY 189 AIRPGSFQGLMHLOKLMWISOIOVTERNAFDNLQSLVEINLAHNNLTLLPHDLFTPL-- 246  
Db 400 RIRPHTFAGLSGLRLFLKNGLVGIEEQSLWGLAELELDLTSNQTHLPQLFQGLGK 459  
QY 247 -----HH----- 248  
Db 460 LEVLLSHNRLAELPADALPQLAFWLDVSHNRLEALPGSLLASGLRLRYLNLRNNSLR 519  
QY 249 -----LERIHLHNPWNCNCDILWLSWIKDAPSNATACCAR----- 285  
Db 520 TFTPQPGLERLWLEGNPWCSPKAL-----RDFALQNPFAVPRFVQAIPEGDCQPPV 575  
QY 286 -----CNTPPNLKGRYIGELDQNYF 305  
Db 576 YTYNNITCASPPVAGLDLRLDGEAHF 602

## RESULT 14

A41915  
insulin-like growth factor-binding complex acid-labile chain precursor - human  
N:Alternate names: Acid-Labile Subunit (ALS)  
C:Species: Homo sapiens (man)  
C:Date: 31-Dec-1993 #sequence\_revision 31-Dec-1993 #text\_change 05-Nov-1999  
C:Accession: A41915  
R:Leong, S.R.; Baxter, R.C.; Camerato, T.; Dai, J.; Wood, W.I.  
Mol. Endocrinol. 6, 870-876, 1992  
A:Title: Structure and functional expression of the acid-labile subunit of the insuli  
A:Reference number: A41915; MUID:92357025  
A:Accession: A41915  
A:Status: preliminary  
A:Molecule type: mRNA; protein  
A:Residues: 1-605 <LEO>  
A:Cross-references: GB:M86826; NID:g184807; PIDN:AAA36047.1; PID:g184808  
A:Experimental source: liver  
A:Note: sequence extracted from NCBI backbone (NCBIP:110171)  
C:Superfamily: leucine-rich alpha-2-glycoprotein repeat homology  
F:75-98/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR1>  
F:99-122/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR2>  
F:123-146/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR3>  
F:147-170/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR4>  
F:171-194/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR5>  
F:195-218/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR6>  
F:219-242/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR7>  
F:243-266/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR8>  
F:267-290/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR9>  
F:291-314/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR10>  
F:315-338/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR11>  
F:339-362/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR12>  
F:363-386/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR13>  
F:387-410/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR14>  
F:411-434/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR15>  
F:435-458/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR16>  
F:459-482/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR17>  
F:483-506/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR18>  
F:507-529/Domain: leucine-rich alpha-2-glycoprotein repeat homology <LRR19>  
Query Match 12.5%; Score 314.5; DB 2; Length 605;  
Best Local Similarity 31.1%; Pred. No. 4.3e-14;  
Matches 89; Conservative 47; Mismatches 117; Indels 33; Gaps 5;  
QY 3 CPVSCS-----NOFSKVIVCRKNLRVDPDGISTNTRLNLNCHENOIQIIVKNSFKHLRH 57  
Db 41 CPACVCSYDDADELS-VFCSSRNLRTPDGPVGGTQALWLDGNNLSSVPPAFAFNLS 99  
QY 58 LEI-----LQLSRNHIRTETGAFNGLANLTLEFDNRLT 93  
Db 100 LGFLNLQGGQGLSLEPQALLGLENLCHLHLERNQLRSLALGTFAHTPALASGLSNRLS 159  
QY 94 TTPNGAFVYLSKLKELWLRNNPIESIPSYAFNRIPSRRLDLGELKRLSYISEGAFGLS 153  
Db 160 RLEDGLFEGGLSGLWLDNLGNSLAVLPDAAFRGLGSLRELVLG--NRLAYLPALFSGLA 218  
QY 154 NLRVNLAMCNLRIPN--LTPLIKDELDELGSNHLSAIRPGSFQGLMHLOKLMWISOI 211  
Db 219 ELRELDLSRNALRAKANVFQALPRLQKLYLDRNLIAAVAPGAFGLKALRWLDLSHRV 278  
QY 212 QVTERNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHLHLRTHLHN 257  
Db 279 AGLEEDTFPGLGLRLVRLSHNATSLRPTFEDLHLEELQGLHN 324  
RESULT 15  
S46224  
peroxidase - fruit fly (Drosophila sp.)  
C:Species: Drosophila sp.  
C:Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 24-Oct-2000  
C:Accession: S46224

R;Nelson, R.E.; Fessler, L.I.; Takagi, Y.; Blumberg, B.; Keene, D.R.; Olson, P.F.; Parke  
EMBO J. 13, 3438-3447, 1994  
A:Title: Peroxidase; a novel enzyme-matrix protein of Drosophila development.  
A:Reference number: S46224; MUID:94341255  
A:Accession: S46224  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-1535 <NEL>  
A:Cross-references: GB:U11052; NID:95311384; PIDN:AAA61568.1; PID:95311385  
C:Superfamily: peroxidase; myeloperoxidase homology; proteoglycan amino-terminal homolo  
F:19-44/Domain: proteoglycan amino-terminal homology <PAH4>  
F:661-1350/Domain: myeloperoxidase homology <MPX>

```
Query Match          12.4%   Score 313; DB 2; Length 1535;
Best Local Similarity 24.7%   Pred. No. 1.8e-13;
Matches 97; Conservative 52; Mismatches 136; Indels 108; Gaps 12;

QY  3 CPYSCGCSNOFSKVCYKRNLRVDPDGISTNRLNLHENOIQIIVNSFKHLRHLILQ 62
   ||: ||: : ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  26 CPAGCTCLER--TVRCIRAKLSAVP-----KLPQDTQTLD 58

QY  63 LSRNHITIEIGANGLANLNTLEFQNLTPNGAFVYLSKLELWLNPNPIESIPSY 122
   | ||: : ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  59 LRFNHIEELPANAFSGLAQLTTLFNDNELAYLQDQALNGLTALRFVYLANNRLSLPAT 118

QY  123 AFNRIPSLRRLDGLKRLSVISGEAFEGSLNRYLNLMCNLREIPNLTPLIKLDEL 182
   | ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  119 IFQMPRL-----EGIF--LEN----- 133

QY  183 SGNHLSAIRPGSFOGLMHQLKLMWIOQIQVIERNAFDNLQSLVEINLAHNNLTLLPHDL 242
   : ||: : ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  134 -----NDIWOLPAGL-----FDNLPRLNRLIMYNNKLTQLPVDG 167

QY  243 FTPLHHLERIHLEHN--PWNCNDI--LWLSWIKMAPSNTACCARCNTPPNLKGRYIG 298
   | ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  168 FNRLNLRRLDGNADIDCNCGVYSLRRWHLL-DVOROLVSLTCAAPQMLQNGFS 226

QY  299 ELQNYFTCYAPVIVEPPADLNVTPEGMAAEKLCRASTSL--TSVSWITPNGTVMTHGAYK 356
   | ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  227 SLGEHFEKCAKQFLVAPQDAQVAAGEQVELSCEV-TGLHRPQITW--HNTQELGLEEQ 283

QY  357 VRIAVLSDGTLNFTNTVTVDGTGMYTCMVNSVG 389
   : ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||: ||:
Db  284 TQAEILPFGSLLHRSADTSDMGTYQCIARNEMG 316
```

Search completed: August 26, 2002, 15:47:05  
Job time: 147 sec

GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 26, 2002, 15:46:43 ; Search time 13.44 Seconds

(without alignments)  
1377.079 Million cell updates/sec

Title: US-09-905-056-292\_COPY\_45\_522

Perfect score: 2524

Sequence: 1 QTCPSVCSNQNFSKVICR.....KTFIPVTDINSIGIPIDEV 478

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 105224 seqs, 38719550 residues

Total number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_40.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	430.5	17.1	713	1 GAC1_HUMAN	O75325 homo sapien
2	394	15.6	361	1 CHAD_BOVIN	Q27972 bos taurus
3	367	14.5	567	1 GPV_MOUSE	O08742 mus musculus
4	356	14.1	567	1 GPV_RAT	O08770 rattus norv
5	350	13.9	1480	1 SLIT_DROME	P24014 drosophila
6	329.5	13.1	560	1 GPV_HUMAN	P40197 homo sapien
7	329.5	13.1	605	1 ALS_PAPHA	O02833 papio hamad
8	314.5	12.5	605	1 ALS_HUMAN	P35858 homo sapien
9	309	12.2	603	1 ALS_RAT	P35859 rattus norv
10	302.5	12.0	603	1 ALS_MOUSE	P70389 mus musculus
11	302	12.0	359	1 PGS2_HUMAN	P07585 homo sapien
12	295	11.7	360	1 PGS2_PIG	O9xsd9 sus scrofa
13	294	11.6	360	1 PGS2_HORSE	O46542 equus caball
14	293	11.6	360	1 PGS2_BOVIN	P21793 bos taurus
15	291	11.5	357	1 PGS2_CHICK	P28675 gallus gall
16	290	11.5	360	1 PGS2_CANFA	Q29393 canis famil
17	289	11.5	360	1 PGS2_RABIT	Q28888 oryctolagus
18	286.5	11.4	536	1 CBP8_HUMAN	P22792 homo sapien
19	286	11.3	354	1 PGS2_MOUSE	P28654 mus.musculus
20	283	11.2	354	1 PGS2_RAT	Q01129 rattus norv
21	282	11.2	626	1 GPBA_HUMAN	P07359 homo sapien
22	276	10.9	353	1 KERA_COTJA	Q9d666 coturnix co
23	274	10.9	353	1 KERA_CHICK	O42235 gallus gall
24	273.5	10.8	331	1 PLIB_AGKBL	O93233 agkistrodon
25	271.5	10.8	368	1 PGS1_HUMAN	P21810 homo sapien
26	271.5	10.8	369	1 PGS1_CANFA	O02678 canis famil
27	271.5	10.8	372	1 PGS1_MOUSE	O46403 equus caball
28	270.5	10.7	369	1 PGS1_HORSE	P28653 mus musculus
29	270.5	10.7	369	1 PGS1_RAT	P47853 rattus norv
30	269.5	10.7	369	1 PGS1_SHEEP	O46390 ovis aries
31	268.5	10.6	369	1 PGS1_BOVIN	P21809 bos taurus
32	268	10.6	423	1 OMD_RAT	Q9zls7 rattus norv
33	259.5	10.3	966	1 Y918_HUMAN	O94991 homo sapien

ALIGNMENTS

RESULT 1

ID	GAC1_HUMAN	STANDARD;	PRT;	713 AA.
AC	O75325;			
DT	16-OCT-2001 (Rel. 40, Created)			
DT	16-OCT-2001 (Rel. 40, Last sequence update)			
DT	01-MAR-2002 (Rel. 41, Last annotation update)			
DE	Glioma amplified on chromosome 1 protein precursor.			
GN	GAC1.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX	NCBI_TaxID:9606;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=Glial tumor;			
RX	MEDLINE=98324709; PubMed=9662332;			
RA	Malfroy B., Almeida A., Zhu X.X., Vogt N., Tyagi R., Muleris M.,			
RA	Dutrillaux A.-M., Dutrillaux B., Ross D., Hanash S.;			
RT	"GAC1, a new member of the leucine-rich repeat superfamily on			
RT	chromosome band 1q32.1, is amplified and overexpressed in malignant			
RT	gliomas."			
RL	Oncogene 16:2957-3002(1998).			
CC	-1- SUBCELLULAR LOCATION: Type I membrane protein (Potential).			
CC	-1- TISSUE SPECIFICITY: OVERAMPLIFIED IN MALIGNANT GLIOMAS.			
CC	-1- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.			
CC	-1- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE C2-TYPE DOMAIN.			
CC	-1- SIMILARITY: CONTAINS 11 LEUCINE-RICH REPEATS (LRR).			
CC	-----			
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration			
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -			
CC	the European Bioinformatics Institute. There are no restrictions on its			
CC	use by non-profit institutions as long as its content is in no way			
CC	modified and this statement is not removed. Usage by and for commercial			
CC	entities requires a license agreement (See <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a>			
CC	or send an email to <a href="mailto:license@isb-sib.ch">license@isb-sib.ch</a> ).			
CC	-----			
CC	EMBL; AF030435; AAC39792.1; -			
DR	MIM; 605492; -			
DR	InterPro; IPR003006; Ig_MHC.			
DR	InterPro; IPR003598; Ig_c2.			
DR	InterPro; IPR001611; LRR.			
DR	InterPro; IPR000483; LRR_Cterm.			
DR	InterPro; IPR000372; LRR_Nterm.			
DR	InterPro; IPR003592; LRR_Out.			
DR	InterPro; IPR003591; LRR_typ.			
DR	Pfam; PF000047; ig; 1.			
DR	Pfam; PF000560; LRR; 10.			
DR	Pfam; PF01463; LRRCT; 1.			
DR	Pfam; PF01462; LRRNT; 1.			
DR	PRINTS; PR00019; LEURICHRPT.			
DR	SMART; SM00408; IGC2; 1.			
DR	SMART; SM00370; LRR; 6.			
DR	SMART; SM00082; LRRCT; 1.			
DR	SMART; SM00013; LRRNT; 1.			
DR	SMART; SM00369; LRR_TYP; 2.			

Q9nyk1 homo sapien  
Q99mb1 mus musculus  
O94933 homo sapien  
P51888 homo sapien  
O15455 homo sapien  
O62702 bos taurus  
O35103 mus musculus  
P12024 drosophila  
O60938 homo sapien  
P23515 homo sapien  
P82963 tribolium c  
Q63912 mus musculus





## RESULT

GPV\_RAT ID GPV\_RAT STANDARD; PRT; 567 AA.  
AC O08770;  
DT 15-JUL-1998 (Rel. 36, Created)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Platelet glycoprotein V precursor (GPV) (CD42D).  
GN GP5.  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Wistar; Tissue=Liver;  
RX MEDLINE=97275136; PubMed=9129030;  
RA Ravanat C., Morales M., Azorsa D.O., Moog S., Schuhler S.,  
RA Grunert P., Loew D., van Dorselaer A., Cazenave J.-P., Lanza F.;  
RT "Gene cloning of rat and mouse platelet glycoprotein V:  
RT identification of megakaryocyte-specific promoters and demonstration  
RT of functional thrombin cleavage.";  
RL Blood 89:3253-3262(1997).  
CC -1- FUNCTION: THE GPIB-V-IX COMPLEX FUNCTIONS AS THE VON WILLEBRAND  
CC FACTOR RECEPTOR AND MEDIATES VON WILLEBRAND FACTOR-DEPENDENT  
CC PLATELET ADHESION TO BLOOD VESSELS. THE ADHESION OF PLATELETS TO  
CC INJURED VASCULAR SURFACES IN THE ARTERIAL CIRCULATION IS A  
CC CRITICAL INITIATING EVENT IN HEMOSTASIS (BY SIMILARITY).  
CC -1- SUBCELLULAR LOCATION: Type I membrane protein.  
CC -1- SIMILARITY: CONTAINS 14 LEUCINE-RICH REPEATS (LRR).  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL; Z69594; CAA93440.1; -;  
DR InterPro: IPR001611; LRR.  
DR InterPro: IPR000483; LRR\_Cterm.  
DR InterPro: IPR000372; LRR\_Nterm.  
DR InterPro: IPR003592; LRR\_out.  
DR InterPro: IPR003591; LRR\_typ.  
DR Pfam: PF00560; LRR; 14.  
DR Pfam: PF01463; LRRCT; 1.  
DR PRINTS: PR00019; LEURICHRPT.  
DR SMART: SM00370; LRR; 2.  
DR SMART: SM00062; LRRCT; 1.  
DR SMART: SM00013; LRRNT; 1.  
DR SMART: SM00369; LRR\_TYP; 10.  
KW Platelet; Transmembrane; Glycoprotein; Blood coagulation;  
KW Repeat; Leucine-rich repeat; Cell adhesion; Signal.  
FT SIGNAL 1 16  
FT CHAIN 17 567  
FT DOMAIN 17 522  
FT TRANSMEM 523 543  
FT POTENTIAL.  
FT PLATELET GLYCOPROTEIN V.  
FT EXTRACELLULAR (POTENTIAL).  
FT POTENTIAL.  
FT DOMAIN 544 567  
FT CYTOPLASMIC (POTENTIAL).  
FT REPEAT 73 96  
FT REPEAT 97 120  
FT REPEAT 122 144  
FT REPEAT 145 168  
FT REPEAT 169 192  
FT REPEAT 194 216  
FT REPEAT 217 240  
FT REPEAT 241 264  
FT REPEAT 266 288  
FT REPEAT 289 312  
FT REPEAT 314 337  
FT REPEAT 338 361  
FT REPEAT 362 385  
FT REPEAT 387 409  
FT CARBOHYD 51 51  
FT N-LINKED (GLCNAC... ) (POTENTIAL).

FT CARBOHYD 181 181 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT CARBOHYD 243 243 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT CARBOHYD 298 298 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT CARBOHYD 312 312 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT CARBOHYD 385 385 N-LINKED (GLCNAC... ) (POTENTIAL).  
FT CARBOHYD 498 498 N-LINKED (GLCNAC... ) (POTENTIAL).  
SQ SEQUENCE 567 AA; 63344 MW; CA10708E0D03707F CRC64;  
Query Match 14.1%; Score 356; DB 1; Length 567;  
Best Local Similarity 29.9%; Pred. No. 4.3e-18;  
Matches 110; Conservative 53; Mismatches 163; Indels 42; Gaps 9;  
QY 6 VCSCSNQFS-----KVICV-RKNLREVPGI---STNTRLNLNHNQIQI 48  
DB 151 LCLNQNLSPANLFSGLKLVLDLSRNLTHLPQGLGAQKLEKLLYSNRLMSLD 210  
QY 49 VNSPKHLRHLLEILOLSRNHIRTIEIGAFNGLANLNTLELFDNRLTTTPNGAFVYLSKLE 108  
DB 211 SGLLANLGALETLELRNHLRSIAPGAFDSLGNLSTLTSGNLLSLPPALFLHVSMLTR 270  
QY 109 LWLNNDIESIPSYAFNRPISLRRLDGLGELKRLSYISEGAFEGSLNRLYNLANCNLREI 168  
DB 271 LTLFENLEELPEVLFGEMLAGRELWNG-THLRTLPAFAAFNLSGLQTLGLTRNPL--L 327  
QY 169 PNLTP-----LIKLELDLSGNHLSAIRPGSFGQGLMHLOKLMWIOSQIOIVTERAFDNLQ 223  
DB 328 SALPGMFHGLTEURLVAVHTNALBELPEDALRGRLGRVSLRHNRLRALPRTLFNLS 387  
QY 224 SLVEINLAHNNLTLPLHDLFTPLHLHLRIHLHNPNCNCDILWLSMWI-----KDM 275  
DB 388 SLVTVQLEHNQKLTLPDGVFAALPQLRVLLGHNPWLCDCGLWPFLQWLRLHLELLGRDE 447  
QY 276 APSWTACARCCTPNLKGRIIGELDQNYFTCYAPVIVEPPADLNVTGMAAEKLCRAST 335  
DB 448 PP-----QCNGPESRASLTFWELQDQMC--PSSRGLPPDPPTNALAKAPDTPRPN 498  
QY 336 SLTSSVSWI 343  
DB 499 SSQSWANV 506

RESULT 5  
SLIT\_DROME ID SLIT\_DROME STANDARD; PRT; 1480 AA.  
AC P24014;  
DT 01-MAR-1992 (Rel. 21, Created)  
DT 01-MAR-1992 (Rel. 21, Last sequence update)  
DT 01-MAR-2002 (Rel. 41, Last annotation update)  
DE Slit protein precursor.  
GN SLI.  
OS Drosophila melanogaster (Fruit fly).  
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;  
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
OC Ephydroidea; Drosophilidae; Drosophila.  
OX NCBI\_TaxID=7227;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=91099665; PubMed=2176636;  
RA Rothberg J.M., Jacobs J.R., Goodman C.S., Artavanis-Tsakonas S.;  
RT "Slit: an extracellular protein necessary for development of midline  
RT glia and commissural axon pathways contains both EGF and LRR  
RT domains.";  
RL Genes Dev. 4:2169-2187(1990).  
CC -1- FUNCTION: NECESSARY FOR DEVELOPMENT OF MIDLINE GLIA AND  
CC COMMISSURAL AXON PATHWAYS. SLIT MAY INTERACT WITH EXTRACELLULAR  
CC MATRIX MOLECULES.  
CC -1- ALTERNATIVE PRODUCTS: 2 ISOFORMS; A LONG FORM (SHOWN HERE) AND A  
CC SHORT FORM; ARE PRODUCED BY ALTERNATIVE SPLICING.  
CC -1- TISSUE SPECIFICITY: EXCRETED BY THE MIDLINE GLIA CELLS AND  
CC EVENTUALLY DISTRIBUTED ALONG THE AXONS.  
CC -1- SIMILARITY: CONTAINS 7 EGF-LIKE DOMAINS.  
CC -1- SIMILARITY: CONTAINS 24 LEUCINE-RICH REPEATS (LRR).



```
QY 167 -----EIPNLTP-----IKLD-----ELDSGNHLSAIRPGS 194*
DB 531 DCTGRRLKEIPDPLHTTELLNDNLGRISDGLGRPLHVLKLEKRNQLTGIEPNA 590
QY 195 FQGLMHQKLWMSQIOVIERNADNLQSLVEINLAHNNTLLPHDFTPLHHLRIHL 254
DB 591 FEGASHIQELQNGKIKETSKMFLGLHQLKTLNLDVNOISCVMPGSGFEHLNLSLNL 650
QY 255 HHNPWNCNDLILWLSWIKDWPNTACCARCNTPPNKLGRYIGELDONVFTCYAPIVE 314
DB 651 ASNPFCNCHLWFAECYVRKSLNGGA--ARCGAPSKYVRDQVQIKDLPHSEFKCSS----- 703
QY 315 PPADLVNTEGMAAEKRASTSLTSVSWITPNTGTVM 350
DB 704 -----ENSEGLGDGCPSPCTCT-----GTVV 726

RESULT 6
GPV_HUMAN STANDARD; PRT; 560 AA.
AC P40197;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Platelet glycoprotein V precursor (GPV) (CD42b).
GN GP5.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RS SEQUENCE FROM N.A.
RC TISSUE=Lung;
RX MEDLINE=93391348; PubMed=7690959;
RA Hickey M.J., Hagen F.S., Yagi M., Roth G.J.;
RT "Human platelet glycoprotein V: characterization of the polypeptide
RT and the related Ib-V-IX receptor system of adhesive, leucine-rich
RT glycoproteins.";
RL Proc. Natl. Acad. Sci. U.S.A. 90:8327-8331(1993).
RN [2]
RS SEQUENCE FROM N.A.
RC TISSUE=Platelet;
RX MEDLINE=94012616; PubMed=8407908;
RA Lanza F., Morales M., de la Salle C., Cazenave J.-P., Clemetson K.J.,
RA Shimomura T., Phillips D.R.;
RT "Cloning and characterization of the gene encoding the human platelet
RT glycoprotein V. A member of the leucine-rich glycoprotein family
RT cleaved during thrombin-induced platelet activation.";
RL J. Biol. Chem. 268:20801-20807(1993).
RN [3]
RS PARTIAL SEQUENCE.
RC TISSUE=Platelet;
RX MEDLINE=90275263; PubMed=2350580;
RA Shimomura T., Fujimura K., Maehama S., Takemoto M., Oda K.,
RA Fujimoto T., Oyama R., Suzuki M., Ichihara-Tanaka K., Titani K.,
RA Kuramoto A.;
RT "Rapid purification and characterization of human platelet
RT glycoprotein V: the amino acid sequence contains leucine-rich
RT repetitive modules as in glycoprotein Ib.";
RL Blood 75:2349-2356(1990).
RN [4]
RS PARTIAL SEQUENCE.
RC TISSUE=Platelet;
RX MEDLINE=90321220; PubMed=2372284;
RA Roth G.J., Church T.A., McMullen B.A., Williams S.A.;
RT "Human platelet glycoprotein V: a surface leucine-rich glycoprotein
RT related to adhesion.";
RL Biochem. Biophys. Res. Commun. 170:153-161(1990).
CC -!- FUNCTION: THE GPIB-V-IX COMPLEX FUNCTIONS AS THE VON WILLEBRAND
CC FACTOR RECEPTOR AND MEDIATES VON WILLEBRAND FACTOR-DEPENDENT
CC PLATELET ADHESION TO BLOOD VESSELS. THE ADHESION OF PLATELETS TO
CC INJURED VASCULAR SURFACES IN THE ARTERIAL CIRCULATION IS A
```

```
CC CRITICAL INITIATING EVENT IN HEMOSTASIS.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- TISSUE SPECIFICITY: PLATELETS AND MEGAKARYOCYTES.
CC -!- PTM: THE N-TERMINUS IS BLOCKED
CC -!- SIMILARITY: CONTAINS 14 LEUCINE-RICH REPEATS (LRR).
CC -----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
CC EMBL; L11238; AAA03069.1; -
CC DR EMBL; Z23091; CAA80637.1; -
CC DR HSP; P16473; IXUM.
CC DR MIM; 173511; -
CC DR InterPro; IPR001611; LRR.
CC DR InterPro; IPR000483; LRR_Cterm.
CC DR InterPro; IPR000372; LRR_Nterm.
CC DR InterPro; IPR003592; LRR_Out.
CC DR InterPro; IPR003591; LRR_Cyp.
CC DR Pfam; PF00560; LRR; 14.
CC DR Pfam; PF01463; LRRCT; 1.
CC DR PRINTS; PR00019; LEURICHRPT.
CC DR SMART; SM00370; LRR; 1.
CC DR SMART; SM00082; LRRCT; 1.
CC DR SMART; SM00013; LRRNT; 1.
CC DR SMART; SM00369; LRR_TYP; 9.
CC DR Platelet; Transmembrane; Glycoprotein; Blood coagulation;
CC KW Repeat; Leucine-rich repeat; Cell adhesion; Signal.
CC FT SIGNAL 1 16
CC FT CHAIN 17 560
CC FT PLATELET GLYCOPROTEIN V.
CC FT DOMAIN 17 523
CC FT EXTRACELLULAR (POTENTIAL).
CC FT TRANSMEM 524 544
CC FT POTENTIAL.
CC FT DOMAIN 545 560
CC FT CYTOPLASMIC (POTENTIAL).
CC FT REPEAT 73 96
CC FT LRR 1.
CC FT REPEAT 97 120
CC FT LRR 2.
CC FT REPEAT 122 144
CC FT LRR 3.
CC FT REPEAT 145 168
CC FT LRR 4.
CC FT REPEAT 169 192
CC FT LRR 5.
CC FT REPEAT 194 216
CC FT LRR 6.
CC FT REPEAT 217 240
CC FT LRR 7.
CC FT REPEAT 241 264
CC FT LRR 8.
CC FT REPEAT 266 288
CC FT LRR 9.
CC FT REPEAT 289 312
CC FT LRR 10.
CC FT REPEAT 314 337
CC FT LRR 11.
CC FT REPEAT 338 361
CC FT LRR 12.
CC FT REPEAT 362 385
CC FT LRR 13.
CC FT REPEAT 386 409
CC FT LRR 14.
CC FT N-LINKED (GLCNAC. . .).
CC FT CARBOHYD 51 51
CC FT N-LINKED (GLCNAC. . .).
CC FT CARBOHYD 181 181
CC FT N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 243 243
CC FT N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 267 267
CC FT N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CARBOHYD 298 298
CC FT N-LINKED (GLCNAC. . .).
CC FT CARBOHYD 312 312
CC FT N-LINKED (GLCNAC. . .).
CC FT CARBOHYD 385 385
CC FT N-LINKED (GLCNAC. . .).
CC FT CARBOHYD 499 499
CC FT N-LINKED (GLCNAC. . .) (POTENTIAL).
CC FT CONFLICT 73 74
CC FT MT -> TK (IN REF. 2).
CC FT CONFLICT 109 109
CC FT K -> T (IN REF. 2).
CC FT CONFLICT 130 130
CC FT D -> W (IN REF. 3).
CC FT CONFLICT 136 138
CC FT GID -> PG (IN REF. 3).
CC FT CONFLICT 209 209
CC FT L -> I (IN REF. 2).
CC FT CONFLICT 267 267
CC FT N -> H (IN REF. 3).
CC FT CONFLICT 327 327
CC FT L -> I (IN REF. 2).
CC FT CONFLICT 478 478
CC FT P -> G (IN REF. 2).
CC FT CONFLICT 509 509
CC FT P -> D (IN REF. 2).
CC SQ SEQUENCE 560 AA; 60959 MW; B1CDB04AF8AF7115 CRC64;
CC
```

Query Match 13.1%; Score 329.5; DB 1; Length 560;  
Best Local Similarity 29.7%; Pred. No. 3.2e-16;

Matches 83; Conservative 43; Mismatches 104; Indels 49; Gaps 3;

QY 22 NLRVDPG-----ISTNRLN-----LHENQIILKVNSEFKH 54  
DB 181 NLTHPLKGLGAQAKLERLLLNLSRLSDGLNSLGAELTELQFHRNHRSTAPGAFDR 240  
QY 55 LRHLEILQLSRNHIRTIEIGAFNGLANLNTLELFDNRLTTPNGAFYLSKLKELWLRNN 114  
DB 241 LPNLSSLTLSRNHLAFPSALFLSHNLTLLTFENPLAELPGVLFQGMGGLQELWLRNT 300  
QY 115 PIESIPSYAFNRIPSLRRDLGKRLSYISBGAFAEGLSNLRNLNAMCNLREIPNUTPL 174  
DB 301 OLRLTLPAAAFNRISRLRYLGVTLSPRSALPQGAFOGGLGELQV----- 343  
QY 175 IKDELDSNHLNSAIRPGSFQGLMHLQKLMWISQIOVIERNAFDNLQSLVLEINLAHN 234  
DB 344 -----LALHNSGLTALPDGLLGLGKLRQVSLRNRLRALPRALFRNLSSLESVOLDHNO 398  
QY 235 LTLPLDPLFTPLHHLRIHLLHNPNWNCNDILWLSMWIK 273  
DB 399 LETLPDGVFGALPRLTEVLLGHNSWRDCDGLGPFPLGLWR 437

RESULT 7

ALS\_PAPHA STANDARD; PRT; 605 AA.

AC 002833;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 01-MAR-2002 (Rel. 41, Last annotation update)  
DE Insulin-like growth factor binding protein complex acid labile chain precursor (ALS).  
DE Insulin-like growth factor binding protein complex acid labile chain precursor (ALS).  
GN IGFALS OR ALS.  
OS Papio hamadryas (Hamadryas baboon).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;  
OC Cercopithecoidea; Papio.  
OX NCBI\_TaxID=9557;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Liver;  
RX MEDLINE=97040714; PubMed=8886027;  
RA Delhanty P., Baxter R.C.;  
RT "The cloning and expression of the baboon acid-labile subunit of the insulin-like growth factor binding protein complex.";  
RL Biochem. Biophys. Res. Commun. 227:897-902(1996).  
CC -I- FUNCTION: INVOLVED IN PROTEIN-PROTEIN INTERACTIONS THAT RESULT IN PROTEIN COMPLEXES, RECEPTOR-LIGAND BINDING OR CELL ADHESION.  
CC -I- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 KDA WITH IGF-I OR IGF-II AND IGFBP-3 (BY SIMILARITY).  
CC -I- SUBCELLULAR LOCATION: Extracellular.  
CC -I- SIMILARITY: CONTAINS 20 LEUCINE-RICH REPEATS (LRR).  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL; S83462; -; NOT\_ANNOTATED\_CDS.  
DR HSSP; P23945; IXUN.  
DR InterPro; IPR001611; LRR.  
DR InterPro; IPR000483; LRR\_Cterm.  
DR InterPro; IPR000372; LRR\_Nterm.  
DR InterPro; IPR003592; LRR\_Out.  
DR InterPro; IPR003591; LRR\_typ.  
DR Pfam; PF00560; LRR; 19.  
DR Pfam; PF01463; LRRCT; 1.  
DR Pfam; PF01462; LRRNT; 1.  
DR PRINTS; PR00019; LEURICHRPT.  
DR SMART; SM00370; LRR; 2.

DR SMART; SM00082; LRRCT; 1.  
DR SMART; SM00013; LRRNT; 1.  
DR SMART; SM00369; LRR\_TYP; 11.  
KW Glycoprotein; Leucine-rich repeat; Repeat; Signal.  
FT SIGNAL 1 27  
FT CHAIN 28 605  
FT REPEAT 53 73  
FT REPEAT 74 96  
FT REPEAT 98 120  
FT REPEAT 121 144  
FT REPEAT 146 168  
FT REPEAT 169 192  
FT REPEAT 194 216  
FT REPEAT 217 240  
FT REPEAT 242 264  
FT REPEAT 265 288  
FT REPEAT 289 312  
FT REPEAT 313 336  
FT REPEAT 338 360  
FT REPEAT 361 384  
FT REPEAT 386 408  
FT REPEAT 409 432  
FT REPEAT 433 456  
FT REPEAT 458 480  
FT REPEAT 482 504  
FT REPEAT 505 530  
FT CARBOHYD 64 64  
FT CARBOHYD 85 85  
FT CARBOHYD 96 96  
FT CARBOHYD 368 368  
FT CARBOHYD 515 515  
FT CARBOHYD 580 580  
FT CARBOHYD 605 AA; 9D71994625F23652 CRC64;  
SQ SEQUENCE 605 AA; 66110 MW; 9D71994625F23652 CRC64;

Query Match 13.1%; Score 329.5; DB 1; Length 605;  
Best Local Similarity 21.0%; Pred. No. 3.5e-16;  
Matches 119; Conservative 61; Mismatches 118; Indels 269; Gaps 12;

QY 3 CPVSVCSS-----NQFSKVICVRKNLRVDPDGISTNRL----- 36  
DB 41 CPATCACSYYDEVNELS-VFCSSRNLRTPDGPQALWLDNSNNLSSIPPAFRNLSS 99  
QY 37 -----LNLHENQIILKVNSEFKHRLHLEILQLSRNHIR 69  
DB 100 LAFNLGGGQLGLEPOALLGLENLCHLHLELNRLSLAVGTFFATALLGLSNRLS 159  
QY 70 TIEIGAFNGLANLNTLELFDNRLTTPNGAF-----VY-----LSK 105  
DB 160 RLEDGLFEGGLNLDNLGWNLSLAVLDAAPRGLGLRELVLGNRLAYLQPALFSGLA 219  
QY 106 LKELWLRNNPESIPSYAFNRIPSLRL----- 133  
DB 220 LRELDLSRNALRAIKANVFAQLPRQLKLYLDRLNLIAAVAPGAFGLKALRWLDLSNRVA 279  
QY 134 -----DLGE 137  
DB 280 GLEDTFGLLGLRVLRSLSHNAIASLRPRTFEDLHLEELQGLHNRIRQLAERSEFGLGQ 339  
QY 138 LK-----RLSYISEGAFEGLSNLRYLINLACNLREIPN--LTPLIKLDELDSGNHLS 188  
DB 340 LEVLTLDHNLQLEVKVGAFLGLTNVAVNNLSGNCNLRNLPQEVFGLGKLSHLEGSCIG 399  
QY 189 AIRPGSFQGLMHLQKLMWISQIOVIERNAFDNLQSLVLEINLAHNLTLLPHDLETP-- 246  
DB 400 RIRPHTFAGLSGLRRLFLKONGLVGIEEQSLWGLAELELDLTSNQLTHLPQOGLGK 459  
QY 247 -----HH----- 248  
DB 460 LEYLLLSHNRLAELPADALGPQRAFWLDVSHNRLALPGSLLASLGLRLRYLNLRNLSR 519  
QY 249 -----LERIHLHNPNCNCDILWLSWIKWMAFSNTACCAR----- 285

```
Db 520 TFTPQPPGLERLWLEGNPDWDCSPLKAL-----RDFALQNPASVPRVQVQICGDDCQPPV 575
Qy 286 -----CNTPPNLKGRVIGELDQNYF 305
Db 576 YTYNNITCASPPEVAGLDRLDGEAHF 602

RESULT 8
ALS_HUMAN
ID ALS_HUMAN STANDARD; PRT; 605 AA.
AC P35858;
DT 01-JUN-1994 (Rel. 29, Created)
DT 01-JUN-1994 (Rel. 29, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE Insulin-like growth factor binding protein complex acid labile chain
DE precursor (ALS).
DE IGFALS OR ALS.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RP TISSUE=Liver;
RC MEDLINE=92357025; PubMed=1379671;
RA Leong S.R., Baxter R.C., Camerato T., Dai J., Wood W.I.;
RT "Structure and functional expression of the acid-labile subunit of
RL the insulin-like growth factor-binding protein complex.";
RL Mol. Endocrinol. 6:870-876(1992).
(2)
RP SEQUENCE FROM N.A.
RA Frankland J.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE OF 28-35.
RX MEDLINE=69308584; PubMed=2473065;
RA Baxter R.C., Martin J.L., Beniac V.A.;
RT "High molecular weight insulin-like growth factor binding protein
RL complex. Purification and properties of the acid-labile subunit from
RL human serum.";
RL J. Biol. Chem. 264:11843-11848(1989).
CC -1- FUNCTION: INVOLVED IN PROTEIN-PROTEIN INTERACTIONS THAT RESULT
CC IN PROTEIN COMPLEXES, RECEPTOR-LIGAND BINDING OR CELL ADHESION.
CC -1- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 kDa WITH
CC IGF-I OR IGF-II AND IGFBP-3.
CC -1- SUBCELLULAR LOCATION: Extracellular.
CC -1- TISSUE SPECIFICITY: PLASMA.
CC -1- SIMILARITY: CONTAINS 20 LEUCINE-RICH REPEATS (LRR).
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC at the European Bioinformatics Institute. There are no restrictions on
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M85826; AAA36047.1; -.
DR EMBL; AL031724; CAC36078.1; -.
DR PIR; A41915; A41915.
DR HSP; P23945; 1XUN.
DR MIN; 601489; -.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003592; LRR_Out.
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF00560; LRR; 19.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01462; LRRNT; 1.
DR PRINTS; PR00019; LEURICRPT.
DR SMART; SM00370; LRR; 2.
```

```
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_Typ; 11.
KW Glycoprotein; leucine-rich repeat; Repeat; Signal.
FT SIGNAL 1 27
FT CHAIN 28 605
FT REPEAT 53 73
FT REPEAT 74 96
FT REPEAT 98 120
FT REPEAT 121 144
FT REPEAT 145 168
FT REPEAT 170 192
FT REPEAT 193 216
FT REPEAT 217 240
FT REPEAT 242 264
FT REPEAT 265 288
FT REPEAT 289 312
FT REPEAT 313 336
FT REPEAT 337 360
FT REPEAT 361 384
FT REPEAT 386 408
FT REPEAT 409 432
FT REPEAT 433 456
FT REPEAT 458 480
FT REPEAT 482 504
FT REPEAT 505 530
FT CARBOHYD 64 64
FT CARBOHYD 85 85
FT CARBOHYD 96 96
FT CARBOHYD 368 368
FT CARBOHYD 515 515
FT CARBOHYD 580 580
FT SEQUENCE 605 AA; 66034 MW; F6562A23CB918F6 CRC64;

Query Match 12.5%; Score 314.5; DB 1; Length 605;
Best Local Similarity 31.1%; Pred. No. 4.1e-15;
Matches 89; Conservative 47; Mismatches 117; Indels 33; Gaps 5;

Qy 3 CPVSCSCS-----NQFSKVICVRKLNREVPDGISTNTNRLNLHENQIQIKVNFKHLRH 57
Db 41 CPAACVSYDDADELS-VFCCSRNLRPLDPGVPGTQALWLDGNNLSSVPPAFAFNLS 99
Qy 58 LEI-----LQSRNHRTIEIGAFNGLANLNTLEFDNRLT 93
Db 100 LGFLNLOGGQLGLEPOALLGLENLCHLERNQLRSLALGTFAHTPALASGLSNRLS 159
Qy 94 TIPNGAFVYLSKELMLRNPNIESIPSYAFNRIPLSRRLDLGELKRLSYISEGAFGLS 153
Db 160 RLEDGLFEGLSLDNLGWNLSAVLPDAAPRGLSLRELVLG-NRLAYLQPALFSGLA 218
Qy 154 NLRVNLAMCNLRIPN--LTPLIKDELDSGNHLSAIRPGSQGLMHQLKLMWISQI 211
Db 219 ELRELDLSRNALRAIKANVFQLPRLQKLYLDRNLIAAVAPGAFGLKALRMLDLSHRV 278
Qy 212 QVIERNAFDNLQSLVEINLAHNLTLLPHDLFTPLHHLERHLLHN 257
Db 279 AGLEDFTFPGLLGLRLVRLSLNSNAIASLRPTFKDLHFEELQLGHN 324

RESULT 9
ALS_RAT
ID ALS_RAT STANDARD; PRT; 603 AA.
AC P35859;
DT 01-JUN-1994 (Rel. 29, Created)
DT 01-JUN-1994 (Rel. 29, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Insulin-like growth factor binding protein complex acid labile chain
DE precursor (ALS).
DE IGFALS OR ALS.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

OC Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Liver;  
RX MEDLINE=93038676; PubMed=1384485;  
RA Dai J., Baxter R.C.;  
RT "Molecular cloning of the acid-labile subunit of the rat insulin-like growth factor binding protein complex.";  
RL Biochem. Biophys. Res. Commun. 188:304-309(1992).  
RN [2]  
RP SEQUENCE OF 24-44, AND CHARACTERIZATION.  
RC STRAIN=Wistar; TISSUE=Serum;  
RX MEDLINE=94130835; PubMed=7507839;  
RA Baxter R.C., Dai J.;  
RT "Purification and characterization of the acid-labile subunit of rat serum insulin-like growth factor binding protein complex.";  
RL Endocrinology 134:848-852(1994).  
CC -1- FUNCTION: MAY HAVE AN IMPORTANT ROLE IN REGULATING THE ACCESS OF CIRCULATING IGFs TO THE TISSUES.  
CC -1- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 kDa WITH IGF-I OR IGF-II AND IGFBP-3.  
CC -1- SUBCELLULAR LOCATION: Extracellular.  
CC -1- TISSUE SPECIFICITY: BRAIN, KIDNEY, LUNG, HEART, SPLEEN, MUSCLE AND LIVER.  
CC -1- SIMILARITY: CONTAINS 21 LEUCINE-RICH REPEATS (LRR).  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
DR EMBL: S46785; AAB33770.2;  
DR PIR: JCI282; JCI282.  
DR HSP; P23945; 1XUN.  
DR InterPro: IPR001611; LRR.  
DR InterPro: IPR000483; LRR\_Cterm.  
DR InterPro: IPR000372; LRR\_Nterm.  
DR InterPro: IPR003592; LRR\_Out.  
DR InterPro: IPR003591; LRR\_Typ.  
DR Pfam: PF00560; LRR; 19.  
DR Pfam: PF01463; LRRCT; 1.  
DR Pfam: PF01462; LRRNT; 1.  
DR PRINTS: PR00019; LEURICHRPT.  
DR SMART: SM00370; LRR; 5.  
DR SMART: SM00082; LRRCT; 1.  
DR SMART: SM00013; LRRNT; 1.  
DR SMART: SM00369; LRR\_Typ; 9.  
KW Glycoprotein; Leucine-rich repeat; Repeat; Signal.  
FT SIGNAL 1 23  
FT CHAIN 24 603 INSULIN-LIKE GROWTH FACTOR BINDING  
FT REPEAT 52 73 PROTEIN COMPLEX ACID LABILE CHAIN.  
FT REPEAT 74 96 LRR 1.  
FT REPEAT 98 120 LRR 2.  
FT REPEAT 121 144 LRR 3.  
FT REPEAT 146 168 LRR 4.  
FT REPEAT 169 192 LRR 5.  
FT REPEAT 194 216 LRR 6.  
FT REPEAT 217 240 LRR 7.  
FT REPEAT 242 264 LRR 8.  
FT REPEAT 266 288 LRR 9.  
FT REPEAT 289 312 LRR 10.  
FT REPEAT 313 336 LRR 11.  
FT REPEAT 337 360 LRR 12.  
FT REPEAT 361 384 LRR 13.  
FT REPEAT 386 408 LRR 14.  
FT REPEAT 409 432 LRR 15.  
FT REPEAT 433 456 LRR 16.  
FT REPEAT 458 478 LRR 17.  
FT REPEAT 480 504 LRR 18.

FT REPEAT 479 504 LRR 19.  
FT REPEAT 506 529 LRR 20.  
FT REPEAT 543 566 LRR 21.  
FT CARBOHYD 64 64 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 85 85 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 96 96 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 368 368 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 515 515 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 578 578 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 586 586 N-LINKED (GLCNAC. . .) (POTENTIAL).  
SQ SEQUENCE 603 AA; 66811 MW; DCD7637D94A5037C CRC64;  
Query Match 12.2%; Score 309; DB 1; Length 603;  
Best Local Similarity 30.3%; Pred. No. 1e-14;  
Matches 96; Conservative 43; Mismatches 126; Indels 52; Gaps 8;  
QY 36 LNLH-----ENQIIKVNFKHLRHLLEILQLSRNHRIETIGAFNGLANLNFLFLFDN 90  
DB 289 LGLHLVRLAHHNAIASLRPTFKDLHFLLEQLGHNRIRQLGERTFEGLGQLEVLTLND 348  
QY 91 RLTIPTNGAFVYLSKELKELMNRNPISIPYAFNRIPSLRRLDLGELKRLSYISGAFE 150  
DB 349 QITEVRVGAESGLFNVAVMNLGNCRLSLPRVFQGLDKLHSLHL-EHSCIGHVRLHTFA 407  
QY 151 GLSNRLYNLAMCNLREI--PNLTPLIKDLDELDSGHNLSAIRPGSQGLMHLQKLMWQ 208  
DB 408 GLSGLRLFLRDSNISIIEQSLAGLSELELDTTNRHLTHLPQFGLGHLVLLSY 467  
QY 209 SQIOVERNAFDNLQSLVEINLAHNNTLLPHDL-----FTPLHL 249  
DB 468 NQLTTLSAEVGLPQAFWLDISHNHLTAELGSSLRVYLSLRNNSIQTFSPQGL 527  
QY 250 ERHLHHPNPNCCDILLSWIKDMAPN-----TAC-----ARCNT 288  
DB 528 ERLWLDANPWCSCPLAK-----RDFALQNPVVPRVQTVCEGDGCPVYNNITCAG 583  
QY 289 PPNLKGRYIGELDQNYF 305  
DB 584 PANVSGLDLRDVSETHF 600  
RESULT 10  
ALS\_MOUSE STANDARD; PRT; 603 AA.  
ID ALS\_MOUSE  
AC P70389;  
DT 01-NOV-1997 (Rel. 35, Created)  
DT 01-NOV-1997 (Rel. 35, Last sequence update)  
DT 01-MAR-2002 (Rel. 41, Last annotation update)  
DE Insulin-like growth factor binding protein complex acid labile chain precursor (ALS).  
GN IGFALS OR ALS OR ALBS.  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OX Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=129/SV;  
RX MEDLINE=96413591; PubMed=8816745;  
RA Boisclair Y.R., Seto D., Hsieh S., Hurst K.R., Ooi G.T.;  
RT "Organization and chromosomal localization of the gene encoding the mouse acid labile subunit of the insulin-like growth factor binding complex.";  
RL Proc. Natl. Acad. Sci. U.S.A. 93:10028-10033(1996).  
CC -1- FUNCTION: MAY HAVE AN IMPORTANT ROLE IN REGULATING THE ACCESS OF CIRCULATING IGFs TO THE TISSUES.  
CC -1- SUBUNIT: FORMS A TERNARY COMPLEX OF ABOUT 140 TO 150 kDa WITH IGF-I OR IGF-II AND IGFBP-3 (BY SIMILARITY).  
CC -1- SUBCELLULAR LOCATION: Extracellular.  
CC -1- SIMILARITY: CONTAINS 21 LEUCINE-RICH REPEATS (LRR).  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration

between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

```
CC EMBL; U66900; AAB17270.1; -.
DR MGD; MGI:107973; Igfals.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003592; LRR_out.
DR InterPro; IPR003591; LRR_cyp.
DR Pfam; PF00560; LRR; 19.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01462; LRRNT; 1.
DR PRINTS; PR00019; LEURICRPT.
DR SMART; SM00370; LRR; 4.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_TVP; 9.
KW Glycoprotein; leucine-rich repeat; Repeat; Signal.
FT SIGNAL 1 23
FT CHAIN 24 603
FT REPEAT 52 73
FT REPEAT 74 96
FT REPEAT 98 120
FT REPEAT 121 144
FT REPEAT 146 168
FT REPEAT 169 192
FT REPEAT 194 216
FT REPEAT 217 240
FT REPEAT 242 264
FT REPEAT 265 288
FT REPEAT 289 312
FT REPEAT 313 336
FT REPEAT 338 360
FT REPEAT 361 384
FT REPEAT 386 409
FT REPEAT 433 456
FT REPEAT 458 480
FT REPEAT 482 504
FT REPEAT 505 529
FT REPEAT 543 566
FT CARBOHYD 64 64
FT CARBOHYD 85 85
FT CARBOHYD 96 96
FT CARBOHYD 368 368
FT CARBOHYD 515 515
FT CARBOHYD 578 578
FT CARBOHYD 586 586
SQ SEQUENCE 603 AA; 66959 MW; 4A6223ABC7026BCC CRC64;

Query Match 12.0%; Score 302.5; DB 1; Length 603;
Best Local Similarity 31.5%; Pred. No. 2.9e-14;
Matches 93; Conservative 41; Mismatches 110; Indels 51; Gaps 7;

QY 3 CPVCTCSYDDYTDLS-VFCCSRNLQTPDGPVSTRALWLDGNLSSIPSAFQNLSS 99
DB 41 CPVCTCSYDDYTDLS-VFCCSRNLQTPDGPVSTRALWLDGNLSSIPSAFQNLSS 99
QY 58 LEILQLSRHRTTEIGAFNGLANLNTLEPDNRLTTPNGAFVLSKELWLRNPPIE 117
DB 100 LDFNLQGSWLRSEPOALLGLQNLHLHLERNLRLSLAAGLFRHTPTSLSLGNLLG 159
QY 118 SIPSFAFNRIPLRLDLGELKRLSYISEGAFGLSNLRVNLNTA-----MCNLR 166
DB 160 RLEGLFRGLSHLDNLNG-WNSLVLPDVTVFQGLGNLHVLVLAGNKLYLPALLCGLG 218
```

```
QY 167 EIPNLTPLIKLDLSDNHLNSAIRPGSFGHQLHQLKLMQISQIVERNAF----- 219
DB 219 E-----LRELDLSRNALRSYKANVFHILPRLOKLYLDNRNLITAVAPRAFLGMKALR 269
QY 220 -----DNLOSLVE-----INLAHNLTLLPHDLETPPLHLHLRIHLHN 257
DB 270 WLDLSLRNRVAGLLEDTFPGLLGLHVLRLAHNAITSLRPTFKDLHFLLEQLQGHN 324

RESULT 11
PGS2_HUMAN
ID PGS2_HUMAN STANDARD; PRT; 359 AA.
AC P07585; Q9Y5N9; Q9Y5N8; Q9P020; Q9P021;
DT 01-APR-1988 (Rel. 07, Created)
DT 01-APR-1988 (Rel. 07, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE Bone proteoglycan II precursor (PG-S2) (Decorin) (PG40).
GN DCN.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID:9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=87017013; PubMed=3484330;
RA Krusius T., Ruoslahti E.;
RT "Primary structure of an extracellular matrix proteoglycan core
RT protein deduced from cloned cDNA.";
RL Proc. Natl. Acad. Sci. U.S.A. 83:7683-7687(1986).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=93162643; PubMed=8432527;
RA Vetter U., Vogel W., Just W., Young M.F., Fisher L.W.;
RT "Human decorin gene: intron-exon junctions and chromosomal
RT localization.";
RL Genomics 15:161-168(1993).
RN [3]
RP SEQUENCE OF 1-70 FROM N.A.
RX MEDLINE=93162642; PubMed=8432526;
RA Danielson K.G., Fazio A., Cohen I.R., Cannizzaro L., Iozzo R.V.;
RT "The human decorin gene: intron-exon organization, discovery of two
RT alternatively spliced exons in the 5' untranslated region, and
RT mapping of the gene to chromosome 12q23.";
RL Genomics 15:146-160(1993).
RN [4]
RP SEQUENCE FROM N.A. (ISOFORMS A; B; C; D AND E).
RA CS-Szabo G., Giant T.T.;
RT "Alternative splicing of human decorin.";
RL Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
RN [5]
RP SEQUENCE OF 31-50.
RX MEDLINE=90073579; PubMed=2590169;
RA Roughley P.J., White R.J.;
RT "Permatan sulphate proteoglycans of human articular cartilage. The
RT properties of dermatan sulphate proteoglycans I and II.";
RL Biochem. J. 262:823-827(1989).
RN [6]
RP SEQUENCE OF 31-49.
RX MEDLINE=87250639; PubMed=3597437;
RA Fisher L.W., Hawkins G.R., Tuross N., Termini J.D.;
RT "Purification and partial characterization of small proteoglycans I
RT and II, bone sialoproteins I and II, and osteonectin from the mineral
RT compartment of developing human bone.";
RL J. Biol. Chem. 262:9702-9708(1987).
CC -1- FUNCTION: BINDS TO TYPE I AND TYPE II COLLAGEN AND AFFECTS THE
CC RATE OF FIBRILS FORMATION. ALSO BINDS TO FIBRONECTIN AND TGF-
CC BETA.
CC -1- PTM: THE GLYCOSAMINOGLYCAN CHAIN ATTACHED TO DECORIN CAN BE EITHER
CC CHONDROITIN SULFATE OR DERMATAN SULFATE DEPENDING UPON THE
CC TISSUE OF ORIGIN.
CC -1- ALTERNATIVE PRODUCTS: 5 isoforms; A (shown here), B, C, D and E;
CC are produced by alternative splicing.
```







DR	Pfam: PF01462; LRRT: 1.	
DR	SMART: SM00370; LRR: 2.	
DR	SMART: SM00013; LRRT: 1.	
DR	SMART: SM00369; LRR_TYP: 2.	
KW	Glycoprotein; Connective tissue; Extracellular matrix; Proteoglycan;	
KW	Repeat; Leucine-rich repeat; Signal	
FT	SIGNAL 1 16	POTENTIAL.
FT	PROPEP 17 30	
FT	CHAIN 31 360	BONE PROTEOGLYCAN II.
FT	REPEAT 78 99	LRR 1.
FT	REPEAT 100 123	LRR 2.
FT	REPEAT 124 146	LRR 3.
FT	REPEAT 147 168	LRR 4.
FT	REPEAT 169 194	LRR 5.
FT	REPEAT 195 218	LRR 6.
FT	REPEAT 219 239	LRR 7.
FT	REPEAT 240 263	LRR 8.
FT	REPEAT 264 286	LRR 9.
FT	REPEAT 287 309	LRR 10.
FT	CARBOHYD 34 34	O-LINKED (GLYCOSAMINOGLYCAN) (BY
FT		SIMILARITY).
FT	CARBOHYD 212 212	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD 263 263	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	CARBOHYD 304 304	N-LINKED (GLCNAC. .) (POTENTIAL).
FT	DISULFID 55 68	BY SIMILARITY.
FT	DISULFID 314 347	BY SIMILARITY.
SQ	SEQUENCE 360 AA; 39837 MW; 71E84DA2D87552C0 CRC64;	
Query Match 11.6%; Score 293; DB 1; Length 360;		
Best Local Similarity 29.9%; Pred. No. 7.2e-14;		
Matches 95; Conservative 46; Mismatches 139; Indels 38; Gaps		
QY	3 CPVCSCSNFSKVICVRKRLREVDPGISNTRLNLHENOIOIKVNSFKHLRHLEILQ 62	
DB	55 CPFCQC--HLRVVQCSDLGLEKVPKDLPPDPTALLDQNNKITEIKDGFKNLKNLHTLI 112	
QY	63 LSRNHIRTIEIGAFNGIANLNTLELFDNRITTPINGAFVYLSKLKELWRNNPIESIPSY 122	
DB	113 LNNKISKISPGAFAPLVKLERLYLSKNQLKELPE---KMPKTLQELRVHENEITKVRKS 169	
QY	123 AFNRIPSLRLDUG--ELKRLSYISEGAFGLSNLRYLNLMCNLRBIPMLTPLIKLDEL 180	
DB	170 VFNGLMQIMVVELGTNP LKS-SGIENGAFQGMKKLSYIRIADTNITTIPOGLP-PSLTEL 227	
QY	181 DLSGNHLSAIRPGSFGCLMHLQKLMIQSOIQVIERNAFDNLSQSLVEINLAHNNLTLP 240	
DB	228 HLDGNKITKVDAAKGLNNLAKLGUSFNISAVDNGSLANTPHLRCHLNNNKAKVPG 287	
QY	241 DLFTPLHLRIHLHHPNWCNCIDIWLWSWIKMDAPSNTPACCARGCTPPNLKRGYIG-- 298	
DB	288 GV-ADHKYIQVVYLNHN---NLSAI-----GSNDFCPGYNTK---KASISGV 329	
QY	299 -----ELDQNYFTC 307	
DB	330 LFSNPVOYWEIQPSTFRC 347	
RESULT 15		
PGS2_CHICK	STANDARD;	PRT; 357 AA.
AC	P28675;	
DT	01-DEC-1992 (Rel. 24, Created)	
DT	01-DEC-1992 (Rel. 24, Last sequence update)	
DE	16-OCT-2001 (Rel. 40, Last annotation update)	
OS	Bone proteoglycan II precursor (pg-S2) (Decorin).	
OS	Gallus gallus (Chicken).	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;	
OC	Gallus.	
OX	NCBI_TaxID=9031;	
RN	SEQUENCE FROM N. A. AND PARTIAL SEQUENCE.	
RP	[1]	

RC	STRAIN-WHITE LGHORN; TISSUE-Cornea;
RX	MEDLINE=92296755; PubMed=1605630;
RA	Li W., Vergnes J.P., Cornuet P.K., Hassel J.R.;
RR	"CDNA clone to chick corneal chondroitin/dermatan sulfate
RT	proteoglycan reveals identity to decorin.";
RT	Arch. Biochem. Biophys. 296:190-197(1992).
RL	-1- FUNCTION: BINDS TO TYPE I AND TYPE II COLLAGEN AND AFFECTS THE
CC	RATE OF FIBRIL FORMATION. ALSO BINDS TO FIBRONECTIN AND 1GF-
CC	BETA.
CC	-1- PTM: THE GLYCOSAMINOGLYCAN CHAIN ATTACHED TO DECORIN CAN BE EITHER
CC	CHONDROITIN SULFATE OR DERMATAN SULFATE DEPENDING UPON THE
CC	TISSUE OF ORIGIN (BY SIMILARITY).
CC	-1- SIMILARITY: BELONGS TO THE SMALL INTERSTITIAL PROTEOGLYCANS
CC	FAMILY.
CC	-1- SIMILARITY: CONTAINS 10 LEUCINE-RICH REPEATS (LRR).
CC	-----
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC	the European Bioinformatics Institute. There are no restrictions on its
CC	use by non-profit institutions as long as its content is in no way
CC	modified and this statement is not removed. Usage by and for commercial
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC	or send an email to licensese@isb-sib.ch).
CC	-----
DR	EMBL; X63797; CAA45318.1; -
DR	PIR; S22197; S22197.
DR	PIR; S24317; S24317.
DR	InterPro; IPRO01611; LRR.
DR	InterPro; IPRO00372; LRR_Nterm.
DR	InterPro; IPRO00352; LRR_out.
DR	InterPro; IPRO03591; LRR_Typ.
DR	Pfam; PF00560; LRR; 10.
DR	Pfam; PF01462; LRRNT; 1.
DR	SMART; SM00370; LRR; 2.
DR	SMART; SM00013; LRRNT; 1.
DR	SMART; SM00369; LRR_Typ; 2.
KW	Glycoprotein; Connective tissue; Extracellular matrix; Proteoglycan;
KW	Repeat; Leucine-rich repeat; Signal.
FT	SIGNAL 1 16
FT	PROPEP 17 30
FT	CHAIN 31 357
FT	REPEAT 75 96 BONE PROTEOGLYCAN II.
FT	REPEAT 97 120 LRR 1.
FT	REPEAT 121 143 LRR 2.
FT	REPEAT 144 165 LRR 3.
FT	REPEAT 166 191 LRR 4.
FT	REPEAT 192 215 LRR 5.
FT	REPEAT 216 236 LRR 6.
FT	REPEAT 237 260 LRR 7.
FT	REPEAT 261 283 LRR 8.
FT	REPEAT 284 306 LRR 9.
FT	CARBOHYD 34 306 LRR 10.
FT	34
FT	-----
FT	CARBOHYD 209 34 N-LINKED (GLYCOSAMINOGLYCAN) (BY
FT	CARBOHYD 260 260 SIMILARITY).
FT	DULSID 52 65 N-LINKED (GLCNAC. . ) (POTENTIAL).
FT	DULSID 311 344 BY SIMILARITY.
FT	SEQUENCE 357 AA; 33687 MW; 31B104C7C3CD711D CRC64;

```

Db 167 VFNGLNQVIVLELGTNPLKS-SGIENGAFQGMKRLSYIRIADTNITSIPKGLP-PSUTEL 224
Qy 181 DLSGNHLSATRPGSFQGLMHQKLMWTQSQIVQTERNAFONLQSLVEINLAHNNLTLLPH 240
Db 225 HLDGNKISKIDAEGLSGLTNKLGLSFNSISSVENGSLNNVPHRLHLLNNNELVRPS 284
Qy 241 DLFTPLHHLERIHLHNN 257
Db 285 GL-GEHKYIQVVYLNHN 300

Search completed: August 26, 2002, 15:50:43
Job time: 240 sec

```

---



GenCore version 4.5  
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 26, 2002, 15:46:18 ; Search time 31.39 Seconds  
(without alignments)  
2634.329 Million cell updates/sec

Title: US-09-905-056-292\_COPY\_45\_522

Perfect score: 2524

Sequence: 1 OTCPGVCSNQSOFKVICVR.....KTFITPVDINSIGIPIDEV 478

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 562222 seqs, 172994929 residues

Total number of hits satisfying chosen parameters: 562222

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- 1: sp\_archaea:\*
- 2: sp\_bacteria:\*
- 3: sp\_fungi:\*
- 4: sp\_human:\*
- 5: sp\_invertebrate:\*
- 6: sp\_mammal:\*
- 7: sp\_mhc:\*
- 8: sp\_organelle:\*
- 9: sp\_phase:\*
- 10: sp\_plant:\*
- 11: sp\_rodent:\*
- 12: sp\_virus:\*
- 13: sp\_vertebrate:\*
- 14: sp\_unclassified:\*
- 15: sp\_rvirus:\*
- 16: sp\_bacteriap:\*
- 17: sp\_archaeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	2524	100.0	640	4	Q9HCJ2
2	1581.5	62.7	653	4	Q9HBW1
3	1556.5	61.7	649	4	Q96A85
4	1151.5	45.6	422	4	Q9NT99
5	872.5	34.6	441	11	Q99PH1
6	565.5	22.4	606	4	Q9BZ20
7	565.5	22.4	614	4	Q96FE5
8	560.5	22.2	614	6	Q9N008
9	559.5	22.2	614	11	Q90LT0
10	453	17.9	719	4	Q96N16
11	443.5	17.6	1021	5	Q9V430
12	421	16.7	705	4	Q43377
13	421	16.7	708	4	Q9H3W5
14	413.5	16.4	1093	4	Q96JA1
15	413.5	16.4	1094	4	Q9BYB8
16	410.5	16.3	730	4	Q9P231

17	410	16.2	707	11	P97860
18	408	16.2	789	6	Q9BE71
19	406	16.1	832	4	Q9ULH4
20	403	16.0	788	11	Q9CYK3
21	402.5	15.9	1091	11	P70193
22	401.5	15.9	359	4	Q96RJ5
23	401.5	15.9	492	11	Q99KT6
24	398.5	15.8	716	11	Q61809
25	398	15.8	718	13	O73675
26	397.5	15.7	359	4	O15335
27	396	15.7	707	11	Q9ESY6
28	393.5	15.6	1531	11	Q9WVB5
29	389.5	15.4	1515	13	Q9DE37
30	389.5	15.4	1531	11	O88279
31	389	15.4	1521	11	Q9RLB9
32	388.5	15.4	358	11	O55226
33	388.5	15.4	674	4	Q9NZ01
34	388	15.4	1521	4	Q95710
35	388	15.4	1529	4	O94813
36	387.5	15.4	1530	11	Q9WUG5
37	386	15.3	1525	4	Q9Y507
38	384.5	15.2	1496	4	Q92626
39	382.5	15.2	358	11	O70210
40	380	15.1	628	4	Q9BTN0
41	378	15.0	796	11	Q9WVC1
42	377.5	15.0	1173	5	Q9V7J8
43	377	14.9	1534	4	O75093
44	376	14.9	1065	4	O94898
45	375	14.9	660	4	O43155

ALIGNMENTS

RESULT 1

Q9HCJ2	PRELIMINARY;	PRT;	640 AA.
ID	Q9HCJ2		
AC	Q9HCJ2;		
DT	01-MAR-2001 (TrEMBLrel. 16, Created)		
DT	01-MAR-2001 (TrEMBLrel. 16, Last sequence update)		
DT	01-DEC-2001 (TrEMBLrel. 19, Last annotation update)		
DE	KIAA1580 PROTEIN (FRAGMENT).		
GN	KIAA1580.		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
OX	NCBI_TaxID=9606;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RX	MEDLINE=20450683; PubMed=10997877;		
RA	Nagase T., Kikuno R., Nakayama M., Hirotsawa M., Ohara O.;		
RT	"Prediction of the coding sequences of unidentified human genes.		
RT	XVIII. The complete sequences of 100 new cDNA clones from brain which		
RT	code for large proteins in vitro."		
RL	DNA Res. 7:273-281(2000).		
RL	EMBL; AB046800; BAB13406.1;		
DR	HSSP; P22886; ILUT.		
DR	InterPro; IPR003599; Ig.		
DR	InterPro; IPR003598; Ig_c2.		
DR	InterPro; IPR003600; Ig_like.		
DR	InterPro; IPR003006; Ig_MHC.		
DR	InterPro; IPR001611; LRR.		
DR	InterPro; IPR000483; LRR_Cterm.		
DR	InterPro; IPR000372; LRR_Nterm.		
DR	InterPro; IPR003592; LRR_out.		
DR	InterPro; IPR003591; LRR_typ.		
DR	Pfam; PF000047; Ig; 1.		
DR	Pfam; PF00560; LRR; 9.		
DR	Pfam; PF01463; LRRCT; 1.		
DR	Pfam; PF01462; LRRNT; 1.		
DR	PRINTS; PR00019; LEURICHRPT.		
DR	SMART; SM00409; IG; 1.		
DR	SMART; SM00408; IGC2; 1.		

p97860	mus musculus
q9be71	macaca fasc
q9ulh4	homo sapien
q9cyk3	mus musculus
p70193	mus musculus
q96rj5	homo sapien
q99kt6	mus musculus
q61809	mus musculus
q73675	xenopus lae
o15335	homo sapien
q9esy6	rattus norv
q9wvb5	mus musculus
q9de37	brachydanio
o88279	rattus norv
q9rlb9	mus musculus
o55226	mus musculus
q9nz01	homo sapien
q95710	homo sapien
o94813	homo sapien
q9wug5	rattus norv
q9y507	homo sapien
q92626	homo sapien
o70210	rattus norv
q9btn0	homo sapien
q9wvc1	rattus norv
q9v7j8	drosophila
o75093	homo sapien
o94898	homo sapien
o43155	homo sapien

```
DR SMART; SM00410; IG-like; 1.
DR SMART; SM00370; LRR; 6.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_TTP; 8.
KW Immunoglobulin domain.
FT NON_TER 1
SQ SEQUENCE 640 AA; 71949 MW; 6058974872636838 CRC64;

Query Match 100.0%; Score 2524; DB 4; Length 640;
Best Local Similarity 100.0%; Pred. No. 1.8e-181;
Matches 478; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QTCPSVCSNQSKVTCVRKNLREVPDGI STNTRLLNLHENQIQI IKVNSFKHLRHL 60
DB 45 QTCPSVCSNQSKVTCVRKNLREVPDGI STNTRLLNLHENQIQI IKVNSFKHLRHL 104

QY 61 LQLSRNHIRTIEIGAFNGLANLTLELFDNRLTTPNGAFVYLSKLKELWLRNNPIESIP 120
DB 105 LQLSRNHIRTIEIGAFNGLANLTLELFDNRLTTPNGAFVYLSKLKELWLRNNPIESIP 164

QY 121 SYAFNRIPSLRRLDGLGELKRLSYISEGAFGLSNLRYLNAMCNLREIPNLTPLIKLDEL 180
DB 165 SYAFNRIPSLRRLDGLGELKRLSYISEGAFGLSNLRYLNAMCNLREIPNLTPLIKLDEL 224

QY 181 DLSGNHLSAIRPGSFGQLMHLQKLMWISQIQVIERNAFDNLQSLVEINLAHNLTLLPH 240
DB 225 DLSGNHLSAIRPGSFGQLMHLQKLMWISQIQVIERNAFDNLQSLVEINLAHNLTLLPH 284

QY 241 DLFTPLHLRIHLHHPNWCNCDILWLSWKIDWAPSNACCARCNTPPNPKRGYIGEL* 300
DB 285 DLFTPLHLRIHLHHPNWCNCDILWLSWKIDWAPSNACCARCNTPPNPKRGYIGEL 344

QY 301 DONFTCYAPVIVPEPPADLVNTEGMAELKCRASSTLSVSWITPNGTVMTHGAYKVRIA 360
DB 345 DONFTCYAPVIVPEPPADLVNTEGMAELKCRASSTLSVSWITPNGTVMTHGAYKVRIA 404

QY 361 VLSGDTLNFTNVVQDTGMTCVNSVSGNTASATLNVTAAATTPSFYSTVTVETM 420
DB 405 VLSGDTLNFTNVVQDTGMTCVNSVSGNTASATLNVTAAATTPSFYSTVTVETM 464

QY 421 SQDEARTDNNVGPVVDWETNTVTSLTQSTRSTEKTFTIPVTDINSIGPIDEV 478
DB 465 SQDEARTDNNVGPVVDWETNTVTSLTQSTRSTEKTFTIPVTDINSIGPIDEV 522

RESULT 2
Q9HBW1 PRELIMINARY; PRT; 653 AA.
AC Q9HBW1;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-OCT-2001 (TrEMBLrel. 18, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE BRAIN TUMOR ASSOCIATED PROTEIN NAG14.
GN NAG14.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
SEQUENCE FROM N.A.
RA Wang J., Bin L., Jiang N., Li G.;
RT "Homo sapiens brain-specific gene (BAG), downregulated in brain tumor, mRNA.";
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF196976; AAC28019.2; -
DR HSSP; P23945; 1XUN.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR003598; Ig_c2.
DR InterPro; IPR003600; Ig-like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR001611; LRR.
```

```
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003592; LRR_Out.
DR InterPro; IPR003591; LRR_typ.
DR Pfam; PF00047; Ig; 1.
DR Pfam; PF00560; LRR; 8.
DR Pfam; PF01462; LRRCT; 1.
DR Pfam; PF01463; LRRNT; 1.
DR SMART; SM00409; IG; 1.
DR SMART; SM00408; IGc2; 1.
DR SMART; SM00410; IG-like; 1.
DR SMART; SM00370; LRR; 3.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_TTP; 7.
KW Immunoglobulin domain.
SQ SEQUENCE 653 AA; 72717 MW; 38159C81F6850E37 CRC64;

Query Match 62.7%; Score 1581.5; DB 4; Length 653;
Best Local Similarity 60.9%; Pred. No. 1.3e-110;
Matches 298; Conservative 77; Mismatches 93; Indels 21; Gaps 8;

QY 1 QTCPSVCSNQSKVTCVRKNLREVPDGI STNTRLLNLHENQIQI IKVNSFKHLRHL 60
DB 44 QTCPSVCSNQSKVTCVRKNLREVPDGI STNTRLLNLHENQIQI IKVNSFKHLRHL 103

QY 61 LQLSRNHIRTIEIGAFNGLANLTLELFDNRLTTPNGAFVYLSKLKELWLRNNPIESIP 120
DB 104 LQLSRNHIRTIEIGAFNGLANLTLELFDNRLTTPNGAFVYLSKLKELWLRNNPIESIP 163

QY 121 SYAFNRIPSLRRLDGLGELKRLSYISEGAFGLSNLRYLNAMCNLREIPNLTPLIKLDEL 180
DB 164 SYAFNRIPSLRRLDGLGELKRLSYISEGAFGLSNLRYLNAMCNLREIPNLTPLIKLDEL 223

QY 181 DLSGNHLSAIRPGSFGQLMHLQKLMWISQIQVIERNAFDNLQSLVEINLAHNLTLLPH 240
DB 224 DLSGNHLSAIRPGSFGQLMHLQKLMWISQIQVIERNAFDNLQSLVEINLAHNLTLLPH 283

QY 241 DLFTPLHLRIHLHHPNWCNCDILWLSWKIDWAPSNACCARCNTPPNPKRGYIGEL 300
DB 284 DLFTPLHLRIHLHHPNWCNCDILWLSWKIDWAPSNACCARCNTPPNPKRGYIGEL 343

QY 301 DONFTCYAPVIVPEPPADLVNTEGMAELKCRASSTLSVSWITPNGTVMTHGAYKVRIA 360
DB 344 DONFTCYAPVIVPEPPADLVNTEGMAELKCRASSTLSVSWITPNGTVMTHGAYKVRIA 402

QY 361 VLSGDTLNFTNVVQDTGMTCVNSVSGNTASATLNVTAAATTPSFYSTVTVETM 418
DB 403 VLSGDTLNFTNVVQDTGMTCVNSVSGNTASATLNVTAAATTPSFYSTVTVETM 462

QY 419 EPSQDEARTDNNVGPVVDWETNTVTSLTQSTRSTEKTFTIPVTDINS 470
DB 463 EPSQDEARTDNNVGPVVDWETNTVTSLTQSTRSTEKTFTIPVTDINS 513

QY 471 GI-PCIDEV 478
DB 514 KMQTSLDEV 522

RESULT 3
Q96A85 PRELIMINARY; PRT; 649 AA.
ID Q96A85;
AC Q96A85;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE HYPOTHETICAL 72.3 KDA PROTEIN.
GN BAG.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
```





```
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF00047; Ig; 1.
DR EMBL; AL353746; CAC22713.1; -.
DR Pfam; PF01463; LRRCT; 1.
DR SMART; SM00409; IGC; 1.
DR SMART; SM00408; IGC2; 1.
DR SMART; SM00410; IG_Like; 1.
DR SMART; SM00370; LRR; 2.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00369; LRR_Typ; 3.
KW Immunoglobulin domain.
FT NON_TER 1
SQ SEQUENCE 441 AA; 48844 MW; E2D17AB4607AC475 CRC64;

Query Match 34.68; Score 872.5; DB 11; Length 441;
Best Local Similarity 52.28; Pred. No. 1.4e-57;
Matches 163; Conservative 57; Mismatches 87; Indels 5; Gaps 4;

Qy 170 NLTPLIKDELDSGNHLSAIRPGSFGGLMHLOKLMIQSQIQTIERNAFNLSQSLVEIN 229
Db 1 NLTPVLGLEELMSGNHPEIRPGSFHGLSSLLKLVWVNSQVSLIERNAFDGLASLYELN 60

Qy 230 LAHNNTLPLPHDLFTPLHLLRIHLHHPNWCNCDILMSWIKDMAPSNACCARCWTP 289
Db 61 LAHNNTLPLPHDLFTPLHLLRIHLHHPNWCNCDILMSWIKDMAPSNACCARCWTP 120

Qy 290 PNLGRYIGELDONVETCYAPVIVPEPPADLVNTEGMAELKCRASTSLTSVSWITPNCVT 349
Db 121 MHMKGRYLVEVDQAQFCSAFIMDAPKDLNISERMAELKCR-TTPMSSVKKWLLPNCVT 179

Qy 350 MTHGAYKVRIVASDGLTNFTNVQDTGMYTCMVNSVGNVTASATLVNTAA--TTTPE 407
Db 180 LSHASRRHPRISVLNDGTLNFSRVLLIDTGVVTCMVTVNAGNSAYLVNVSSAELNTPNF 239

Qy 408 SYFSTVTVTEWPEODEARTDNNVGPVVDVETNTVTTSLTQSTRTSEKTTTPIPTVD 467
Db 240 SFFTVTVTEWPEODEARTDNNVGPVVDVETNTVTTSLTQSTRTSEKTTTPIPTVD 298

Qy 468 INSGI-PGIDEV 478
Db 299 TTDKMQTSLDEV 310

RESULT 6
Q9Bz20 PRELIMINARY; PRT; 606 AA.
AC Q9Bz20
DT 01-JUN-2001 (TrEMBLrel. 17, Created)
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE B4438B23.1 (NEURONAL LEUCINE-RICH REPEAT PROTEIN) (CDNA FLJ31810 FIS,
DE CLONE NT2R12009289, WEAKLY SIMILAR TO CARBOXYPEPTIDASE N 83 KDA
DE CHAIN).
DE B4438B23.1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Babbage A.;
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.
[2]
RP SEQUENCE FROM N.A.
RA Ishibashi T., Kanehori K., Yosida M., Watanabe S., Ishida S., Ono Y.,
RA Hotuta T., Hiraoka S., Murakawa K., Takiguchi S., Kusano J.,
RA Watanabe M., Fujimori K., Tanai H., Ishida M., Yamashita H., Chiba Y.,
RA Sugiyama T., Irie R., Otsuki T., Sato H., Wakamatsu A., Ishii S.,
RA Yamamoto J., Isono Y., Kawai-Hio Y., Saito K., Nishikawa T.,
RA Kimura K., Matsuo K., Nakamura Y., Sekine M., Kikuchi H., Kanda K.,
RA Wagatsuma M., Takahashi-Fujii A., Oshina A., Sugiyama A., Kawakami B.,
RA Suzuki Y., Sugano S., Naganari K., Masuno Y., Nagai K., Isogai T.;
```

```
*NEDO human cDNA sequencing project.*;
Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL353746; CAC22713.1; -.
DR EMBL; AK056372; BAB71167.1; -.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR003598; Ig_C2.
DR InterPro; IPR003600; Ig_Like.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003591; LRR_Typ.
DR Pfam; PF00047; Ig; 1.
DR Pfam; PF00560; LRR; 11.
DR Pfam; PF01463; LRRCT; 1.
DR Pfam; PF01482; LRRNT; 1.
DR PRINTS; PR00019; LEURICHRPT.
DR SMART; SM00409; IGC; 1.
DR SMART; SM00408; IGC2; 1.
DR SMART; SM00410; IG_Like; 1.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_Typ; 10.
KW Immunoglobulin domain.
SQ SEQUENCE 606 AA; 68065 MW; CB08E281B066B9D CRC64;

Query Match 22.48; Score 565.5; DB 4; Length 606;
Best Local Similarity 29.38; Pred. No. 2.6e-34;
Matches 157; Conservative 79; Mismatches 196; Indels 103; Gaps 11;

Qy 3 CPVSCVCSNQSFQVCKVIRKKNREVDPDGISTNTRLLNLHENOIQIKVNSFKHLRHLILQ 62
Db 28 CPARCECSAQNKSQVCHRRRLIAIPGPIETKILDKSLKSLVNPPEEFTSYPLLEID 87

Qy 63 LSRNHIETIEGANGLANLTLEFONRLTTPINGAFVYLSKLKELWLRNPIESIPSY 122
Db 88 LSDNIIANVEGAFNLFNLSRLKGNRLKLVPLGVFTGLSNLTKLDISENKIVILDY 147

Qy 123 AFNRIPSLRLDLGELKRLSVISEGAPEGLSNRLYNLNCMLNREIP----- 169
Db 148 MFQDLHNLKSLVEGD-NDLVYISHRAFSGLLSLQLTLEKCNLTAVPTFEALSHRLSL 206

Qy 170 -----NLTP----- 173
Db 207 HLKHLINNMPPVAFKRLFLHLKLEIDYWPLLDMPANSLYGLNLTSLSTNTNLSTVPF 266

Qy 174 -----LKLDELDSGNHLSAIRPGSFGGLMHLOKLMIQSQIQTIERNAFNLSQSLVEI 228
Db 267 LAFKHLVYLTHLNSYNPISTIEAGMFSDLRLQELHIVGAQLRTIEPHSPQGLRFLVL 326

Qy 229 NLAHNNLTLLPHDLFTPLHLLRIHLHHPNWCNCDILWL-----SMWIKDMAPSNACC 283
Db 327 NVSONLLETLEENVFSPRALEVLISINNPLACOCRLNLIQROPTLQFGQQP----- 380

Qy 284 ARCTPNPLKGRYIGELDON-----YFTCYAPVIVPEPPAD-LNVTEGMAELKCRASTSLT 338
Db 381 -MCAGPDTIRERSFKDFHSTALSIFYFTCKPKIREKKLQHLVDEGQTVQLECSADGDPQ 439

Qy 339 SV-SWITPNC---TWVTHGAYKVRIVASDGLTNFTNVQDTGMYTCMVNSVGNVTAS 394
Db 440 PVISWVTPRRRFRITTKNG-----RATVLGDTGLEIRFAQQDQDSGMVYCIASNAAGNDTFT 495

Qy 395 ATLNVTAATTPFSYFSTVTVTEWPEODEARTDNNVGPVVDVETNTVTTSL 449
Db 496 ASLTVKGFASDRFLYANRTPMWYDTSNDTISNGTNAN---TFLDLKTLILYSTAM 547

RESULT 7
Q96FE5 PRELIMINARY; PRT; 614 AA.
ID Q96FE5
AC Q96FE5
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
```

01-DEC-2001 (TrEMBLrel. 19, Last sequence update)  
01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
UNKNOWN (PROTEIN FOR MGC:17422).  
Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=BRIN, AND ANAPLASTIC OLIGODENDROGLIOMA WITH 1P/19Q LOSS;  
RA Strausberg R.; and 2001 to the EMBL/GenBank/DBJ databases.  
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC011057; AAH11057.1; -  
SQ SEQUENCE 614 AA; 69145 MW; EFD967E3B716698D CRC64;

Query Match 22.4%; Score 565.5; DB 4; Length 614;  
Best Local Similarity 30.3%; Pred. No. 2.7e-34;  
Matches 162; Conservative 74; Mismatches 202; Indels 93; Gaps 12;

QY 3 CPVSCSNQFSKVICVRKRLNREVPDGISTNRLNLHENOIOIKVNSFKHLRLHLEIQ 62  
DB 36 CPPCECSAQRVLCRKRFVAVPEGIPTETRLDLGKNRIKTLNODFAFPHELE 95  
QY 63 LSRNHRTIEIGAFNGLANLTLEFDNRLTTPNGAFVYLSKLKELWLNRPPIESIPSY 122  
DB 96 LNEIVSAVEPGAFNNFLNRLTGLRSNRLKLPGLVFTGLSNLTLDISENKIVILLY 155  
QY 123 AFNRIPLRLDLGELKRLSYISEGAFEGLSNRLYLNAMCNLREIP- 169  
DB 156 MFQDLYNLKSLVGD-NDLYIISHRAFSGLSLEQLTLEKCNLTSTPTALSHLHGLIVL 244  
QY 170 -----NLTP- 173  
DB 215 RLRHLNINARDYFKRLYRLKLVLEISHWPYLDTPMPCLYGLNLTSLSTHCHNLTA 274  
QY 174 -----LIKLELDLSGNHLSAIRPGSQGLMHLOKLMWIOSQIOVIERNADNLSLVEI 228  
DB 275 LAVRHLYLRLNLSYNPISITIEGSMHLLRLQEIOLVGGLAVVEPYAFRLNLYRLV 334  
QY 229 NLAHNNLTLLPHDLFTPLHHLRLTHLHNPWCNCDTLWL- - -SWWIKDMAPSNTACCAR 285  
DB 335 NVSGNQTLLEESVFHSGVGNLETLILDSNPLACDRLWVFRRLNFRNQPT- - - 389  
QY 286 CNTPNLKGRIYGE- - -LDQNYFTCYAPVIVEPPA-DLNVTEGMAAEKRA-STSLTS 339  
DB 390 CATPEFVGQKEKDFPDVLLPNYETCRRARIRDRKAQOVFDEGHTVQFCRADGDP 449  
QY 340 VSWITPNTGVTWTHGAYKRVIAVSDGLNTFTNTVQDTGMVTCMVSNGVNTTASATLV 399  
DB 450 ILWLSPRKHLVS-AKSNGLRTVFPDGTLEVRYAQOVQNGTYLCTAANAGGNDSP 508  
QY 400 TA-ATTPFPFSYFVTVETMEPSODEARTDNNVGPVVDWETNTTSL 449  
DB 509 RSYSPDHPHQPNTFAFIPNQPGEGEANSTRATV-PFP-FDIKTLIIATTM 557

RESULT 8  
Q9N008 PRELIMINARY; PRT; 614 AA.  
AC Q9N008;  
DT 01-OCT-2000 (TrEMBLrel. 15, Created)  
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)  
DE 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE HYPOTHETICAL 69.2 KDA PROTEIN.  
OS Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;  
OC Cercopithecoidea; Macaca.  
OX NCBI\_TaxID=9541;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=CEREBELLUM CORTEX;

Osada N., Hida M., Kusuda J., Tanuma R., Iseki K., Hirai M., Terao K.,  
Suzuki Y., Sugano S., Hashimoto K.;  
"Isolation of full-length cDNA clones from macaque brain CDNA  
libraries";  
RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AB046639; BAB03557.1; -  
DR HSSP; P23945; 1XUN.  
DR InterPro; IPR003598; Iq\_c2.  
DR InterPro; IPR003006; Iq\_MHC.  
DR InterPro; IPR001611; LRR.  
DR InterPro; IPR000483; LRR\_Cterm.  
DR InterPro; IPR000372; LRR\_Nterm.  
DR InterPro; IPR003592; LRR\_Out.  
DR InterPro; IPR003591; LRR\_type.  
DR Pfam; PF00047; Iq; 1.  
DR Pfam; PF00560; LRR; 9.  
DR Pfam; PF01463; LRRCT; 1.  
DR Pfam; PF01462; LRRNT; 1.  
DR SMART; SM00408; IGC2; 1.  
DR SMART; SM00370; LRR; 5.  
DR SMART; SM00082; LRRCT; 1.  
DR SMART; SM00013; LRRNT; 1.  
DR SMART; SM00369; LRR\_type; 1.  
KW Hypothetical protein; Immunoglobulin domain.  
SQ SEQUENCE 614 AA; 69187 MW; BA6C8BC7C993BE9A CRC64;

Query Match 22.2%; Score 560.5; DB 6; Length 614;  
Best Local Similarity 30.3%; Pred. No. 6.3e-34;  
Matches 161; Conservative 74; Mismatches 203; Indels 93; Gaps 12;

QY 3 CPVSCSNQFSKVICVRKRLNREVPDGISTNRLNLHENOIOIKVNSFKHLRLHLEIQ 62  
DB 36 CPPCECSAQRVLCRKRFVAVPEGIPTETRLDLGKNRIKTLNODFAFPHELE 95  
QY 63 LSRNHRTIEIGAFNGLANLTLEFDNRLTTPNGAFVYLSKLKELWLNRPPIESIPSY 122  
DB 96 LNEIVSAVEPGAFNNFLNRLTGLRSNRLKLPGLVFTGLSNLTLDISENKIVILLY 155  
QY 123 AFNRIPLRLDLGELKRLSYISEGAFEGLSNRLYLNAMCNLREIP- 169  
DB 156 MFQDLYNLKSLVGD-NDLYIISHRAFSGLSLEQLTLEKCNLTSTPTALSHLHGLIVL 214  
QY 170 -----NLTP- 173  
DB 215 RLRHLNINARDYFKRLYRLKLVLEISHWPYLDTPMPCLYGLNLTSLSTHCHNLTA 274  
QY 174 -----LIKLELDLSGNHLSAIRPGSQGLMHLOKLMWIOSQIOVIERNADNLSLVEI 228  
DB 275 LAVRHLYLRLNLSYNPISITIEGSMHLLRLQEIOLVGGLAVVEPYAFRLNLYRLV 334  
QY 229 NLAHNNLTLLPHDLFTPLHHLRLTHLHNPWCNCDTLWL- - -SWWIKDMAPSNTACCAR 285  
DB 335 NVSGNQTLLEESVFHSGVGNLETLILDSNPLACDRLWVFRRLNFRNQPT- - - 389  
QY 286 CNTPNLKGRIYGE- - -LDQNYFTCYAPVIVEPPA-DLNVTEGMAAEKRA-STSLTS 339  
DB 390 CATPEFVGQKEKDFPDVLLPNYETCRRARIRDRKAQOVFDEGHTVQFCRADGDP 449  
QY 340 VSWITPNTGVTWTHGAYKRVIAVSDGLNTFTNTVQDTGMVTCMVSNGVNTTASATLV 399  
DB 450 ILWLSPRKHLVS-AKSNGLRTVFPDGTLEVRYAQOVQNGTYLCTAANAGGNDSP 508  
QY 400 TA-ATTPFPFSYFVTVETMEPSODEARTDNNVGPVVDWETNTTSL 449  
DB 509 RSYSPDHPHQPNTFAFIPNQPGEGEANSTRATV-PFP-FDIKTLIIATTM 557

RESULT 9  
Q9D1T0 PRELIMINARY; PRT; 614 AA.  
ID Q9D1T0  
AC Q9D1T0;  
DT 01-JUN-2001 (TrEMBLrel. 17, Created)



```

Oy 239 PHDLFTPLHLHLRI-----HLHNPWNCNDILWLSWIKDMAPSNATACCA 284
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 211 PPD---PLFQRAQVATSGIISPSTFALSGFNGNLCNCELLWL-----RRLSREDDLE 261
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Oy 285 RCNTPPNLKGRIYIGELQNYTCVAPVIEPPADNLNTEGMAELKCPA-STSLTSVSWI 343
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 262 TCASPPLLTGRFYWSIEEELFCPEPLITRTHEMRVLEGORATLRCKARGDPEPAHWI 321
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Oy 344 TPNGTVMTHGAYKRIAVLSGDTLNFTNVTVQDTGMVTCMYSVNGVNTASATLNVTAAT 403
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 322 SPEGKLISNA---TRSLVYDNGTLDLITTVKDGATFCIASNPAGEATQIVDLHI---I 375
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Oy 404 TTPSYSTVTVMEPSQDEARTDNNVGTPPVVDWETTNVTSLLPQSTRSTEKFTFI 463
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 376 KLPHLLNSTNIHEPDPGSSDISTSXGSNT-----SSSNGDKLSQDKIWAETSSST 430
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Oy 464 PVTIDN--SGIPGI 475
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 431 ALLKFNFORNIPGI 444
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 11
O9V430
ID Q9V430 PRELIMINARY: PRT: 1021 AA.
AC Q9V430;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DE 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE KEK3 PROTEIN
GN KEK3 OR BG:DS04862.1 OR CC4192.
OS Drosophila melanogaster (fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
OC Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP
RP SEQUENCE FROM N.A.
RC STRAIN=BERKELEY;
RX MEDLINE=20196006; PubMed=10731132;
RA Adams M.D., Celnik S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scher S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA Balow R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cavley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA Foster C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodra C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Laspo P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.M.,
RA Palazzolo M., Pittman G.S., Fan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA Shue B.C., Siden-Klamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wassarman D.A., Weinstein G.M., Weissenbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,

```

```

RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Y, AND CN BW SP;
RX MEDLINE=99403001; PubMed=10471707;
RA Ashburner M., Misra S., Roote J., Lewis S.E., Blazej R., Davis T.,
RA Doyle C., Galle R., George R., Harris N., Hartzell G., Harvey D.,
RA Hong L., Houston K., Hoskins R., Johnson G., Martin C., Moshrefi A.,
RA Palazzolo M., Reese M.G., Spradling A., Tsang G., Wan K., Whitefaw K.,
RA Celnik S., Rubin G.M.;
RT "An exploration of the sequence of a 2.9-Mb region of the genome of
RT Drosophila melanogaster: the Adh region.";
RL Genetics 153:179-219(1999).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Y, AND CN BW SP;
RA Celnik S.E., Agbayani A., Arcaina T.T., Baxter E., Blazej R.G.,
RA Butenhoff C., Champe M., Chavez C., Chew M., Ciesiolka L., Doyle C.M.,
RA Farfan D.E., Galle R., George R.A., Harris N.L., Hoskins R.A.,
RA Houston K.A., Hummasti S.R., Karra K., Kearney L., Kim E., Lee B.,
RA Lewis S., Li P., Lomotan M.A., Mazda P., Moshrefi A.R., Moshrefi M.,
RA Nixon K., Pacleb J.M., Park S., Pfeiffer B., Poon L., Sequeira A.,
RA Sethi H., Snir E., Svirskas R.R., Wan K.H., Weinburg T., Zhang R.,
RA Zieran L.L., Rubin G.M.;
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
RN EMBL; AE003648; AAF53467.1; -
DR EMBL; AE003413; AAF44948.1; -
DR FlyBase; FBgn0028370; kek3.
DR InterPro; IPR003598; Iq_C2.
DR InterPro; IPR003006; Iq_MHC.
DR InterPro; IPR001611; LRR.
DR InterPro; IPR000483; LRR_Cterm.
DR InterPro; IPR000372; LRR_Nterm.
DR InterPro; IPR003592; LRR_out.
DR InterPro; IPR003591; LRR_typ.
DR Pfam; PF00047; Iq; 1.
DR Pfam; PF00560; LRR; 6.
DR Pfam; PF01463; LRRCT; 1.
DR SMART; SM00408; IGC2; 1.
DR SMART; SM00370; LRR; 2.
DR SMART; SM00082; LRRCT; 1.
DR SMART; SM00013; LRRNT; 1.
DR SMART; SM00369; LRR_TYP; 2.
KW Immunoglobulin domain.
SQ SEQUENCE 1021 AA; 109770 MW; 23CB5712EFD60969 CRC64;

Query Match 17.6% Score 443.5; DB 5; Length 1021;
Best Local Similarity 30.08; Pred. No. 7 8e-25;
Matches 127; Conservative 54; Mismatches 144; Indels 99; Gaps 13;

Oy 3 CPVSCSNQFSK--VICVRKNLREVDPGISTNRLNLNHNQIQIKVNSF--KHLRHL 58
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 79 CPAVCEKWKSGKSVLCNLANLTHIPQPDAGTQQLDLDSGNIQLIPDDSFATAQLNL 138
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | |

Oy 59 EILQSRNHRTIETGAPNGLANLNTLFDNRLTTTPNGAFVYLSKLKLWLRNPIS 118
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 139 QKVYLARLCHLRIERHAFKRLINLVELDSQNLISAIPLSYHVSELRLSGNPILR 198
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | |

Oy 119 IPSVAFNRIPSLRLDGLCEKRLSVISBGAEGISNRLYLNAMCNLEIPNLPLIKLD 178
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 199 VPDDAFGHVPLVKLEISDC-RLSHIAVRAPAGLES-----SLE 236
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | |

Oy 179 ELDSLGNHLSAIRPFSQGLMHLQKLMQISQIQVIERNAFDNLQSLVEINLAHNLTLL 238
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 237 WLKLDGNRLSEVRSGTITSL----- 256

Oy 239 PHDLFTPLHLHLHLHNPWNCNDILWLSWIKDMAPSNATACRCNTPPNLKGRIYI 297
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 257 -----ASLHGLE---LARNTWNCSCSLRPLRAWLQQNIPSGIP--PTCESPPRLSGRAW 306
   ||| | | | | | | | | | | | | | | | | | | | | | | | | | |

```





Query Match		16.4%;	Score 413.5;	DB 4;	Length 1094;
Best Local Similarity		28.3%;	Pred. No. 1.5e-22;		
Matches 127;		Conservative	78;	Mismatches 170;	Indels 73; Gaps 15;
Qy	37	LNHNHQIITIKVNSFKHLRHLLEILQLSRNHIRTETIGAFNGLANLNTLELFDNRLTIP	96		
Db	216	LDLNRNRIITLFTGLTFOGLNSLEVLIKQRNNISKLTDCAFWGLSKMHVHLHLEYNLSLVEVN	275		
Qy	97	NGAFVYLSKLELNRNPIESIPS-----YAFNRIPSLRDLGELKRL--	141		
Db	276	SGSLYGLTALHQLHLSNNSIARIHRKGSFCQKLHELVLSPNNLTRDDEESLAELSLSV	335		
Qy	142	-----SYISEGAFEGLSNLYINLAMCNLREIPNLPLIKDELDELDSGNHLSAIRPG	193		
Db	336	LRLSHNSISHIAEGAFGLSLRVLD-----LDHNEISGTIEDT--SG	376		
Qy	194	SFOGLMHLQKLMWIOSQIQVIERNAFQNLQSLVEINLAHNNLTLLPHDLFTPLHHLERIH	253		
Db	377	AFSGLDLSLKLTLFGNKIKSVAKRAFSGLEHNLGGNAIRSVQFDFAVYKMKNLKELH	436		
Qy	254	LHHNPWNCNCDILNLSMWI--KDMAPNTACCARCNTPPNLKGRYIGELDONYETC---	308		
Db	437	ISSDSFLDCOLKWLPPWLIIGRLQAFVTATCAH---PESLKGSIFSVPPESEFVCDDFL	493		
Qy	309	APVIVEPPADLNVTEGMAAELKCRASSTLS---VSWITPNGTVMTGAYKVRIAV-LSD	364		
Db	494	KPQIITQPETTMAMVGKDIRETCSAASSSSPMTFAWKKDN-EVLTNADMENFVHVHAQD	552		
Qy	365	G-----TLNFTNVTVODTGMVTCMVNSVGNV---TASATLNVTAA-TTTPFSYFSTV	413		
Db	553	GEVMEYTTILHLRQVTEGHEGRYOCVITNHFGSTYSHKARLTNVNLPSTFKTPHD----	608		
Qy	414	TVETMEPSODEARTDNNVPTPVVDWE	441		
Db	609	TIRTTMARLECAATGH---PNQIAWQ	633		

Search completed: August 26, 2002, 15:50:24  
Job time: 246 sec



GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 26, 2002, 15:43:48 ; Search time 16.37 seconds  
(without alignments)  
713.221 Million cell updates/sec

Title: US-09-905-056-292\_COPY\_45\_522

Perfect score: 2524

Sequence: 1 QTCPSVCSNQSFGSKVICR.....KTFIPVTINDINSIPGIDEV 478

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 231628 seqs, 24425594 residues

Total number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued\_Patents\_AA.\*

- 1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pep.\*
- 2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pep.\*
- 3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pep.\*
- 4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pep.\*
- 5: /cgn2\_6/ptodata/2/iaa/PCTUS\_COMB.pep.\*
- 6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	421	16.7	708	US-09-131-648-2	Sequence 2, Appli
2	402.5	15.9	1091	US-08-986-485-5	Sequence 5, Appli
3	393	15.6	1101	US-08-986-485-2	Sequence 2, Appli
4	386	15.3	1523	US-09-191-647-2	Sequence 2, Appli
5	386	15.3	1525	US-09-540-245A-2	Sequence 2, Appli
6	386	15.3	1525	US-09-540-153-2	Sequence 2, Appli
7	372	14.7	1523	US-09-182-024A-2	Sequence 2, Appli
8	362	14.3	673	US-09-063-950-2	Sequence 2, Appli
9	354	14.0	649	US-09-188-930-305	Sequence 305, App
10	350	13.9	1480	US-09-191-647-7	Sequence 7, Appli
11	350	13.9	1480	US-09-540-245A-7	Sequence 7, Appli
12	350	13.9	1480	US-09-540-153-7	Sequence 7, Appli
13	350	13.9	1480	PCT-US91-05055-2	Sequence 2, Appli
14	347	13.7	1480	US-09-182-024A-5	Sequence 2, Appli
15	329.5	13.1	560	US-08-592-500-2	Sequence 2, Appli
16	329.5	13.1	560	US-08-195-006-2	Sequence 2, Appli
17	329.5	13.1	560	US-09-063-950-4	Sequence 4, Appli
18	329.5	13.1	560	PCT-US94-07644A-2	Sequence 2, Appli
19	329.5	13.1	605	US-09-063-950-5	Sequence 5, Appli
20	314.5	12.5	605	US-08-190-802A-49	Sequence 49, Appli
21	314.5	12.5	605	US-08-477-346-49	Sequence 49, Appli
22	314.5	12.5	605	US-08-473-089-49	Sequence 49, Appli
23	309	12.2	603	US-08-190-802A-50	Sequence 50, Appli
24	309	12.2	603	US-08-477-346-50	Sequence 50, Appli
25	309	12.2	603	US-08-473-089-50	Sequence 50, Appli
26	303.5	12.0	353	US-08-986-485-6	Sequence 6, Appli
27	302	12.0	282	US-08-442-063A-45	Sequence 45, Appli

ALIGNMENTS

RESULT 1

US-09-131-648-2  
; Sequence 2, Application US/09131648  
; Patent No. 6168920

GENERAL INFORMATION:

; APPLICANT: Hillman, Jennifer L.  
; APPLICANT: Yue, Henry

; APPLICANT: Corley, Neil C.  
; APPLICANT: Guegler, Karl J.

; APPLICANT: Patterson, Chandra

; TITLE OF INVENTION: EXTRACELLULAR ADHESIVE PROTEINS

; FILE REFERENCE: PF-0576 US

; CURRENT APPLICATION NUMBER: US/09/131,648

; CURRENT FILING DATE: 1998-08-10

; NUMBER OF SEQ ID NOS: 5

; SOFTWARE: PERL Program

; SEQ ID NO 2

; LENGTH: 708

; TYPE: PRT

; ORGANISM: Homo sapiens

; FEATURE: -

; OTHER INFORMATION: 2687731

US-09-131-648-2

Query Match 16.7%; Score 421; DB 4; Length 708;

Best Local Similarity 27.1%; Pred. No. 7.9e-27;

Matches 133; Conservative 74; Mismatches 185; Indels 98; Gaps 12;

QY	3	CPSVCS	-----NQFSKVICVRKNLRVDPGISTNTLLNHNQIIRK---48	
DB	29	CPRCTCEIRPFWTPRSIYMEASTVDCNDGLTFFPARLPANTOILLQTNNAKIYST	88	
QY	49	---VN-----SFKHLRHLLEILQLSRNHRITIGAFNGLANLELFL	88	
DB	89	DFPNVLTGLDLSQNNSSVINVKMPQLLSVYLEENKLTPEKCLSELNQELYIN	148	
QY	89	DNRLTTPNGAFVYLSKELWLRNNPIESIPYAFNRIPSLRDLGELKRLSYSEGA	148	
DB	149	HNLLSTISPGAFIGHLLRLHLNSRLQMINSKWFDALPNLEILMIGE-NPIIRIKDMN	207	
QY	149	FEGLSNRLYNLAMCNLEIRPN-----LTPLIKLELDL	182	
DB	208	FKPLNLSRVIAGINTEIPDNALVGLNLESISFYDNRILIKVPHVALQVKNLKFELD	267	
QY	183	SGNHLSPGCSFQGLMHLOKLWM-----IQS-----OIQVIER	216	
DB	268	NKNPINRIRGDFSMLHMLKELGINNPPELISIDSLAVDNLPLDKTEATNPNRSLIHP	327	
QY	217	NAFDNLSQSLVEINLAHNNLTLLPHDLFTPLHHLRIHLHHPWNCNDILWSW---WIK	273	

Db 328 NAFRLPKLESMLNSALSALYHGTIESLPNLKEISHSNPIRCDVCVIRWMNNKNIR 387  
QY 274 DMASNTACCARCNTPNLGRYIGELD-QNYFTCYAPVIVEP--PADLNVTEGMAAELK 330  
Db 388 FMEPDSLCV---DPPEFOGONVRQVHFRDMMEICLPLIAPESFPSNLNVEAGSVSFH 443  
QY 331 CRASTS-LTYSWLTPTNGTVMTHGAYKVRIVAVLSGDTLNTNTVQDTGMYTCMVNSVYG 389  
Db 444 CRATAEPOEYIWTSPGQKLLPNTLTKDFYVHSEGTLDNGVTPKREGGLYTCATNLVG 503  
QY 390 NTTASATLV 399  
Db 504 ADLKSVMIKV 513

## RESULT 2

US-08-986-485-5  
; Sequence 5, Application US/08986485  
; Patent No. 6046030  
; GENERAL INFORMATION:  
; APPLICANT: WU, SHUJIAN  
; APPLICANT: SWEET, RAYMOND  
; APPLICANT: TRUNEH, ALEMSEGED  
; TITLE OF INVENTION: A HUMAN LIG-1 HOMOLOG (HLIG-1)  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: RATNER & PRESTIA  
; STREET: P.O. BOX 980  
; CITY: VALLEY FORGE  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19482  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FASTSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/986,485  
; FILING DATE: 08-DEC-1997  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/059,448  
; FILING DATE: 22-SEP-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: PRESTIA, PAUL F  
; REGISTRATION NUMBER: 23,031  
; REFERENCE/DOCKET NUMBER: GH-70264  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 610-407-0700  
; TELEFAX: 610-407-0701  
; TELEX: 846169

## INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:  
LENGTH: 1091 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-986-485-5

Query Match 15.9%; Score 402.5; DB 3; Length 1091;  
Best Local Similarity 24.1%; Pred. No. 5.1e-25;  
Matches 134; Conservative 77; Mismatches 168; Indels 177; Gaps 14;

QY 37 LNLHENOIQIKVNSFKLRLHLEIQLSRNHRTIEIGAFNGLANLNTLFLFNRLTTP 96  
Db 218 LDNNRRLRIEGLTFQGLDLSLEVLRLQRNLSRLTDGAFGLSKMHVHLHLYNSLVEVN 277  
QY 97 NGAFVYLSKLKELMLRNNPTSTPS-----YAFNRIPIRLRLDLGELKRL-- 141

Db 278 SGLSYGLTALHQLHLSNNSISRIQDGSFCQKLEHILSFNNLTRLDESLAELSLSI 337  
QY 142 -----SYISEGAFGLSNLRYLNLMCNLRIPNLTPLIKDELDSLGNHLSAIRPG 193  
Db 338 LRLSHNAISHIAEGAFGLKSLRYLD-----LDHNEISGTIEDT--SG 378  
QY 194 SFQGLHLOKLWMTQSOIQVIERNAFDNLOSLEINLAHNNLTLLPHDLFTPLHLERIH 253  
Db 379 AFTGLDNLKLTLPNGKIKSVAKRAFSGLSELEHNLGENAIRSVQDFDAFAKMKNLKELY 438  
QY 254 LHHNPWCNDIILWLSWI--KDMAPNTACCARCNTPNLKGRIY-GELDNQY----- 304  
Db 439 ISSSEFLDCOLKWLPPWLMGRMLQAFVTATCAH---PESLKGOSIFSVLPSDFVCDP 495  
QY 305 -----FTCYA----- 309  
Db 496 KPQIITQPETTMAYVGKDIRFTCSAASSSSSPMTFAWKONEVLANADMENFAHRAQDG 555  
QY 310 -----PVIVEPPADLNVTEG 324  
Db 556 EVMEYTTILHLRHVTFGHEGRYQCIITNHRGSGTYSHKARLTVNVLPSETKIPHDIAIRTG 615  
QY 325 MAELKCRASLT-SVSWITPNGTVMTHGAYKVRIVAVLSGDTLNF-TNVTQDTGMYTC 382  
Db 616 TTRLECAATGHPNPQIAWQKDGTDGP-AARERRMHVMPDDDDVFFITDKIDDGMGVSC 674  
QY 383 MVSNSVGNNTASATLVNTAATTTTFSYFSTVTVETMPSODEARTDNNV-----GP 434  
Db 675 TAQNSAGSVSANATLVLE-----TPSLAVPLEDRVVTVGETVAFQCKATGSP 722  
QY 435 TPVVDWETTNVTTSLT 450  
Db 723 TPRITLWKGGRPLSLT 738

## RESULT 3

US-08-986-485-2  
; Sequence 2, Application US/08986485  
; Patent No. 6046030  
; GENERAL INFORMATION:  
; APPLICANT: WU, SHUJIAN  
; APPLICANT: SWEET, RAYMOND  
; APPLICANT: TRUNEH, ALEMSEGED  
; TITLE OF INVENTION: A HUMAN LIG-1 HOMOLOG (HLIG-1)  
; NUMBER OF SEQUENCES: 8  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: RATNER & PRESTIA  
; STREET: P.O. BOX 980  
; CITY: VALLEY FORGE  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19482  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FASTSEQ for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/986,485  
; FILING DATE: 08-DEC-1997  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/059,448  
; FILING DATE: 22-SEP-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: PRESTIA, PAUL F  
; REGISTRATION NUMBER: 23,031  
; REFERENCE/DOCKET NUMBER: GH-70264  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 610-407-0700  
; TELEFAX: 610-407-0701  
; TELEX: 846169  
; INFORMATION FOR SEQ ID NO: 2:





Qy 161 AMCN-----LRETP-NL-----TPL 174  
Db 271 PSCNANSICSPCTCSNNIVDCRGKGLMETPANLPEGIVEIRLEQNSIKAIPAGAFQY 330  
Qy 175 IKLDELDSGNHLSAIRGFSQ-----GLMHLOKLMHTSQ 210  
Db 331 KKLAKRIDISKNOISDIAPAFQGLKSLTSLVLYGNKITEIAKGLFDGLVSLQLLLLNANK 390  
Qy 211 IQVTERNAFDLQSLVEINLAHNNTLLPHDLFTPLHHLRIHLHHPNWCNCDILWLSW 270  
Db 391 INCLRVNTFQDLQNLNLSLDNKLQTLKGLFAPLQSIQTLHLAQNPFVCDCHLKLWAD 450  
Qy 271 WIKMAPNTACCARCNTPPNLKGRYIGELDONFTCYAPVIVEPPADLANVTEGMAELK 330  
Db 451 YLOD-NPIETS-GARCSSPRRLANKRISQIKSKFRCSGSEDYRSFSESCFMDLVCPCK 508  
Qy 331 CRASLTSLTSWITPNCVTHGAYK-VRI-----AVLSDGTLNFTNTV-ODTGMV 380  
Db 509 CRC-----EGTIVDCSNOKLVRIPSHLPEYVTDLRNDNEVSLVLEATGIF 553

RESULT 8  
US-09-063-950-2  
; Sequence 2, Application US/09063950C  
; Patent No. 6225085  
; GENERAL INFORMATION:  
; APPLICANT: Holtzman, Douglas A.  
; TITLE OF INVENTION: NOVEL LRSG PROTEIN AND NUCLEIC ACID MOLECULES AND USES  
; FILE REFERENCE: MEI-019  
; CURRENT APPLICATION NUMBER: US/09/063.950C  
; CURRENT FILING DATE: 1998-04-21  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-063-950-2

Query Match 14.38; Score 362; DB 4; Length 673;  
Best Local Similarity 29.94; Pred. No. 6e-22;  
Matches 115; Conservative 56; Mismatches 150; Indels 64; Gaps 11;

Qy 1 QTCPSVCSNOFSKVICVRKNLREVPDGISTNTRLLMLHENQIOIKVNSFKHLRLHLEI 60  
Db 22 QCCPSGCCQS-QPQVFTCAQGTVPDVPDVTGLVVFENGITMLDAGSFAGLPGLQL 80  
Qy 61 LQLSRNHRTIEIGAFNGLANLTLLEFDNRLLTTPINGAFVYLSKLKELWLNRNPIESIP 120  
Db 81 LDLSQNIASLPQSGVQPLANLSLDLTANRLHEITNETFRGLRLRLYLKGNRIHQ 140  
Qy 121 SYAFN-----RTPSLRLDLGLKRLSYISEGAFGLSLNRLYL 159  
Db 141 PGAFPTLRLLEKLQDNELRALPLRLPLRLDLLDSNLSLAL--EPGILDTANVEALR 198  
Qy 160 LAMCNLRIPN--LTPLLKDELDSGNHLSAIRGFSGFOGLMHLOKLMWI-OSQIOVTER 216  
Db 199 LAGLQLOLDGELSRNLNHLDDVSDNQLERV-PPVIRGLRGLTRLRAGNTRIAQLRP 257  
Qy 217 NAFDNLQSLVEINLAHNNTLLPHDLFTPLHHLRIHLHHPNWCNCDILWLSWKID-- 274  
Db 258 EDLAGLAALQELDVSNLSLQALPGDLSGLFPLRLRLAAARNPFCVCLPWFPGWVRESH 317  
Qy 275 ---MAPSNTACCARCNTPPNLKGRYIGELDONFTCYA-----PVIVEPPADLN 320  
Db 318 VTLASPEET----RCHFFPKNAGRLLLDYADFEGCAPTTTATVPTTRPVVREPTA--- 370  
Qy 321 VTEGMAELKCRASLTSLTSVSWITP 345  
Db 371 -----LSSSL-APTWLSP 382

RESULT 9  
US-09-188-930-305  
; Sequence 305, Application US/09188930A  
; Patent No. 6150502  
; GENERAL INFORMATION:  
; APPLICANT: Watson, James D.  
; APPLICANT: Strachan, Lorna  
; APPLICANT: Sleeman, Matthew  
; APPLICANT: Onrust, Rene  
; APPLICANT: Murison, James Greg  
; TITLE OF INVENTION: Compositions Isolated From Skin Cells  
; FILE REFERENCE: 11000.1011c1  
; CURRENT APPLICATION NUMBER: US/09/188.930A  
; CURRENT FILING DATE: 1998-11-09  
; NUMBER OF SEQ ID NOS: 348  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 305  
; LENGTH: 649  
; TYPE: PRT  
; ORGANISM: Mouse  
US-09-188-930-305

Query Match 14.08; Score 354; DB 4; Length 649;  
Best Local Similarity 24.68; Pred. No. 2.7e-21;  
Matches 136; Conservative 88; Mismatches 202; Indels 126; Gaps 20;

Qy 1 QTCPSVCSNOFSKVICVRKNLREVPDGISTNTRLLMLHENQIOIKVNS-FKHL----- 55  
Db 29 KSCPSCVRCDAGF--IYCNDRSLTIPVIGIPEDATTLVQNNQINNNGIPSDLKMLKLVQ 86  
Qy 56 -----RHLETLQLSNRHIRTETGAFNGLANLTLLEFONRLT--TIP 96  
Db 87 RIYLYHNSLDEFPPTNLPYVRELHLQENNRITTYVDSKIPYELDELHDDNSVSAVSIE 146  
Qy 97 NGAFVYLSKLKELWLNRNPIESIPYAFNRIPSLRRLDLGELKRLSYISEGAFGLSLNR 156  
Db 147 EGAFRDSNYLRLLFLSRNHLSTIPGGLPRTTEELRLDD---NRISTISSPSLHGLTSLK 202  
Qy 157 YINLAMCNLRIPNTP-----LIKDELDSGNHLSAIRGFSGFOGLMHLOKLMWISQOI 211  
Db 203 RLVLDD-GNLLNNHGLGDKVFFNLVNLTELSLVRNLSLA-APVNLPG-TSLRKLXLQDNHI 259  
Qy 212 QVIERNAFDNLQSLVEINLAHNNTLLPHDLFTPLHHLRIHLHHPNWCNCDILWLSW 271  
Db 260 NRVPNFAFSYLRQLYRLDMNNSNLSNLPGIFDDLDNITQLILRNPNWYCCCKMKWRDW 319  
Qy 272 IKDMAPSNTACCARCNTPPNLKGRYIGELDONFTCY----- 308  
Db 330 LQSLPVKYNVRGLMCQAPKVRGMAIKDLSAELFDCGSGIVSTIQTITTAIPTATYPAQG 379  
Qy 309 ---APVIVEPP-----ADLNVTEGMAELKCRASLTSLTSVSWITPNCVTHGAYKVR 358  
Db 380 QMPAPVTQPDIKNPKLIKQDQRTTGPSRK-----TILITVKSVPD---TIHISWRIA 430  
Qy 359 IAVLSDGTLNFTNTVQDTGMVTCMVNSVGNVTASATLNVTAAATTPFSYFST----- 412  
Db 431 LPM-----TALRLSWL--KLGHSPAGSGITETIVTGERSEYLVTALEPES 473  
Qy 413 ---VTVETMEPSQ-----DEARTDNNVGTPV-VDWETT-----NVVTSLSLTQSTRTEK 459  
Db 474 PYRCVMPMETSNLYLFDE-----TPVCIETQAPLRMYNPTITLNRQEKEPKYK 523  
Qy 460 TETPVTDTNSG 471  
Db 524 NPNLPALAAIIG 535

RESULT 10  
US-09-191-647-7  
; Sequence 7, Application US/09191647



US-09-540-153-7

```

Query Match      13.9%   Score 350;   DB 4;   Length 1480;
Best Local Similarity 23.9%;   Pred. No. 1.9e-20;
Matches 109; Conservative    65; Mismatches 152; Indels 130; Gaps    9;

QY      2 TPCSVCSGSCNQFQKVICVRKNLRVDPQIGISTNTLLNLHENOIQIIVKNSFKHLRHLEIL 61
DB      294 SCPIPCADGI--VDCEKSLTSVPVTLPDDTTDVRLEQNFEITLPPKSFSSFFRLRRI 351
QY      62 QLSRNHIIRTEIGAENGIANLTLEFDNRLRTTPNGAFVYLTKLKLWLRNNPTIESIPS 121
DB      352 DLSNNNISRIAHDAISGLKQLTTLVLGYNKIKDLPSGVKFGLGSURLLLLNAEISCIRK 411
QY     122 YAFNRIPSLRLDIGELKRLSYISEGAFAEGLSNLRYLNLM-----CNLR----- 166
DB     412 DAFRDLHSLSLSLYD--NNIOSLANGTFDAMKSMKTVHLAKNPFTCDCLNRLWLADYLHN 470
QY     167 ----- 166
DB     471 PIETSGARCESPKRMHRRRRIESREEKFCSWGELRMKLSGECRMDSDCPAMCHCGE TV 530
QY     167 -----EPNLTPL-----TKLD-----ELDLSGNHLSAIRPGS 194
DB     531 DCTGRRLKEIPRIDPLHTTELLANDNELGRISDDGLFGRLPHLVKLELKRNLQTGIEPNA 590
QY     195 FOGLMHLOKLMWISOQIOVIERNAFDNLSIVEINLAHNLTLLPHDLFTPLHHLERHL 254
DB     591 FEGASHLOELQOLGENKIKEINSKKMFLGUHQUTLINLYDNQISCVMPGSFEHLNSLTSLN 650
QY     255 HHNPWCNCIDLWLSWIKOMAPSNATCACRCNTPPNLKRGYIGELDONCYETCYAPVIVE 314
DB     651 ASFPNCNCHLAWAECAECVRKWSLNGA--ARGAPSKVDRDVQIKDLPHSEFKCSS----- 703
QY     315 PPADLVNTEGMAAEKCRASSTLSVSUITPNGTVM 350
DB     704 ----ENSEGCGDGVCYPPSCTCT-----GTVV 726

RESULT 13
PCT-US91-09055-2
; Sequence 2, Application PC/TUS9109055
; GENERAL INFORMATION:
; APPLICANT: Rothberg, Jonathan Marc and Artavanis-Tsakonas, Spyridon
; TITLE OF INVENTION: Purified SLIT protein and Sequence Elements Thereof
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Yale University
; ADDRESSEE: Office of Cooperative Research
; STREET: 246 Church Street
; STREET: Suite 401
; CITY: New Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06510
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 800 Kb storage
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: Microsoft Word 4.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/09055
; FILING DATE: 19911127
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/624,135
; FILING DATE: 7-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Barth, Richard J.
; REGISTRATION NUMBER: 28,180
; REFERENCE/DOCKET NUMBER: 900964/RSB
; TELECOMMUNICATION INFORMATION:

```

RESULT 14  
US-09-182-024A-5  
; Sequence 5, Application US/09182024A  
; Patent No. 6342370  
; GENERAL INFORMATION:  
; APPLICANT: Connolly, Timothy  
; APPLICANT: Rajput, Bhanu  
; TITLE OF INVENTION: Human Slit Polypeptide and Polynucleotides Encoding  
; TITLE OF INVENTION: Same  
; FILE REFERENCE: 640100-271  
; CURRENT APPLICATION NUMBER: US/09/182,024A  
; CURRENT FILING DATE: 1998-10-29  
; PRIOR APPLICATION NUMBER: 60/063,946  
; PRIOR FILING DATE: 1997-10-31  
; PRIOR APPLICATION NUMBER: 60/096,420  
; PRIOR FILING DATE: 1998-08-13  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 1480  
; TYPE: PRT  
; ORGANISM: Drosophila melanogaster  
US-09-182-024A-5

Query Match 13.7%; Score 347; DB 4; Length 1480;  
Best Local Similarity 23.9%; Pred. No. 3.3e-20;  
Matches 109; Conservative 65; Mismatches 152; Indels 130; Gaps 9;  
QY 2 TCPVSCSNQFVKVRCVKNRLREVPDGIISNTLLNLHENOIQIIVKNSFKHLRHLLEIL 61  
Db 294 SCPPCRCADGI--VDCREKSLTSVPVTLDDTDDVLEQNFITELPKFSFSSFRRLRI 351  
QY 62 QLSNRHIRTIEIGAFNGLANLTLEFDNRLTTPNGAFVYLSKLKELWLRNPIESIPS 121  
Db 352 DLSNNISRIAHNDALSLGKQLTLLVYGNKIKDLPFGVFKGLSLRLLLLNANEISCIK 411  
QY 122 YAFNRIPSLRRLDGLKRLSYISEGAFEGLSNRLRYNLAM-----CNLR----- 166  
Db 412 DAFRDLHSLSLSYD--NNIQLANGTFDAMKSMKTVHLAKNPFCIDCNLRWLADYLHN 470  
QY 167 ----- 166  
Db 471 PIETSGARCEPKRMHRRRIEESREKFKGWSGELRMKLSGECRMDSCPMCHCEGTV 530  
QY 167 -----ETPNTPL-----IKLD-----ELDSGNHLSAIRPGS 194  
Db 531 DCTGRRLKEIPRDIPLHTTELLNDNELGRISDGLFGRPLHLVKLEKRNQLTGIEPNA 590  
QY 195 FQGLMHQLQKLMWISQIQVIERNAFDNLQSLVEINLAHNNLTLLPHDLFTPLHHLRIHL 254  
Db 591 FEGASHIQELQGENKIKEISNKMFLGLHQLKTLNLYDNQISCVMPGSEFHLNLSLNL 650  
QY 255 HHNPWNCNDILWSWIKMDAPNSNTACCARNTPPNLKGRIYIGELDQNTFTCYAPVIVE 314  
Db 651 ASNPFCNCHLAWFAECVRKSLNGGA--ARCCAPSKVRVDQIKDLPHSEFKSS----- 703  
QY 315 PPADLVNTEGMAELKCRASLTLSVSWITPNTGV 350  
Db 704 -----ENSEGLDGYCPPTCT-----GTIV 726

RESULT 15  
US-08-592-500-2  
; Sequence 2, Application US/08592500  
; Patent No. 6005089  
; GENERAL INFORMATION:  
; APPLICANT: Lanza, Francois  
; APPLICANT: Phillips, David R.  
; APPLICANT: Cazenave, Jean-Pierre  
; TITLE OF INVENTION: Platelet Glycoprotein V Gene and Uses  
; NUMBER OF SEQUENCES: 43  
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend Kourie and Crew  
; STREET: 379 Lytton Avenue  
; CITY: Palo Alto  
; STATE: California  
; COUNTRY: US  
; ZIP: 94301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/592,500  
; FILING DATE:  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/089,455  
; FILING DATE: 09-JUL-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Dow, Karen B.  
; REGISTRATION NUMBER: 29,684  
; REFERENCE/DOCKET NUMBER: 12418-28  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 326-2400  
; TELEFAX: (415) 326-2422  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 560 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
US-08-592-500-2

Query Match 13.1%; Score 329.5; DB 3; Length 560;  
Best Local Similarity 29.7%; Pred. No. 2.4e-19;  
Matches 83; Conservative 43; Mismatches 104; Indels 49; Gaps 3;  
QY 22 NLREVDPG-----ISTNRLN-----LHENOIQIIVKNSFKH 54  
Db 181 NLHLPGKLGAKAKLERLLHNSRLVSLDGLNSLGLTELQFHRNHRISAPGAFDR 240  
QY 55 LRHLLEILQLSNRHIRTIEIGAFNGLANLTLEFDNRLTTPNGAFVYLSKLKELWLRNN 114  
Db 241 LPNLSLTLNRHLAFLPSALFLHSHNLTLTLFENPLAELPGVLFGEIMGGLQELWLRNT 300  
QY 115 PIESIPYANRIPSLRRLDGLKRLSYISEGAFEGLSNRLRYNLAMCNLRIPNLTP 174  
Db 301 QLRTLPAAAFNRSLRRLYLGVTLSPLSALPQGAFOGLGELQV----- 343  
QY 175 IKLDELDSGNHLSAIRPGSFQGLMHQLKLMWISQIQVIERNAFDNLQSLVEINLAHNN 234  
Db 344 -----LALHNSGLTALPDGLLRGLGKLRQVSLRNRRLRALPRALFRNLSSLESYQLDHNQ 398  
QY 235 LTLPHDLFTPLHHLRIHLHNPWNCNDILWLSWIK 273  
Db 399 LETLPQGVFGALPRLTEVLLGHNSWRCDGCLGPGPLGLWR 437

Search completed: August 26, 2002, 15:46:38  
Job time: 170 sec





